US20110082107A1 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 - Google Patents

Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 Download PDF

Info

Publication number
US20110082107A1
US20110082107A1 US12/898,279 US89827910A US2011082107A1 US 20110082107 A1 US20110082107 A1 US 20110082107A1 US 89827910 A US89827910 A US 89827910A US 2011082107 A1 US2011082107 A1 US 2011082107A1
Authority
US
United States
Prior art keywords
alkyl
aryl
heterocyclyl
thiazol
bicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/898,279
Inventor
Martin Henriksson
Evert Homan
Lars Johansson
Jerk Vallgarda
Meredith Williams
Eric A. Bercot
Christopher H. Fotsch
Aiwen Li
Guolin Cai
Randall W. Hungate
Chester Chenguang Yuan
Christopher Tegley
David J.St. Jean, JR.
Nianhe Han
Qi Huang
Qingyian Liu
Michael D. Bartberger
George A. Moniz
Matthew J. Frizzle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Amgen Inc
Original Assignee
Biovitrum AB
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0401324A external-priority patent/SE0401324D0/en
Priority claimed from SE0402509A external-priority patent/SE0402509D0/en
Application filed by Biovitrum AB, Amgen Inc filed Critical Biovitrum AB
Priority to US12/898,279 priority Critical patent/US20110082107A1/en
Publication of US20110082107A1 publication Critical patent/US20110082107A1/en
Priority to US13/233,699 priority patent/US8686011B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Definitions

  • the present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme (11 ⁇ HSD1).
  • 11 ⁇ HSD1 human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme
  • HSDs Hydroxysteroid dehydrogenases
  • the 11-beta-hydroxysteroid dehydrogenases catalyze the interconversion of active glucocorticoids (such as cortisol and corticosterone), and their inert forms (such as cortisone and 11-dehydrocorticosterone).
  • the isoform 11-beta-hydroxysteroid dehydrogenase type 1 (11 ⁇ -HSD1) is expressed in liver, adipose tissue, brain, lung and other glucocorticoid tissue and is a potential target for therapy directed at numerous disorders that may be ameliorated by reduction of glucocorticoid action, such as diabetes, obesity and age-related cognitive dysfunction. Seckl, et al., Endocrinology, 2001, 142:1371-1376.
  • the various isozymes of the 17-beta-hydroxysteroid dehydrogenases (17 ⁇ -HSDs) bind to androgen receptors or estrogen receptors and catalyze the interconversion of various sex hormones including estradiol/estrone and testosterone/androstenedione.
  • 17-beta-Hydroxysteroid dehydrogenase type 2 (17 ⁇ -HSD2) is expressed in human endometrium and its activity has been reported to be linked to cervical cancer. Kitawaki et al., J. Clin. Endocrin.
  • 17-beta-Hydroxysteroid dehydrogenase type 3 (17 ⁇ -HSD3) is expressed in the testes and its modulation may be useful for the treatment of androgen-related disorders.
  • Androgens and estrogens are active in their 17 ⁇ -hydroxy configurations, whereas their 17-keto derivatives do not bind to androgen and estrogen receptors and are thus inactive.
  • the conversion between the active and inactive forms (estradiol/estrone and testosterone/androstenedione) of sex hormones is catalyzed by members of the 17 ⁇ -HSD family.
  • 17 ⁇ -HSD1 catalyzes the formation of estradiol in breast tissue, which is important for the growth of malignant breast tumors. Labrie et al., Mol. Cell. Endocrinol. 1991, 78:C113-C118.
  • a similar role has been suggested for 17 ⁇ -HSD4 in colon cancer. English et al., J. Clin.
  • 17 ⁇ -HSD3 is almost exclusively expressed in the testes and converts androstenedione into testosterone. Deficiency of this enzyme during fetal development leads to male pseudohermaphroditism. Geissler et al., Nat. Genet. 1994, 7:34-39. Both 17 ⁇ -HSD3 and various 3 ⁇ -HSD isozymes are involved in complex metabolic pathways which lead to androgen shuffles between inactive and active forms. Penning et al., Biochem. J. 2000, 351:67-77. Thus, modulation of certain HSDs can have potentially beneficial effects in the treatment of androgen- and estrogen-related disorders.
  • the 20-alpha-hydroxysteroid dehydrogenases (20 ⁇ -HSDs) catalyze the interconversion of progestins (such as between progesterone and 20 ⁇ -hydroxy progesterone).
  • Other substrates for 20 ⁇ -HSDs include 17 ⁇ -hydroxypregnenolone or 17 ⁇ -hydroxyprogesterone, leading to 20 ⁇ -OH steroids.
  • 20 ⁇ -HSD isoforms have been identified and 20 ⁇ -HSDs are expressed in various tissues, including the placenta, ovaries, testes and adrenals. Peltoketo, et al., J. Mol. Endocrinol. 1999, 23:1-11.
  • the 3-alpha-hydroxysteroid dehydrogenases (3 ⁇ -HSDs) catalyze the interconversion of the androgens dihydrotestosterone (DHT) and 5 ⁇ -androstane-3 ⁇ ,17 ⁇ -diol and the interconversion of the androgens DHEA and androstenedione and therefore play an important role in androgen metabolism.
  • DHT dihydrotestosterone
  • DHEA dihydrotestosterone
  • androstenedione and therefore play an important role in androgen metabolism.
  • glucocorticoids have a central role in diabetes. For example, the removal of the pituitary gland or the adrenal gland from a diabetic animal alleviates the most severe symptoms of diabetes and lowers the concentration of glucose in the blood (Long, C. D. and Leukins, F. D. W. (1936) J. Exp. Med. 63: 465-490; Houssay, B. A. (1942) Endocrinology 30: 884-892). It is also well established that glucocorticoids enable the effect of glucagon on the liver.
  • 11 ⁇ HSD1 as an important regulator of local glucocorticoid effect and thus of hepatic glucose production is well substantiated (see, e.g., Jamieson et al. (2000) J. Endocrinol. 165: 685-692). Hepatic insulin sensitivity was improved in healthy human volunteers treated with the non-specific 11 ⁇ HSD1 inhibitor carbenoxolone (Walker, B. R. et al. (1995) J. Clin. Endocrinol. Metab. 80: 3155-3159). Furthermore, the expected mechanism has been established by different experiments with mice and rats.
  • FR 2,384,498 discloses compounds having a high hypoglycemic effect. Therefore, treatment of hyperglycemia with these compounds may lead to hypoglycemia.
  • Obesity is an important factor in syndrome X as well as in the majority (>80%) of type 2 diabetes, and omental fat appears to be of central importance.
  • Abdominal obesity is closely associated with glucose intolerance, hyperinsulinemia, hypertriglyceridemia, and other factors of the so-called syndrome X (e.g. increased blood pressure, decreased levels of HDL and increased levels of VLDL) (Montague & O′Rahilly, Diabetes 49: 883-888, 2000)
  • Inhibition of the 11 ⁇ HSD1 enzyme in pre-adipocytes (stromal cells) has been shown to decrease the rate of differentiation into adipocytes.
  • Adrenalectomy attenuates the effect of fasting to increase both food intake and hypothalamic neuropeptide Y expression. This supports the role of glucocorticoids in promoting food intake and suggests that inhibition of 11 ⁇ HSD1 in the brain might increase satiety and therefore reduce food intake (Woods, S. C. et al. (1998) Science, 280: 1378-1383).
  • glucocorticoids suppress the immune system. But in fact there is a dynamic interaction between the immune system and the HPA (hypothalamo-pituitary-adrenal) axis (Rook, G. A. W. (1999) Bailliér's Clin. Endocrinol. Metab. 13: 576-581).
  • HPA hypothalamo-pituitary-adrenal
  • the balance between the cell-mediated response and humoral responses is modulated by glucocorticoids.
  • a high glucocorticoid activity such as at a state of stress, is associated with a humoral response.
  • inhibition of the enzyme 11 ⁇ HSD1 has been suggested as a means of shifting the response towards a cell-based reaction.
  • 11 ⁇ HSD1 In the eye, expression of 11 ⁇ HSD1 is confined to basal cells of the corneal epithelium and the non-pigmented epithelialium of the cornea (the site of aqueous production), to ciliary muscle and to the sphincter and dilator muscles of the iris.
  • the distant isoenzyme 11 ⁇ HSD2 is highly expressed in the non-pigmented ciliary epithelium and corneal endothelium. None of the enzymes is found at the trabecular meshwork, the site of drainage.
  • 11 ⁇ HSD1 is suggested to have a role in aqueous production, rather than drainage, but it is presently unknown if this is by interfering with activation of the glucocorticoid or the mineralocorticoid receptor, or both.
  • Glucocorticoids have an essential role in skeletal development and function but are detrimental in excess.
  • Glucocorticoid-induced bone loss is derived, at least in part, via inhibition of bone formation, which includes suppression of osteoblast proliferation and collagen synthesis (Kim, C. H., Cheng, S. L. and Kim, G. S. (1999) J. Endocrinol. 162: 371-379).
  • the negative effect on bone nodule formation could be blocked by the non-specific inhibitor carbenoxolone suggesting an important role of 11 ⁇ HSD1 in the glucocorticoid effect (Bellows, C. G., Ciaccia, A. and Heersche, J. N. M. (1998) Bone 23: 119-125).
  • WO 99/65884 discloses carbon substituted aminothiazole inhibitors of cyclin dependent kinases. These compounds may, e.g., be used against cancer, inflammation and arthritis.
  • U.S. Pat. No. 5,856,347 discloses an antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof.
  • U.S. Pat. No. 5,403,857 discloses benzenesulfonamide derivatives having 5-lipoxygenase inhibitory activity.
  • tetrahydrothiazolo[5,4-c]pyridines are disclosed in: Analgesic tetrahydrothiazolo[5,4-c]pyridines. Fr. Addn. (1969), 18 pp, Addn. to Fr.
  • WO 98/16520 discloses compounds inhibiting matrix metalloproteinases (MMPs) and TNF- ⁇ converting enzyme (TACE).
  • MMPs matrix metalloproteinases
  • TACE TNF- ⁇ converting enzyme
  • EP 0 749 964 A1 and U.S. Pat. No. 5,962,490 disclose compounds having an endothelin receptor antagonist activity.
  • WO 00/02851 discloses compounds associated with a disturbed cGMP balance. None of these compounds fall within formula (I) according to the present invention. Furthermore, nothing is said about the activity on 11 ⁇ HSD1.
  • U.S. Pat. No. 5,783,697 discloses thiophene derivatives as inhibitors of PGE2 and LTB4. None is said about the activity on 11 ⁇ HSD1.
  • EP 0 558 258, EP 0 569 193, and EP 1 069 114 disclose isoxazole derivatives as endothelin agonists and antagonists. None is said about the activity on 11 ⁇ HSD1.
  • Cortisol performs a broad range of metabolic functions and other functions.
  • the multitude of glucocorticoid action is exemplified in patients with prolonged increase in plasma glucocorticoids, so called “Cushing's syndrome”.
  • Patients with Cushing's syndrome have prolonged increase in plasma glucocorticoids and exhibit impaired glucose tolerance, type 2 diabetes, central obesity, and osteoporosis. These patients also have impaired wound healing and brittle skin (Ganong, W. F. Review of Medical Physiology. Eighteenth edition ed. Stamford, Conn.: Appleton & Lange; 1997).
  • Glucocorticoids have been shown to increase risk of infection and delay healing of open wounds (Anstead, G. M. Steroids, retinoids, and wound healing. Adv Wound Care 1998; 11(6):277-85). Patients treated with glucocorticoids have 2-5-fold increased risk of complications when undergoing surgery (Diethelm, A. G. Surgical management of complications of steroid therapy. Ann Surg 1977; 185(3):251-63).
  • the European patent application No. EP 0902288 discloses a method for diagnosing the status of wound healing in a patient, comprising detecting cortisol levels in said wound.
  • the authors suggest that elevated levels of cortisol in wound fluid, relative to normal plasma levels in healthy individuals, correlates with large, non-healing wounds (Hutchinson, T. C., Swaniker, H. P., Wound diagnosis by quantitating cortisol in wound fluids.
  • the 11 ⁇ -HSD catalyzes the conversion of cortisol to cortisone, and vice versa.
  • the parallel function of 11 ⁇ -HSD in rodents is the interconversion of corticosterone and 11-dehydrocorticosterone (Frey, F. J., Escher, G., Frey, B. M. Pharmacology of 11 beta-hydroxysteroid dehydrogenase. Steroids 1994; 59(2):74-9).
  • Two isoenzymes of 11 ⁇ -HSD, 11 ⁇ -HSD1 and 11 ⁇ -HSD2 have been characterized, and differ from each other in function and tissue distribution (Albiston, A. L., Obeyesekere, V. R., Smith, R.
  • 11 ⁇ -HSD1 is expressed in numerous tissues like liver, adipose tissue, adrenal cortex, gonads, lung, pituitary, brain, eye etc (Monder C, White PC. 11 beta-hydroxysteroid dehydrogenase. Vitam Horm 1993; 47:187-271; Stewart, P. M., Krozowski, Z. S. 11 beta-Hydroxysteroid dehydrogenase.
  • Wound healing consists of serial events including inflammation, fibroblast proliferation, secretion of ground substances, collagen production, angiogenesis, wound contraction and epithelialization. It can be divided in three phases; inflammatory, proliferative and remodeling phase (reviewed in Anstead et al., supra).
  • glucocorticoid receptor antagonist RU486 Mercado, A. M., Quan, N., Padgett, D. A., Sheridan, J. F., Marucha, P. T. Restraint stress alters the expression of interleukin-1 and keratinocyte growth factor at the wound site: an in situ hybridization study. J Neuroimmunol 2002; 129(1-2):74-83; Rojas, I. G., Padgett, D.
  • Glucocorticoids produce these effects by suppressing inflammation, decrease wound strength, inhibit wound contracture and delay epithelialization (Anstead et al., supra). Glucocorticoids influence wound healing by interfering with production or action of cytokines and growth factors like IGF, TGF- ⁇ , EGF, KGF and PDGF (Beer, H. D., Fassler, R., Werner, S. Glucocorticoid-regulated gene expression during cutaneous wound repair. Vitam Horm 2000; 59:217-39; Hamon, G.
  • Transforming growth factor beta reverses the glucocorticoid-induced wound-healing deficit in rats: possible regulation in macrophages by platelet-derived growth factor. Proc Natl Acad Sci USA 1989; 86(7):2229-33). It has also been shown that glucocorticoids decrease collagen synthesis in rat and mouse skin in vivo and in rat and human fibroblasts (Oishi, Y., Fu, Z. W., Ohnuki, Y., Kato, H., Noguchi, T. Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol 2002; 147(5):859-68).
  • WO 01/90090 discloses thiazole compounds, which compounds inhibit the human 11 ⁇ -HSD1, and may be useful for treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders and immune disorders.
  • Other 11 ⁇ -HSD1 inhibitors are disclosed in e.g. WO 01/90091; WO 01/90092; WO 01/90093; WO 01/90094; WO 03/043999; WO 03/044000; WO 03/044009; U.S. Patent Publication No.
  • the compounds according to the present invention solves the above problems and embraces a novel class of compounds which has been developed and which inhibit the human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme (11- ⁇ -HSD1), and may therefore be of use in treating disorders related to 11- ⁇ -HSD1 activity, such as, but not limited to diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, hypertension, and wound healing.
  • 11- ⁇ -HSD1 human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme
  • One object of the present invention is a compound of the general formula (I)
  • Z is sulfur, R 1 is hydrogen, R 2 is selected from hydrogen; C 3-10 -cycloalkyl optionally independently substituted by one or more of C 1-8 -alkyl and aryl; C 3-10 -cycloalkyl-C 1-8 -alkyl; aryl; aryl-C 1-8 -alkyl; heterocyclyl; heterocyclyl-C 1-8 -alkyl; wherein any aryl or heterocyclyl residue is optionally independently substituted by one or more C 1-8 -alkyl and halogen; or R 1 and R 2 form together with the nitrogen atom bonded thereto a monocyclic heterocyclyl optionally independently substituted by one or more of aryl-C 1-8 -alkyl, C 1-8 -alkyl and halogen; R 3 and R 4 are each independently selected from hydrogen; C 1-8 -alkyl; C 3-10 -cycloalkyl-C 1-8 -alkyl; cyano-C 1-8 -
  • Z is oxygen, R 1 is hydrogen, R 2 is selected from hydrogen; C 5-10 -cycloalkyl optionally independently substituted by one or more of C 1-8 -alkyl and aryl; C 3-10 -cycloalkyl-C 1-8 -alkyl; aryl, but not an unsubstituted phenyl group; aryl-C 1-8 -alkyl; heterocyclyl; heterocyclyl-C 3-8 -alkyl; wherein any aryl or heterocyclyl residue is optionally independently substituted by one or more of C 1-8 -alkyl and halogen; R 3 and R 4 are each independently selected from hydrogen; C 1-8 -alkyl; C 3-10 -cycloalkyl-C 1-8 -alkyl; cyano-C 1-8 -alkyl; aryl, but not an unsubstituted phenyl group; aryl-C 1-8 -alkyl; heterocyclyl-C 1-8 --al
  • Z is oxygen and R 3 ⁇ H, then R 4 is not methyl.
  • R 1 and R 2 are each independently selected from hydrogen, cyclohexyl, cycloheptyl, cyclooctyl, 2,2,3,3-tetramethylcyclopropyl, 1-(4-chlorophenyl)cyclobutyl, bicyclo[2.2.1]hept-2-yl, tricyclo[3.3.1.0 ⁇ 3,7 ⁇ ]non-3-yl, cyclohexylmethyl, phenyl, 2-methylphenyl, 3-methylphenyl, 2-isopropylphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-phenylpropyl, 2-chlorobenzyl, 4-chlorobenzyl, 4-(2,2,6,6-tetramethyl)piperidyl, 2-morpholinyl-4-ylethyl, or R 1 and R 2 form together with the nitrogen atom bonded thereto morpholinyl, azocane, or 4-benzylpiperidyl;
  • R 3 and R 4 are each independently selected from hydrogen, methyl, ethyl, isopropyl, isobutyl, tert-butyl, cyclohexylmethyl, cyanomethyl, phenyl, 2-hydroxyphenyl, benzyl, 2-hydroxybenzyl, 4-hydroxybenzyl, 3,4-dihydroxybenzyl, 1H-imidazol-4-ylmethyl, indol-3-ylmethyl, 3-pyridylmethyl, or R 3 and R 4 form together with the carbon atom bonded thereto cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl;
  • R 2 as an aryl group is selected from 2-methylphenyl, 3-methylphenyl, 2-isopropylphenyl, 2-fluorophenyl, and 2-chlorophenyl.
  • Z sulfur
  • R 3 is ethyl and R 4 is hydrogen
  • R 2 as an aryl group is selected from 2-methylphenyl, 2-isopropylphenyl, 2-fluorophenyl, and 2-chlorophenyl.
  • each of R 2 , R 3 , and R 4 as an aryl group is selected from 2-methylphenyl, 3-methylphenyl, 2-isopropylphenyl, 2-fluorophenyl, and 2-chlorophenyl.
  • R 4 as a C 1-8 -alkyl group is selected from C 2-8 -alkyl.
  • Preferred compounds are Examples 1-38, 40-66, 68, and 73-79.
  • Another object of the present invention is a process for the preparation of a compound above comprising at least one of the following steps:
  • X is S or O
  • R 5 is selected from hydrogen, C 1 -C 8 alkyl, C 3-10 -cycloalkyl, C 3-10 -cycloalkyl-C 1-8 -alkyl, aryl, aryl-C 1-8 -alkyl, heterocyclyl, heterocyclyl-C 1-8 -alkyl and haloalkyl;
  • R 6 is selected from C 1-8 -alkyl, C 1-8 -alkoxy, C 3-10 -cycloalkyl, heterocyclyl, C 3-10 -cycloalkyl-C 1-8 -alkyl, CN—C 1-8 -alkyl, aryl, aryl-C 1-8 -alkyl, heterocyclyl-C 1-8 -alkyl and haloalkyl;
  • R 7 is selected from —NR 8 R 9 , halo, C 1-8 -alkyl, —(CR 8 R 9 ) n —OR 8 , —S—C 1 -C 8 -alkyl, C 3-10 -cycloalkyl, heterocyclyl, C 3-10 -cycloalkyl-C 1-8 -alkyl, cyano-C 1-8 -alkyl, aryl, aryl-C 1-8 -alkyl, heterocyclyl-C 1-8 -alkyl, heterocyclyl-C(O)—C 1-8 -alkyl, heterocyclyl-SO 2 —C 1-8 -alkyl, C 1-8 -haloalkyl, R 8 R 9 N—C 1-8 -alkyl, HO—C 1-8 -alkyl, —C(O)—C 3 -C 10 -cycloalkyl, —C(O)—C 1 -C 8 -haloalky
  • R 8 and R 9 are each independently selected from hydrogen, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, —NR 10 R 10 , —S—(C 1 -C 8 )alkyl, aryl and heterocyclyl;
  • R 10 is independently selected from hydrogen, C 1 -C 8 alkyl, aryl-C 1 -C 8 alkyl, C 1 -C 8 alkoxy, —S—(C 1 -C 8 )alkyl, heterocyclyl and aryl;
  • R 6 and R 7 form, together with the carbon atom bonded thereto, a saturated, partially unsaturated or unsaturated C 3-10 -cycloalkyl or a saturated, partially unsaturated or unsaturated C 4 -C 14 heterocyclyl;
  • X is S, R 6 and R 7 combine to form a cyclopropyl ring, then R 5 is not n-butyl, cyclohexyl, benzyl, phenyl or naphthyl.
  • R 5 is selected from hydrogen, C 1 -C 8 alkyl, C 3-10 -cycloalkyl, C 3-10 -cycloalkyl-C 1-8 -alkyl, aryl, aryl-C 1-8 -alkyl, heterocyclyl, heterocyclyl-C 1-8 -alkyl and haloalkyl;
  • R 6 is selected from C 1-8 -alkyl, C 1-8 -alkoxy, C 3-10 -cycloalkyl, heterocyclyl, C 3-10 -cycloalkyl-C 1-8 -alkyl, CN—C 1-8 -alkyl, aryl, aryl-C 1-8 -alkyl, heterocyclyl-C 1-8 -alkyl and haloalkyl;
  • R 7 is selected from —NR 8 R 9 , halo, C 1-8 -alkyl, —(CR 8 R 9 ) n —OR 8 , —S—C 1 -C 8 -alkyl, C 3-10 -cycloalkyl, heterocyclyl, C 3-10 -cycloalkyl-C 1-8 -alkyl, cyano-C 1-8 -alkyl, aryl, aryl-C 1-8 -alkyl, heterocyclyl-C 1-8 -alkyl, heterocyclyl-C(O)—C 1-8 -alkyl, heterocyclyl-SO 2 —C 1-8 -alkyl, C 1-8 -haloalkyl, R 8 R 9 N—C 1-8 -alkyl, HO—C 1-8 -alkyl, —C(O)—C 3 -C 10 -cycloalkyl, —C(O)—C 1 -C 8 -haloalky
  • R 8 and R 9 are each independently selected from hydrogen, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, —NR 10 R 10 , —S—(C 1 -C 8 )alkyl, aryl and heterocyclyl;
  • R 10 is independently selected from hydrogen, C 1 -C 8 alkyl, aryl-C 1 -C 8 alkyl, C 1 -C 8 alkoxy, heterocyclyl and aryl;
  • R 6 and R 7 form, together with the carbon atom bonded thereto, a saturated, partially unsaturated or unsaturated C 3-10 -cycloalkyl or a saturated, partially unsaturated or unsaturated C 4 -C 14 heterocyclyl;
  • R 6 ⁇ R 7 methyl, then R 5 is not phenyl or 4-iodophenyl,
  • R 6 ⁇ R 7 phenyl, then R 5 is not phenyl,
  • R 6 and R 7 combine to form a cyclopropyl ring, then R 5 is not n-butyl, cyclohexyl, benzyl, phenyl or naphthyl.
  • R 5 is selected from hydrogen, C 1 -C 8 alkyl, C 3-10 -cycloalkyl, C 3-10 -cycloalkyl-C 1-8 -alkyl, aryl, aryl-C 1-8 -alkyl, heterocyclyl, heterocyclyl-C i-8 -alkyl and haloalkyl;
  • R 6 is selected from C 1-8 -alkyl, C 1-8 -alkoxy, C 3-10 -cycloalkyl, heterocyclyl, C 3-10 -cycloalkyl-C 1-8 -alkyl, CN—C 1-8 -alkyl, aryl, aryl-C 1-8 -alkyl, heterocyclyl-C 1-8 -alkyl and haloalkyl;
  • R 7 is selected from —NR 8 R 9 , halo, C 1-8 -alkyl, —(CR 8 R 9 ) n —OR 8 , —S—C 1 -C 8 -alkyl, C 3-10 -cycloalkyl, heterocyclyl, C 3-10 -cycloalkyl-C 1-8 -alkyl, cyano-C 1-8 -alkyl, aryl, aryl-C 1-8 -alkyl, heterocyclyl-C 1-8 -alkyl, heterocyclyl-C(O)—C 1-8 -alkyl, heterocyclyl-SO 2 —C 1-8 -alkyl, C 1-8 -haloalkyl, R 8 R 9 N—C 1-8 -alkyl, HO—C 1-8 -alkyl, —C(O)—C 3 -C 10 -cycloalkyl, —C(O)—C 1 -C 8 -haloalky
  • R 8 and R 9 are each independently selected from hydrogen, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, —NR 10 R 10 , —S—(C 1 -C 8 )alkyl, aryl and heterocyclyl;
  • R 10 is independently selected from hydrogen, C 1 -C 8 alkyl, aryl-C 1 -C 8 alkyl, C 1 -C 8 alkoxy, heterocyclyl and aryl;
  • R 6 and R 7 form, together with the carbon atom bonded thereto, a saturated, partially unsaturated or unsaturated C 3-10 -cycloalkyl or a saturated, partially unsaturated or unsaturated C 4 -C 14 heterocyclyl;
  • One embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein:
  • R 5 is selected from cyclohexyl, cycloheptyl, cyclooctyl, 2,2,3,3-tetramethylcyclopropyl, 1-(4-chlorophenyl)cyclobutyl, bicyclo[2.2.1]hept-2-yl, tricyclo[3.3.1.0 ⁇ 3,7 ⁇ ]non-3-yl, cyclohexylmethyl, phenyl, 2-methylphenyl, 3-methylphenyl, 2-isopropylphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-phenylpropyl, 2-chlorobenzyl, 4-chlorobenzyl, 4-(2,2,6,6-tetramethyl)piperidyl, 2-morpholinyl-4-ylethyl and tetrahydropyran-4-yl-methyl; and
  • R 6 and R 7 are each independently selected from methyl, ethyl, isopropyl, isobutyl, tert-butyl, cyclohexylmethyl, cyanomethyl, phenyl, 2-hydroxyphenyl, benzyl, 2-hydroxybenzyl, 4-hydroxybenzyl, 3,4-dihydroxybenzyl, 1H-imidazol-4-ylmethyl, indol-3-ylmethyl, 3-pyridylmethyl;
  • R 6 and R 7 form together with the carbon atom bonded thereto cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 6 is methyl and R 7 is isopropyl.
  • R 5 is selected from optionally substituted C 1 -C 8 alkyl, optionally substituted C 3 -C 10 cycloalkyl and optionally substituted aryl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 5 is C 3 -C 8 alkyl.
  • R 5 is optionally substituted phenyl-(CR 10a R 10a ) 1-3 ; and wherein R 10a is independently selected from H, methyl, fluoro or R 10a and R 10a may combine together to form a C 3 -C 6 -cycloalkyl ring.
  • R 5 is (optionally substituted phenyl)-(C(CH 3 ) 2 )— (optionally substituted phenyl)-(CHCH 3 ) or benzyl.
  • R 5 is C 3 -C 10 cycloalkyl.
  • R 5 is selected from cyclohexyl, norbornyl and adamantyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 5 is norbornyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 5 is aryl.
  • R 5 is selected from optionally substituted phenyl.
  • R 6 is selected from C 1 -C 8 alkyl, C 3 -C 10 cycloalkyl, saturated or partially unsaturated heterocyclyl, heteroaryl and aryl.
  • R 6 is C 1 -C 8 alkyl.
  • the alkyl is selected from methyl, ethyl, n-propyl and iso-propyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 6 is C 3 -C 10 cycloalkyl.
  • R 6 is selected from cyclohexyl, norbornyl and adamantyl.
  • R 6 is saturated or partially unsaturated 5 or 6-membered heterocyclyl.
  • R 6 is selected from tetrahydrofuryl, piperidinyl and tetrahydropyranyl.
  • R 6 is a 5 or 6 membered heteroaryl ring.
  • R 6 is selected from pyridyl, furyl and pyrrolyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 6 is C 6 -C 10 aryl.
  • R 6 is selected from optionally substituted phenyl and optionally substituted benzyl.
  • R 7 is selected from —NR 8 R 9 , C 1 -C 8 alkoxy, heterocyclyl and heterocyclyl-C 1 -C 8 -alkyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 7 is —NR 8 R 9 .
  • R 8 is methyl, ethyl, isopropyl or butyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 8 is isopropyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 9 is methyl or H.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 7 is C 1 -C 8 alkoxy.
  • R 7 is methoxy, ethoxy, propoxy or butoxy.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 7 is n-butoxy.
  • R 7 is saturadted or partially unsaturated 5 or 6-membered heterocyclyl.
  • R 7 is pyrroldinyl, morpholinyl or piperidinyl.
  • R 7 is piperidinyl
  • R 7 is heterocycyl-C 1 -C 8 -alkyl.
  • R 7 is heterocycyl-C 1 -C 3 -alkyl.
  • R 7 is optionally substituted piperidin-4-yl-CH 2 —.
  • R 7 is R 8 -piperidin-4-yl-CH 2 —.
  • R 6 and R 7 form, together with the carbon atom bonded thereto, an optionally unsaturated C 3-10 -cycloalkyl or an optionally unsaturated C 4 -C 14 heterocyclyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 6 and R 7 form an optionally unsaturated C 3 -C 10 cycloalkyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 6 and R 7 form a six-membered spiro ring.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 6 and R 7 form a five-membered spiro ring.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R 6 and R 7 form an optionally unsaturated C 4 -C 14 heterocyclyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: the optionally unsaturated C 4 -C 14 heterocyclyl is a six-membered heterocyclic spiro ring.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: the C 4 -C 14 heterocyclyl is a cyclic amide spiro ring.
  • One embodiment relates to a pharmaceutical formulation
  • a pharmaceutical formulation comprising a compound according to Formula (I), (II), (III), or (IV) as active ingredient, in combination with a pharmaceutically acceptable diluent or carrier.
  • the pharmaceutical formulation is formulated for oral delivery.
  • the oral delivery form is a tablet.
  • One embodiment relates to a method for the prophylaxis or treatment of a 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation comprising administering the compound of Formula (I), (II), (III), or (IV) to an individual.
  • the disorder is selected from diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, and inflammatory diseases.
  • Another embodiment relates to the treatment or prophylaxis of a medical condition involving delayed or impaired wound healing.
  • Another embodiment relates to methods of treatment wherein the medical condition involving delayed or impaired wound healing is diabetes.
  • Another embodiment relates to methods of treatment wherein the medical condition involving delayed or impaired wound healing is caused by treatment with glucocorticoids.
  • Another embodiment relates to methods of treatment for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
  • Another embodiment relates to methods of treatment wherein immuno-modulation is selected from tuberculosis, lepra, and psoriasis.
  • Another embodiment relates to a method for inhibiting a 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme, which comprises administering to a subject in need of such treatment an effective amount of a compound according to Formula (I), (II), (III) or (IV).
  • Another object of the present invention is a compound according to general formula (I) for use in therapy:
  • R 1 and R 2 are each independently selected from hydrogen; C 3-10 -cycloalkyl optionally independently substituted by one or more of C 1-8 -alkyl and aryl; C 3-10 -cycloalkyl-C 1-8 -alkyl; aryl; aryl-C 1-8 -alkyl; heterocyclyl; heterocyclyl-C 1-8 -alkyl; or R 1 and R 2 form together with the nitrogen atom bonded thereto heterocyclyl optionally independently substituted by one or more of aryl-C 1-8 -alkyl, wherein any aryl or heterocyclyl residue is optionally independently substituted by one or more of C 1-8 -alkyl and halogen;
  • R 3 and R 4 are each independently selected from hydrogen; C 1-8 -alkyl; C 3-10 -cycloalkyl-C 1-8 -alkyl; cyano-C 1-8 -alkyl; aryl; aryl-C 1-8 -alkyl; heterocyclyl-C 1-8 -alkyl; heteroaryl-C 1-8 -alkyl; or R 3 and R 4 form together with the carbon atom bonded thereto C 3-10 -cycloalkyl, wherein any aryl residue is optionally independently substituted by one or more of hydroxy;
  • Z is sulfur or oxygen
  • R 1 and R 2 are each independently selected from hydrogen, cyclohexyl, cycloheptyl, cyclooctyl, 2,2,3,3-tetramethylcyclopropyl, 1-(4-chlorophenyl)cyclobutyl, bicyclo[2.2.1]hept-2-yl, tricyclo[3.3.1.0 ⁇ 3,7 ⁇ ]non-3-yl, cyclohexylmethyl, phenyl, 2-methylphenyl, 3-methylphenyl, 2-isopropylphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-phenylpropyl, 2-chlorobenzyl, 4-chlorobenzyl, 4-(2,2,6,6-tetramethyl)piperidyl, 2-morpholinyl-4-ylethyl, or R 1 and R 2 form together with the nitrogen atom bonded thereto morpholinyl, azocane, or 4-benzylpiperidyl;
  • R 3 and R 4 are each independently selected from hydrogen, methyl, ethyl, isopropyl, isobutyl, tert-butyl, cyclohexylmethyl, cyanomethyl, phenyl, 2-hydroxyphenyl, benzyl, 2-hydroxybenzyl, 4-hydroxybenzyl, 3,4-dihydroxybenzyl, 1H-imidazol-4-ylmethyl, indol-3-ylmethyl, 3-pyridylmethyl, or R 3 and R 4 form together with the carbon atom bonded thereto cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • the compounds of Formula (I) when using the compounds of Formula (I) in therapy (e.g., Examples 39, 67, and 69-72), they may advantageously be used in the prophylaxis or treatment of an 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation.
  • the disorder may be selected from diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, and inflammatory diseases.
  • the treatment or prophylaxis is of the medical condition involves delayed or impaired wound healing.
  • the medical condition involving delayed or impaired wound healing may be associated with diabetes and may have been caused by treatment with glucocorticoids.
  • the compounds of Formula (I) for use in therapy may be for promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
  • Iimmuno-modulation may encompass tuberculosis, lepra, and psoriasis.
  • Another object of the present invention is a pharmaceutical formulation comprising a compound according to Formula (I) for use in therapy as active ingredient, in combination with a pharmaceutically acceptable diluent or carrier, especially for use in the prophylaxis or treatment of a 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation.
  • the pharmaceutical formulation can include a second active ingredient.
  • the second active ingredient can be an inhibitor of 11- ⁇ -hydroxysteroid dehydrogenase type 1 or it can have some other activity.
  • Another object of the present invention is a method for the prophylaxis or treatment of a 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation, which comprises administering to a subject in need of such treatment an effective amount of a compound according to Formula (I), (II), (III) and (IV).
  • Another object of the present invention is a method for inhibiting a 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme, which comprises administering to a subject in need of such treatment an effective amount of a compound according to Formula (I), (II), (III) and (IV).
  • Another object of the present invention is the use of a compound according to Formula (I), (II), (III) and (IV) for the manufacture of a medicament for use in the prophylaxis or treatment of a 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation.
  • 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme-mediated disorders include: diabetes, syndrome X, obesity, glaucoma, osteoporosis, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, cognitive disorders, dementia, depression, immune disorders, virus diseases, wond healing and inflammatory diseases.
  • the medical condition involving delayed or impaired wound healing is diabetes.
  • the medical condition involving delayed or impaired wound healing is caused by treatment with glucocorticoids.
  • the compound according to Formula (I), (II), (III) and (IV) may be used for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
  • the immuno-modulation is selected from tuberculosis, lepra, and psoriasis.
  • a method for making a compound of formula (I) includes taking any intermediate compound delineated herein, reacting it with one or more reagents to form a compound of Formula (I), (II), (III) and (IV) including any processes specifically delineated herein.
  • the disorder is selected from diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, and inflammatory diseases.
  • the medical condition involving delayed or impaired wound healing is diabetes.
  • the medical condition involving delayed or impaired wound healing is caused by treatment with glucocorticoids.
  • the use is for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
  • the immuno-modulation is selected from tuberculosis, lepra, and psoriasis.
  • the compounds according to the present invention may be used in several indications which involve 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme.
  • the compounds according to the present invention may be used against dementia (see WO97/07789), osteoporosis (see Canalis, E.
  • aryl in the present description is intended to include aromatic rings (monocyclic or bicyclic) having from 6 to 10 ring carbon atoms, such as phenyl (Ph), naphthyl, and indanyl (i. e., 2,3-dihydroindenyl), which optionally may be substituted by C 1-6 -alkyl.
  • substituted aryl groups are benzyl, and 2-methylphenyl.
  • heteroaryl means in the present description a monocyclic, bi- or tricyclic aromatic ring system (only one ring need to be aromatic) having from 5 to 14, preferably 5 to 10 ring atoms such as 5, 6, 7, 8, 9 or 10 ring atoms (mono- or bicyclic), in which one or more of the ring atoms are other than carbon, such as nitrogen, sulfur, oxygen and selenium as part of the ring system.
  • heteroaryl rings examples include pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzopyrazole; benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,5-na
  • heterocyclic and “heterocyclyl” in the present description is intended to include unsaturated as well as partially and fully saturated mono-, bi- and tricyclic rings having from 4 to 14, preferably 4 to 10 ring atoms having one or more heteroatoms (e.g., oxygen, sulfur, or nitrogen) as part of the ring system and the reminder being carbon, such as, for example, the heteroaryl groups mentioned above as well as the corresponding partially saturated or fully saturated heterocyclic rings.
  • heteroatoms e.g., oxygen, sulfur, or nitrogen
  • Exemplary saturated heterocyclic rings are azetidine, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, 1,4-oxazepane, azepane, phthalimide, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, 3,4-dihydro-2H-1,4-benzoxazine, hexahydroazepine, 3,4-dihydro-2(1H)isoquinoline, 2,3-dihydro-1H-indole, 1,3-dihydro-2H-isoindole, azocane, 1-oxa-4-azaspiro[4.5]dec-4-ene, decahydroisoquinoline, and 1,4-diazepane.
  • the heterocyclyl or heterocyclic moiety may optionally be substituted with one or more oxo groups.
  • C 1-8 -alkyl in the compound of formula (I) according to the present application may be a straight or branched alkyl group containing 1-8 carbon atoms.
  • exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, n-heptyl, and n-octyl.
  • C 1-8 -alkyl For parts of the range “C 1-8 -alkyl” all subgroups thereof are contemplated such as C 1-7 -alkyl, C 1-6 -alkyl, C 1-5 -alkyl, C 1-4 -alkyl, C 2-8 -alkyl, C 2-6 -alkyl, C 2-5 -alkyl, C 4-6 -alkyl, etc.
  • C 1-8 -alkoxy in the compound of formula (I) according to the present application may be a straight or branched alkoxy group containing 1-8 carbon atoms.
  • exemplary alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, hexyloxy, isohexyloxy, n-heptyloxy, and n-octyloxy.
  • C 1-6 -alkoxy For parts of the range “C 1-6 -alkoxy” all subgroups thereof are contemplated such as C 1-7 -alkoxy, C 1-6 -alkoxy, C 1-5 -alkoxy, C 1-4 -alkoxy, C 2-8 -alkoxy, C 2-7 -alkoxy, C 2-6 -alkoxy, C 2-5 -alkoxy, C 3-7 -alkoxy, C 4-6 -alkoxy, etc.
  • C 1-8 -acyl in the compound of formula (I) according to the present application may be a straight or branched acyl group containing 1-8 carbon atoms.
  • exemplary acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, n-hexanoyl, n-heptanoyl, and n-octanoyl.
  • C 1-8 -acyl For parts of the range “C 1-8 -acyl” all subgroups thereof are contemplated such as C 1-7 -acyl, C 1-6 -acyl, C 1-5 -acyl, C 1-4 -acyl, C 2-8 -acyl, C 2-7 -acyl, C 2-6 -acyl, C 2-5 -acyl, C 3-7 -acyl, C 4-6 -acyl, etc.
  • C 2-8 -alkenyl in the compound of formula (I) according to the present application may be a straight or branched acyl group containing 2-8 carbon atoms.
  • exemplary alkenyl groups include vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 1-hexenyl, 2-hexenyl, 1-heptenyl, and 1-octenyl.
  • C 2-8 -alkenyl all subgroups thereof are contemplated such as C 2-7 -alkenyl, C 2-6 -alkenyl, C 2-5 -alkenyl, C 2-4 -alkenyl, C 3-8 -alkenyl, C 3-7 -alkenyl, C 3-6 -alkenyl, C 3-5 -alkenyl, C 4-7 -alkenyl, C 5-6 -alkenyl, etc.
  • C 3-10 -cycloalkyl in the compound of formula (I) according to the present application may be an optionally substituted monocyclic, bicyclic or tricyclic alkyl group containing between 3-10 carbon atoms.
  • exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, bicyclo[2.2.1]hept-2-yl, tricyclo[3.3.1.0 ⁇ 3,7 ⁇ ]non-3-yl, (1R,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl, (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl, 1-adamantyl, noradamantyl, and 2,2,3,3-tetramethylcycl
  • C 3-10 -cycloalkyl For parts of the range “C 3-10 -cycloalkyl” all subgroups thereof are contemplated such as C 3-9 -cycloalkyl, C 3-8 -cycloalkyl, C 3-7 -cycloalkyl, C 3-6 -cycloalkyl, C 3-5 -cycloalkyl, C 4-10 -cycloalkyl, C 5-10 -cycloalkyl, C 6-10 -cycloalkyl, C 7-10 -cycloalkyl, C 8-9 -cycloalkyl, etc.
  • the cycloalkyl moiety may optionally be substituted with one or more oxo groups.
  • C 3-10 -cycloalkenyl in the compound of formula (I) according to the present application may be an optionally alkyl substituted cyclic, bicyclic or tricyclic alkenyl group containing totally 3-10 carbon atoms.
  • exemplary cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl, and bicyclo[2.2.1]hept-5-en-2-yl.
  • C 3-10 -cycloalkenyl For parts of the range “C 3-10 -cycloalkenyl” all subgroups thereof are contemplated such as C 3-9 -cycloalkenyl, C 3-8 -cycloalkenyl, C 3-7 -cycloalkenyl, C 3-6 -cycloalkenyl, C 3-5 -cycloalkenyl, C 4-10 -cycloalkenyl, C 5-10 -cycloalkenyl, C 6-10 -cycloalkenyl, C 7-10 -cycloalkenyl, C 8-9 -cycloalkenyl, etc.
  • the cycloalkenyl moiety may optionally be substituted with one or more oxo groups.
  • halogen or “halo” in the present description is intended to include fluorine, chlorine, bromine and iodine.
  • sulfanyl in the present description means a thio group.
  • hetero(C 1 -C 8 )alkyl refers to a moiety wherein a hetero atom, selected from optionally substituted nitrogen, sulfur and oxygen, is the point of attachment to the core molecule and is attached to a C 1 -C 8 alkyl chain.
  • cyclic amide spiro ring refers to compounds where the substituents at the 5-position of the thiazolinone or the oxazolone ring combine together to form a cyclic ring having a —NR 10 C(O)— therein.
  • An example of such a moiety is shown in the example below:
  • the functionalities in question may be substituted with independently C 1-8 -acyl, C 2-8 -alkenyl, C 1-8 -(cyclo)alkyl, aryl, pyridylmethyl, or heterocyclic rings e.g. azetidine, pyrrolidine, piperidine, piperazine, morpholine and thiomorpholine, which heterocyclic rings optionally may be substituted with C 1-8 -alkyl.
  • the expression “optionally mono- or disubstituted” is meant in the present description that the functionalities in question may also be substituted with independently hydrogen.
  • C 3-10 -cycloalkyl-C 1-8 -alkyl means a C 1-8 -alkyl group that is substituted by a C 3-10 -cycloalkyl group.
  • a C 1-8 -haloalkyl means a C 1-8 -alkyl group that is substituted by a halogen atom.
  • Metabolites of the compounds of Formula (I), (II), (III) and (IV) can take on many forms and the present invention encompasses the metabolites of the compounds as well as the parent compound.
  • prodrug means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide an active compound, particularly a benzamide derivative.
  • prodrugs include, but are not limited to, derivatives and metabolites of a benzamide derivative that include biohydrolyzable groups such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues (e.g., monophosphate, diphosphate or triphosphate).
  • prodrugs of compounds with carboxyl functional groups are the lower alkyl esters of the carboxylic acid.
  • the carboxylate esters are conveniently formed by esterifying any of the carboxylic acid moieties present on the molecule.
  • Prodrugs can typically be prepared using well-known methods, such as those described by Burger's Medicinal Chemistry and Drug Discovery 6 th ed. (Donald J. Abraham ed., 2001, Wiley) and Design and Application of Prodrugs (H. Bundgaard ed., 1985, Harwood Academic Publishers Gmfh).
  • Tautomer is one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another, in the present case, tautomers of the structures below are encompassed by the present invention.
  • hydrate is a form of a compound of Formula (I), (II), (III), or (IV) where water molecules are combined in a definite ratio as an integral part of the crystal structure of the compound.
  • solvate is a form of of a compound of Formula (I), (II), (III), or (IV) where solvent molecules are combined in a definite ratio as an integral part of the crystal structure of the compound.
  • the phrase “pharmaceutically acceptable salt,” as used herein, refers to a pharmaceutically acceptable organic or inorganic acid or base salt of a benzamide derivative.
  • Representative pharmaceutically acceptable salts include, e.g., alkali metal salts, alkali earth salts, ammonium salts, water-soluble and water-insoluble salts, such as the acetate, amsonate(4,4-diaminostilbene-2, 2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, he
  • geometrical isomers refers compounds that have the same molecular formula but the atoms are in different non-equivalent positions to one another.
  • optical isomers refers to compounds with chiral atoms which have the ability to rotate plane polarized light, R/S configuration.
  • optical isomer include enantiomers and diastereomers as well as compounds which can be distinguished one from the other by the designations of (D) and (L).
  • DCM dichloromethane
  • DEAD means diethyl azocarboxylate
  • DMF means dimethylformamide
  • EDCI means 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • Ether means diethyl ether
  • HOBt means 1-hydroxybenzotriazole
  • HPLC means high-performance liquid chromatography
  • MeCN means acetonitrile
  • DPPA means diphenylphosphoryl azide
  • TEA means triethylamine
  • THF means tetrahydrofuran
  • stable refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic administration to a subject for the treatment of disease, 11- ⁇ -HSD1 inhibition, 11- ⁇ -HSD1-mediated disease).
  • prodrug forms in the present description means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug (see Goodman and Gilman's, The Pharmacological basis of Therapeutics, 8 th ed., McGraw-Hill, Int. Ed. 1992, “Biotransformation of Drugs, p. 13-15).
  • “Pharmaceutically acceptable” means in the present description being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
  • “Pharmaceutically acceptable salts” mean in the present description salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with organic and inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid and the like.
  • organic and inorganic acids such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid
  • Base addition salts may be formed with organic and inorganic bases, such as sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, choline and the like. Included in the invention are pharmaceutically acceptable salts or compounds of any of the formulae herein.
  • compositions according to the present invention contain a pharmaceutically acceptable carrier together with at least one of the compounds comprising the formula (I) as described herein above, dissolved or dispersed therein as an active, antimicrobial, ingredient.
  • the therapeutic composition is not immunogenic when administered to a human patient for therapeutic purposes, unless that purpose is to induce an immune response.
  • compositions that contains active ingredients dissolved or dispersed therein are well understood in the art.
  • compositions are prepared as sterile injectables either as liquid solutions or suspensions, aqueous or non-aqueous, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared.
  • the preparation can also be emulsified.
  • the active ingredient may be mixed with excipients, which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein.
  • Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof.
  • the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.
  • Adjuvants may also be present in the composition.
  • aqueous carriers are well known in the art.
  • exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline.
  • aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, propylene glycol, polyethylene glycol and other solutes.
  • Liquid compositions can also contain liquid phases in addition to and to the exclusion of water.
  • additional liquid phases are glycerine, vegetable oils such as cottonseed oil, organic esters such as ethyl oleate, and water-oil emulsions.
  • compositions comprising compounds comprising the formula (I), may include pharmaceutically acceptable salts of that component therein as set out above.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic acid, tartaric acid, mandelic acid and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylaminoethanol, histidine, procaine and the like.
  • the preparations according to the preferred embodiments may be administered orally, topically, intraperitoneally, intraarticularly, intracranially, intradermally, intramuscularly, intraocularly, intrathecally, intravenously, subcutaneously.
  • Other routes are known to those of ordinary skill in the art.
  • compositions according to the present invention may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical or sterile parenteral solutions or suspensions.
  • Tablets and capsules for oral administration may be in unit dose presentation form and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, traganath or polyvinyl-pyrrolidone; fillers e.g. lactose, sugar, maize-starch, calcium phosphate, calcium hydrogen phosphate, sodium starch glycolate, sorbitol or glycine; tabletting lubricant e.g.
  • Oral liquid preparations may be in the form of e.g. aqueous or oily suspensions, solutions, emulsions, syrups or elixirs or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, e.g. sorbitol, syrup, methyl cellulose (optionally microcrystalline), glucose syrup, gelatin hydrogenated edible fats; emulsifying agents e.g.
  • non-aqueous vehicles which may include edible oils, e.g. almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives e.g. methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • edible oils e.g. almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol
  • preservatives e.g. methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • a pharmaceutical composition according to the present invention may comprise typically an amount of at least 0.1 weight percent of compound comprising the formula (I) per weight of total therapeutic composition.
  • a weight percent is a ratio by weight of total composition.
  • 0.1 weight percent is 0.1 grams of compound comprising the formula (I) per 100 grams of total composition.
  • a suitable daily oral dose for a mammal, preferably a human being may vary widely depending on the condition of the patient. However a dose of compound comprising the formula (I) of about 0.1 to 300 mg/kg body weight may be appropriate.
  • compositions according to the present invention may also be used veterinarily and thus they may comprise a veterinarily acceptable excipient or carrier.
  • the compounds and compositions may be thus administered to animals, e.g., cats, dogs, or horses, in treatment methods.
  • the compounds of the present invention in labelled form may be used as a diagnostic agent.
  • This invention relates to methods of making compounds of any of the formulae herein comprising reacting any one or more of the compounds of the formulae delineated herein, including any processes delineated herein.
  • the compounds of formula (I) above may be prepared by, or in analogy with, conventional methods, and especially according to or in analogy with the following methods. Further, the pharmacology in-vitro was studied using the following reagents and methods.
  • the chemicals used in the synthetic routes delineated herein may include, for example, solvents, reagents, catalysts, and protecting group and deprotecting group reagents.
  • the methods described above may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compounds.
  • various synthetic steps may be performed in an alternate sequence or order to give the desired compounds.
  • Synthetic chemistry transformations and protecting group methodologies protecting group methodologies (protection and deprotection) useful in synthesizing applicable compounds are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M.
  • [1,2(n)- 3 H]-cortisone was purchased from Amersham Pharmacia Biotech.
  • Anti-cortisol monoclonal mouse antibody, clone 6D6.7 was obtained from Immunotech and Scintillation proximity assay (SPA) beads coated with monoclonal antimouse antibodies were from Amersham Pharmacia Biotech.
  • NADPH, tetrasodium salt was from Calbiochem and glucose-6-phosphate (G-6-P) was supplied by Sigma.
  • the human 11- ⁇ -hydroxysteroid dehydrogenase type-1 enzyme (11- ⁇ -HSD 1 ) was expressed in Pichia pastoris.
  • 18- ⁇ -glycyrrhetinic acid (GA) was obtained from Sigma.
  • the 11- ⁇ -HSD 1 enzyme assay was carried out in 96 well microtiter plates (Packard, Optiplate) in a total well volume of 220 ⁇ L and contained 30 mM Tris-HCl, pH 7.2 with 1 mM EDTA, a substrate mixture tritiated Cortisone/NADPH (175 nM/181 ⁇ M), G-6-P (1 mM) and inhibitors in serial dilutions (9 to 0.15 ⁇ M). Reactions were initiated by the addition of human 11- ⁇ -HSD 1 , either as Pichia pastoris cell homogenate or microsomes prepared from Pichia pastoris (the final amount of enzyme used was varied between 0.057 to 0.11 mg/mL).
  • the plates were covered with plastic film and incubated on a shaker for 30 minutes, at room temperature, before counting.
  • the amount of [ 3 H]-cortisol, bound to the beads was determined in a microplate liquid scintillation counter.
  • the calculation of the K i values for the inhibitors was performed by use of Activity Base.
  • the IC 50 is measured experimentally in an assay wherein the decrease of the turnover of cortisone to cortisol is dependent on the inhibition potential of each substance.
  • the Ki values of the compounds of the present invention for the 11- ⁇ -HSD1 enzyme lie typically between about 10 nM and about 10 ⁇ M. Below follow some Ki examples according to the present invention.
  • the expression and purification of the murine enzyme is described by J. Zhang, et al. Biochemistry, 44, 2005, pp 6948-57.
  • the expression and purification of the human enzyme is similar to that of the murine sequence.
  • the IC50 and Ki of the compounds are determined by the following method:
  • NADPH (Sigma, 200 ⁇ M)
  • Compound Stock Solution (10 mM in DMSO), serially diluted in assay buffer. Each compound is tested at six different concentrations usually (10 ⁇ M to 0.1 nM). All of the solutions and dilutions are made in the Assay Buffer.
  • Assay is run using white/white, 96-well assay plates (Corning) in a total volume of 100 ⁇ L.
  • the plate is covered with tape and incubated on an orbital shaker for 1 h at RT.
  • the plate is incubated (30 min) on an orbital shaker at RT.
  • the counts are read on a TopCount NXT reader.
  • a dose-reponse curve is first plotted using the Graphpad Prism software, to generate the IC50 values.
  • the compounds of the present invention all show 11 ⁇ -HSD1 enzyme activity (IC 50 ) in the assays ranging from 10 nM and 10 ⁇ M.
  • Analytical HPLC were performed on Agilent 1100 system equipped with System A: ACE 3 (C8, 50 ⁇ 3.0 mm) or System B: YMC ODS-AQ, (33 ⁇ 3.0 mm) using the eluent system: water/0.1% TFA and CH 3 CN, 1 mL/min, with a gradient time of 3 min.
  • System A ACE 3 (C8, 50 ⁇ 3.0 mm) or System B: YMC ODS-AQ, (33 ⁇ 3.0 mm) using the eluent system: water/0.1% TFA and CH 3 CN, 1 mL/min, with a gradient time of 3 min.
  • Preparative HPLC was performed on a Gilson system equipped with System A: ACE 5 C8 column (50 ⁇ 20 mm) gradient time 5 min, system B: YMC ODS-AQ (150 ⁇ 30 mm) gradient time 8.5 min or system C: YMC ODS-AQ (50 ⁇ 20 mm) gradient time 5 min using the eluent system: water/0.1% TFA and CH 3 CN.
  • Preparative flash chromatography was performed on Merck silica gel 60 (230-400 mesh).
  • Method A or B was used depending if the isothiocyanate or of the corresponding amine was used.
  • the amine or the isothiocyanate was purchased from either Maybridge Plc. or from Sigma-Aldrich Co.
  • the thiourea (1.0 eq.) and the ⁇ -bromoester/ ⁇ -bromoacid (1.0 eq.) was dissolved in acetone and heated to 60° C. in a sealed tube for 15-72 hours. The solvent was removed. And the product purified by crystallization from MeOH/preparative reverse-phase HPLC.
  • the thiourea (1.0 eq.) and the ⁇ -bromoester/ ⁇ -bromoacid (1.0 eq.) was mixed in water and heated in the microwave at 140° C. for 1 hour.
  • the aqueous phase was extracted twice with DCM.
  • the combined orgaic phases were evaporated and the obtained crude product was purified by preparative reverse-phase HPLC.
  • the thiourea (1.0 eq.) and the ⁇ -bromoester (1.0 eq.) was dissolved in 1,4-dioxane and heated to 100° C. in a sealed tube for 1-11 days. The solvent was removed, and the residue was purified by preparative reverse-phase HPLC.
  • the thiourea (1.0 eq.) and the ⁇ -bromoester (1.0 eq.) was dissolved in THF and heated to 70° C. in a sealed tube for 1 day. The solvent was removed, and the residue was purified by preparative reverse-phase HPLC.
  • the thiourea (1.0 eq.) and the ⁇ -bromoester (1.0 eq.) was dissolved in 2-propanol and heated to 95° C. in a sealed tube for 3 days. The solvent was removed, and the residue was purified by preparative reverse-phase HPLC.
  • the thiourea (1.0 eq.) and the ⁇ -bromoester/ ⁇ -bromoacid (1.0 eq.) was dissolved in MeCN and heated to 60° C. in a sealed tube for 2 days. The solvent was removed, and the residue was purified by preparative reverse-phase HPLC.
  • the amino acid (1 eq.) was suspended in 2.0 M H 2 SO 4 , KBr (8 eq.) was added and the mixture was cooled in an ice-bath. NaNO 2 (1.3 eq.) dissolved in water was slowly added. The reaction mixture was stirred for 4 h while cooling was continued. The reaction mixture was then extracted with EtOAc, washed with brine and brine containing Na 2 S 2 O 3 . The organic phase was concentrated in vacuum. The product was used in the next step without further purification.
  • the thiourea (1 eq.) and 3-bromo-2-coumarone (1 eq.) was dissolved in acetone and heated to 60° C. for 3 hours. Water was added. The obtained solid was collected. Recrystallised from water/MeCN. The solid was collected. The mother liquor was concentrated and the obtained solid was dried in vaccum to give the product.
  • Examples 60-63 were prepared using one of the methodologies described above.
  • the thioisocyante intermediates can be prepared by the method K. Formation of the acid chloride, such as by treatment with oxalyl chloride and DMF, or thionyl chloride, followed by treatment with KNCS provides the thioisocyantes. Alternatively, treatment of the carboxylic acid with thionyl chloride, then bromination, such as with Br 2 and PBr 3 , followed by treatment with KNCS also provides the thioisocyantes.
  • bromination of the carboxylic acid such as with Br 2 , PCl 3 (cat.), followed by formation of the acid chloride, such as by treatment with oxalyl chloride or thionyl chloride, and treatment with alcohols, TMSCHN 2 or CH 2 N 2 , yields the desired compounds.
  • the acid chloride can be formed first, followed by bromination step.
  • Starting from esters treatment with strong base, e.g. LDA, and a leaving group supplier such as TMSCl, followed by bromination provides the desired esters.
  • TMSCl a leaving group supplier
  • bromination such as by reaction with HBr in the presence of NaNO 2 , yields the desired bromo acids.
  • Method N Conversion of various ketones to the esters is accomplished by Method N.
  • an appropriate dithiane such as 2-trimethylsilyl-1,3-dithiane
  • base e.g. n-BuLi
  • chlorination such as with N-chlorosuccinimide
  • Method O Formation of the desired thioureas is detailed in Method O.
  • the thiourea is formed through treatment with 1,1-thiocarbonyldiimidazole in the presence of base, e.g. NEt 3 , followed by treatment with ammonia.
  • the thiourea is formed as described in Method P. Treatment of a substituted thioisocyanate with ammonia yields the desired thioureas.
  • Bicyclo[2.2.1]heptanyl thioureas are provided via Method S. Bromination of carboxylic acids, such as with Br 2 , PCl 3 , and the resulting rearrangement provides the 2-bromo-1-carboxylic acids. Dehalogenation, such as with Zn in AcOH, yields the 1-carboxylic acids. The Curtius rearrangement such as by treatment with DPPA and a base, e.g. NEt 3 , and an alcohol provides the protected amine. Deprotection, such as with acid, followed by formation of the thiourea and deprotection, as described above, provides the desired thioureas.
  • Base mediated substitution of a nitrophenol with a alkyl halide provides the nitrophenyl ether.
  • Cs 2 CO 3 can be used in the presence of NaI.
  • Method U describes the formation of cyclopropanamines from benzonitriles is accomplished by treatment with EtMgBr in the presence of Ti(Oi-Pr) 4 , followed by treatment with BF 3 .OEt 2 .
  • Formation of (bicyclo[2.2.1]heptanylmethyl)-thioureas from the carboxylic acids is described in Method W.
  • Formation of the acid chloride such as by treatment with oxalyl chloride and DMF (cat.), followed by treatment with ammonia or ammonium hydroxide, provides the amide.
  • Reduction of the amide such as with treatment with LiAlH 4 , to the amine, followed by chemistry previously described, yields the desired thioureas.
  • Thiazolones can be prepared by many methods, including that described in Method X. Treatment of a bromo-substituted carboxylic acid or ester with thiourea in the presence of base, such as DIEA provides the condensation/ring closure to the desired 2-amino-thiazolones.
  • Thiazolones also can be prepared from amines by the method described in Method Z. Coupling of an amine with an isothiocyante, e.g. in the presence of base, such as NEt 3 , provides the condensation/ring closure to the desired 2-amino-thiazolones.
  • 5,5-Disubstituted thiazolones can be prepared from thiazolones via the method described in Method AA. Treatment first with strong base, e.g. LDA or NaHMDS, then with a compound comprising an appropriate leaving group, such as R B -LG, provides the desired compounds.
  • strong base e.g. LDA or NaHMDS
  • R B -LG a compound comprising an appropriate leaving group
  • 5-fluoro-thiazolones can be prepared as described in Method BB. Treatment first with strong base, e.g. LDA or NaHMDS, and TMSCl, followed by fluorination, e.g. with Selectfluor, provides the desired compounds.
  • strong base e.g. LDA or NaHMDS
  • TMSCl e.g. TMSCl
  • fluorination e.g. with Selectfluor
  • 5-trifluoromethyl-thiazolones can be prepared as described in Method CC. Treatment first with strong base, e.g. LDA or NaHMDS, and TMSCl, followed by trifluoromethylation, e.g. with S-(trifluoromethyl)dibenzothiophenium salt, provides the desired compounds.
  • strong base e.g. LDA or NaHMDS
  • TMSCl trifluoromethylation
  • Formation of 5-spiro-thiazolones can be prepared as described in Method EE. Coupling of the thiazolone in the presence of strong base, e.g. LDA or NaHMDS, provides the desired compounds. Alternatively, the cyclization can be achieved in two steps, alkylation first with base, e.g. HMDS, in the presence of TMSCl; followed by further treatment with base, e.g. LDA, in the presence of a bis-electrophile.
  • strong base e.g. LDA or NaHMDS
  • Formation of 5-hydroxymethyl-thiazolones can be prepared as described in Method FF.
  • the compounds of the invention can be prepared by the method described in this scheme. Alkylation of the racemic thiazalone with a chiral base, such as
  • R m and R n are independently selected from alkyl, aryl, and heterocyclyl, where R o and R p are independently selected from aryl, where J is alkyl, O, NH or S, and where M 1 and M 2 are independently selected from Li, Na, K, Cs, Cu, Zn, and Mg, e.g. a chiral lithium base, more specifically
  • an appropriate alkylating agent such as a alkyl halide (e.g. an alkyl iodide) or sulfonate (e.g., mesylate, triflate), [LG is halide, tosylate, mesylate, triflate, or the like] provides the desired chiral di-substituted thiazolone.
  • the alkylation is performed in the presence of amine base, such as TMEDA.
  • Treatment with the R,R form of the base provides the stereochemistry shown when R 3 is methyl.
  • Treatment with the S,S form provides the opposite stereochemistry to that shown when R 3 is methyl.
  • the reaction is maintained at a temperature below about RT, preferably below about 0° C., more preferably at or below about ⁇ 15° C.
  • An aprotic solvent e.g. toluene is acceptable.
  • thiazolone amines and ethers can be prepared as described in Method II. Bromination of thiazolones e.g. with NBS or other techniques known to one skilled in the art, followed by treatment with an amine or alcohol, provides the desired compounds.
  • thiazolone amines can be prepared from the alcohols as described in Method JJ. Following the procedure for the Dess-Martin Periodinane or Swern reactions, followed reductive amidation, such as with reacting with an amine together with NaBH(OAc) 3 or NaBH 3 CN, provides the desired compounds.
  • 5-spiro-thiazolones can be prepared from the furanone as described in Method KK.
  • Treatment of the furanone with a thiourea provides thiazolone alcohol. Protection of the alcohol, such as with dihydropyran in the presence of acid, followed by treatment with strong base, e.g. LDA, and 3-bromo-2-methylprop-1-ene, and deprotection, e.g. with PTSA, and cyclization, such as with acid, provides the desired compounds.
  • 5-spiro-thiazolones can be prepared from the thiazolone as described in Method LL.
  • Treatment of the thiazolone with strong base, e.g. LDA or NaHMDS and alkylation, such as with (2-bromoethoxy)(tert-butyl)dimethylsilane provides the protected thiazolone alcohol.
  • a subsequent round of base and silane provides the disubstituted thiazolone.
  • Deprotection e.g. with acid, followed with addition of a compound containing an appropriate leaving group, e.g. MsCl, in the presence of base, e.g. DIEA, and cyclization, such as with a substituted amine, provides the desired spiro piperidine compounds.
  • 1-Substituted piperidinemethylthiazolones can be prepared by method MM.
  • deprotection such as by treatment with acid, treatment with sulfonyl chlorides (R 12 SO 2 Cl) in the presence of base, e.g. NEt 3 , provides compounds where R Q ⁇ SO 2 R S .
  • treatment with carboxylic acid (R R CO 2 H) with standard coupling chemistry, e.g. EDCI, and HOBt provides compounds where R Q ⁇ COR R .
  • treatment with active carbonyl compounds e.g. acid anhydrides (R R CO—O—COR R ) in the presence of base, e.g. DIEA, provides compounds where R Q ⁇ COR R .
  • Formation of 5-spiro-thiazolones can be prepared from the thiazolone as described in Method NN.
  • Treatment of the thiazolone with strong base, e.g. LDA and alkylation, such as with BrCH 2 CH 2 Br provides the thiazolone bromoethyl compound.
  • Further treatment with strong base, e.g. LDA, and dimethylketone provides the desired spiro tetrahydrofuryl compounds.
  • Substituted amidomethylthiazolones can be prepared by method OO.
  • Treatment of the acid with an amine, such as in the presence of a coupling reagent, e.g. HATU and base such as DIEA provides the desired amides.
  • Substituted thiazolone esters can be prepared from the alcohol by method PP.
  • active carbonyl compounds e.g. an acid chloride
  • base e.g. DIEA
  • NPLC normal phase liquid chromatography
  • SFC supercritical fluid chromatography

Abstract

The present invention relates to compounds with the formula (I), (II), (III) or (IV):
Figure US20110082107A1-20110407-C00001
    • wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.

Description

    CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
  • This application claims priority to Swedish Patent Application No. 0401324-9, filed May 24, 2004, Swedish Patent Application No. 0402509-4, filed Oct. 15, 2004, and U.S. Provisional Patent Application No. 60/650,777, filed Jan. 31, 2005.
    • FIELD OF THE INVENTION
  • The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme (11βHSD1).
    • BACKGROUND OF THE INVENTION
  • Hydroxysteroid dehydrogenases (HSDs) regulate the occupancy and activation of steroid hormone receptors by converting steroid hormones into their inactive metabolites. For a recent review, see Nobel et al., Eur. J. Biochem. 2001, 268:4113-4125.
  • There exist numerous classes of HSDs. The 11-beta-hydroxysteroid dehydrogenases (11β-HSDs) catalyze the interconversion of active glucocorticoids (such as cortisol and corticosterone), and their inert forms (such as cortisone and 11-dehydrocorticosterone). The isoform 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is expressed in liver, adipose tissue, brain, lung and other glucocorticoid tissue and is a potential target for therapy directed at numerous disorders that may be ameliorated by reduction of glucocorticoid action, such as diabetes, obesity and age-related cognitive dysfunction. Seckl, et al., Endocrinology, 2001, 142:1371-1376.
  • The various isozymes of the 17-beta-hydroxysteroid dehydrogenases (17β-HSDs) bind to androgen receptors or estrogen receptors and catalyze the interconversion of various sex hormones including estradiol/estrone and testosterone/androstenedione. To date, six isozymes have been identified in humans and are expressed in various human tissues including endometrial tissue, breast tissue, colon tissue, and in the testes. 17-beta-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) is expressed in human endometrium and its activity has been reported to be linked to cervical cancer. Kitawaki et al., J. Clin. Endocrin. Metab., 2000, 85:1371-3292-3296. 17-beta-Hydroxysteroid dehydrogenase type 3 (17β-HSD3) is expressed in the testes and its modulation may be useful for the treatment of androgen-related disorders.
  • Androgens and estrogens are active in their 17β-hydroxy configurations, whereas their 17-keto derivatives do not bind to androgen and estrogen receptors and are thus inactive. The conversion between the active and inactive forms (estradiol/estrone and testosterone/androstenedione) of sex hormones is catalyzed by members of the 17β-HSD family. 17β-HSD1 catalyzes the formation of estradiol in breast tissue, which is important for the growth of malignant breast tumors. Labrie et al., Mol. Cell. Endocrinol. 1991, 78:C113-C118. A similar role has been suggested for 17β-HSD4 in colon cancer. English et al., J. Clin. Endocrinol. Metab. 1999, 84:2080-2085. 17β-HSD3 is almost exclusively expressed in the testes and converts androstenedione into testosterone. Deficiency of this enzyme during fetal development leads to male pseudohermaphroditism. Geissler et al., Nat. Genet. 1994, 7:34-39. Both 17β-HSD3 and various 3α-HSD isozymes are involved in complex metabolic pathways which lead to androgen shuffles between inactive and active forms. Penning et al., Biochem. J. 2000, 351:67-77. Thus, modulation of certain HSDs can have potentially beneficial effects in the treatment of androgen- and estrogen-related disorders.
  • The 20-alpha-hydroxysteroid dehydrogenases (20α-HSDs) catalyze the interconversion of progestins (such as between progesterone and 20α-hydroxy progesterone). Other substrates for 20α-HSDs include 17α-hydroxypregnenolone or 17α-hydroxyprogesterone, leading to 20α-OH steroids. Several 20α-HSD isoforms have been identified and 20α-HSDs are expressed in various tissues, including the placenta, ovaries, testes and adrenals. Peltoketo, et al., J. Mol. Endocrinol. 1999, 23:1-11.
  • The 3-alpha-hydroxysteroid dehydrogenases (3α-HSDs) catalyze the interconversion of the androgens dihydrotestosterone (DHT) and 5α-androstane-3α,17β-diol and the interconversion of the androgens DHEA and androstenedione and therefore play an important role in androgen metabolism. Ge et al., Biology of Reproduction 1999, 60:855-860.
    • 1. Glucorticoids, Diabetes and Hepatic Glucose Production
  • It has been known for more than half a century that glucocorticoids have a central role in diabetes. For example, the removal of the pituitary gland or the adrenal gland from a diabetic animal alleviates the most severe symptoms of diabetes and lowers the concentration of glucose in the blood (Long, C. D. and Leukins, F. D. W. (1936) J. Exp. Med. 63: 465-490; Houssay, B. A. (1942) Endocrinology 30: 884-892). It is also well established that glucocorticoids enable the effect of glucagon on the liver.
  • The role of 11βHSD1 as an important regulator of local glucocorticoid effect and thus of hepatic glucose production is well substantiated (see, e.g., Jamieson et al. (2000) J. Endocrinol. 165: 685-692). Hepatic insulin sensitivity was improved in healthy human volunteers treated with the non-specific 11βHSD1 inhibitor carbenoxolone (Walker, B. R. et al. (1995) J. Clin. Endocrinol. Metab. 80: 3155-3159). Furthermore, the expected mechanism has been established by different experiments with mice and rats. These studies showed that the mRNA levels and activities of two key enzymes in hepatic glucose production were reduced, namely: the rate-limiting enzyme in gluconeogenesis, phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase (G6Pase) the enzyme catalyzing the last common step of gluconeogenesis and glycogenolysis. Finally, blood glucose levels and hepatic glucose production are reduced in mice in which the 11βHSD1 gene is knocked-out. Data from this model also confirm that inhibition of 11βHSD1 will not cause hypoglycemia, as predicted since the basal levels of PEPCK and G6Pase are regulated independently of glucocorticoids (Kotelevtsev, Y. et al., (1997) Proc. Natl. Acad. Sci. USA 94: 14924-14929).
  • FR 2,384,498 discloses compounds having a high hypoglycemic effect. Therefore, treatment of hyperglycemia with these compounds may lead to hypoglycemia.
    • 2. Possible Reduction of Obesity and Obesity Related Cardiovascular Risk Factors
  • Obesity is an important factor in syndrome X as well as in the majority (>80%) of type 2 diabetes, and omental fat appears to be of central importance. Abdominal obesity is closely associated with glucose intolerance, hyperinsulinemia, hypertriglyceridemia, and other factors of the so-called syndrome X (e.g. increased blood pressure, decreased levels of HDL and increased levels of VLDL) (Montague & O′Rahilly, Diabetes 49: 883-888, 2000) Inhibition of the 11βHSD1 enzyme in pre-adipocytes (stromal cells) has been shown to decrease the rate of differentiation into adipocytes. This is predicted to result in diminished expansion (possibly reduction) of the omental fat depot, i.e., reduced central obesity (Bujalska, I. J., S. Kumar, and P. M. Stewart (1997) Lancet 349: 1210-1213).
  • Inhibition of 11βHSD1 in mature adipocytes is expected to attenuate secretion of the plasminogen activator inhibitor 1 (PAI-1)—an independent cardiovascular risk factor (Halleux, C. M. et al. (1999) J. Clin. Endocrinol. Metab. 84: 4097-4105). Furthermore, there is a clear correlation between glucocorticoid “activity” and cardiovascular risk factor suggesting that a reduction of the glucocorticoid effects would be beneficial (Walker, B. R. et al. (1998) Hypertension 31: 891-895; Fraser, R. et al. (1999) Hypertension 33: 1364-1368).
  • Adrenalectomy attenuates the effect of fasting to increase both food intake and hypothalamic neuropeptide Y expression. This supports the role of glucocorticoids in promoting food intake and suggests that inhibition of 11βHSD1 in the brain might increase satiety and therefore reduce food intake (Woods, S. C. et al. (1998) Science, 280: 1378-1383).
    • 3. Possible Beneficial Effect on the Pancreas
  • Inhibition of 11βHSD1 in isolated murine pancreatic β-cells improves glucose-stimulated insulin secretion (Davani, B. et al. (2000) J. Biol. Chem. 2000 Nov. 10; 275(45): 34841-4). Glucocorticoids were previously known to reduce pancreatic insulin release in vivo (Billaudel, B. and B. C. J. Sutter (1979) Horm. Metab. Res. 11: 555-560). Thus, inhibition of 11βHSD1 is predicted to yield other beneficial effects for diabetes treatment, besides the effects on liver and fat.
  • 4. Possible Beneficial effects on Cognition and Dementia
  • Stress and glucocorticoids influence cognitive function (de Quervain, D. J.-F., B. Roozendaal, and J. L. McGaugh (1998) Nature 394: 787-790). The enzyme 11βHSD1 controls the level of glucocorticoid action in the brain and thus contributes to neurotoxicity (Rajan, V., C. R. W. Edwards, and J. R. Seckl, J. (1996) Neuroscience 16: 65-70; Seckl, J. R., Front. (2000) Neuroendocrinol. 18: 49-99). Unpublished results indicate significant memory improvement in rats treated with a non-specific 11βHSD1 inhibitor (J. Seckl, personal communication). Based the above and on the known effects of glucocorticoids in the brain, it may also be suggested that inhibiting 11βHSD1 in the brain may result in reduced anxiety (Tronche, F. et al. (1999) Nature Genetics 23: 99-103). Thus, taken together, the hypothesis is that inhibition of 11βHSD1 in the human brain would prevent reactivation of cortisone into cortisol and protect against deleterious glucocorticoid-mediated effects on neuronal survival and other aspects of neuronal function, including cognitive impairment, depression, and increased appetite.
    • 5. Possible Use of Immuno-Modulation Using 11βHSD1 Inhibitors
  • The general perception is that glucocorticoids suppress the immune system. But in fact there is a dynamic interaction between the immune system and the HPA (hypothalamo-pituitary-adrenal) axis (Rook, G. A. W. (1999) Bailliér's Clin. Endocrinol. Metab. 13: 576-581). The balance between the cell-mediated response and humoral responses is modulated by glucocorticoids. A high glucocorticoid activity, such as at a state of stress, is associated with a humoral response. Thus, inhibition of the enzyme 11βHSD1 has been suggested as a means of shifting the response towards a cell-based reaction.
  • In certain disease states, including tuberculosis, lepra and psoriasis the immune reaction is normaly biased towards a humoral response when in fact the appropriate response would be cell based. Temporal inhibition of 11βHSD1, local or systemic, might be used to push the immune system into the appropriate response (Mason, D. (1991) Immunology Today 12: 57-60; Rook et al., supra).
  • An analogous use of 11βHSD1 inhibition, in this case temporal, would be to booster the immune response in association with immunization to ensure that a cell based response would be obtained, when desired.
    • 6. Reduction of Intraocular Pressure
  • Recent data suggest that the levels of the glucocorticoid target receptors and the 11βHSD enzymes determines the susceptibility to glaucoma (Stokes, J. et al. (2000) Invest. Ophthalmol. 41: 1629-1638). Further, inhibition of 11βHSD1 was recently presented as a novel approach to lower the intraocular pressure (Walker E. A. et al, poster P3-698 at the Endocrine society meeting Jun. 12-15, 1999, San Diego). Ingestion of carbenoxolone, a non-specific inhibitor of 11βHSD1, was shown to reduce the intraocular pressure by 20% in normal subjects. In the eye, expression of 11βHSD1 is confined to basal cells of the corneal epithelium and the non-pigmented epithelialium of the cornea (the site of aqueous production), to ciliary muscle and to the sphincter and dilator muscles of the iris. In contrast, the distant isoenzyme 11βHSD2 is highly expressed in the non-pigmented ciliary epithelium and corneal endothelium. None of the enzymes is found at the trabecular meshwork, the site of drainage. Thus, 11βHSD1 is suggested to have a role in aqueous production, rather than drainage, but it is presently unknown if this is by interfering with activation of the glucocorticoid or the mineralocorticoid receptor, or both.
    • 7. Reduced Osteoporosis
  • Glucocorticoids have an essential role in skeletal development and function but are detrimental in excess. Glucocorticoid-induced bone loss is derived, at least in part, via inhibition of bone formation, which includes suppression of osteoblast proliferation and collagen synthesis (Kim, C. H., Cheng, S. L. and Kim, G. S. (1999) J. Endocrinol. 162: 371-379). The negative effect on bone nodule formation could be blocked by the non-specific inhibitor carbenoxolone suggesting an important role of 11βHSD1 in the glucocorticoid effect (Bellows, C. G., Ciaccia, A. and Heersche, J. N. M. (1998) Bone 23: 119-125). Other data suggest a role of 11βHSD1 in providing sufficiently high levels of active glucocorticoid in osteoclasts, and thus in augmenting bone resorption (Cooper, M. S. et al. (2000) Bone 27: 375-381). Taken together, these different data suggest that inhibition of 11βHSD1 may have beneficial effects against osteoporosis by more than one mechanism working in parallel.
    • 8. Reduction of Hypertension
  • Bile acids inhibit 11β-hydroxysteroid dehydrogenase type 2. This results in a shift in the overall body balance in favour of cortisol over cortisone, as shown by studying the ratio of the urinary metabolites (Quattropani, C., Vogt, B., Odermatt, A., Dick, B., Frey, B. M., Frey, F. J. (2001) J Clin Invest. November; 108(9):1299-305. “Reduced activity of 11beta-hydroxysteroid dehydrogenase in patients with cholestasis”.). Reducing the activity of 11bHSD1 in the liver by a selective inhibitor is predicted to reverse this imbalance, and acutely counter the symptoms such as hypertension, while awaiting surgical treatment removing the biliary obstruction.
  • WO 99/65884 discloses carbon substituted aminothiazole inhibitors of cyclin dependent kinases. These compounds may, e.g., be used against cancer, inflammation and arthritis. U.S. Pat. No. 5,856,347 discloses an antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof. Further, U.S. Pat. No. 5,403,857 discloses benzenesulfonamide derivatives having 5-lipoxygenase inhibitory activity. Additionally, tetrahydrothiazolo[5,4-c]pyridines are disclosed in: Analgesic tetrahydrothiazolo[5,4-c]pyridines. Fr. Addn. (1969), 18 pp, Addn. to Fr. 1498465. CODEN: FAXXA3; FR 94123 19690704 CAN 72:100685 AN 1970:100685 CAPLUS and 4,5,6,7-Tetrahydrothiazolo[5,4-c]pyridines. Neth. Appl. (1967), 39 pp. CODEN: NAXXAN NL 6610324 19670124 CAN 68:49593, AN 1968: 49593 CAPLUS. However, none of the above disclosures discloses the compounds according to the present invention, or their use for the treatment of diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, depression, and hypertension.
  • WO 98/16520 discloses compounds inhibiting matrix metalloproteinases (MMPs) and TNF-α converting enzyme (TACE). EP 0 749 964 A1 and U.S. Pat. No. 5,962,490 disclose compounds having an endothelin receptor antagonist activity. WO 00/02851 discloses compounds associated with a disturbed cGMP balance. None of these compounds fall within formula (I) according to the present invention. Furthermore, nothing is said about the activity on 11βHSD1.
  • U.S. Pat. No. 5,783,697 discloses thiophene derivatives as inhibitors of PGE2 and LTB4. Nothing is said about the activity on 11βHSD1.
  • EP 0 558 258, EP 0 569 193, and EP 1 069 114 disclose isoxazole derivatives as endothelin agonists and antagonists. Nothing is said about the activity on 11βHSD1.
    • 9. Wound Healing
  • Cortisol performs a broad range of metabolic functions and other functions. The multitude of glucocorticoid action is exemplified in patients with prolonged increase in plasma glucocorticoids, so called “Cushing's syndrome”. Patients with Cushing's syndrome have prolonged increase in plasma glucocorticoids and exhibit impaired glucose tolerance, type 2 diabetes, central obesity, and osteoporosis. These patients also have impaired wound healing and brittle skin (Ganong, W. F. Review of Medical Physiology. Eighteenth edition ed. Stamford, Conn.: Appleton & Lange; 1997).
  • Glucocorticoids have been shown to increase risk of infection and delay healing of open wounds (Anstead, G. M. Steroids, retinoids, and wound healing. Adv Wound Care 1998; 11(6):277-85). Patients treated with glucocorticoids have 2-5-fold increased risk of complications when undergoing surgery (Diethelm, A. G. Surgical management of complications of steroid therapy. Ann Surg 1977; 185(3):251-63).
  • The European patent application No. EP 0902288 discloses a method for diagnosing the status of wound healing in a patient, comprising detecting cortisol levels in said wound. The authors suggest that elevated levels of cortisol in wound fluid, relative to normal plasma levels in healthy individuals, correlates with large, non-healing wounds (Hutchinson, T. C., Swaniker, H. P., Wound diagnosis by quantitating cortisol in wound fluids. European patent application No. EP 0 902 288, published 17 Mar. 1999).
  • In humans, the 11β-HSD catalyzes the conversion of cortisol to cortisone, and vice versa. The parallel function of 11β-HSD in rodents is the interconversion of corticosterone and 11-dehydrocorticosterone (Frey, F. J., Escher, G., Frey, B. M. Pharmacology of 11 beta-hydroxysteroid dehydrogenase. Steroids 1994; 59(2):74-9). Two isoenzymes of 11β-HSD, 11β-HSD1 and 11β-HSD2, have been characterized, and differ from each other in function and tissue distribution (Albiston, A. L., Obeyesekere, V. R., Smith, R. E., Krozowski, Z. S. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105(2):R11-7). Like GR, 11β-HSD1 is expressed in numerous tissues like liver, adipose tissue, adrenal cortex, gonads, lung, pituitary, brain, eye etc (Monder C, White PC. 11 beta-hydroxysteroid dehydrogenase. Vitam Horm 1993; 47:187-271; Stewart, P. M., Krozowski, Z. S. 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm 1999; 57:249-324; Stokes, J., Noble, J., Brett, L., Phillips, C., Seckl, J. R., O'Brien, C., et al. Distribution of glucocorticoid and mineralocorticoid receptors and 11beta-hydroxysteroid dehydrogenases in human and rat ocular tissues. Invest Ophthalmol Vis Sci 2000; 41(7):1629-38). The function of 11β-HSD1 is to fine-tune local glucocorticoid action. 11β-HSD activity has been shown in the skin of humans and rodents, in human fibroblasts and in rat skin pouch tissue (Hammami, M. M., Siiteri, P. K. Regulation of 11 beta-hydroxysteroid dehydrogenase activity in human skin fibroblasts: enzymatic modulation of glucocorticoid action. J Clin Endocrinol Metab 1991; 73(2):326-34); Cooper, M. S., Moore, J., Filer, A., Buckley, C. D., Hewison, M., Stewart, P. M. 11beta-hydroxysteroid dehydrogenase in human fibroblasts: expression and regulation depends on tissue of origin. ENDO 2003 Abstracts 2003; Teelucksingh, S., Mackie, A. D., Burt, D., McIntyre, M. A., Brett, L., Edwards, C. R. Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet 1990; 335(8697):1060-3; Slight, S. H., Chilakamarri, V. K., Nasr, S., Dhalla, A. K., Ramires, F. J., Sun, Y., et al. Inhibition of tissue repair by spironolactone: role of mineralocorticoids in fibrous tissue formation. Mol Cell Biochem 1998; 189(1-2):47-54).
  • Wound healing consists of serial events including inflammation, fibroblast proliferation, secretion of ground substances, collagen production, angiogenesis, wound contraction and epithelialization. It can be divided in three phases; inflammatory, proliferative and remodeling phase (reviewed in Anstead et al., supra).
  • In surgical patients, treatment with glucocorticoids increases risk of wound infection and delay healing of open wounds. It has been shown in animal models that restraint stress slows down cutaneous wound healing and increases susceptibility to bacterial infection during wound healing. These effects were reversed by treatment with the glucocorticoid receptor antagonist RU486 (Mercado, A. M., Quan, N., Padgett, D. A., Sheridan, J. F., Marucha, P. T. Restraint stress alters the expression of interleukin-1 and keratinocyte growth factor at the wound site: an in situ hybridization study. J Neuroimmunol 2002; 129(1-2):74-83; Rojas, I. G., Padgett, D. A., Sheridan, J. F., Marucha, P. T. Stress-induced susceptibility to bacterial infection during cutaneous wound healing. Brain Behav Immun 2002; 16(1):74-84). Glucocorticoids produce these effects by suppressing inflammation, decrease wound strength, inhibit wound contracture and delay epithelialization (Anstead et al., supra). Glucocorticoids influence wound healing by interfering with production or action of cytokines and growth factors like IGF, TGF-β, EGF, KGF and PDGF (Beer, H. D., Fassler, R., Werner, S. Glucocorticoid-regulated gene expression during cutaneous wound repair. Vitam Horm 2000; 59:217-39; Hamon, G. A., Hunt, T. K., Spencer, E. M. In vivo effects of systemic insulin-like growth factor-I alone and complexed with insulin-like growth factor binding protein-3 on corticosteroid suppressed wounds. Growth Regul 1993; 3(1):53-6; Laato, M., Heino, J., Kahari, V. M., Niinikoski, J., Gerdin, B. Epidermal growth factor (EGF) prevents methylprednisolone-induced inhibition of wound healing. J Surg Res 1989; 47(4):354-9; Pierce, G. F., Mustoe, T. A., Lingelbach, J., Masakowski, V. R., Gramates, P., Deuel, T. F. Transforming growth factor beta reverses the glucocorticoid-induced wound-healing deficit in rats: possible regulation in macrophages by platelet-derived growth factor. Proc Natl Acad Sci USA 1989; 86(7):2229-33). It has also been shown that glucocorticoids decrease collagen synthesis in rat and mouse skin in vivo and in rat and human fibroblasts (Oishi, Y., Fu, Z. W., Ohnuki, Y., Kato, H., Noguchi, T. Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol 2002; 147(5):859-68).
  • WO 01/90090 discloses thiazole compounds, which compounds inhibit the human 11β-HSD1, and may be useful for treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders and immune disorders. Other 11β-HSD1 inhibitors are disclosed in e.g. WO 01/90091; WO 01/90092; WO 01/90093; WO 01/90094; WO 03/043999; WO 03/044000; WO 03/044009; U.S. Patent Publication No. 2005/009821; WO 04/103980; WO 04/112784; WO 04/112781; WO 04/112785; WO 04/112783; WO 04/112782; WO 04/113310; WO 04/112779; and Swedish patent application No. SE 0400227-5, filed on Feb. 4, 2004. However, the use of the 11β-HSD1 inhibitors according to the present invention for diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, and wound healing has not previously been disclosed.
  • Although not disclosed as 11β-HSD1 inhibitors, Okawara et al. disclose the preparation of thiazole-5-spiropropan-4(5H)-ones, see J. Chem. Soc. Perkin Trans. I, 1733-1735 (1986).
    • SUMMARY OF THE INVENTION
  • The compounds according to the present invention solves the above problems and embraces a novel class of compounds which has been developed and which inhibit the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme (11-β-HSD1), and may therefore be of use in treating disorders related to 11-β-HSD1 activity, such as, but not limited to diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, hypertension, and wound healing.
  • One object of the present invention is a compound of the general formula (I)
  • Figure US20110082107A1-20110407-C00002
  • wherein
  • either
  • (a) Z is sulfur, R1 is hydrogen, R2 is selected from hydrogen; C3-10-cycloalkyl optionally independently substituted by one or more of C1-8-alkyl and aryl; C3-10-cycloalkyl-C1-8-alkyl; aryl; aryl-C1-8-alkyl; heterocyclyl; heterocyclyl-C1-8-alkyl; wherein any aryl or heterocyclyl residue is optionally independently substituted by one or more C1-8-alkyl and halogen; or R1 and R2 form together with the nitrogen atom bonded thereto a monocyclic heterocyclyl optionally independently substituted by one or more of aryl-C1-8-alkyl, C1-8-alkyl and halogen; R3 and R4 are each independently selected from hydrogen; C1-8-alkyl; C3-10-cycloalkyl-C1-8-alkyl; cyano-C1-8-alkyl; aryl; aryl-C1-8-alkyl; heterocyclyl-C1-8-alkyl; heteroaryl-C1-8-alkyl; or R3 and R4 form together with the carbon atom bonded thereto C3-10-cycloalkyl, wherein any aryl residue is optionally independently substituted by one or more of hydroxy; or
  • (b) Z is oxygen, R1 is hydrogen, R2 is selected from hydrogen; C5-10-cycloalkyl optionally independently substituted by one or more of C1-8-alkyl and aryl; C3-10-cycloalkyl-C1-8-alkyl; aryl, but not an unsubstituted phenyl group; aryl-C1-8-alkyl; heterocyclyl; heterocyclyl-C3-8-alkyl; wherein any aryl or heterocyclyl residue is optionally independently substituted by one or more of C1-8-alkyl and halogen; R3 and R4 are each independently selected from hydrogen; C1-8-alkyl; C3-10-cycloalkyl-C1-8-alkyl; cyano-C1-8-alkyl; aryl, but not an unsubstituted phenyl group; aryl-C1-8-alkyl; heterocyclyl-C1-8-alkyl; heteroaryl-C1-8-alkyl; or R3 and R4 form together with the carbon atom bonded thereto C3-10-cycloalkyl, wherein any aryl residue is optionally independently substituted by one or more of hydroxy; and
  • pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof; with the proviso that:
  • when R1 is hydrogen and
  • Z is sulfur and R3═R4=methyl, then R2 is not phenyl;
  • Z is sulfur and R3═R4=methyl, then R2 is not 4-iodophenyl;
  • Z is sulfur and R3═R4=phenyl, then R2 is not phenyl;
  • Z is sulfur, R3=ethyl and R4═H, then R2 is not 3-methylphenyl;
  • Z is oxygen and R3═H, then R4 is not methyl.
  • It is preferred that:
  • R1 and R2 are each independently selected from hydrogen, cyclohexyl, cycloheptyl, cyclooctyl, 2,2,3,3-tetramethylcyclopropyl, 1-(4-chlorophenyl)cyclobutyl, bicyclo[2.2.1]hept-2-yl, tricyclo[3.3.1.0˜3,7˜]non-3-yl, cyclohexylmethyl, phenyl, 2-methylphenyl, 3-methylphenyl, 2-isopropylphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-phenylpropyl, 2-chlorobenzyl, 4-chlorobenzyl, 4-(2,2,6,6-tetramethyl)piperidyl, 2-morpholinyl-4-ylethyl, or R1 and R2 form together with the nitrogen atom bonded thereto morpholinyl, azocane, or 4-benzylpiperidyl;
  • R3 and R4 are each independently selected from hydrogen, methyl, ethyl, isopropyl, isobutyl, tert-butyl, cyclohexylmethyl, cyanomethyl, phenyl, 2-hydroxyphenyl, benzyl, 2-hydroxybenzyl, 4-hydroxybenzyl, 3,4-dihydroxybenzyl, 1H-imidazol-4-ylmethyl, indol-3-ylmethyl, 3-pyridylmethyl, or R3 and R4 form together with the carbon atom bonded thereto cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl;
  • provided that when Z is oxygen, then neither of R2, R3, and R4 is phenyl.
  • In a preferred embodiment of the present invention, when Z is sulfur and both R3 and R4 are methyl or both R3 and R4 are phenyl, then R2 as an aryl group is selected from 2-methylphenyl, 3-methylphenyl, 2-isopropylphenyl, 2-fluorophenyl, and 2-chlorophenyl. When Z is sulfur, R3 is ethyl and R4 is hydrogen, then R2 as an aryl group is selected from 2-methylphenyl, 2-isopropylphenyl, 2-fluorophenyl, and 2-chlorophenyl.
  • In a preferred embodiment of the present invention, when Z is oxygen, each of R2, R3, and R4 as an aryl group is selected from 2-methylphenyl, 3-methylphenyl, 2-isopropylphenyl, 2-fluorophenyl, and 2-chlorophenyl. When Z is oxygen and R3 is hydrogen, then R4 as a C1-8-alkyl group is selected from C2-8-alkyl.
  • Preferred compounds are Examples 1-38, 40-66, 68, and 73-79.
  • Another object of the present invention is a process for the preparation of a compound above comprising at least one of the following steps:
  • a) reaction of an isothiocyanate with ammonia to give a thiourea,
  • b) reaction of an amine with ethoxycarbonylisothiocyanate to give a thiourea,
  • c) reaction of a thiourea with an α-bromocarboxylic acid to give a thiazolone,
  • d) reaction of a thiourea with an α-bromocarboxylic ester to give a thiazolone,
  • e) reaction of an amino acid to give an α-bromocarboxylic acid,
  • f) reaction of a thiourea with 3-bromo-2-coumarone,
  • g) reaction of a guanidine with an α-hydroxy ester to give a primary amino-oxazolone,
  • h) reaction of a primary amino-oxazolone and an amine to give a secondary or a tertiary amino-oxazolone,
  • i) reaction of a thiourea and an α-bromocarboxylic acid chloride to give a thiazolone, and
  • j) reaction of a carboxylic acid with thionyl chloride and N-bromosuccinimide to give an α-bromocarboxylic ester.
  • An additional embodiment is directed to a compound of the general formula (II):
  • Figure US20110082107A1-20110407-C00003
  • wherein:
  • X is S or O;
  • R5 is selected from hydrogen, C1-C8 alkyl, C3-10-cycloalkyl, C3-10-cycloalkyl-C1-8-alkyl, aryl, aryl-C1-8-alkyl, heterocyclyl, heterocyclyl-C1-8-alkyl and haloalkyl;
      • wherein any aryl, cycloalkyl, or heterocyclyl residue is optionally independently substituted by one or more C1-8-alkyl, aryl, halogen, halo-C1-C8-alkyl, HO—C1-C8-alkyl, R8R9N—C1-C8-alkyl, C1-C8-alkyl-OR10, —OR10, (C3-C10)-cycloalkyl or C1-C8-alkyl-sulfonyl;
  • R6 is selected from C1-8-alkyl, C1-8-alkoxy, C3-10-cycloalkyl, heterocyclyl, C3-10-cycloalkyl-C1-8-alkyl, CN—C1-8-alkyl, aryl, aryl-C1-8-alkyl, heterocyclyl-C1-8-alkyl and haloalkyl;
  • R7 is selected from —NR8R9, halo, C1-8-alkyl, —(CR8R9)n—OR8, —S—C1-C8-alkyl, C3-10-cycloalkyl, heterocyclyl, C3-10-cycloalkyl-C1-8-alkyl, cyano-C1-8-alkyl, aryl, aryl-C1-8-alkyl, heterocyclyl-C1-8-alkyl, heterocyclyl-C(O)—C1-8-alkyl, heterocyclyl-SO2—C1-8-alkyl, C1-8-haloalkyl, R8R9N—C1-8-alkyl, HO—C1-8-alkyl, —C(O)—C3-C10-cycloalkyl, —C(O)—C1-C8-haloalkyl, —(CR8R9)n—Y—(CR8R9)n-heterocyclyl and —(CR8R9)n—Y—(CR8R9)n—C(O)—R8 (wherein n is 0-5, Y is NR10, O or S);
      • wherein any aryl, alkyl, heterocyclyl or cycloalkyl residue is optionally substituted by one or more of
      • —C1-C8-alkyl,
      • -halo,
      • —OH,
      • —OR10,
      • —SO2-aryl,
      • —C(O)—(CR8R9)n-carbamate,
      • —C(O)—(CR8R9)n—C(O)—NR8R9,
      • —C(O)—(CR8R9)n—NR8—C(O)—C1-C8-alkyl
      • —C(O)—(CR8R9)n—NR8R9,
      • —C(O)—C3-C10-cycloalkyl,
      • —C(O)-aryl,
      • —C(O)—(CR8R9)n-heterocyclyl,
      • —C1-C8 alkyl-OR8,
      • —C(O)-halo-C1-C8-alkyl or
      • —C(O)—(CR8R9)n-aryl,
        • wherein any aryl, alkyl, cycloalkyl, or heterocyclyl residue is optionally independently substituted by one or more C1-8-alkyl, aryl, halogen, —NR10R10, C1-C8-haloalkyl, R8R9N—C1-C8-alkyl, C1-C8-alkyl-OR10, —OR10, (C3-C10)-cycloalkyl or C1-C8-alkyl-sulfonyl, —O—(CR8R9)n-heterocyclyl, —O—(CR8R9)n—C(O)—NR8R9, —O—(CR8R9)n—NR8R9, —Y—(CR8R9)n—NR8—C(O)—C1-C8-alkyl, —Y—(CR8R9)n-heterocyclyl, —O—(CR8R9)n—NR8R9, C1-C8-alkyl-SO2, or —O—(CR8R9)n—N—C(O)-heterocyclyl;
  • wherein R8 and R9 are each independently selected from hydrogen, C1-C8 alkyl, C1-C8 alkoxy, —NR10R10, —S—(C1-C8)alkyl, aryl and heterocyclyl;
      • any alkyl, alkoxy, heterocyclyl or aryl may be substituted with one to three substituents selected from -halo, unsubstituted C1-C8 alkyl, unsubstituted C1-C8 alkoxy, unsubstituted C1-C8 thioalkoxy and unsubstituted aryl(C1-C4)alkyl;
  • wherein R10 is independently selected from hydrogen, C1-C8 alkyl, aryl-C1-C8 alkyl, C1-C8 alkoxy, —S—(C1-C8)alkyl, heterocyclyl and aryl;
      • any alkyl, heterocyclyl or aryl may be substituted with one to three substituents selected from -halo, unsubstituted C1-C8 alkyl, unsubstituted C1-C8 alkoxy, unsubstituted C1-C8 thioalkoxy and unsubstituted aryl(C1-C4)alkyl;
  • or R6 and R7 form, together with the carbon atom bonded thereto, a saturated, partially unsaturated or unsaturated C3-10-cycloalkyl or a saturated, partially unsaturated or unsaturated C4-C14 heterocyclyl;
      • wherein the cycloalkyl or the heterocyclyl may be optionally substituted by one or more of C1-C8-alkyl, aryl, C1-C8-haloalkyl, aryl-C1-C8-alkyl, C3-C10-cycloalkyl, —OR8, ═O, ═NR8, ═N—OR8, —NR8R9, —SR8, -halo, —OC(O)R8, —C(O)R8, —CO2R8, —CONR8R9, —OC(O)NR8R9, —NR9C(O)R8, —NR8C(O)NR8R9, —NR8SO2NR8R9, —NR8CO2R9, —NHC(NH2)═NH, —NR8C(NH2)═NH, —NHC(NH2)═NR8, —S(O)R8, —SO2R8, —SO2NR8R9, —NR8SO2R9, —CN and —NO2;
  • and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof, with the proviso that:
  • when
  • X is S, R6═R7=methyl, then R5 is not phenyl or 4-iodophenyl,
  • X is S, R6═R7=phenyl, then R5 is not phenyl,
  • and
  • X is S, R6 and R7 combine to form a cyclopropyl ring, then R5 is not n-butyl, cyclohexyl, benzyl, phenyl or naphthyl.
  • In another embodiment is a compound of the general formula (III):
  • Figure US20110082107A1-20110407-C00004
  • wherein:
  • R5 is selected from hydrogen, C1-C8 alkyl, C3-10-cycloalkyl, C3-10-cycloalkyl-C1-8-alkyl, aryl, aryl-C1-8-alkyl, heterocyclyl, heterocyclyl-C1-8-alkyl and haloalkyl;
      • wherein any aryl, cycloalkyl, or heterocyclyl residue is optionally independently substituted by one or more C1-8-alkyl, aryl, halogen, halo-C1-C8-alkyl, R8R9N—C1-C8-alkyl, C1-C8-alkyl-OR10, —OR10, (C3-C10)-cycloalkyl or C1-C8-alkyl-sulfonyl;
  • R6 is selected from C1-8-alkyl, C1-8-alkoxy, C3-10-cycloalkyl, heterocyclyl, C3-10-cycloalkyl-C1-8-alkyl, CN—C1-8-alkyl, aryl, aryl-C1-8-alkyl, heterocyclyl-C1-8-alkyl and haloalkyl;
  • R7 is selected from —NR8R9, halo, C1-8-alkyl, —(CR8R9)n—OR8, —S—C1-C8-alkyl, C3-10-cycloalkyl, heterocyclyl, C3-10-cycloalkyl-C1-8-alkyl, cyano-C1-8-alkyl, aryl, aryl-C1-8-alkyl, heterocyclyl-C1-8-alkyl, heterocyclyl-C(O)—C1-8-alkyl, heterocyclyl-SO2—C1-8-alkyl, C1-8-haloalkyl, R8R9N—C1-8-alkyl, HO—C1-8-alkyl, —C(O)—C3-C10-cycloalkyl, —C(O)—C1-C8-haloalkyl, —(CR8R9)n—Y—(CR8R9)n-heterocyclyl and —(CR8R9)n—Y—(CR8R9 n—C(O)—R8 (wherein n is 0-5, Y is NR10, O or S);
      • wherein any aryl, alkyl, heterocyclyl or cycloalkyl residue is optionally substituted by one or more of
      • —C1-C8-alkyl,
      • -halo,
      • —OH,
      • —OR10,
      • C1-C8-alkyl-SO2—,
      • —SO2-aryl,
      • —C(O)—(CR8R9)n-carbamate,
      • —C(O)—O—C1-C8-alkyl,
      • —C(O)—(CR8R9)n—C(O)—NR8R9,
      • —C(O)—(CR8R9)n—NR8—C(O)—C1-C8-alkyl
      • —C(O)—(CR8R9)n—NR8R9,
      • —C(O)—C3-C10-cycloalkyl,
      • —C(O)-aryl,
      • —C(O)—(CR8R9)n-heterocyclyl,
      • —C1-C8 alkyl-OR8,
      • —C(O)-halo-C1-C8-alkyl or
      • —C(O)—(CR8R9)n-aryl,
        • wherein any aryl, alkyl, cycloalkyl, or heterocyclyl residue is optionally independently substituted by one or more C1-8-alkyl, aryl, halogen, —NR10R10, C1-C8-haloalkyl, R8R9N—C1-C8-alkyl, C1-C8-alkyl-OR10, —OR10, (C3-C10)-cycloalkyl or C1-C8-alkyl-sulfonyl, —O—(CR8R9)n-heterocyclyl, —O—(CR8R9)n—C(O)—NR8R9, —O—(CR8R9)n—NR8R9, —Y—(CR8R9)n—NR8—C(O)—C1-C8-alkyl, —Y—(CR8R9)n-heterocyclyl, —O—(CR8R9)n—NR8R9, C1-C8-alkyl-SO2, or —O—(CR8R9)n—N—C(O)-heterocyclyl;
  • wherein R8 and R9 are each independently selected from hydrogen, C1-C8 alkyl, C1-C8 alkoxy, —NR10R10, —S—(C1-C8)alkyl, aryl and heterocyclyl;
      • any alkyl, alkoxy, heterocyclyl or aryl may be substituted with one to three substituents selected from -halo, unsubstituted C1-C8 alkyl, unsubstituted C1-C8 alkoxy, unsubstituted C1-C8 thioalkoxy and unsubstituted aryl(C1-C4)alkyl;
  • wherein R10 is independently selected from hydrogen, C1-C8 alkyl, aryl-C1-C8 alkyl, C1-C8 alkoxy, heterocyclyl and aryl;
      • any alkyl, heterocyclyl or aryl may be substituted with one to three substituents selected from -halo, unsubstituted C1-C8 alkyl, unsubstituted C1-C8 alkoxy, unsubstituted C1-C8thioalkoxy and unsubstituted aryl(C1-C4)alkyl;
  • or R6 and R7 form, together with the carbon atom bonded thereto, a saturated, partially unsaturated or unsaturated C3-10-cycloalkyl or a saturated, partially unsaturated or unsaturated C4-C14 heterocyclyl;
      • wherein the cycloalkyl or the heterocyclyl may be optionally substituted by one or more of C1-C8-alkyl, aryl, C1-C8-haloalkyl, aryl-C1-C8-alkyl, C3-C10-cycloalkyl, —OR8, ═O, ═NR8, ═N—OR8, —NR8R9, —SR8, -halo, —OC(O)R8, —C(O)R8, —CO2R8, —CONR8R9, —OC(O)NR8R9, —NR9C(O)R8, —NR8C(O)NR8R9, —NR8SO2NR8R9, —NR8CO2R9, —NHC(NH2)═NH, —NR8C(NH2)═NH, —NHC(NH2)═NR8, —S(O)R8, —SO2R8, —SO2NR8R9, —NR8SO2R9, —CN and —NO2;
  • and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof, with the proviso that:
  • when
  • R6═R7=methyl, then R5 is not phenyl or 4-iodophenyl,
  • R6═R7=phenyl, then R5 is not phenyl,
  • and
  • R6 and R7 combine to form a cyclopropyl ring, then R5 is not n-butyl, cyclohexyl, benzyl, phenyl or naphthyl.
  • In another embodiment is a compound of the general formula (IV):
  • Figure US20110082107A1-20110407-C00005
  • wherein:
  • R5 is selected from hydrogen, C1-C8 alkyl, C3-10-cycloalkyl, C3-10-cycloalkyl-C1-8-alkyl, aryl, aryl-C1-8-alkyl, heterocyclyl, heterocyclyl-Ci-8-alkyl and haloalkyl;
      • wherein any aryl, cycloalkyl, or heterocyclyl residue is optionally independently substituted by one or more C1-8-alkyl, aryl, halogen, halo-C1-C8-alkyl, HO—C1-C8-alkyl, R8R9N—C1-C8-alkyl, C1-C8-alkyl-OR10, —OR10, (C3-C10)-cycloalkyl or C1-C8-alkyl-sulfonyl;
  • R6 is selected from C1-8-alkyl, C1-8-alkoxy, C3-10-cycloalkyl, heterocyclyl, C3-10-cycloalkyl-C1-8-alkyl, CN—C1-8-alkyl, aryl, aryl-C1-8-alkyl, heterocyclyl-C1-8-alkyl and haloalkyl;
  • R7 is selected from —NR8R9, halo, C1-8-alkyl, —(CR8R9)n—OR8, —S—C1-C8-alkyl, C3-10-cycloalkyl, heterocyclyl, C3-10-cycloalkyl-C1-8-alkyl, cyano-C1-8-alkyl, aryl, aryl-C1-8-alkyl, heterocyclyl-C1-8-alkyl, heterocyclyl-C(O)—C1-8-alkyl, heterocyclyl-SO2—C1-8-alkyl, C1-8-haloalkyl, R8R9N—C1-8-alkyl, HO—C1-8-alkyl, —C(O)—C3-C10-cycloalkyl, —C(O)—C1-C8-haloalkyl, —(CR8R9)n—Y—(CR8R9)n-heterocyclyl and —(CR8R9)n—Y—(CR8R9)n—C(O)—R8 (wherein n is 0-5, Y is NR10, O or S);
      • wherein any aryl, alkyl, heterocyclyl or cycloalkyl residue is optionally substituted by one or more of
      • —C1-C8-alkyl,
      • -halo,
      • —OH,
      • —OR10,
      • C1-C8-alkyl-SO2—,
      • —SO2-aryl,
      • —C(O)—(CR8R9)n-carbamate,
      • —C(O)—O—C1-C8-alkyl,
      • —C(O)—(CR8R9)n—C(O)—NR8R9,
      • —C(O)—(CR8R9)n—NR8—C(O)—C1-C8-alkyl
      • —C(O)—(CR8R9)n—NR8R9,
      • —C(O)—C3-C10-cycloalkyl,
      • —C(O)-aryl,
      • —C(O)—(CR8R9)n-heterocyclyl,
      • —C1-C8 alkyl-OR8,
      • —C(O)-halo-C1-C8-alkyl or
      • —C(O)—(CR8R9)n-aryl,
        • wherein any aryl, alkyl, cycloalkyl, or heterocyclyl residue is optionally independently substituted by one or more C1-8-alkyl, aryl, halogen, —NR10R10, C1-C8-haloalkyl, R8R9N—C1-C8-alkyl, C1-C8-alkyl-OR10, —OR10, (C3-C10)-cycloalkyl or C1-C8-alkyl-sulfonyl, —O—(CR8R9)n-heterocyclyl, —O—(CR8R9)n—C(O)—NR8R9, —O—(CR8R9)n—NR8R9, —Y—(CR8R9)n—NR8—C(O)—C1-C8-alkyl, —Y—(CR8R9)n-heterocyclyl, —O—(CR8R9)n—NR8R9, C1-C8-alkyl-SO2, or —O—(CR8R9)n—N—C(O)-heterocyclyl;
  • wherein R8 and R9 are each independently selected from hydrogen, C1-C8 alkyl, C1-C8 alkoxy, —NR10R10, —S—(C1-C8)alkyl, aryl and heterocyclyl;
      • any alkyl, alkoxy, heterocyclyl or aryl may be substituted with one to three substituents selected from -halo, unsubstituted C1-C8 alkyl, unsubstituted C1-C8 alkoxy, unsubstituted C1-C8 thioalkoxy and unsubstituted aryl(C1-C4)alkyl;
  • wherein R10 is independently selected from hydrogen, C1-C8 alkyl, aryl-C1-C8 alkyl, C1-C8 alkoxy, heterocyclyl and aryl;
      • any alkyl, heterocyclyl or aryl may be substituted with one to three substituents selected from -halo, unsubstituted C1-C8 alkyl, unsubstituted C1-C8 alkoxy, unsubstituted C1-C8 thioalkoxy and unsubstituted aryl(C1-C4)alkyl;
  • or R6 and R7 form, together with the carbon atom bonded thereto, a saturated, partially unsaturated or unsaturated C3-10-cycloalkyl or a saturated, partially unsaturated or unsaturated C4-C14 heterocyclyl;
      • wherein the cycloalkyl or the heterocyclyl may be optionally substituted by one or more of C1-C8-alkyl, aryl, C1-C8-haloalkyl, aryl-C1-C8-alkyl, C3-C10-cycloalkyl, —OR8, ═O, ═NR8, ═N—OR8, —NR8R9, —SR8, -halo, —OC(O)R8, —C(O)R8, —CO2R8, —CONR8R9, —OC(O)NR8R9, —NR9C(O)R8, —NR8C(O)NR8R9, —NR8SO2NR8R9, —NR8CO2R9, —NHC(NH2)═NH, —NR8C(NH2)═NH, —NHC(NH2)═NR8, —S(O)R8, —SO2R8, —SO2NR8R9, —NR8SO2R9, —CN and —NO2;
  • and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof.
  • One embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein:
  • R5 is selected from cyclohexyl, cycloheptyl, cyclooctyl, 2,2,3,3-tetramethylcyclopropyl, 1-(4-chlorophenyl)cyclobutyl, bicyclo[2.2.1]hept-2-yl, tricyclo[3.3.1.0˜3,7˜]non-3-yl, cyclohexylmethyl, phenyl, 2-methylphenyl, 3-methylphenyl, 2-isopropylphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-phenylpropyl, 2-chlorobenzyl, 4-chlorobenzyl, 4-(2,2,6,6-tetramethyl)piperidyl, 2-morpholinyl-4-ylethyl and tetrahydropyran-4-yl-methyl; and
  • R6 and R7 are each independently selected from methyl, ethyl, isopropyl, isobutyl, tert-butyl, cyclohexylmethyl, cyanomethyl, phenyl, 2-hydroxyphenyl, benzyl, 2-hydroxybenzyl, 4-hydroxybenzyl, 3,4-dihydroxybenzyl, 1H-imidazol-4-ylmethyl, indol-3-ylmethyl, 3-pyridylmethyl;
  • or R6 and R7 form together with the carbon atom bonded thereto cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 is methyl and R7 is isopropyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R5 is selected from optionally substituted C1-C8 alkyl, optionally substituted C3-C10 cycloalkyl and optionally substituted aryl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R5 is C3-C8 alkyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R5 is optionally substituted phenyl-(CR10aR10a)1-3; and wherein R10a is independently selected from H, methyl, fluoro or R10a and R10a may combine together to form a C3-C6-cycloalkyl ring.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R5 is (optionally substituted phenyl)-(C(CH3)2)— (optionally substituted phenyl)-(CHCH3) or benzyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R5 is C3-C10 cycloalkyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R5 is selected from cyclohexyl, norbornyl and adamantyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R5 is norbornyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R5 is aryl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R5 is selected from optionally substituted phenyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 is selected from C1-C8 alkyl, C3-C10 cycloalkyl, saturated or partially unsaturated heterocyclyl, heteroaryl and aryl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 is C1-C8 alkyl. Preferably, the alkyl is selected from methyl, ethyl, n-propyl and iso-propyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 is C3-C10 cycloalkyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 is selected from cyclohexyl, norbornyl and adamantyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 is saturated or partially unsaturated 5 or 6-membered heterocyclyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 is selected from tetrahydrofuryl, piperidinyl and tetrahydropyranyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 is a 5 or 6 membered heteroaryl ring.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 is selected from pyridyl, furyl and pyrrolyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 is C6-C10 aryl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 is selected from optionally substituted phenyl and optionally substituted benzyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R7 is selected from —NR8R9, C1-C8 alkoxy, heterocyclyl and heterocyclyl-C1-C8-alkyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R7 is —NR8R9.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R8 is methyl, ethyl, isopropyl or butyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R8 is isopropyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R9 is methyl or H.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R7 is C1-C8 alkoxy.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R7 is methoxy, ethoxy, propoxy or butoxy.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R7 is n-butoxy.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R7 is saturadted or partially unsaturated 5 or 6-membered heterocyclyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R7 is pyrroldinyl, morpholinyl or piperidinyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R7 is piperidinyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R7 is heterocycyl-C1-C8-alkyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R7 is heterocycyl-C1-C3-alkyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R7 is optionally substituted piperidin-4-yl-CH2—.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R7 is R8-piperidin-4-yl-CH2—.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 and R7 form, together with the carbon atom bonded thereto, an optionally unsaturated C3-10-cycloalkyl or an optionally unsaturated C4-C14 heterocyclyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 and R7 form an optionally unsaturated C3-C10 cycloalkyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 and R7 form a six-membered spiro ring.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 and R7 form a five-membered spiro ring.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: R6 and R7 form an optionally unsaturated C4-C14 heterocyclyl.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: the optionally unsaturated C4-C14 heterocyclyl is a six-membered heterocyclic spiro ring.
  • Another embodiment relates to compounds of Formula (I), (II), (III) or (IV) wherein: the C4-C14 heterocyclyl is a cyclic amide spiro ring.
  • One embodiment relates to a compound which is selected from:
  • 2-(bicyclo[2.2.1]hept-2-ylamino)-5-isopropyl-1,3-thiazol-4(5H)-one,
  • 2-(bicyclo[2.2.1]hept-2-ylamino)-5-ethyl-1,3-thiazol-4(5H)-one,
  • 2-(bicyclo[2.2.1]hept-2-ylamino)-5-phenyl-1,3-thiazol-4(5H)-one,
  • 2-(cyclohexylamino)-5-ethyl-1,3-thiazol-4(5H)-one,
  • 2-(bicyclo[2.2.1]hept-2-ylamino)-5,5-dimethyl-1,3-thiazol-4(5H)-one,
  • 5-Isopropyl-2-(tricyclo[3.3.1.0˜3,7˜]non-3-ylamino)-1,3-thiazol-4(5H)-one,
  • 6-(tricyclo[3.3.1.0˜3,7˜]non-3-ylamino)-5-thia-7-azaspiro[3.4]oct-6-en-8-one,
  • 2-(Tricyclo[3.3.1.0˜3,7˜]non-3-ylamino)-1,3-thiazol-4(5H)-one,
  • 6-(Cyclooctylamino)-5-thia-7-azaspiro[3.4]oct-6-en-8-one,
  • 6-(Cycloheptylamino)-5-thia-7-azaspiro [3.4]oct-6-en-8-one,
  • 6-(Bicyclo[2.2.1]hept-2-ylamino)-5-thia-7-azaspiro[3.4]oct-6-en-8-one,
  • 6-[(2,2,3,3-Tetramethylcyclopropyl)amino]-5-thia-7-azaspiro[3.4]oct-6-en-8-one,
  • 6-[(2-Methylphenyl)amino]-5-thia-7-azaspiro[3.4]oct-6-en-8-one,
  • 2-[(cyclohexylmethyl)amino]-5,5-dimethyl-1,3-thiazol-4(5H)-one,
  • 2-[(2-fluorophenyl)amino]-5-isopropyl-1,3-thiazol-4(5H)-one,
  • 2-[(cyclohexylmethyl)amino]-5-(2-hydroxyphenyl)-1,3-thiazol-4(5H)-one,
  • (5S)-2-(cycloheptylamino)-5-methyl-1,3-thiazol-4(5H)-one,
  • (5R)-2-(cycloheptylamino)-5-methyl-1,3-thiazol-4(5H)-one,
  • 2-(cycloheptylamino)-5-ethyl-1,3-thiazol-4(5H)-one,
  • 2-(cycloheptylamino)-5-isopropyl-1,3-thiazol-4(5H)-one,
  • 5-tert-butyl-2-(cycloheptylamino)-1,3-thiazol-4(5H)-one,
  • 2-(cyclooctylamino)-5-ethyl-1,3-thiazol-4(5H)-one,
  • 5-isopropyl-2-[(2-isopropylphenyl)amino]-1,3-thiazol-4(5H)-one,
  • 5-ethyl-2-[(2-isopropylphenyl)amino]-1,3-thiazol-4(5H)-one,
  • 2-[(2-chlorophenyl)amino]-5-ethyl-1,3-thiazol-4(5H)-one,
  • 5-ethyl-2-[(2-methylphenyl)amino]-1,3-thiazol-4(5H)-one,
  • 5-isopropyl-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-1,3-thiazol-4(5H)-one,
  • 2-(bicyclo[2.2.1]hept-2-ylamino)-5-(4-hydroxybenzyl)-1,3-thiazol-4(5H)-one,
  • 5-[(cyclohexylmethyl)amino]-4-thia-6-azaspiro[2.4]hept-5-en-7-one,
  • 2-(cycloheptylamino)-5-(3,4-dihydroxybenzyl)-1,3-thiazol-4(5H)-one,
  • 2-(cycloheptylamino)-5-(1H-imidazol-4-ylmethyl)-1,3-thiazol-4(5H)-one,
  • 2-(cycloheptylamino)-5-isobutyl-1,3-thiazol-4(5H)-one,
  • 2-(cycloheptylamino)-5-(1H-indol-3-ylmethyl)-1,3-thiazol-4(5H)-one,
  • 2-(cycloheptylamino)-5-(4-hydroxybenzyl)-1,3-thiazol-4(5H)-one,
  • (5R)-2-(cycloheptylamino)-5-(cyclohexylmethyl)-1,3-thiazol-4(5H)-one,
  • 2-(cyclooctylamino)-5-(4-hydroxybenzyl)-1,3-thiazol-4(5H)-one,
  • (5S)-2-(cycloheptylamino)-5-(cyclohexylmethyl)-1,3-thiazol-4(5H)-one,
  • [2-(cycloheptylamino)-4-oxo-4,5-dihydro-1,3-thiazol-5-yl]acetonitrile,
  • 2-(cycloheptylamino)-5-(pyridin-3-ylmethyl)-1,3-thiazol-4(5H)-one,
  • 5-Isopropyl-2-[(2-methylphenyl)amino]-1,3-thiazol-4(5H)-one,
  • 2-(Cyclooctylamino)-5 ,5-dimethyl-1,3-thiazol-4(5H)-one,
  • 2-(Cyclooctylamino)-5-isopropyl-1,3-thiazol-4(5H)-one,
  • 2-(Bicyclo[2.2.1]hept-2-ylamino)-1-thia-3-azaspiro[4.5]dec-2-en-4-one,
  • 2-(Tricyclo[3.3.1.0˜3,7˜]non-3-ylamino)-1-thia-3-azaspiro[4.5]dec-2-en-4-one,
  • 2-(Cycloheptylamino)-1-thia-3-azaspiro[4.5]dec-2-en-4-one,
  • 2-(Cyclooctylamino)-1-thia-3-azaspiro[4.5]dec-2-en-4-one,
  • 2-{[1-(4-Chlorophenyl)cyclobutyl]amino}-5-isopropyl-1,3-thiazol-4(5H)-one,
  • 6-{[1-(4-Chlorophenyl)cyclobutyl]amino}-5-thia-7-azaspiro[3.4]oct-6-en-8-one,
  • 2-(cycloheptylamino)-5,5-diethyl-1,3-thiazol-4(5H)-one,
  • (5S)-5-isopropyl-2-{[(2S)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one,
  • (5R)-5-ethyl-2-{[(2S)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one,
  • (5S)-5-ethyl-2-{[(2S)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one,
  • (5R)-5-isopropyl-2-{[(2R)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one,
  • (5S)-5-isopropyl-2-{[(2R)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one,
  • (5R)-5-ethyl-2-{[(2R)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one,
  • (5S)-5-ethyl-2-{[(2R)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one,
  • 2-Anilino-5-isopropyl-1,3-thiazol-4(5H)-one,
  • 5-Isopropyl-2-[(2-morpholin-4-ylethyl)amino]-1,3-thiazol-4(5H)-one,
  • 2-(Bicyclo[2.2.1]hept-2-ylamino)-1-thia-3-azaspiro[4.4]non-2-en-4-one,
  • 2-(Cycloheptylamino)-1-thia-3-azaspiro[4.4]non-2-en-4-one,
  • 2-(Cyclooctylamino)-1-thia-3-azaspiro[4.4]non-2-en-4-one,
  • 2-[(2,2,3,3-Tetramethylcyclopropyl)amino]-1-thia-3-azaspiro[4.4]non-2-en-4-one,
  • 2-[(2-chlorobenzyl)amino]-5-isopropyl-1,3-oxazol-4(5H)-one,
  • 2-[(4-chlorobenzyl)amino]-5-isopropyl-1,3-oxazol-4(5H)-one,
  • 5-isopropyl-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-oxazol-4(5H)-one,
  • 5-isopropyl-2-[(2-morpholin-4-ylethyl)amino]-1,3-oxazol-4(5H)-one,
  • 5-benzyl-2-[(cyclohexylmethyl)amino]-1,3-oxazol-4(5H)-one,
  • 2-(cycloheptylamino)-5-isopropyl-1,3-oxazol-4(5H)-one,
  • 2-(bicyclo[2.2.1]hept-2-ylamino)-5-isopropyl-1,3-oxazol-4(5H)-one,
  • 2-(bicyclo[2.2.1]hept-2-ylamino)-5-isobutyl-1,3-oxazol-4(5H)-one,
  • 2-(cycloheptylamino)-5-isobutyl-1,3-oxazol-4(5H)-one,
  • 5-isobutyl-2-[(2-methylphenyl)amino]-1,3-oxazol-4(5H)-one,
  • 2-(bicyclo[2.2.1]hept-2-ylamino)-5-isopropyl-5-methyl-1,3-thiazol-4(5H)-one,
  • 5-ethyl-2-[(3-methylphenyl)amino]-1,3-thiazol-4(5H)-one,
  • 5-isopropyl-2-morpholin-4-yl-1,3-oxazol-4(5H)-one,
  • 2-(4-benzylpiperidin-1-yl)-5-isopropyl-1,3-oxazol-4(5H)-one,
  • 2-azocan-1-yl-5-isopropyl-1,3-oxazol-4(5H)-one,
  • 2-[(cyclohexylmethyl)amino]-5-phenyl-1,3-oxazol-4(5H)-one, and
  • 2-(cycloheptylamino)-5-phenyl-1,3-oxazol-4(5H)-one, and
  • pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof.
  • One embodiment relates to a pharmaceutical formulation comprising a compound according to Formula (I), (II), (III), or (IV) as active ingredient, in combination with a pharmaceutically acceptable diluent or carrier.
  • In one embodiment, the pharmaceutical formulation is formulated for oral delivery.
  • In one embodiment, the oral delivery form is a tablet.
  • One embodiment relates to a method for the prophylaxis or treatment of a 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation comprising administering the compound of Formula (I), (II), (III), or (IV) to an individual.
  • In one embodiment, the disorder is selected from diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, and inflammatory diseases.
  • Another embodiment relates to the treatment or prophylaxis of a medical condition involving delayed or impaired wound healing.
  • Another embodiment relates to methods of treatment wherein the medical condition involving delayed or impaired wound healing is diabetes.
  • Another embodiment relates to methods of treatment wherein the medical condition involving delayed or impaired wound healing is caused by treatment with glucocorticoids.
  • Another embodiment relates to methods of treatment for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
  • Another embodiment relates to methods of treatment wherein immuno-modulation is selected from tuberculosis, lepra, and psoriasis.
  • Another embodiment relates to a method for inhibiting a 11-β-hydroxysteroid dehydrogenase type 1 enzyme, which comprises administering to a subject in need of such treatment an effective amount of a compound according to Formula (I), (II), (III) or (IV).
  • One embodiment relates to a compound selected from
  • 2-[1-(4-Fluoro-phenyl)-ethylamino]-5-methyl-5-(tetrahydro-pyran-4-ylmethyl)-thiazol-4-one;
  • (5S)-5-((1-acetyl-4-piperidinyl)methyl)-2-((1S,4R)-bicyclo[2.2.1]hept-2-ylamino)-5-methyl-1,3-thiazol-4(5H)-one;
  • (5R)-2-((1S,4R)-bicyclo[2.2.1]hept-2-ylamino)-5-methyl-5-(tetrahydro-2H-pyran-4-ylmethyl)-1,3-thiazol-4(5H)-one;
  • (5S)-2-((1S,4R)-bicyclo[2.2.1]hept-2-ylamino)-5-methyl-5-tetrahydro-2H-pyran-4-yl-1,3-thiazol-4(5H)-one;
  • 2-((1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino)-8-oxa-1-thia-3-azaspiro[4.5]dec-2-en-4-one;
  • (5S)-2-((1S,4R)-bicyclo[2.2.1]hept-2-ylamino)-5-((1-(3-furanylcarbonyl)-4-piperidinyl)methyl)-5-methyl-1,3-thiazol-4(5H)-one;
  • 2-(1-Cyclohexyl-ethylamino)-5-isopropyl-5-methyl-thiazol-4-one;
  • 2-(5,5-Difluoro-bicyclo[2.2.1]hept-2-ylamino)-5-isopropyl-5-methyl-thiazol-4-one;
  • 2-[1-(2-Trifluoromethyl-phenyl)-ethylamino]-8-oxa-1-thia-3-aza-spiro[4.5]dec-2-en-4-one;
  • (5R)-2-((1S,2S,4R)-bicyclo[2.2.1]hept-2-ylamino)-5-methyl-5-(trifluoromethyl)-1,3-thiazol-4(5H)-one;
  • 2-(Bicyclo[2.2.1]hept-2-ylamino)-5-(1-fluoro-1-methyl-ethyl)-5-methyl-thiazol-4-one;
  • 2-[1-(4-Fluoro-phenyl)-ethylamino]-5-methyl-5-pyridin-4-yl-thiazol-4-one;
  • 5-Methyl-5-pyridin-4-yl-2-[1-(2-trifluoromethyl-phenyl)-ethylamino]-thiazol-4-one;
  • 2-[1-(2-Fluoro-phenyl)-ethylamino]-5-methyl-5-pyridin-4-yl-thiazol-4-one;
  • 5-(1-Fluoro-1-methyl-ethyl)-2-[1-(2-fluoro-phenyl)-ethylamino]-5-methyl-thiazol-4-one;
  • 2-[1-(2-Fluoro-phenyl)-ethylamino]-5-methyl-5-trifluoromethyl-thiazol-4-one;
  • 5-(1,1-Difluoro-ethyl)-2-[1-(4-fluoro-phenyl)-ethylamino]-5-methyl-thiazol-4-one;
  • 2-[1-(2-Chloro-phenyl)-ethylamino]-5-methyl-5-trifluoromethyl-thiazol-4-one;
  • 2-[1-(4-Fluoro-phenyl)-ethylamino]-5-methyl-5-trifluoromethyl-thiazol-4-one;
  • 2-[1-(2-Chloro-phenyl)-ethylamino]-5-methyl-5-trifluoromethyl-thiazol-4-one;
  • 2-[1-(4-Fluoro-phenyl)-ethylamino]-5-(2-methoxy-pyridin-4-yl)-5-methyl-thiazol-4-one;
  • 5-(1,1-Difluoro-ethyl)-2-[1-(4-fluoro-phenyl)-ethylamino]-5-methyl-thiazol-4-one; and
  • 5-(1-Fluoro-1-methyl-ethyl)-2-[1-(4-fluoro-phenyl)-ethylamino]-5-methyl-thiazol-4-one, and
  • pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof.
  • Another object of the present invention is a compound according to general formula (I) for use in therapy:
  • Figure US20110082107A1-20110407-C00006
  • wherein
  • R1 and R2 are each independently selected from hydrogen; C3-10-cycloalkyl optionally independently substituted by one or more of C1-8-alkyl and aryl; C3-10-cycloalkyl-C1-8-alkyl; aryl; aryl-C1-8-alkyl; heterocyclyl; heterocyclyl-C1-8-alkyl; or R1 and R2 form together with the nitrogen atom bonded thereto heterocyclyl optionally independently substituted by one or more of aryl-C1-8-alkyl, wherein any aryl or heterocyclyl residue is optionally independently substituted by one or more of C1-8-alkyl and halogen;
  • R3 and R4 are each independently selected from hydrogen; C1-8-alkyl; C3-10-cycloalkyl-C1-8-alkyl; cyano-C1-8-alkyl; aryl; aryl-C1-8-alkyl; heterocyclyl-C1-8-alkyl; heteroaryl-C1-8-alkyl; or R3 and R4 form together with the carbon atom bonded thereto C3-10-cycloalkyl, wherein any aryl residue is optionally independently substituted by one or more of hydroxy;
  • Z is sulfur or oxygen; and
  • pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof.
  • Within the above embodiment, it is preferred that:
  • R1 and R2 are each independently selected from hydrogen, cyclohexyl, cycloheptyl, cyclooctyl, 2,2,3,3-tetramethylcyclopropyl, 1-(4-chlorophenyl)cyclobutyl, bicyclo[2.2.1]hept-2-yl, tricyclo[3.3.1.0˜3,7˜]non-3-yl, cyclohexylmethyl, phenyl, 2-methylphenyl, 3-methylphenyl, 2-isopropylphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-phenylpropyl, 2-chlorobenzyl, 4-chlorobenzyl, 4-(2,2,6,6-tetramethyl)piperidyl, 2-morpholinyl-4-ylethyl, or R1 and R2 form together with the nitrogen atom bonded thereto morpholinyl, azocane, or 4-benzylpiperidyl;
  • R3 and R4 are each independently selected from hydrogen, methyl, ethyl, isopropyl, isobutyl, tert-butyl, cyclohexylmethyl, cyanomethyl, phenyl, 2-hydroxyphenyl, benzyl, 2-hydroxybenzyl, 4-hydroxybenzyl, 3,4-dihydroxybenzyl, 1H-imidazol-4-ylmethyl, indol-3-ylmethyl, 3-pyridylmethyl, or R3 and R4 form together with the carbon atom bonded thereto cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • When using the compounds of Formula (I) in therapy (e.g., Examples 39, 67, and 69-72), they may advantageously be used in the prophylaxis or treatment of an 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation. In this embodiment, the disorder may be selected from diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, and inflammatory diseases. It is also possible that the treatment or prophylaxis is of the medical condition involves delayed or impaired wound healing. The medical condition involving delayed or impaired wound healing may be associated with diabetes and may have been caused by treatment with glucocorticoids. The compounds of Formula (I) for use in therapy may be for promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers. Iimmuno-modulation may encompass tuberculosis, lepra, and psoriasis.
  • In addition to the examples, the following compounds, according to Formula (I), may be effectively used in therapy:
  • 5-ethyl-2-[(3-methylphenyl)amino]-1,3-thiazol-4(5H)-one,
  • 5-isopropyl-2-morpholin-4-yl-1,3-oxazol-4(5H)-one,
  • 2-(4-benzylpiperidin-1-yl)-5-isopropyl-1,3-oxazol-4(5H)-one,
  • 2-azocan-1-yl-5-isopropyl-1,3-oxazol-4(5H)-one,
  • 2-[(cyclohexylmethyl)amino]-5-phenyl-1,3-oxazol-4(5H)-one,
  • 2-(cycloheptylamino)-5-phenyl-1,3-oxazol-4(5H)-one.
  • Another object of the present invention is a pharmaceutical formulation comprising a compound according to Formula (I) for use in therapy as active ingredient, in combination with a pharmaceutically acceptable diluent or carrier, especially for use in the prophylaxis or treatment of a 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation. The pharmaceutical formulation can include a second active ingredient. The second active ingredient can be an inhibitor of 11-β-hydroxysteroid dehydrogenase type 1 or it can have some other activity.
  • Another object of the present invention is a method for the prophylaxis or treatment of a 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation, which comprises administering to a subject in need of such treatment an effective amount of a compound according to Formula (I), (II), (III) and (IV).
  • Another object of the present invention is a method for inhibiting a 11-β-hydroxysteroid dehydrogenase type 1 enzyme, which comprises administering to a subject in need of such treatment an effective amount of a compound according to Formula (I), (II), (III) and (IV).
  • Another object of the present invention is the use of a compound according to Formula (I), (II), (III) and (IV) for the manufacture of a medicament for use in the prophylaxis or treatment of a 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation.
  • Examples of 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorders include: diabetes, syndrome X, obesity, glaucoma, osteoporosis, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, cognitive disorders, dementia, depression, immune disorders, virus diseases, wond healing and inflammatory diseases.
  • It is preferred that the medical condition involving delayed or impaired wound healing is diabetes.
  • It is also preferred that the medical condition involving delayed or impaired wound healing is caused by treatment with glucocorticoids.
  • The compound according to Formula (I), (II), (III) and (IV) may be used for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
  • It is preferred that the immuno-modulation is selected from tuberculosis, lepra, and psoriasis.
  • Also, within the scope of this invention is a method for making a compound of formula (I). The method includes taking any intermediate compound delineated herein, reacting it with one or more reagents to form a compound of Formula (I), (II), (III) and (IV) including any processes specifically delineated herein.
  • Use of a compound of Formula (I), (II), (III) or (IV) for the manufacture of a medicament for use in the prophylaxis or treatment of a 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation. In one embodiment , the disorder is selected from diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, and inflammatory diseases. In another embodiment, the medical condition involving delayed or impaired wound healing. In another embodiment, the medical condition involving delayed or impaired wound healing is diabetes. In another embodiment, the medical condition involving delayed or impaired wound healing is caused by treatment with glucocorticoids. In another embodiment, the use is for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers. In another embodiment, the immuno-modulation is selected from tuberculosis, lepra, and psoriasis.
  • Other features and advantages of the invention will be apparent from the detailed description and claims.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The compounds according to the present invention may be used in several indications which involve 11-β-hydroxysteroid dehydrogenase type 1 enzyme. Thus, the compounds according to the present invention may be used against dementia (see WO97/07789), osteoporosis (see Canalis, E. 1996, Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis, Journal of Clinical Endocrinology and Metabolism, 81, 3441-3447) and may also be used for disorders in the immune system (see Franchimont et al, “Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat 4 phosphorylation in T lymphocytes”, The journal of Immunology 2000, Feb. 15, vol 164 (4), pages 1768-74) and also in the above listed indications.
  • The various terms used, separately and in combinations, in the above definition of the compounds having the Formula (I), (II), (III) and (IV) will be explained.
  • The term “aryl” in the present description is intended to include aromatic rings (monocyclic or bicyclic) having from 6 to 10 ring carbon atoms, such as phenyl (Ph), naphthyl, and indanyl (i. e., 2,3-dihydroindenyl), which optionally may be substituted by C1-6-alkyl. Examples of substituted aryl groups are benzyl, and 2-methylphenyl.
  • The term “heteroaryl” means in the present description a monocyclic, bi- or tricyclic aromatic ring system (only one ring need to be aromatic) having from 5 to 14, preferably 5 to 10 ring atoms such as 5, 6, 7, 8, 9 or 10 ring atoms (mono- or bicyclic), in which one or more of the ring atoms are other than carbon, such as nitrogen, sulfur, oxygen and selenium as part of the ring system. Examples of such heteroaryl rings are pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzopyrazole; benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,5-naphthyridine, 1,8-naphthyridine, acridine, fenazine and xanthene.
  • The term “heterocyclic” and “heterocyclyl” in the present description is intended to include unsaturated as well as partially and fully saturated mono-, bi- and tricyclic rings having from 4 to 14, preferably 4 to 10 ring atoms having one or more heteroatoms (e.g., oxygen, sulfur, or nitrogen) as part of the ring system and the reminder being carbon, such as, for example, the heteroaryl groups mentioned above as well as the corresponding partially saturated or fully saturated heterocyclic rings. Exemplary saturated heterocyclic rings are azetidine, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, 1,4-oxazepane, azepane, phthalimide, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, 3,4-dihydro-2H-1,4-benzoxazine, hexahydroazepine, 3,4-dihydro-2(1H)isoquinoline, 2,3-dihydro-1H-indole, 1,3-dihydro-2H-isoindole, azocane, 1-oxa-4-azaspiro[4.5]dec-4-ene, decahydroisoquinoline, and 1,4-diazepane. In addition, the heterocyclyl or heterocyclic moiety may optionally be substituted with one or more oxo groups.
  • C1-8-alkyl in the compound of formula (I) according to the present application may be a straight or branched alkyl group containing 1-8 carbon atoms. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, n-heptyl, and n-octyl. For parts of the range “C1-8-alkyl” all subgroups thereof are contemplated such as C1-7-alkyl, C1-6-alkyl, C1-5-alkyl, C1-4-alkyl, C2-8-alkyl, C2-6-alkyl, C2-5-alkyl, C4-6-alkyl, etc.
  • C1-8-alkoxy in the compound of formula (I) according to the present application may be a straight or branched alkoxy group containing 1-8 carbon atoms. Exemplary alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, hexyloxy, isohexyloxy, n-heptyloxy, and n-octyloxy. For parts of the range “C1-6-alkoxy” all subgroups thereof are contemplated such as C1-7-alkoxy, C1-6-alkoxy, C1-5-alkoxy, C1-4-alkoxy, C2-8-alkoxy, C2-7-alkoxy, C2-6-alkoxy, C2-5-alkoxy, C3-7-alkoxy, C4-6-alkoxy, etc.
  • C1-8-acyl in the compound of formula (I) according to the present application may be a straight or branched acyl group containing 1-8 carbon atoms. Exemplary acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, n-hexanoyl, n-heptanoyl, and n-octanoyl. For parts of the range “C1-8-acyl” all subgroups thereof are contemplated such as C1-7-acyl, C1-6-acyl, C1-5-acyl, C1-4-acyl, C2-8-acyl, C2-7-acyl, C2-6-acyl, C2-5-acyl, C3-7-acyl, C4-6-acyl, etc.
  • C2-8-alkenyl in the compound of formula (I) according to the present application may be a straight or branched acyl group containing 2-8 carbon atoms. Exemplary alkenyl groups include vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 1-hexenyl, 2-hexenyl, 1-heptenyl, and 1-octenyl. For parts of the range “C2-8-alkenyl” all subgroups thereof are contemplated such as C2-7-alkenyl, C2-6-alkenyl, C2-5-alkenyl, C2-4-alkenyl, C3-8-alkenyl, C3-7-alkenyl, C3-6-alkenyl, C3-5-alkenyl, C4-7-alkenyl, C5-6-alkenyl, etc.
  • C3-10-cycloalkyl in the compound of formula (I) according to the present application may be an optionally substituted monocyclic, bicyclic or tricyclic alkyl group containing between 3-10 carbon atoms. Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, bicyclo[2.2.1]hept-2-yl, tricyclo[3.3.1.0˜3,7˜]non-3-yl, (1R,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl, (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl, 1-adamantyl, noradamantyl, and 2,2,3,3-tetramethylcyclopropyl. For parts of the range “C3-10-cycloalkyl” all subgroups thereof are contemplated such as C3-9-cycloalkyl, C3-8-cycloalkyl, C3-7-cycloalkyl, C3-6-cycloalkyl, C3-5-cycloalkyl, C4-10-cycloalkyl, C5-10-cycloalkyl, C6-10-cycloalkyl, C7-10-cycloalkyl, C8-9-cycloalkyl, etc. In addition, the cycloalkyl moiety may optionally be substituted with one or more oxo groups.
  • C3-10-cycloalkenyl in the compound of formula (I) according to the present application may be an optionally alkyl substituted cyclic, bicyclic or tricyclic alkenyl group containing totally 3-10 carbon atoms. Exemplary cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl, and bicyclo[2.2.1]hept-5-en-2-yl. For parts of the range “C3-10-cycloalkenyl” all subgroups thereof are contemplated such as C3-9-cycloalkenyl, C3-8-cycloalkenyl, C3-7-cycloalkenyl, C3-6-cycloalkenyl, C3-5-cycloalkenyl, C4-10-cycloalkenyl, C5-10-cycloalkenyl, C6-10-cycloalkenyl, C7-10-cycloalkenyl, C8-9-cycloalkenyl, etc. In addition, the cycloalkenyl moiety may optionally be substituted with one or more oxo groups.
  • The term “halogen” or “halo” in the present description is intended to include fluorine, chlorine, bromine and iodine.
  • The term “sulfanyl” in the present description means a thio group.
  • The term “-hetero(C1-C8)alkyl” refers to a moiety wherein a hetero atom, selected from optionally substituted nitrogen, sulfur and oxygen, is the point of attachment to the core molecule and is attached to a C1-C8 alkyl chain.
  • The term “cyclic amide spiro ring” refers to compounds where the substituents at the 5-position of the thiazolinone or the oxazolone ring combine together to form a cyclic ring having a —NR10C(O)— therein. An example of such a moiety is shown in the example below:
  • Figure US20110082107A1-20110407-C00007
  • With the expression “mono- or di-substituted” is meant in the present description that the functionalities in question may be substituted with independently C1-8-acyl, C2-8-alkenyl, C1-8-(cyclo)alkyl, aryl, pyridylmethyl, or heterocyclic rings e.g. azetidine, pyrrolidine, piperidine, piperazine, morpholine and thiomorpholine, which heterocyclic rings optionally may be substituted with C1-8-alkyl. With the expression “optionally mono- or disubstituted” is meant in the present description that the functionalities in question may also be substituted with independently hydrogen.
  • When two of the above-mentioned terms are used together, it is intended that the latter group is substituted by the former. For example, C3-10-cycloalkyl-C1-8-alkyl means a C1-8-alkyl group that is substituted by a C3-10-cycloalkyl group. Likewise, a C1-8-haloalkyl means a C1-8-alkyl group that is substituted by a halogen atom.
  • Metabolites of the compounds of Formula (I), (II), (III) and (IV) can take on many forms and the present invention encompasses the metabolites of the compounds as well as the parent compound.
  • As used herein, the term “prodrug” means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide an active compound, particularly a benzamide derivative. Examples of prodrugs include, but are not limited to, derivatives and metabolites of a benzamide derivative that include biohydrolyzable groups such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues (e.g., monophosphate, diphosphate or triphosphate). Preferably, prodrugs of compounds with carboxyl functional groups are the lower alkyl esters of the carboxylic acid. The carboxylate esters are conveniently formed by esterifying any of the carboxylic acid moieties present on the molecule. Prodrugs can typically be prepared using well-known methods, such as those described by Burger's Medicinal Chemistry and Drug Discovery 6th ed. (Donald J. Abraham ed., 2001, Wiley) and Design and Application of Prodrugs (H. Bundgaard ed., 1985, Harwood Academic Publishers Gmfh).
  • “Tautomer” is one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another, in the present case, tautomers of the structures below are encompassed by the present invention.
  • Figure US20110082107A1-20110407-C00008
  • As used herein, “hydrate” is a form of a compound of Formula (I), (II), (III), or (IV) where water molecules are combined in a definite ratio as an integral part of the crystal structure of the compound.
  • As used herein,“solvate” is a form of of a compound of Formula (I), (II), (III), or (IV) where solvent molecules are combined in a definite ratio as an integral part of the crystal structure of the compound.
  • Depending on its structure, the phrase “pharmaceutically acceptable salt,” as used herein, refers to a pharmaceutically acceptable organic or inorganic acid or base salt of a benzamide derivative. Representative pharmaceutically acceptable salts include, e.g., alkali metal salts, alkali earth salts, ammonium salts, water-soluble and water-insoluble salts, such as the acetate, amsonate(4,4-diaminostilbene-2, 2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate(1,1-methene-bis-2-hydroxy-3-naphthoate, einbonate), pantothenate, phosphate/diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosaliculate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts. Furthermore, a pharmaceutically acceptable salt can have more than one charged atom in its structure. In this instance the pharmaceutically acceptable salt can have multiple counterions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counterions.
  • As used herein , the term “geometrical isomers” refers compounds that have the same molecular formula but the atoms are in different non-equivalent positions to one another.
  • As used herein, the term “optical isomers” refers to compounds with chiral atoms which have the ability to rotate plane polarized light, R/S configuration. The term optical isomer include enantiomers and diastereomers as well as compounds which can be distinguished one from the other by the designations of (D) and (L).
  • As used herein:
  • DCM means dichloromethane,
  • DEAD means diethyl azocarboxylate,
  • DMF means dimethylformamide,
  • EDCI means 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride,
  • Ether means diethyl ether,
  • EtOAc means ethylacetate,
  • HOBt means 1-hydroxybenzotriazole,
  • HPLC means high-performance liquid chromatography,
  • LC means liquid chromatography,
  • MeCN means acetonitrile,
  • DPPA means diphenylphosphoryl azide,
  • RT means room temperature,
  • SM means starting material,
  • TEA means triethylamine, and
  • THF means tetrahydrofuran.
  • Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term “stable”, as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic administration to a subject for the treatment of disease, 11-β-HSD1 inhibition, 11-β-HSD1-mediated disease).
  • The term “prodrug forms” in the present description means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug (see Goodman and Gilman's, The Pharmacological basis of Therapeutics, 8th ed., McGraw-Hill, Int. Ed. 1992, “Biotransformation of Drugs, p. 13-15).
  • “Pharmaceutically acceptable” means in the present description being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
  • “Pharmaceutically acceptable salts” mean in the present description salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with organic and inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid and the like. Base addition salts may be formed with organic and inorganic bases, such as sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, choline and the like. Included in the invention are pharmaceutically acceptable salts or compounds of any of the formulae herein.
  • Pharmaceutical compositions according to the present invention contain a pharmaceutically acceptable carrier together with at least one of the compounds comprising the formula (I) as described herein above, dissolved or dispersed therein as an active, antimicrobial, ingredient. In a preferred embodiment, the therapeutic composition is not immunogenic when administered to a human patient for therapeutic purposes, unless that purpose is to induce an immune response.
  • The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art. Typically such compositions are prepared as sterile injectables either as liquid solutions or suspensions, aqueous or non-aqueous, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified.
  • The active ingredient may be mixed with excipients, which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof. In addition, if desired, the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient. Adjuvants may also be present in the composition.
  • Pharmaceutically acceptable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, propylene glycol, polyethylene glycol and other solutes.
  • Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerine, vegetable oils such as cottonseed oil, organic esters such as ethyl oleate, and water-oil emulsions.
  • The pharmaceutical composition according to one of the preferred embodiments of the present invention comprising compounds comprising the formula (I), may include pharmaceutically acceptable salts of that component therein as set out above. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic acid, tartaric acid, mandelic acid and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylaminoethanol, histidine, procaine and the like.
  • The preparations according to the preferred embodiments may be administered orally, topically, intraperitoneally, intraarticularly, intracranially, intradermally, intramuscularly, intraocularly, intrathecally, intravenously, subcutaneously. Other routes are known to those of ordinary skill in the art.
  • The orally administrable compositions according to the present invention may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, traganath or polyvinyl-pyrrolidone; fillers e.g. lactose, sugar, maize-starch, calcium phosphate, calcium hydrogen phosphate, sodium starch glycolate, sorbitol or glycine; tabletting lubricant e.g. magnesium stearate, talc, polyethylene glycol or silicon dioxide (optionally colloidal); disintegrants e.g. potato starch, or acceptable wetting agents such as sodium lauryl sulfate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of e.g. aqueous or oily suspensions, solutions, emulsions, syrups or elixirs or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, e.g. sorbitol, syrup, methyl cellulose (optionally microcrystalline), glucose syrup, gelatin hydrogenated edible fats; emulsifying agents e.g. lecithin, sorbitan monooleate or acacia, non-aqueous vehicles (which may include edible oils), e.g. almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives e.g. methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • “An effective amount” refers to an amount of a compound which confers a therapeutic effect on the treated subject. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect). A pharmaceutical composition according to the present invention, may comprise typically an amount of at least 0.1 weight percent of compound comprising the formula (I) per weight of total therapeutic composition. A weight percent is a ratio by weight of total composition. Thus, for example, 0.1 weight percent is 0.1 grams of compound comprising the formula (I) per 100 grams of total composition. A suitable daily oral dose for a mammal, preferably a human being, may vary widely depending on the condition of the patient. However a dose of compound comprising the formula (I) of about 0.1 to 300 mg/kg body weight may be appropriate.
  • The compositions according to the present invention may also be used veterinarily and thus they may comprise a veterinarily acceptable excipient or carrier. The compounds and compositions may be thus administered to animals, e.g., cats, dogs, or horses, in treatment methods.
  • The compounds of the present invention in labelled form, e.g. isotopically labelled, may be used as a diagnostic agent.
  • This invention relates to methods of making compounds of any of the formulae herein comprising reacting any one or more of the compounds of the formulae delineated herein, including any processes delineated herein. The compounds of formula (I) above may be prepared by, or in analogy with, conventional methods, and especially according to or in analogy with the following methods. Further, the pharmacology in-vitro was studied using the following reagents and methods.
  • The chemicals used in the synthetic routes delineated herein may include, for example, solvents, reagents, catalysts, and protecting group and deprotecting group reagents. The methods described above may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compounds. In addition, various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing applicable compounds are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and subsequent editions thereof.
  • All publications mentioned herein are hereby incorporated by reference. By the expression “comprising” means “including but not limited to.” Thus, other non-mentioned substances, additives or carriers may be present.
  • The invention will now be described in reference to the following Examples. These Examples are not to be regarded as limiting the scope of the present invention, but shall only serve in an illustrative manner.
    • EXAMPLES BIOLOGICAL EXAMPLES Scintillation Proximity Assay
  • [1,2(n)-3H]-cortisone was purchased from Amersham Pharmacia Biotech. Anti-cortisol monoclonal mouse antibody, clone 6D6.7 was obtained from Immunotech and Scintillation proximity assay (SPA) beads coated with monoclonal antimouse antibodies were from Amersham Pharmacia Biotech. NADPH, tetrasodium salt was from Calbiochem and glucose-6-phosphate (G-6-P) was supplied by Sigma. The human 11-β-hydroxysteroid dehydrogenase type-1 enzyme (11-β-HSD1) was expressed in Pichia pastoris. 18-β-glycyrrhetinic acid (GA) was obtained from Sigma. The serial dilutions of the compounds were performed on a Tecan Genesis RSP 150. Compounds to be tested were dissolved in DMSO (1 mM) and diluted in 50 mM Tris-HCl, pH 7.2 containing 1 mM EDTA.
  • The multiplication of plates was done on a WallacQuadra. The amount of the product [3H]-cortisol, bound to the beads was determined in a Packard, Top Count microplate liquid scintillation counter.
  • The 11-β-HSD1 enzyme assay was carried out in 96 well microtiter plates (Packard, Optiplate) in a total well volume of 220 μL and contained 30 mM Tris-HCl, pH 7.2 with 1 mM EDTA, a substrate mixture tritiated Cortisone/NADPH (175 nM/181 μM), G-6-P (1 mM) and inhibitors in serial dilutions (9 to 0.15 μM). Reactions were initiated by the addition of human 11-β-HSD1, either as Pichia pastoris cell homogenate or microsomes prepared from Pichia pastoris (the final amount of enzyme used was varied between 0.057 to 0.11 mg/mL). Following mixing, the plates were shaken for 30 to 45 minutes at room temperature. The reactions were terminated with 10 gL 1 mM GA stop solution. Monoclonal mouse antibody was then added (10 μL of 4 μM) followed by 100 μL of SPA beads (suspended according to the manufacturers instructions). Appropriate controls were set up by omitting the 11-β-HSD1 to obtain the non-specific binding (NSB) value.
  • The plates were covered with plastic film and incubated on a shaker for 30 minutes, at room temperature, before counting. The amount of [3H]-cortisol, bound to the beads was determined in a microplate liquid scintillation counter. The calculation of the Ki values for the inhibitors was performed by use of Activity Base. The Ki value is calculated from IC50 and the Km value is calculated using the Cheng Prushoff equation (with reversible inhibition that follows the Michaelis-Menten equation): Ki=IC50(1+[S]/Km) [Cheng, Y. C.; Prushoff, W. H. Biochem. Pharmacol. 1973, 22, 3099-3108]. The IC50 is measured experimentally in an assay wherein the decrease of the turnover of cortisone to cortisol is dependent on the inhibition potential of each substance. The Ki values of the compounds of the present invention for the 11-β-HSD1 enzyme lie typically between about 10 nM and about 10 μM. Below follow some Ki examples according to the present invention.
  • Example Ki value (nM)
    10 250
    14 107
    48 174
    • Cloning, Expression and Purification of 11β-HSD1
  • The expression and purification of the murine enzyme is described by J. Zhang, et al. Biochemistry, 44, 2005, pp 6948-57. The expression and purification of the human enzyme is similar to that of the murine sequence.
    • Enzyme Assay:
  • The IC50 and Ki of the compounds are determined by the following method:
  • 1. Prepare an Assay Buffer, (pH 7.2, 50 mM Tris-HCL, 1 mM EDTA) fresh each week.
  • 2. Prepare the following solutions:
  • NADPH (Sigma, 200 μM)
  • 3H-Cortisone(Amersham Biosciences, 45 Ci/mmol, 200 nM)
  • Enzyme Prep (20 nM for human, 10 nM for mouse)
  • Cortisol Antibody (East Coast Biologicals, (1:50 dilution)
  • Anti-mouse SPA beads (Amersham Biosciences, 15 mg/ml)
  • 18β-Glycyrrhetinic acid (“GA”) (Aldrich, 1 μM)
  • Compound Stock Solution (10 mM in DMSO), serially diluted in assay buffer. Each compound is tested at six different concentrations usually (10 μM to 0.1 nM). All of the solutions and dilutions are made in the Assay Buffer.
  • 3. Assay is run using white/white, 96-well assay plates (Corning) in a total volume of 100 μL.
  • 4. Into each well of a 96-well plate is added Assay Buffer (30 μL), compound (10 μL) NADPH (10 μL), and 3H-cortisone (10 μL).
  • 5. Initiate reaction by adding 40 μL of HSD-1 enzyme prep to the wells.
  • 6. The plate is covered with tape and incubated on an orbital shaker for 1 h at RT.
  • 7. After 1 h, the tape is removed and anti-cortisol antibody (10 μL), GA solution (10 μL), and SPA bead preparation (100 μL) is added.
  • 8. The plate is incubated (30 min) on an orbital shaker at RT.
  • 9. The counts are read on a TopCount NXT reader.
  • 10. A dose-reponse curve is first plotted using the Graphpad Prism software, to generate the IC50 values.
  • With this IC50 value and the known Km value for the substrate and HSD1 enzyme, an estimated Ki can be calculated with the Chen and Prusoff equation {Ki=IC50/[1+(substrate/Km)]}.
  • In addition to the above examples, the compounds of the present invention all show 11β-HSD1 enzyme activity (IC50) in the assays ranging from 10 nM and 10 μM.
  • The following compounds exhibited activity in the Enzyme assay with IC50 values less than 20 nM:
  • 2-((3-chloro-2-methylphenyl)amino)-5-(1-methylethyl)-1,3-thiazol-4(5H)-one;
  • 5-methyl-5-(pyridin-4-yl)-2-(2-(trifluoromethyl)phenylamino)thiazol-4(5H)-one;
  • 2-((2-chlorophenyl)amino)-5-methyl-5-phenyl-1,3-thiazol-4(5H)-one;
  • (5S)-2-((2-chlorophenyl)amino)-5-methyl-5-phenyl-1,3-thiazol-4(5H)-one;
  • (5R)-2-((2-chlorophenyl)amino)-5-methyl-5-(1-methylethyl)-1,3-thiazol-4(5H)-one;
  • 2-((2-chlorophenyl)amino)-5-methyl-5-(1-methylethyl)-1,3-thiazol-4(5H)-one;
  • 2-((S)-1-cyclohexylethylamino)-5-isopropyl-5-methylthiazol-4(5H)-one;
  • (5S,7R)-2-(cyclooctylamino)-7-(methyloxy)-1-thia-3-azaspiro[4.5]dec-2-en-4-one;
  • 2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5-((tetrahydro-2H-pyran-4-yl)methyl)thiazol-4(5H)-one;
  • 2-((5-fluoro-2-methylphenyl)amino)-5-(1-methylethyl)-1,3-thiazol-4(5H)-one;
  • 2-(2-chlorophenylamino)-5-methyl-5-(tetrahydro-2H-pyran-4-yl)thiazol-4(5H)-one;
  • 2-((R)-1-(4-fluorophenyl)ethylamino)-5-isopropyl-5-methylthiazol-4(5H)-one;
  • 2-((2,5-difluorophenyl)amino)-5-(1-methylethyl)-1,3-thiazol-4(5H)-one;
  • 2-(cyclohexylmethylamino)-5-methyl-5-((S)-tetrahydrofuran-3-yl)thiazol-4(5H)-one;
  • 5-methyl-5-(1-methylethyl)-2-((2-(trifluoromethyl)phenyl)amino)-1,3-thiazol-4(5H)-one;
  • 2-((1R,2R,4S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5-propylthiazol-4(5H)-one;
  • 2-(o-toluidino)-5-cyclopentylthiazol-4(5H)-one;
  • 2-((2-fluorophenyl)amino)-1-thia-3-azaspiro[4.4]non-2-en-4-one;
  • 2-((3-fluorotricyclo[3.3.1.1˜3,7˜]dec-1-yl)amino)-5-methyl-5-(1-methylethyl)-1,3-thiazol-4(5H)-one;
  • (R)-5-isopropyl-5-methyl-2-((S)-1-phenylethylamino)thiazol-4(5H)-one;
  • 2-((2,6-dichlorophenyl)amino)-5-(1-methylethyl)-1,3-thiazol-4(5H)-one;
  • 2-(cyclohexylmethylamino)-5-((S)-tetrahydrofuran-3-yl)thiazol-4(5H)-one;
  • 2-(bicyclo[2.2.1]hept-2-ylamino)-5-isopropyl-5-methyl-1,3-thiazol-4(5H)-one;
  • 2-(2-chlorophenylamino)-5-cyclopentylthiazol-4(5H)-one;
  • 2-(2-chlorophenylamino)-5-cyclohexylthiazol-4(5H)-one;
  • 2-((2-chlorophenyl)amino)-5-(1-methylethyl)-1,3-thiazol-4(5H)-one;
  • 2-((S)-1-(4-fluorophenyl)ethylamino)-5-methyl-5-(pyridin-4-yl)thiazol-4(5H)-one;
  • 2-((S)-1-(2-fluorophenyl)ethylamino)-5-methyl-5-(pyridin-4-yl)thiazol-4(5H)-one;
  • 2-(2-fluorophenylamino)-5-((S)-tetrahydrofuran-3-yl)thiazol-4(5H)-one;
  • 2-((1R,2R,4S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5-(2,2,2-trifluoroethyl)thiazol-4(5H)-one;
  • 5-ethyl-5-methyl-2-(tricyclo[3.3.1.1˜3 ,7˜]dec-1-ylamino)-1,3-thiazol-4(5H)-one;
  • 2-(2-chlorophenylamino)-5-methyl-5-(pyridin-4-yl)thiazol-4(5H)-one;
  • 5-cyclopentyl-2-(2-fluorophenylamino)thiazol-4(5H)-one;
  • 5-cyclohexyl-2-(2-fluorophenylamino)thiazol-4(5H)-one;
  • 2-((R)-1-(2-fluorophenyl)ethylamino)-5-isopropyl-5-methylthiazol-4(5H)-one;
  • (R)-2-((S)-1-(2-fluorophenyl)ethylamino)-5-isopropyl-5-methylthiazol-4(5H)-one; and 2-((2,4-dichlorophenyl)amino)-5-(1-methylethyl)-1,3-thiazol-4(5H)-one.
    • SYNTHESIS EXAMPLES
  • Figure US20110082107A1-20110407-C00009
  • All commercial starting materials are used without any purification.
  • If the appropriate α-bromocarboxylic acid or ester not is commercially availiable, the substances has been prepared in accordance to this method:
  • The 2-amino-carboxylic acid (1.0 eq.) was suspended in 2.0 M H2SO4 (4 eq.), KBr (8 eq.) was added and the mixture was cooled in an ice-bath. NaNO2 (1.3 eq.) dissolved in water was added slowly. The reaction mixture was stirred for 4 h at ice-bath, before allowed to reach room temperature. The reaction mixture was extracted with EtOAc. The organic phase was dried over MgSO4 before concentrated in vacuum. This gave the crude product which was used in the next step without further purification (J. Org. Chem. 2002, 67 (11), 3595-3600; Xinhua Qian; Bin Zheng; Brian Burke; Manohar T. Saindane and David R. Kronenthal).
    • Methods and Materials
  • 1H nuclear magnetic resonance (NMR) and 13C NMR were recorded on a Bruker PMR 500 spectrometer at 500.1 MHz and 125.1 MHz, respectively or on a JEOL eclipse 270 spectrometer at 270.0 MHz and 67.5 MHz, respectively. All spectra were recorded using residual solvent or tetramethylsilane (TMS) as internal standard. IR spectra were recorded on a Perkin-Elmer Spectrum 1000 FT-IR spectrometer. Electrospray mass spectrometry (MS) was obtained using an Agilent MSD mass spectrometer. Accurate mass measurements were performed on a Micromass LCT dual probe. Elemental analyses were performed on a Vario El instrument or sent to Mikro Kemi in Uppsala.
  • Analytical HPLC were performed on Agilent 1100 system equipped with System A: ACE 3 (C8, 50×3.0 mm) or System B: YMC ODS-AQ, (33×3.0 mm) using the eluent system: water/0.1% TFA and CH3CN, 1 mL/min, with a gradient time of 3 min.
  • Preparative HPLC was performed on a Gilson system equipped with System A: ACE 5 C8 column (50×20 mm) gradient time 5 min, system B: YMC ODS-AQ (150×30 mm) gradient time 8.5 min or system C: YMC ODS-AQ (50×20 mm) gradient time 5 min using the eluent system: water/0.1% TFA and CH3CN. Preparative flash chromatography was performed on Merck silica gel 60 (230-400 mesh).
    • Synthetic Methodolology
  • Method A or B was used depending if the isothiocyanate or of the corresponding amine was used. The amine or the isothiocyanate was purchased from either Maybridge Plc. or from Sigma-Aldrich Co.
    • Method A
  • 1.0 eq. of the appropriate isothiocyanate was stirred in 2 M ammonia in ethanol (5 eq.) for 18 h at RT. Evaporation in vacuo afforded the crude product, which crystallized upon addition of DCM. The crystals were collected on a filter and air-dried to afford the thiourea.
    • Method B
  • 1.0 eq. of the amine and ethoxycarbonylisothiocyanate (1.0 eq) were mixed in a test tube. A violently exothermic reaction resulted in a white paste. This was taken up in 5M KOH solution and stirred at 70° C. for 2 hours at which point LC analysis indicated full hydrolysis of the intermediate. The mixture was cooled, diluted with water and extracted 3 times with chloroform. Subsequent preparative LC yielded the desired thiourea.
    • Method C
  • The thiourea (1.0 eq.) and the α-bromoester/α-bromoacid (1.0 eq.) was dissolved in acetone and heated to 60° C. in a sealed tube for 15-72 hours. The solvent was removed. And the product purified by crystallization from MeOH/preparative reverse-phase HPLC.
    • Method C1
  • The thiourea (1.0 eq.) and the α-bromoester/α-bromoacid (1.0 eq.) was mixed in water and heated in the microwave at 140° C. for 1 hour. The aqueous phase was extracted twice with DCM. The combined orgaic phases were evaporated and the obtained crude product was purified by preparative reverse-phase HPLC.
    • Method D
  • The thiourea (1.0 eq.) and the α-bromoester (1.0 eq.) was dissolved in 1,4-dioxane and heated to 100° C. in a sealed tube for 1-11 days. The solvent was removed, and the residue was purified by preparative reverse-phase HPLC.
    • Method D1
  • The thiourea (1.0 eq.) and the α-bromoester (1.0 eq.) was dissolved in THF and heated to 70° C. in a sealed tube for 1 day. The solvent was removed, and the residue was purified by preparative reverse-phase HPLC.
    • Method D2
  • The thiourea (1.0 eq.) and the α-bromoester (1.0 eq.) was dissolved in 2-propanol and heated to 95° C. in a sealed tube for 3 days. The solvent was removed, and the residue was purified by preparative reverse-phase HPLC.
    • Method D3
  • The thiourea (1.0 eq.) and the α-bromoester/α-bromoacid (1.0 eq.) was dissolved in MeCN and heated to 60° C. in a sealed tube for 2 days. The solvent was removed, and the residue was purified by preparative reverse-phase HPLC.
    • Method E
  • The amino acid (1 eq.) was suspended in 2.0 M H2SO4, KBr (8 eq.) was added and the mixture was cooled in an ice-bath. NaNO2 (1.3 eq.) dissolved in water was slowly added. The reaction mixture was stirred for 4 h while cooling was continued. The reaction mixture was then extracted with EtOAc, washed with brine and brine containing Na2S2O3. The organic phase was concentrated in vacuum. The product was used in the next step without further purification.
    • Method F
  • The thiourea (1 eq.) and 3-bromo-2-coumarone (1 eq.) was dissolved in acetone and heated to 60° C. for 3 hours. Water was added. The obtained solid was collected. Recrystallised from water/MeCN. The solid was collected. The mother liquor was concentrated and the obtained solid was dried in vaccum to give the product.
    • Method G
  • The carbonate salt of guanidine (1 eq.) and the alpha hydroxy ester (1 eq.) was dissolved in EtOH and heated to reflux for 2-10 hours. The mixture was then poured in to H2O and left at 8° C. for 16 hours. The product was collected by filtration.
    • Method H
  • The amino-oxazolone (1 eq.) and the amine (3 eq.) was added to 4 ml EtOH and put in the microwave oven at 130° C. for 30 min. The solvent was removed under vacuum and the products purified by preparative reverse-phase HPLC.
    • Method I
  • To an ice-cooled solution with 1 eq. of the thiourea in DCM was 3 eq. 5% NaOH (aq) and 2 eq. dibromobutyryl chloride added followed by a small amount of benzyltriethylammonium chloride. The reaction was allowed to reach rt and additional 5 eq. 5% NaOH (aq) was added. The DCM-layer was separated and washed twice with water, dried over MgSO4, filtered and concentrated. The product was isolated by preparative reverse-phase HPLC.
    • Method J
  • The acid (1 eq.) was dissolved in SOCl2 and heated to 60° C. for 2 hours. NBS (2 eq.), SOCl2 and 1 drop of HBr (aq) was added at r.t. The reaction was heated to reflux for 75 min. The solvent was removed under vacuum, CCl4 was added and this was filtered. CCl4 was removed under vacuum. The remaining oil was dissolved in EtOH and left for 16 hours at r.t. The solvent was then removed under vacuum. This gave the product as an α-bromoester.
    • EXAMPLES
  • Methods A-J were employed for preparing the compounds of Examples 1-79 as described below.
    • Example 1 2-(bicyclo[2.2.1]hept-2-ylamino)-5-isopropyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00010
  • Synthesis was performed from N-bicyclo[2.2.1]hept-2-ylthiourea and ethyl 2-bromoisovalerate according to Method C.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.79 (m, 3H) 0.97 (m, 3H) 1.10 (m, 3H) 1.45 (m, 4H) 1.69 (m, 1H) 2.22 (m, 2H) 2.36 (m, 1H) 3.74 (m, 1H) 4.37 (m, 1H) 9.56 (s, 1H). MS (ESI+) for C13H20N2OS m/z 253 (M+H)+.
    • Example 2 2-(bicyclo[2.2.1]hept-2-ylamino)-5-ethyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00011
  • Synthesis was performed from N-bicyclo[2.2.1]hept-2-ylthiourea and ethyl 2-bromobutyrate according to Method C.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.90 (m, 3H) 1.03-1.23 (m, 3H) 1.35-1.56 (m, 4H) 1.65-1.84 (m, 2H) 1.98 (m, 1H) 2.24 (m, 2H) 3.75 (m, 1H) 4.22-4.40 (m, 1H) 9.84 (s, 1H). MS (ESI+) for C12H18N2OS m/z 239 (M+H)+.
    • Example 3 2-(bicyclo[2.2.1]hept-2-ylamino)-5-phenyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00012
  • Synthesis was performed from N-bicyclo[2.2.1]hept-2-ylthiourea and methyl alpha-bromophenylacetate according to Method C.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 1.05-1.24 (m, 3H) 1.36-1.56 (m, 4H) 1.66-1.80 (m, 1H) 2.22-2.33 (m, 2H) 3.78-3.90 (m, 1H) 5.41 (s, 0.5H) 5.43 (s, 0.5H) 7.21-7.41 (m, 5H) 9.39 (d, J=6.35 Hz, 1H). MS (ESI+) for C16Hi8N2OS m/z 287 (M+H)+.
    • Example 4 2-(cyclohexylamino)-5-ethyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00013
  • Synthesis was performed from n-cyclohexylthiourea and ethyl 2-bromobutyrate according to Method C. Gave 201 mg (75%).
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.91 (m, 3H) 1.05-2.06 (m, 12H) 3.76 (m, 1H) 4.36 (m, 1H) 10.11 (s, 1H). MS (ESI+) for C11H18N2OS m/z 227 (M+H)+
    • Example 5 2-(bicyclo[2.2.1]hept-2-ylamino)-5,5-dimethyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00014
  • Synthesis was performed from N-bicyclo[2.2.1]hept-2-ylthiourea and Ethyl 2-bromoisobutyrate according to Method C.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 1.05-1.21 (m, 3H) 1.34-1.54 (m, 4H) 1.48 (s, 2H) 1.49 (s, 2H) 1.50 (s, 1H) 1.51 (s, 1H) 1.67-1.74 (m, 1H) 2.18-2.28 (m, 2H) 3.20 (dd, J=7.69, 2.93 Hz, 0.25H) 3.73-3.82 (m, 0.75H) 9.12 (d, J=6.59 Hz, 1H). MS (ESI+) for C12H18N2OS m/z 239 (M+H)+
    • Example 6 5-Isopropyl-2-(tricyclo[3.3.1.0˜3,7˜]non-3-ylamino)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00015
  • Synthesis was performed from N-tricyclo[3.3.1.0˜3,7˜]non-3-ylthiourea and ethyl 2-bromo-3-methylbutanoate according to Method C.
  • 1H NMR (400 MHz, DMSO-d6) δ 0.75 (d, J=6.6 Hz, 3H), 0.95 (d, J=6.8 Hz, 3H), 1.46-1.57 (m, 4H), 1.88-2.10 (m, 6H), 2.22-2.37 (m, 3H), 2.43 (t, J=6.7 Hz, 1H), 4.23 (d, J=3.5 Hz, 1H), 9.29 (s, 1H). MS (ESI+) for C15H22N2OS m/z 279 (M+H)+.
    • Example 7 6-(tricyclo[3.3.1.0˜3,7˜]non-3-ylamino)-5-thia-7-azaspiro[3.4]oct-6-en-8-one
  • Figure US20110082107A1-20110407-C00016
  • Synthesis was performed from N-tricyclo[3.3.1.0˜3,7˜]non-3-ylthiourea and ethyl 1-bromocyclobutanecarboxylate according to Method D.
  • 1H NMR (400 MHz, DMSO-d6) δ 1.45-1.57 (m, 4H), 1.90-2.16 (m, 8H), 2.22-2.27 (m, 2H), 2.44-2.55 (m, 5H, obscured by solvent signal), 9.24 (s, 1H). MS (ESI+) for C15H20N2OS m/z 277 (M+H)+.
    • Example 8 2-(Tricyclo[3.3.1.0˜3,7˜]non-3-ylamino)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00017
  • Synthesis was performed from N-tricyclo[3.3.1.0˜3,7˜]non-3-ylthiourea and ethyl bromoacetate according to Method Dl.
  • 1H NMR (400 MHz, DMSO-d6) δ 1.45-1.61 (m, 4H), 1.92-2.07 (m, 6H), 2.23 (m, 1.7H, major rotamer), 2.82 (m, 0.3H, minor rotamer), 2.45 (t, J=6.7 Hz, 0.85H, major rotamer), 2.66 (t, J=6.8 Hz, 0.15H, minor rotamer), 3.83 (s, 1.7H, major rotamer), 4.09 (s, 0.3H, minor rotamer), 9.38 (s, 1H). MS (ESI+) for C12H16N2OS m/z 237 (M+H)−.
    • Example 9 6-(Cyclooctylamino)-5-thia-7-azaspiro[3.4]oct-6-en-8-one
  • Figure US20110082107A1-20110407-C00018
  • Synthesis was performed from N-cyclooctylthiourea and ethyl 1-bromocyclobutanecarboxylate according to Method D2.
  • 1H NMR (400 MHz, DMSO-d6) δ 1.45-1.79 (m, 14H), 1.86-2.00 (m, 1H), 2.05-2.17 (m, 1H), 2.41-2.53 (m, 4H, obscured by solvent signal), 4.01 (m, 1H), 9.09 (d, J=7.5 Hz, 1H).
  • 13C NMR (100 MHz, DMSO-d6) δ 16.31, 23.07, 24.97, 26.69, 30.88, 33.52, 54.69, 60.30, 175.09, 191.25. MS (ESI+) for C14H22N2OS m/z 267 (M+H)+.
    • Example 10 6-(Cycloheptylamino)-5-thia-7-azaspiro[3.4]oct-6-en-8-one
  • Figure US20110082107A1-20110407-C00019
  • Synthesis was performed from N-cycloheptylthiourea and ethyl 1-bromocyclobutanecarboxylate according to Method D.
  • 1H NMR (400 MHz, DMSO-d6) δ 1.35-1.65 (m, 10H), 1.83-1.97 (m, 3H), 2.05-2.17 (m, 1H), 2.41-2.53 (m, 4H, obscured by solvent signal), 3.96 (m, 1H), 9.09 (d, J=7.5 Hz, 1H). MS (ESI+) for C13H20N2OS m/z 253 (M+H)+.
    • Example 11 6-(Bicyclo[2.2.1]hept-2-ylamino)-5-thia-7-azaspiro[3.4]oct-6-en-8-one
  • Figure US20110082107A1-20110407-C00020
  • Synthesis was performed from N-bicyclo[2.2.1]hept-2-ylthiourea and ethyl 1-bromocyclobutanecarboxylate according to Method D.
  • 1H NMR (400 MHz, DMSO-d6) δ 1.05-1.22 (m, 3H), 1.33-1.49 (m, 4H), 1.63-1.70 (m, 1H), 1.86-2.00 (m, 1H), 2.05-2.22 (m, 3H), 2.42-2.53 (m, 4H, obscured by solvent signal), 3.74 (m, 1H), 8.98 (d, J=7.5 Hz, 1H). MS (ESI+) for C13H18N2OS m/z 251 (M+H)+.
    • Example 12 6-[(2,2,3,3-Tetramethylcyclopropyl)amino]-5-thia-7-azaspiro[3.4] oct-6-en-8-one
  • Figure US20110082107A1-20110407-C00021
  • Synthesis was performed from N-(2,2,3,3-tetramethylcyclopropyl)thiourea and ethyl 1-bromocyclobutanecarboxylate according to Method D.
  • 1H NMR (400 MHz, DMSO-d6) δ 0.92 (s, 3H), 0.94 (s, 3H), 1.06 (s, 3H), 1.08 (s, 3H), 1.88-2.00 (m, 1H), 2.01 (s, 1H), 2.06-2.17 (m, 1H), 2.40-2.54 (m, 4H, obscured by solvent signal), 8.78 (s br., 1H). MS (ESI+) for C13H20N2OS m/z 253 (M+H)+.
    • Example 13 6-[(2-Methylphenyl)amino]-5-thia-7-azaspiro[3.4]oct-6-en-8-one
  • Figure US20110082107A1-20110407-C00022
  • Synthesis was performed from N-(2-methylphenyl)thiourea and ethyl 1-bromocyclobutanecarboxylate according to Method D.
  • 1H NMR (400 MHz, DMSO-d6) δ 1.89 (m, 1H), 2.04-2.13 (m, 1H), 2.08 (s, 3H), 2.39-2.48 (m, 2H), 2.56-2.66 (m, 2H), 6.81 (d, J=7.6 Hz, 1H), 7.03 (m, 1H), 7.14 (m, 1H), 7.20 (d, J=7.4 Hz, 1H), 11.67 (s br., 1H). MS (ESI+) for C13H14N2OS m/z 247 (M+H)+.
    • Example 14 2-[(cyclohexylmethyl)amino]-5,5-dimethyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00023
  • Synthesis was performed from N-(cyclohexylmethyl)thiourea and ethyl 2-bromoisobutyrate according to Method C.
  • 1H NMR (270 MHz, DMSO-d6) δ ppm 0.81-1.04 (m, 2H) 1.03-1.32 (m, 3H) 1.43-1.54 (m, 6H) 1.55-1.78 (m, 6H) 3.18-3.32 (m, 2H) 9.28 (s, 1H). MS (ESI+) for C12H20N2OS m/z 242 (M+H)+.
    • Example 15 2-[(2-fluorophenyl)amino]-5-isopropyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00024
  • Synthesis was performed from N-(2-fluorophenyl)thiourea and Ethyl 2-bromo-2-methylbutyrate according to Method C.
  • 1H NMR (270 MHz, DMSO-d6) δ ppm 0.79-0.98 (m, 6H) 2.29-2.44 (m, 1H) 4.48 (d, J=3.59 Hz, 1H) 6.91-7.40 (m, 4H). MS (ESI+) for C12H13FN2OS m/z 253 (M+H)−.
    • Example 16 2-[(cyclohexylmethyl)amino]-5-(2-hydroxyphenyl)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00025
  • Synthesis was performed from N-(cyclohexylmethyl)thiourea and 3-bromo-2-coumarone according to Method F.
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.80-1.00 (m, 2H) 1.05-1.27 (m, 3H) 1.55-1.81 (m, 6H) 3.24-3.34 (m, 2H), 5.42 (s, 1H) 6.73-6.81 (m, 2H) 7.02-7.14 (m,2H) 9.19 (br.s, 1H, N—H) 9.81 (br.s, 1H, N—H). MS (ESI+) for C16H20N2O2S m/z 305 (M+H)+.
    • Example 17 (5S)-2-(cycloheptylamino)-5-methyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00026
  • Synthesis was performed from N-cycloheptylthiourea and (2S)-2-bromopropanoic acid according to Method C.
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.35-1.70 (m, 12H) 1.45 (d, J=7.3 Hz, 3H) 1.72-2.00 (m, 1H) 3.90-4.03 (m, 1H). MS (ESI+) for C11H18N2OS m/s 227 (M+H)+.
    • Example 18 (5R)-2-(cycloheptylamino)-5-methyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00027
  • Synthesis was performed from N-cycloheptylthiourea and (2R)-2-bromopropanoic acid according to Method C.
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.36-1.70 (m, 12H) 1.45 (d, J=7.5 Hz, 3H) 1.82-1.96 (m, 1H) 3.93-4.02 (m, 1H). MS (ESI+) for C11H18N2OS m/z 227 (M+H)+.
    • Example 19 2-(cycloheptylamino)-5-ethyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00028
  • Synthesis was performed from N-cycloheptylthiourea and 2-bromobutyric acid according to Method C.
  • 1H NMR (270 MHz, METHANOL-d4) δppm 0.90-1.06 (m, 3H) 1.40-2.17 (m, 14H) 4.26 (dd, J=7.86, 4.02 Hz, 1H) 4.52-4.68 (m, 1H). MS (ESI+) for C12H20N2OS m/z 241 (M+H)+.
    • Example 20 2-(cycloheptylamino)-5-isopropyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00029
  • Synthesis was performed from N-cycloheptylthiourea and Ethyl 2-bromo-2-methylbutyrate according to Method C.
  • 1H NMR (270 MHz, METHANOL-d4) mixture of three different rotamers ˜40%/30%/30% only the major; δ ppm 0.92-1.08 (m, 6H) 1.43-2.16 (m, 12H) 2.39-2.56 (m, 1H) 3.98-4.20 (m, 1H) 4.24-4.34 (m, 1H). MS (ESI+) for C13H22N2OS m/z 255 (M+H)+.
    • Example 21 5-tert-butyl-2-(cycloheptylamino)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00030
  • Synthesis was performed from 2-amino-3,3-dimethylbutanoic acid and N-cycloheptylthiourea according to Method E and C.
  • 1H NMR (270 MHz, METHANOL-d4) δ ppm 0.83-0.94 (m, 4.5H) 0.98-1.12 (m, 4.5H) 1.47-1.97 (m, 11H) 2.36-2.58 (m, 1H) 4.03-4.18 (m, 1H) 4.34-4.42 (m, 1H). MS (ESI+) for C14H24N2OS m/z 269 (M+H)+.
    • Example 22 2-(cyclooctylamino)-5-ethyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00031
  • Synthesis was performed from N-cyclooctyl-thiourea and 2-bromo-butyric acid according to Method C1.
  • 1H NMR (270 MHz, METHANOL-d4) δ ppm 0.89-1.03 (m, 3H) 1.43-1.99 (m, 15H) 1.98-2.16 (m, 1H) 4.21-4.32 (m, 1H) 4.55-4.66 (m, 1H). MS (ESI+) for C13H22N2OS m/z 255 (M+H)+.
    • Example 23 5-isopropyl-2-[(2-isopropylphenyl)amino]-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00032
  • Synthesis was performed from N-(2-isopropylphenyl)thiourea and 2-bromo-3-methylbutyric acid according to Method C1.
  • 1H NMR (270 MHz, DMSO-d6) δ ppm 0.87 (dd, J=8.78, 6.80 Hz, 6H) 1.12-1.17 (m, 6H) 2.28-2.44 (m, 1H) 2.93-3.09 (m, 1H) 4.40 (d, J=3.46 Hz, 1H) 6.83 (dd, J=7.24, 1.79 Hz, 1H) 7.07-7.21 (m, 2H) 7.26-7.36 (m, 1H).
  • MS (ESI+) for C15H20N2OS m/z 277 (M+H)+.
    • Example 24 5-ethyl-2-[(2-isopropylphenyl)amino]-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00033
  • Synthesis was performed from N-(2-isopropylphenyl)thiourea and 2-bromo-butyric acid according to Method C1.
  • 1H NMR (270 MHz, DMSO-d6) δ ppm 0.88 (t, J=7.30 Hz, 3H) 1.14 (d, J=6.93 Hz, 6H) 1.63-2.06 (m, 2H) 2.93-3.11 (m, 1H) 4.32 (dd, J=7.36, 4.27 Hz, 1H) 6.75-6.92 (m, 1H) 7.06-7.21 (m, 2H) 7.24-7.42 (m, 1H). MS (ESI+) for C14H18N2OS m/z 263 (M+H)+.
    • Example 25 2-[(2-chlorophenyl)amino]-5-ethyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00034
  • Synthesis was performed from N-(2-chlorophenyl)thiourea and 2-bromo-butyric acid according to Method C1.
  • 1H NMR (270 MHz, METHANOL-4δ ppm 1.01-1.23 (m, 3H) 1.98-2.34 (m, 2H) 4.58-4.72 (m, 1H) 7.28-7.54 (m, 3H) 7.54-7.68 (m, 1H). MS (ESI+) for C11H11ClN2OS m/z 255 (M+H)+.
    • Example 26 5-ethyl-2-[(2-methylphenyl)amino]-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00035
  • Synthesis was performed from N-(2-methylphenyl)thiourea and 2-bromo-butyric acid according to Method C1.
  • 1H NMR (270 MHz, METHANOL-d4) δ ppm 1.07-1.18 (m, J=7.36, 7.36 Hz, 3H) 1.98-2.36 (m, 2H) 2.11-2.13 (m, 3H) 4.52-4.75 (m, 1H) 7.12 (dd, J=20.54, 7.67 Hz, 1H) 7.22-7.46 (m, 3H). MS (ESI+) for C12H14N2OS m/z 235 (M+H)+.
    • Example 27 5-isopropyl-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00036
  • Synthesis was performed from N-(2,2,3,3-tetramethylcyclopropyl)thiourea and ethyl-2-bromoisovalerate according to Method C.
  • 1H NMR (400 MHz, CDCl3) δ ppm 0.99 (d, J=6.6 Hz, 3H), 1.08-1.16 (m, 9H), 1.20 (d, J=3.4 Hz, 6H), 2.17 (s, 1H), 2.59-2.72 (m, 1H), 4.25 (d, J=3.9 Hz, 1H). MS (ES+) m/z 255 (M+H+).
    • Example 28 2-(bicyclo[2.2.1]hept-2-ylamino)-5-(4-hydroxybenzyl)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00037
  • Synthesis was performed from (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid and N-bicyclo[2.2.1]hept-2-ylthiourea according to Method E and C.
  • 1H NMR (270 MHz, DMSO-d6) δ 1.11 (d, J=9.65 Hz, 3H) 1.24-1.54 (m, 4H) 1.56-1.76 (m, 1H) 2.04-2.27 (m, 2H) 2.61-2.84 (m, 1H) 3.26 (dd, J=14.10, 3.96 Hz, 1H) 3.70 (s, 1H) 4.42-4.52 (obscured by HDO peak) (m, 1H) 6.57-6.72 (m, 2H) 6.92-7.08 (m, 2H) 9.07 (d, J=6.19 Hz, 1H)
  • 1H NMR (270 MHz, METHANOL-4) δ 1.07-1.62 (m, 7H) 1.67-1.88 (m, 1H) 2.07-2.36 (m, 2H) 2.92-3.11 (m, 1H) 3.32-3.44 (partly obscured by MeOD peak) (m, 1H) 3.64-3.76 (m, 1H) 4.51-4.68 (m, 1H) 6.62-6.76 (m, 2H) 6.99-7.12 (m, 2H). MS (ESI+) for C17H20N2O2S m/z 317 (M+H)−
    • Example 29-5 [(cyclohexylmethyl)amino]-4-thia-6-azaspiro[2.4]hept-5-en-7-one
  • Figure US20110082107A1-20110407-C00038
  • Synthesis was performed from N-(cyclohexylmethyl)thiourea according to Method I.
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.94-1.07 (m, 2H) 1.10-1.36 (m, 3H) 1.49-1.54 (m, 2H) 1.66-1.86 (m, 8H) 3.19 (d, J=6.59 Hz, 2H). MS m/z 239 (M+H)+
    • Example 30 2-(cycloheptylamino)-5-(3,4-dihydroxybenzyl)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00039
  • Synthesis was performed from (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid and N-cycloheptylthiourea according to Method E and C.
  • 1H NMR (500 MHz, Solvent) δ 1.43-1.57 (m, 6H) 1.56-1.73 (m, 5H) 1.84-2.01 (m, 2H) 2.87 (dd, J=14.13, 9.42 Hz, 1H) (1H hidden in MeOD peak) 3.97-4.06 (m, 1H) 4.44-4.51 (m, 1H) 6.52-6.57 (m, 1H) 6.64-6.68 (m, 2H). MS (ESI+) for C17H22N2O3S m/z 335 (M+H)+
    • Example 31 2-(cycloheptylamino)-5-(1H-imidazol-4-ylmethyl)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00040
  • Synthesis was performed from (2S)-2-amino-3-(1H-imidazol-4-yl)propanoic acid and N-cycloheptylthiourea according to Method E and C.
  • 1H NMR (270 MHz, METHANOL-d4) δ 1.43-2.06 (m, 12H) 3.33-3.56 (m, 2H) 3.93-4.08 (m, 1H) 4.57-4.69 (m, 1H) 7.27-7.42 (m, 1H) 8.76-8.87 (m, 1H). MS (ESI+) for C14H20N4OS m/z 293 (M+H)+
    • Example 32 2-(cycloheptylamino)-5-isobutyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00041
  • Synthesis was performed from (2S)-2-amino-4-methylpentanoic acid and N-cycloheptylthiourea according to Method E and C.
  • 1H NMR (270 MHz, METHANOL-d4) δ 0.91-1.04 (m, 6H) 1.43-1.86 (m, 12H) 1.92-2.12 (m, 3H) 3.95-4.11 (m, 1H) 4.29-4.48 (m, 1H). MS (ESI+) for C14H24N2OS m/z 269 (M+H)+
    • Example 33 2-(cycloheptylamino)-5-(1H-indol-3-ylmethyl)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00042
  • Synthesis was performed from (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid and N-cycloheptylthiourea according to Method E and C.
  • 1H NMR (270 MHz, CHLOROFORM-D) δ 1.27-1.80 (m, 11H) 1.84-1.99 (m, 1H) 3.23-3.40 (m, 2H) 3.76 (dd, J=15.09, 3.46 Hz, 1H) 4.65 (d, J=9.15, 3.96 Hz, 1H) 7.10-7.28 (m, 3H) 7.40 (d, J=7.92 Hz, 1H) 7.59 (d, J=7.92 Hz, 1H) 8.26 (s, 1H). MS (ESI+) for C19H23N3OS m/z 342 (M+H)+
    • Example 34 2-(cycloheptylamino)-5-(4-hydroxybenzyl)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00043
  • Synthesis was performed from (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid and N-cycloheptylthiourea according to Method E and C.
  • 1H NMR (270 MHz, METHANOL-d4) δ ppm 1.37-2.07 (m, 12H) 2.91-3.11 (m, 1H) 3.32-3.43 (m, 1H) 3.86-4.02 (m, 1H) 4.48-4.66 (m, 1H) 6.60-6.76 (m, 2H) 6.99-7.11 (m, 2H). MS (ESI+) for C17H22N2O2S m/z 319 (M+H)+
    • Example 35 (5R)-2-(cycloheptylamino)-5-(cyclohexylmethyl)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00044
  • Synthesis was performed from (2S)-2-amino-3-cyclohexylpropanoic acid and N-cycloheptylthiourea according to Method E and C.
  • 1H NMR (270 MHz, CHLOROFORM-D) δ ppm 0.85-1.90 (m, 22H) 1.93-2.10 (m, 2H) 2.14-2.30 (m, 1H) 3.35-3.57 (m, 1H) 4.23 (dd, J=11.32, 3.77 Hz, 1H). MS (ESI+) for C17H28N2OS m/z 309 (M+H)−
    • Example 36 2-(cyclooctylamino)-5-(4-hydroxybenzyl)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00045
  • Synthesis was performed from (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid and N-cyclooctylthiourea according to Method E and C.
  • 1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.41-1.95 (m, 14H) 3.07 (dd, J=14.47, 9.65 Hz, 1H) 3.43-3.59 (m, 2H) 4.46 (dd, J=9.65, 3.96 Hz, 1H) 6.81 (d, J=8.41 Hz, 2H) 7.08 (d, J=8.41 Hz, 2H). MS (ESI+) for C18H24N2O2S m/z 333 (M+H)+
    • Example 37 (5S)-2-(cycloheptylamino)-5-(cyclohexylmethyl)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00046
  • Synthesis was performed from (2R)-2-amino-3-cyclohexylpropanoic acid and N-cycloheptylthiourea according to Method E and C.
  • 1H NMR (270 MHz, CHLOROFORM-D) δ ppm 0.87-1.86 (m, 22H) 1.89-2.11 (m, 2H) 2.11-2.30 (m, 1H) 3.34-3.60 (m, 1H) 4.23 (dd, J=11.32, 3.77 Hz, 1H) 8.81 (br.s, 1H). MS (ESI+) for C17H28N2OS m/z 309 (M+H)+
    • Example 38 [2-(cycloheptylamino)-4-oxo-4,5-dihydro-1,3-thiazol-5-yl]acetonitrile
  • Figure US20110082107A1-20110407-C00047
  • Synthesis was performed from (2S)-2-amino-3-cyanopropanoic acid and N-cycloheptylthiourea according to Method E and C.
  • 1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.36-2.14 (m, 12H) 2.85-3.11 (m, 1H) 3.12-3.32 (m, 1H) 3.43-3.58 (m, 1H) 4.31-4.46 (m, 1H). MS (ESI+I) for C12H17N3OS m/z 252 (M+H)+
    • Example 39 5-ethyl-2-[(3-methylphenyl)amino]-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00048
  • Commercial compound, SPECS.
  • MS (HI+) for C12H14N2OS m/z 235 (M+H)+
  • HPLC 99%, RT=2.10 min (System A, 10-97% MeCN over 3 min).
  • HPLC 99%, RT=1.58 min (System B, 10-97% MeCN over 3 min).
    • Example 40 2-(cycloheptylamino)-5-(pyridin-3-ylmethyl)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00049
  • Synthesis was performed from (2S)-2-amino-3-pyridin-3-ylpropanoic acid and N-cycloheptylthiourea according to Method E and C.
  • 1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.39-1.84 (m, 9H) 1.88-2.06 (m, 2H) 3.39-3.54 (m, 1H) 3.64 (s, 2H) 3.97 (s, 1H) 4.75 (s, 1H) 7.84-7.95 (m, 1H) 8.34 (d, J=7.67 Hz, 1H) 8.75 (d, J=5.07 Hz, 1H) 9.10 (s, 1H). MS (ESI+) for C16H21N3OS m/z 304 (M+H)+
    • Example 41 5-Isopropyl-2-[(2-methylphenyl)amino]-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00050
  • Synthesis was performed from N-(2-methylphenyl)thiourea and ethyl 2-bromo-3-methylbutanoate according to Method C.
  • 1H NMR (400 MHz, DMSO-d6) δ 0.84 (d, J=6.6 Hz, 3H), 0.88 (d, J=7.0 Hz, 3H), 2.10 (s, 3H), 2.34 (m, 1H), 4.32 (d, J=3.4 Hz, 1H), 6.83 (d, J=7.8 Hz, 1H), 7.03 (m, 1H), 7.16 (m, 1H), 7.21 (d, J=7.6 Hz, 1H). MS (ESI+) for C13H16N2OS m/s 249 (M+H)+.
    • Example 42 2-(Cyclooctylamino)-5,5-dimethyl-1,3-thiazol-4(5H)-one
  • Synthesis was performed from ethyl-2-bromo-2-methylpropanoate and N-cyclooctylthiourea according to Method C1.
  • 1H NMR (270 MHz, DMSO-d6) δ ppm 1.46 (s, 3H), 1.47 (s, 3H), 1.81-1.43 (m, 15H). MS (EI+) for C13H22N2OS m/z 255 (M+H)+.
    • Example 43 2-(Cyclooctylamino)-5-isopropyl-1,3-thiazol-4(5H)-one
  • Synthesis was performed from 2-bromo-3-methylbutyric acid and N-cyclooctylthiourea according to Method C1.
  • 1H NMR (270 MHz, METHANOL-d4) Major isomer: δ ppm 0.85 (d, J=6.68 Hz, 3H) 1.01 (d, J=6.93 Hz, 3H) 1.44-1.91 (m, 14H) 2.36-2.52 (m, 1H) 3.98-4.12 (m, 1H) 4.36 (d, J=3.71 Hz, 1H). MS (EI+) for C14H24N2OS m/z 269 (M+H)+.
    • Example 44 2-(Bicyclo[2.2.1]hept-2-ylamino)-1-thia-3-azaspiro[4.5]dec-2-en-4-one
  • Figure US20110082107A1-20110407-C00051
  • Synthesis was performed from N-bicyclo[2.2.1]hept-2-ylthiourea and methyl 1-bromocyclohexanecarboxylate according to Method D.
  • 1H NMR (400 MHz, CDCl3) δ 1.12-2.44 (m, 21H), 3.34 (m, 1H).
  • MS (ESI+) for C15H22N2OS m/z 279 (M+H)+.
    • Example 45 2-(Tricyclo[3.3.1.0˜3,7˜]non-3-ylamino)-1-thia-3-azaspiro[4.5]dec-2-en-4-one
  • Figure US20110082107A1-20110407-C00052
  • Synthesis was performed from N-tricyclo[3.3.1.0˜3,7˜]non-3-ylthiourea and methyl 1-bromocyclohexanecarboxylate according to Method D.
  • 1H NMR (400 MHz, CDCl3) δ 1.24-2.19 (m, 20H), 2.30 (m, 0.5H, minor rotamer), 2.41 (m, 1.5H, major rotamer), 2.53 (m, 0.25H, minor rotamer), 2.75 (m, 0.75H, major rotamer).
  • MS (ESI+) for C17H24N2OS m/z 305 (M+H)+.
    • Example 46 2-(Cycloheptylamino)-1-thia-3-azaspiro[4.5]dec-2-en-4-one
  • Figure US20110082107A1-20110407-C00053
  • Synthesis was performed from N-cycloheptylthiourea and methyl 1-bromocyclohexanecarboxylate according to Method D.
  • 1H NMR (400 MHz, CDCl3) δ 1.24-2.14 (m, 23H), 3.48 (m, 1H).
  • MS (ESI+) for C15H24N2OS m/z 281 (M+H)+.
    • Example 47 2-(Cyclooctylamino)-1-thia-3-azaspiro[4.5]dec-2-en-4-one
  • Figure US20110082107A1-20110407-C00054
  • Synthesis was performed from N-cyclooctylthiourea and methyl 1-bromocyclohexanecarboxylate according to Method D.
  • 1H NMR (400 MHz, CDCl3) δ 1.24-2.13 (m, 25H), 3.55 (m, 1H).
  • MS (ESI+) for C16H26N2OS m/z 295 (M+H)+.
    • Example 48 2-{[1-(4-Chlorophenyl)cyclobutyl]amino}-5-isopropyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00055
  • Synthesis was performed from N-[1-(4-chlorophenyl)cyclobutyl]thiourea and ethyl 2-bromo-3-methylbutanoate according to Method D.
  • 1H NMR (400 MHz, DMSO-d6) δ 0.60 (d, J=6.5 Hz, 0.75H, minor rotamer), 0.68 (d, J=6.6 Hz, 2.25H, major rotamer), 0.82 (d, J=6.8 Hz, 0.75H, minor rotamer), 0.92 (d, J=6.8 Hz, 2.25H, major rotamer), 1.77-1.87 (m, 1H), 1.93-2.03 (m, 1H), 2.21-2.33 (m, 1H), 2.42-2.65 (m, 4H, obscured by solvent signal), 4.14 (d, J=3.5 Hz, 0.25H, minor rotamer), 0.68 (d, J=3.7 Hz, 0.75H, major rotamer), 7.38 (m, 3H, major rotamer), 7.45 (m, 1H, minor rotamer), 9.87 (s, 1H).
  • MS (ESI+) for C16H19ClN2OS m/z 323 (M+H)+.
    • Example 49 6-{[1-(4-Chlorophenyl)cyclobutyl]amino}-5-thia-7-azaspiro[3.4]oct-6-en-8-one
  • Figure US20110082107A1-20110407-C00056
  • Synthesis was performed from N-[1-(4-chlorophenyl)cyclobutyl]thiourea and ethyl 1-bromocyclobutanecarboxylate according to Method D.
  • 1H NMR (400 MHz, DMSO-d6) δ 1.73-2.12 (m, 4H), 2.32-2.60 (m, 8H, obscured by solvent signal), 7.39 (m, 3.3H, major rotamer), 7.44 (m, 0.7H, minor rotamer), 9.83 (s, 1H).
  • MS (ESI+) for C16H17ClN2OS m/z 321 (M+H)+.
    • Example 50 2-(cycloheptylamino)-5,5-diethyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00057
  • Synthesis was performed from N-cycloheptylthiourea and 2-ethylbutyric acid according to Method J and D.
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.89-1.01 (m, 6H) 1.40-2.09 (m, 16H) 3.44-3.55 (m, 1H)
  • MS (ESI+) for C14H24N2OS m/z 269 (M+H)+
    • Example 51 (5S)-5-isopropyl-2-{[(2S)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00058
  • Synthesis was performed from N-[(2S)-2-phenylpropyl]thiourea and 2-bromo-3-methylbutyric acid according to Method D3.
  • 1H NMR (270 MHz, DMSO-d6) the major rotamer δ ppm 0.54-0.85 (m, 3H) 0.84-1.08 (m, 3H) 1.08-1.37 (m, 3H) 2.18-2.43 (m, 1H) 2.91-3.22 (m, 1H) 3.27-3.47 (m, J=7.30 Hz, 1H) 3.44-3.62 (m, 1H) 4.18-4.37 (m, 1H) 6.95-7.43 (m, 5H) 9.26 (s, 1H, N—H).
  • MS (ESI+) for C15H20N2OS m/z 277 (M+H)+.
    • Example 52 (5R)-5-ethyl-2-{[(2S)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00059
  • Synthesis was performed from N-[(2S)-2-phenylpropyl]thiourea and 2-bromo-butyric acid according to Method D3.
  • 1H NMR (270 MHz, DMSO-d6) the major rotamer δ ppm 0.51-0.70 (m, 3H) 1.10-1.36 (m, 3H) 1.45-1.80 (m, 1H) 3.11-3.34 (m, 1H) 3.65-3.84 (m, 2H) 3.80-4.07 (m, 1H) 4.30-4.48 (m, 1H) 7.10-7.41 (m, 5H).
  • MS (ESI+) for C14H18N2OS m/z 263 (M+H)+.
    • Example 53 (5S)-5-ethyl-2-{[(2S)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00060
  • Synthesis was performed from N-[(2S)-2-phenylpropyl]thiourea and 2-bromo-butyric acid according to Method D3.
  • 1H NMR (270 MHz, DMSO-d6) the major rotamer δ ppm 0.73-0.97 (m, 3H) 1.10-1.35 (m, 3H) 1.53-1.82 (m, 1H) 1.83-2.11 (m, 1H) 2.92-3.13 (m, 1H) 3.48-3.67 (m, 2H) 4.10-4.32 (m, 1H) 7.09-7.45 (m, 5H) 9.27 (s, 1H, N—H).
  • MS (ESI+) for C14H18N2OS m/z 263 (M+H)+.
    • Example 54 (5R)-5-isopropyl-2-{[(2R)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00061
  • Synthesis was performed from N-[(2R)-2-phenylpropyl]thiourea and 2-bromo-3-methylbutyric acid according to Method D3.
  • 1H NMR (270 MHz, DMSO-d6) the major rotamer δ ppm 0.50-0.80 (m, 3H) 0.84-1.06 (m, 3H) 1.09-1.32 (m, 3H) 2.22-2.43 (m, 1H) 2.91-3.19 (m, 1H) 3.27-3.45 (m, 2H) 4.14-4.38 (m, 1H) 7.07-7.44 (m, 5H) 9.25 (s, 1H, N—H).
  • MS (ESI+) for C15H20N2OS m/z 277 (M+H)+.
    • Example 55 (5S)-5-isopropyl-2-{[(2R)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00062
  • Synthesis was performed from N-[(2R)-2-phenylpropyl]thiourea and 2-bromo-3-methylbutyric acid according to Method D3.
  • 1H NMR (270 MHz, DMSO-d6) the major rotamer δ ppm 0.40-0.58 (m, J=6.68 Hz, 3H) 0.71-0.87 (m, 3H) 1.03-1.29 (m, 3H) 2.11-2.24 (m, 1H) 3.62-3.81 (m, 2H) 3.83-4.03 (m, 1H) 4.36-4.51 (m, 1H) 7.10-7.41 (m, 5H).
  • MS (ESI+) for C15H20N2OS m/z 277 (M+H)+.
    • Example 56 (5R)-5-ethyl-2-{[(2R)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00063
  • Synthesis was performed from N-[(2R)-2-phenylpropyl]thiourea and 2-bromo-butyric acid according to Method D3.
  • 1H NMR (270 MHz, DMSO-d6) the major rotamer δ ppm 0.75-0.97 (m, 3H) 1.05-1.35 (m, 3H) 1.58-1.82 (m, 1H) 1.82-2.05 (m, 1H) 2.92-3.17 (m, 1H) 3.44-3.65 (m, 2H) 4.12-4.36 (m, 1H) 7.09-7.49 (m, 5H) 9.26 (s, 1H).
  • MS (ESI+) for C14H18N2OS m/z 263 (M+H)+.
    • Example 57 (5S)-5-ethyl-2-{[(2R)-2-phenylpropyl]amino}-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00064
  • Synthesis was performed from N-[(2R)-2-phenylpropyl]thiourea and 2-bromo-butyric acid according to Method D3.
  • 1H NMR (270 MHz, DMSO-d6) the major rotamer δ ppm 0.53-0.74 (m, J=7.30, 7.30 Hz, 3H) 1.08-1.33 (m, 3H) 1.43-1.63 (m, 1H) 1.62-1.89 (m, 1H) 3.13-3.36 (m, 1H) 3.66-3.86 (m, J=13.61, 7.17 Hz, 1H) 3.83-4.04 (m, 1H) 4.26-4.51 (m, J=4.95 Hz, 1H) 7.09-7.44 (m, 5H).
  • MS (ESI+) for C14H18N2OS m/z 263 (M+H)+.
    • Example 58 2-Anilino-5-isopropyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00065
  • Synthesis was performed from N-phenylthiourea and ethyl 2-bromo-3-methylbutanoate according to Method C.
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.00 (s, 6H), 2.40-2.73 (m, 1H), 4.04-4.34 (m, 1H), 7.01-7.56 (m, 6H); MS [M+H]+ m/z=235.
    • Example 59 5-Isopropyl-2-[(2-morpholin-4-ylethyl)amino]-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00066
  • Synthesis was performed from N-(2-morpholin-4-ylethyl)thiourea and ethyl 2-bromo-3-methylbutanoate according to Method C.
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.70-1.25 (m, 8H), 2.58 (s, 1H), 2.78-4.09 (m, 10H), 4.18-4.54 (m, 1H); MS [M+H]+ m/z=272.
    • Example 60 2-(Bicyclo[2.2.1]hept-2-ylamino)-1-thia-3-azaspiro[4.4]non-2-en-4-one Example 61 2-(Cycloheptylamino)-1-thia-3-azaspiro[4.4]non-2-en-4-one Example 62 2-(Cyclooctylamino)-1-thia-3-azaspiro[4.4]non-2-en-4-one Example 63 2-[(2,2,3,3-Tetramethylcyclopropyl)amino]-1-thia-3-azaspiro[4.4]non-2-en-4-one
  • Examples 60-63 were prepared using one of the methodologies described above.
    • Example 64 2-[(2-chlorobenzyl)amino]-5-isopropyl-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00067
  • Synthesis was performed from 2-amino-5-isopropyl-1,3-oxazol-4(5H)-one and 2-Chlorobenzylamine according to Method G+H.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.62 (d, J=6.84 Hz, 0.75H) 0.82 (d, J=6.84 Hz, 2.25H) 0.90 (d, J=6.96 Hz, 0.75H) 0.99 (d, J=6.84 Hz, 2.25H) 1.97-2.13 (m, 1H) 4.41-4.50 (m, 0.5H) 4.51-4.56 (m, 1.5H) 4.59 (d, J=3.66 Hz, 0.25H) 4.63 (d, J=3.66 Hz, 0.75H) 7.30-7.41 (m, 3H) 7.45-7.49 (m, 1H) 9.30 (s, 1H). MS (ESI+) for C13H15ClN2O2m/z 267 (M+H)+
    • Example 65 2-[(4-chlorobenzyl)amino]-5-isopropyl-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00068
  • Synthesis was performed from 2-amino-5-isopropyl-1,3-oxazol-4(5H)-one and 4-Chlorobenzylamine according to Method G+H.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.63 (d, J=6.84 Hz, 0.75H) 0.80 (d, J=6.84 Hz, 2.25H) 0.90 (d, J=6.96 Hz, 0.75H) 0.98 (d, J=6.84 Hz, 2.25H) 1.96-2.13 (m, 1H) 4.37-4.41 (m, 0.5H) 4.44 (d, J=6.10 Hz, 1.5H) 4.58 (d, J=3.54 Hz, 0.25H) 4.61 (d, J=3.78 Hz, 0.75H) 7.27-7.34 (m, 2H) 7.37-7.45 (m, 2H) 9.28 (t, J=5.98 Hz, 0.75H) 9.49 (s, 0.25H).
  • MS (ESI+) for C13H15ClN2O2 m/z 267 (M+H)−
    • Example 66 5-isopropyl-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00069
  • Synthesis was performed from 2-amino-5-isopropyl-1,3-oxazol-4(5H)-one and 4-amino-2,2,6,6-tetramethylpiperidine according to Method G+H.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.78-0.84 (m, 3H) 0.95-1.04 (m, 3H) 1.33-1.43 (m, 12H) 1.44-1.58 (m, 2H) 1.91-2.16 (m, 3H) 3.96-4.09 (m, 1H) 4.60 (d, J=3.78 Hz, 0.9H) 4.84 (d, J=4.03 Hz, 0.1H) 7.83 (d, J=11.60 Hz, 0.75H) 8.16 (s, 0.25H) 8.76 (d, J=11.48 Hz, 1H) 9.00 (d, J=7.45 Hz, 1H). MS (ESI+) for C15H27N3O2 m/z 282 (M+H)+
    • Example 67 5-isopropyl-2-morpholin-4-yl-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00070
  • Synthesis was performed from 2-amino-5-isopropyl-1,3-oxazol-4(5H)-one and morpholine according to Method G+H.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.81 (d, J=6.84 Hz, 2H) 0.87 (d, J=6.84 Hz, 1H) 0.97-1.01 (m, 3H) 2.02-2.17 (m, 1H) 3.06-3.13 (m, 2H) 3.53-3.77 (m, 6H) 4.66 (d, J=3.91 Hz, 0.67H) 4.84 (d, J=4.15 Hz, 0.33H). MS (ESI+) for C10H16N2O3 m/z 213 (M+H)+
    • Example 68 5-isopropyl-2-[(2-morpholin-4-ylethyl)amino]-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00071
  • Synthesis was performed from 2-amino-5-isopropyl-1,3-oxazol-4(5H)-one and N-(2-aminoethyl)morpholine according to Method G+H.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.87 (d, J=6.84 Hz, 1H) 0.92 (d, J=6.84 Hz, 2H) 1.02 (d, J=6.96 Hz, 3H) 2.01-2.24 (m, 1H) 2.63-2.72 (m, 2H) 2.72-2.81 (m, 1H) 3.03 (t, J=6.41 Hz, 1H) 3.08-3.36 (m, 3H) 3.54-3.67 (m, 1H) 3.65-3.71 (m, 2H) 3.75-3.86 (m, 2H) 4.57 (d, J=4.15 Hz, 0.5H) 4.82 (d, J=4.39 Hz, 0.5H) 7.32-8.39 (m, 1H). MS (ESI+) for C12H21N3O3 m/z 256 (M+H)+
    • Example 69 2-(4-benzylpiperidin-1-yl)-5-isopropyl-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00072
  • Synthesis was performed from 2-amino-5-isopropyl-1,3-oxazol-4(5H)-one and 4-benzylpiperidine according to Method G+H.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.76-0.82 (m, 2.25H) 0.87 (d, J=6.84 Hz, 0.75H) 0.95-1.01 (m, 3H) 1.07-1.35 (m, 2H) 1.60-1.88 (m, 3H) 2.00-2.18 (m, 1H) 2.53 (d, J=7.08 Hz, 2H) 2.74-2.86 (m, 0.5H) 2.95-3.10 (m, 1.5H) 3.23 (d, J=12.57 Hz, 0.5H) 4.03 (d, J=13.55 Hz, 0.75H) 4.10 (d, J=13.18 Hz, 0.75H) 4.62 (d, J=3.78 Hz, 0.75H) 4.84 (d, J=4.15 Hz, 0.25H) 7.15-7.22 (m, 3H) 7.24-7.32 (m, 2H). MS (ESI+) for C18H24N2O2 m/z 301 (M+H)+
    • Example 70 2-azocan-1-yl-5-isopropyl-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00073
  • Synthesis was performed from 2-amino-5-isopropyl-1,3-oxazol-4(5H)-one and heptamethyleneimine according to Method G+H.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.80 (d, J=6.84 Hz, 3H) 1.00 (d, J=6.96 Hz, 3H) 1.32-1.43 (m, 1H) 1.47-1.56 (m, 5H) 1.67-1.76 (m, 4H) 2.04-2.13 (m, 1H) 3.37-3.47 (m, 2H) 3.58-3.71 (m, 2H) 4.64 (d, J=3.54 Hz, 1H). MS (ESI+) for C13H22N2O2 m/z 239 (M+H)+
    • Example 71 2-[(cyclohexylmethyl)amino]-5-phenyl-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00074
  • Synthesis was performed from 2-amino-5-phenyl-1,3-oxazol-4(5H)-one and aminomethylcyclohexane according to Method G+H.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.92 (m, 2H) 1.14 (m, 3H) 1.57 (m, 6H) 3.14 (m, 2H) 5.72 (s, 0.7H) 5.74 (s, 0.3H) 7.28 (m, 2H) 7.39 (m, 3H) 9.00 (t, J=5.74 Hz, 0.7H) 9.25 (s, 0.3H). MS (ESI+) for C16H20N2O2 m/z 273 (M+H)+
    • Example 72 2-(cycloheptylamino)-5-phenyl-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00075
  • Synthesis was performed from 2-amino-5-phenyl-1,3-oxazol-4(5H)-one and cycloheptylamine according to Method G+H.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 1.35-1.70 (m, 10H) 1.92 (m, 2H) 3.78 (m, 1H) 5.69 (s, 0.75H) 5.73 (s, 0.25H) 7.28 (m, 2H) 7.39 (m, 3H) 8.92 (s, 1H). MS (ESI+) for C16H20N2O2 m/z 273 (M+H)+
    • Example 73 5-benzyl-2-[(cyclohexylmethyl)amino]-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00076
  • Synthesis was performed from 2-amino-5-benzyl-1,3-oxazol-4(5H)-one and aminomethylcyclohexane according to Method G+H.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.7-1.7 (m, 11H) 2.93 (m, 3H) 3.16 (m, 1H) 4.95 (m, 1H) 7.23 (m, 5H) 8.56 (s, 1H). MS (ESI+) for C17H22N2O2 m/z 287 (M+H)+
    • Example 74 2-(cycloheptylamino)-5-isopropyl-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00077
  • Synthesis was performed from 2-amino-5-isopropyl-1,3-oxazol-4(5H)-one and cycloheptylamine according to Method G+H.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.77-082 (m, 3H) 0.94-1.01 (m, 3H) 1.32-1.67 (m, 10H) 1.80-1.90 (m, 2H) 2.00-2.11 (m, 1H) 3.62-3.74 (m, 1H) 4.53 (d, J=3.66 Hz, 0.73H) 4.57 (d, J=3.66 Hz, 0.27H) 8.80 (d, J=8.06 Hz, 0.73H) 9.06 (s, 0.23H). MS (ESI+) for C13H22N2O2 m/z 239 (M+H)+
    • Example 75 2-(bicyclo[2.2.1]hept-2-ylamino)-5-isopropyl-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00078
  • Synthesis was performed from 2-amino-5-isopropyl-1,3-oxazol-4(5H)-one and bicyclo[2.2.1]hept-2-amine according to Method G+H.
  • 1H NMR (400 MHz, DMSO-d6) δ ppm 0.75-0.84 (m, 3H) 0.93-1.02 (m, 3H) 1.03-1.17 (m, 3H) 1.34-1.52 (m, 4H) 1.60-1.71 (m, 1H) 1.98-2.25 (m, 3H) 3.46-3.53 (m, 1H) 4.50-4.58 (m, 1H) 8.67 (s, 1H). MS (ESI+) for C13H20N2O2 m/z 237 (M+H)+
    • Example 76 2-(bicyclo[2.2.1]hept-2-ylamino)-5-isobutyl-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00079
  • Synthesis was performed from 2-amino-5-isobutyl-1,3-oxazol-4(5H)-one and bicyclo[2.2.1]hept-2-amine according to Method G+H.
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.93-1.02 (m, 6H) 1.08-1.37 (m, 3H) 1.42-1.97 (m, 8H) 2.28-2.41 (m, 2H) 3.55-3.62 (m, 0,8H) 3.75-3.83 (m, 0.2H) 4.57-4.63 (m, 0.2H) 4.68-4.75 (m, 0.8H) 10.21 (s, 1H)
  • MS (ESI+) for C14H17N3O3 m/z 251 (M+H)+
    • Example 77 2-(cycloheptylamino)-5-isobutyl-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00080
  • Synthesis was performed from 2-amino-5-isobutyl-1,3-oxazol-4(5H)-one and cycloheptylamine according to Method G+H.
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.93-1.01 (m, 6H) 1.37-2.10 (m, 15H) 3.71-3.82 (m, 0.65H) 3.92-4.02 (m, 0.35H) 4.60 (dd, J=10.07, 2.99 Hz, 0.35H) 4.66 (dd, J=9.89, 3.05 Hz, 0.65H) 9.38 (s, 1H)
  • MS (ESI+) for C14H17N3O3 m/z 253 (M+H)+
    • Example 78 5-isobutyl-2-[(2-methylphenyl)amino]-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00081
  • Synthesis was performed from 2-amino-5-isopropyl-1,3-oxazol-4(5H)-one and 2-methylphenylamine according to Method G+H.
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.93-1.03 (m, 6H) 1.64-1.76 (m, 1H) 1.81-1.95 (m, 2H) 2.35 (s, 3H) 4.82-4.89 (m, 1H) 7.22-7.31 (m, 4H)
  • MS (ESI+) for C14H17N3O3 m/z 247 (M+H)+
    • Example 79 2-(bicyclo[2.2.1]hept-2-ylamino)-5-isopropyl-5-methyl-1,3-thiazol-4(5H)-one
  • To a solution of 2-amino-2,3-dimethylbutanoic acid (400 mg, 3.05 mmol) and potassium bromide (1.190 g, 10.00 mmol) in H2O (4 mL) and concentrated H2SO4 (345 μL) at 0° C. under stirring was added via a syringe over 50 min a solution of NaNO2 (295 mg, 4.27 mmol) in H2O (900 μL). The reaction was allowed to slowly reach ambient temperature, and was then stirred overnight. The resulting solution was extracted with diethyl ether (2×15 mL), and the combined organic phases were washed with brined and dried over MgSO4. The solvent was removed to give a transparent oil (290 mg), which was used without any further purification. A mixture of the crude oil (250 mg) and N-bicyclo[2.2.1]hept-2-ylthiourea (F18616001) (100 mg, 0.587 mmol) in 1,4-dioxane (600 μL) was stirred at 100° C. in a sealed tube for 3 days. The solvent was removed, and the residue was purified by preparative reverse-phase HPLC chromatography to give the product as a white solid.
  • 1H NMR (400 MHz, CDCl3) δ 0.85-0.88 (m, 3H), 0.99-1.04 (m, 3H), 1.10-1.27 (m, 4H), 1.46-1.58 (m, 2H), 1.61-1.65 (m, 3H), 1.71-1.88 (m, 2H), 2.12-2.23 (m, 1H), 2.27-2.42 (m, 2H), 3.35 (m, 0.8H, major isomer), 4.03 (m, 0.2H, minor isomer).
  • MS (ESI+) for C14H22N2OS m/z 267 (M+H)+.
    • General Methodologies K-PP Methodologies for Synthesis of Starting Materials: Carboxylic Acids, Esters, Acid Chlorides, Acyl Isothiocyanates: Method K
  • Figure US20110082107A1-20110407-C00082
  • The thioisocyante intermediates can be prepared by the method K. Formation of the acid chloride, such as by treatment with oxalyl chloride and DMF, or thionyl chloride, followed by treatment with KNCS provides the thioisocyantes. Alternatively, treatment of the carboxylic acid with thionyl chloride, then bromination, such as with Br2 and PBr3, followed by treatment with KNCS also provides the thioisocyantes.
    • Method L
  • Figure US20110082107A1-20110407-C00083
  • Preparation of bromo substituted esters and carboxylic acids is described in Method L. Bromination of the carboxylic acid, such as with Br2, PCl3 (cat.), followed by formation of the acid chloride, such as by treatment with oxalyl chloride or thionyl chloride, and treatment with alcohols, TMSCHN2 or CH2N2, yields the desired compounds. Alternatively, the acid chloride can be formed first, followed by bromination step. Starting from esters, treatment with strong base, e.g. LDA, and a leaving group supplier such as TMSCl, followed by bromination provides the desired esters. Using amino acid starting materials (A=NH2), bromination, such as by reaction with HBr in the presence of NaNO2, yields the desired bromo acids.
    • Method M
  • Figure US20110082107A1-20110407-C00084
  • Methylation of various substituted acids and esters, such as by treatment with base and an methyl halide, followed by bromination, yields the desired α-bromo-α-methyl compounds.
    • Method N
  • Figure US20110082107A1-20110407-C00085
  • Conversion of various ketones to the esters is accomplished by Method N. Treatment with an appropriate dithiane, such as 2-trimethylsilyl-1,3-dithiane, in the presence of base, e.g. n-BuLi, followed by chlorination, such as with N-chlorosuccinimide, yields the desired compounds.
    • Methodologies for Synthesis of Starting Materials: Thioureas and Amines: Method O
  • Figure US20110082107A1-20110407-C00086
  • Formation of the desired thioureas is detailed in Method O. Treatment of amines with BzNCS, followed by deprotection, such as with base, yields the thioureas. Alternatively, the thiourea is formed through treatment with 1,1-thiocarbonyldiimidazole in the presence of base, e.g. NEt3, followed by treatment with ammonia.
    • Method P
  • Figure US20110082107A1-20110407-C00087
  • Alternatively, the thiourea is formed as described in Method P. Treatment of a substituted thioisocyanate with ammonia yields the desired thioureas.
    • Method Q
  • Figure US20110082107A1-20110407-C00088
  • Preparation of substituted bicyclo[2.2.1]heptane amines is described in the synthetic scheme in shown in Example 97.
    • Method R
  • Figure US20110082107A1-20110407-C00089
  • Preparation of 1-amino-1-methylethyl benzenes is described in Method R. Methylation of cyanomethylbenzenes, such as with treatment with methyl halides in the presence of non-nucleophilic base, e.g. KHMDS, yields the 1-cyano-1-methylethyl benzenes. Oxidation of the cyano compounds, such as with H2O2, in the presence of base, e.g. K2CO3, yields the amides. Hofmann rearrangement of the amides, such as by treatment with (O2CCF3)2IPh, yields the desired amines.
    • Method S
  • Figure US20110082107A1-20110407-C00090
  • Bicyclo[2.2.1]heptanyl thioureas are provided via Method S. Bromination of carboxylic acids, such as with Br2, PCl3, and the resulting rearrangement provides the 2-bromo-1-carboxylic acids. Dehalogenation, such as with Zn in AcOH, yields the 1-carboxylic acids. The Curtius rearrangement such as by treatment with DPPA and a base, e.g. NEt3, and an alcohol provides the protected amine. Deprotection, such as with acid, followed by formation of the thiourea and deprotection, as described above, provides the desired thioureas.
    • Method T
  • Figure US20110082107A1-20110407-C00091
  • Base mediated substitution of a nitrophenol with a alkyl halide, provides the nitrophenyl ether. For example Cs2CO3 can be used in the presence of NaI. Reduction of the nitro group, such as with H2 in the presence of a catalyst, e.g. Pd/C, yields the desired amines.
    • Method U
  • Figure US20110082107A1-20110407-C00092
  • Method U describes the formation of cyclopropanamines from benzonitriles is accomplished by treatment with EtMgBr in the presence of Ti(Oi-Pr)4, followed by treatment with BF3.OEt2.
    • Method V
  • Figure US20110082107A1-20110407-C00093
  • Formation of bicyclo[2.2.2]octanyl amines is described in Method V. De-esterification of the esters, such as with base, e.g. LiOH, followed the Curtius rearrangement as described previously and deprotection, e.g. acid, provides the desired amines.
    • Method W
  • Figure US20110082107A1-20110407-C00094
  • Formation of (bicyclo[2.2.1]heptanylmethyl)-thioureas from the carboxylic acids is described in Method W. Formation of the acid chloride, such as by treatment with oxalyl chloride and DMF (cat.), followed by treatment with ammonia or ammonium hydroxide, provides the amide. Reduction of the amide, such as with treatment with LiAlH4, to the amine, followed by chemistry previously described, yields the desired thioureas.
    • Methodologies for Synthesis of Final Products: Method X
  • Figure US20110082107A1-20110407-C00095
  • Thiazolones can be prepared by many methods, including that described in Method X. Treatment of a bromo-substituted carboxylic acid or ester with thiourea in the presence of base, such as DIEA provides the condensation/ring closure to the desired 2-amino-thiazolones.
    • Method Y
  • Figure US20110082107A1-20110407-C00096
  • Alternatively, as shown in Method Y, treatment of a bromo-substituted carboxylic acid with thiourea in the presence of base, such as NaOAc provides the condensation/ring closure to the desired 2-amino-thiazolones.
    • Method Z
  • Figure US20110082107A1-20110407-C00097
  • Thiazolones also can be prepared from amines by the method described in Method Z. Coupling of an amine with an isothiocyante, e.g. in the presence of base, such as NEt3, provides the condensation/ring closure to the desired 2-amino-thiazolones.
    • Method AA
  • Figure US20110082107A1-20110407-C00098
  • 5,5-Disubstituted thiazolones can be prepared from thiazolones via the method described in Method AA. Treatment first with strong base, e.g. LDA or NaHMDS, then with a compound comprising an appropriate leaving group, such as RB-LG, provides the desired compounds.
    • Method BB
  • Figure US20110082107A1-20110407-C00099
  • Similarly, formation of 5-fluoro-thiazolones can be prepared as described in Method BB. Treatment first with strong base, e.g. LDA or NaHMDS, and TMSCl, followed by fluorination, e.g. with Selectfluor, provides the desired compounds.
    • Method CC
  • Figure US20110082107A1-20110407-C00100
  • Similarly, formation of 5-trifluoromethyl-thiazolones can be prepared as described in Method CC. Treatment first with strong base, e.g. LDA or NaHMDS, and TMSCl, followed by trifluoromethylation, e.g. with S-(trifluoromethyl)dibenzothiophenium salt, provides the desired compounds.
    • Method DD
  • Figure US20110082107A1-20110407-C00101
  • Formation of 5-carboxymethyl-thiazolones or the corresponding esters can be prepared as described in Method DD. Coupling of carboxylic acids with a substituted alkene, such as in the presence of DBU, followed by treatment with base, e.g. LiOH, provides the desired compounds.
    • Method EE
  • Figure US20110082107A1-20110407-C00102
  • Formation of 5-spiro-thiazolones can be prepared as described in Method EE. Coupling of the thiazolone in the presence of strong base, e.g. LDA or NaHMDS, provides the desired compounds. Alternatively, the cyclization can be achieved in two steps, alkylation first with base, e.g. HMDS, in the presence of TMSCl; followed by further treatment with base, e.g. LDA, in the presence of a bis-electrophile.
    • Method FF
  • Figure US20110082107A1-20110407-C00103
  • Formation of 5-hydroxymethyl-thiazolones can be prepared as described in Method FF. Treatment of a thiazolone with a ketone in the presence of strong base, e.g. LDA or NaHMDS, provides the desired compounds.
    • Method GG
  • Figure US20110082107A1-20110407-C00104
  • Formation of 5-fluoromethyl-thiazolones can be prepared as described in Method GG. Fluorination of 5-hydroxymethyl-thiazolones e.g. with DAST or Deoxo-Fluor, provides the desired compounds.
    • Method HH
  • Figure US20110082107A1-20110407-C00105
  • The compounds of the invention can be prepared by the method described in this scheme. Alkylation of the racemic thiazalone with a chiral base, such as
  • Figure US20110082107A1-20110407-C00106
  • where Rm and Rn are independently selected from alkyl, aryl, and heterocyclyl, where Ro and Rp are independently selected from aryl, where J is alkyl, O, NH or S, and where M1 and M2 are independently selected from Li, Na, K, Cs, Cu, Zn, and Mg, e.g. a chiral lithium base, more specifically
  • Figure US20110082107A1-20110407-C00107
  • and an appropriate alkylating agent, such as a alkyl halide (e.g. an alkyl iodide) or sulfonate (e.g., mesylate, triflate), [LG is halide, tosylate, mesylate, triflate, or the like] provides the desired chiral di-substituted thiazolone. Preferably, the alkylation is performed in the presence of amine base, such as TMEDA. Treatment with the R,R form of the base provides the stereochemistry shown when R3 is methyl. Treatment with the S,S form provides the opposite stereochemistry to that shown when R3 is methyl. The reaction is maintained at a temperature below about RT, preferably below about 0° C., more preferably at or below about −15° C. An aprotic solvent, e.g. toluene is acceptable.
    • Method II
  • Figure US20110082107A1-20110407-C00108
  • Formation of thiazolone amines and ethers can be prepared as described in Method II. Bromination of thiazolones e.g. with NBS or other techniques known to one skilled in the art, followed by treatment with an amine or alcohol, provides the desired compounds.
    • Method JJ
  • Figure US20110082107A1-20110407-C00109
  • Formation of thiazolone amines can be prepared from the alcohols as described in Method JJ. Following the procedure for the Dess-Martin Periodinane or Swern reactions, followed reductive amidation, such as with reacting with an amine together with NaBH(OAc)3 or NaBH3CN, provides the desired compounds.
    • Method KK
  • Figure US20110082107A1-20110407-C00110
  • Alternatively, formation of 5-spiro-thiazolones can be prepared from the furanone as described in Method KK. Treatment of the furanone with a thiourea provides thiazolone alcohol. Protection of the alcohol, such as with dihydropyran in the presence of acid, followed by treatment with strong base, e.g. LDA, and 3-bromo-2-methylprop-1-ene, and deprotection, e.g. with PTSA, and cyclization, such as with acid, provides the desired compounds.
    • Method LL
  • Figure US20110082107A1-20110407-C00111
  • Further, formation of 5-spiro-thiazolones can be prepared from the thiazolone as described in Method LL. Treatment of the thiazolone with strong base, e.g. LDA or NaHMDS and alkylation, such as with (2-bromoethoxy)(tert-butyl)dimethylsilane provides the protected thiazolone alcohol. A subsequent round of base and silane provides the disubstituted thiazolone. Deprotection, e.g. with acid, followed with addition of a compound containing an appropriate leaving group, e.g. MsCl, in the presence of base, e.g. DIEA, and cyclization, such as with a substituted amine, provides the desired spiro piperidine compounds.
    • Method MM
  • Figure US20110082107A1-20110407-C00112
  • 1-Substituted piperidinemethylthiazolones can be prepared by method MM. After deprotection, such as by treatment with acid, treatment with sulfonyl chlorides (R12SO2Cl) in the presence of base, e.g. NEt3, provides compounds where RQ═SO2RS. Alternatively, after deprotection, treatment with carboxylic acid (RRCO2H) with standard coupling chemistry, e.g. EDCI, and HOBt, provides compounds where RQ═CORR. Alternatively, after deprotection, treatment with active carbonyl compounds, e.g. acid anhydrides (RRCO—O—CORR) in the presence of base, e.g. DIEA, provides compounds where RQ═CORR.
    • Method NN
  • Figure US20110082107A1-20110407-C00113
  • Formation of 5-spiro-thiazolones can be prepared from the thiazolone as described in Method NN. Treatment of the thiazolone with strong base, e.g. LDA and alkylation, such as with BrCH2CH2Br provides the thiazolone bromoethyl compound. Further treatment with strong base, e.g. LDA, and dimethylketone, provides the desired spiro tetrahydrofuryl compounds.
    • Method OO
  • Figure US20110082107A1-20110407-C00114
  • Substituted amidomethylthiazolones can be prepared by method OO. Treatment of a substituted thioureas and with active carbonyl compounds, e.g. maleic anhydride in the presence of acid, e.g. AcOH, provides the thiazolone carboxylic acids. Treatment of the acid with an amine, such as in the presence of a coupling reagent, e.g. HATU and base such as DIEA provides the desired amides.
    • Method PP
  • Figure US20110082107A1-20110407-C00115
  • Substituted thiazolone esters can be prepared from the alcohol by method PP. Treatment of an alcohol-substituted thiourea with active carbonyl compounds, e.g. an acid chloride, in the presence of base, e.g. DIEA, provides the desired esters. Separation Methods
  • Many of the final compounds were separated by two main chromatographic methods. Normal phase liquid chromatography (NPLC) and supercritical fluid chromatography (SFC) were the two techniques utilized. NPLC was performed with Chiralpak AD/AD-H and Chiralcel OJ-H columns. The mobile phase consisted of hexane (0.2% diethylamine (DEA)) and/or methanol, ethanol (0.2% DEA), or isopropanol (0.2% DEA). All separations were conducted at ambient temperatures. Columns used with SFC were the Chiralpak AD-H and AS-H, the Chiralcel OD-H, and the Astec (R,R) P-CAP. The mobile phased was comprised of liquid carbon dioxide and an organic modifier such as methanol (with or without 0.2% DEA), ethanol (with or without 0.2% DEA), isopropanol (with or without 0.2% DEA), or acetonitrile (with or without 0.2% DEA). Organic modifiers were used individually with liquid carbon dioxide or in combinations with each other and the liquid carbon dioxide. Column/oven temperature was between 35 and 40° C., and the outlet pressure was either 100 or 120 bar.
    • Illustrative Method for Separating Enantiomers of Thioureas:
  • Stationary phase: ChiralPAK-AD, 20 u, from Chiral Technology
  • Column: MODCOL spring load column, 4″×30 cm containing of 2.0 kg of stationary phase.
  • Mobile phase: 100% MeOH
  • Flow rate: 500 ml/min
  • Temperature: 30° C.
  • Detection wavelength: 230 nm
    • Abbreviations
  • AIBN, 2,2′-Azobisisobutyronitrile
  • aq., aqueous
  • brine, a saturated solution of NaCl in water
  • conc., concentrated
  • DAST, Diethylaminosulfur trifluoride
  • DBU, 1,8-Diazabicyclo[5.4.0]undec-7-ene
  • DCM, dichloromethane
  • DEAD, diethyl azodicarboxylate
  • Deoxo-Fluor, Bis(2-methoxyethyl)aminosulfur trifluoride
  • Dess-Martin Periodinane, 1,1,1-Tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3(1H)-one
  • DIEA, N,N-Diisopropylethylamine
  • DMF, N,N-Dimethylformamide
  • DPPA, Diphenylphosphoryl azide
  • EDCl, 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
  • EtOAc, ethyl acetate
  • EtOH, ethanol
  • HOBT, 1-Hydroxy-1H-benzotriazole
  • Hunig's base, N,N-Diisopropylethylamine
  • KHMDS, Potassium bis(trimethylsilyl)amine
  • LDA, Lithium diisopropylamide
  • LiHMDS, Lithium bis(trimethylsilyl)amine
  • MeOH, methanol
  • (R)-MOP, (R)-(+)-2-(diphenylphosphino)-2′-methoxy-1,1′-binaphthyl
  • MS; Mass Spectrum
  • MsCl, Methanesulfonyl chloride
  • MTBE, methyl tert-butyl ether
  • MW, microwave
  • NaHMDS, Sodium bis(trimethylsilyl)amine
  • NBS, N-Bromosuccinimide
  • n-BuLi, n-Butyllithium
  • PCC, Pyridinium chlorochromate
  • i-PrOH, iso-propanol
  • PTSA, p-toluenesulfonic acid
  • r.t., room temperature
  • sat'd, saturated solution in water
  • Selectfluor™, N-Fluoro-N′-chloromethyltriethylenediamine bis(tetrafluoroborate)
  • TBDMS, tert-butyl dimethylsilyl
  • THF, Tetrahydrofuran
  • TLC, thin layer chromatography
  • TMSCl, chlorotrimethylsilane
    • Synthesis of Starting Materials: Carboxylic Acids, Esters, Acid Chlorides, and Acyl Isothiocyanates (Procedures Method-L, Method-M, Method-N, Method-K).
  • Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. All parts are by weight and temperatures are in degrees centigrade unless otherwise indicated. All microwave-assisted reactions were conducted with a Smith Synthesizer from Personal Chemistry, Uppsala, Sweden or a Discover Instrument from CEM, Matthews, N.C. All compounds showed NMR spectra consistent with their assigned structures. Melting points were determined on a Buchi apparatus and are uncorrected. Mass spectral data was determined by electrospray ionization technique. All examples were purified to >95% purity as determined by high-performance liquid chromatography. Unless otherwise stated, reactions were run at RT.
    • Example 80 (S)-2-Bromo-3-methylbutanoic acid
  • Figure US20110082107A1-20110407-C00116
    • Method L
  • A 2 L jacketed reactor was charged with toluene (150 mL), water (150 mL) and 48% hydrobromic acid (260 mL, 2.30 mol). To this stirred, two-phase solution at 0° C., was added L-valine (96.2 g, 0.82 mol) in one portion (a mild exotherm was observed, temperature rose to 3.5° C.). The mixture was further cooled to −5° C., whereupon an aqueous solution of sodium nitrite (73.7 g, 1.07 mol) was added drop-wise over 6 h. The solution turned dark brown. Once the sodium nitrite was completely added, the reaction mixture was stirred for an additional 3 h at −5° C. Then, the reaction mixture was diluted with toluene (250 mL), warmed to 20° C., and stirred for 12 h. The organic layer was separated and the aqueous layer was extracted with toluene (300 mL). The toluene layers were combined and washed with a 20% sodium thiosulfate solution (200 mL) (virtually all color disappeared) followed by a 20% NaCl solution (200 mL). The organic layer was separated, and the solvent was concentrated in vacuo, and then placed on the high vacuum pump for 4 h to afford the title compound (107 g) as a pale yellow crystalline solid. MS (ESI, pos. ion) m/z: 179.1/180.9.
    • Example 81 1-Bromocyclopentanecarboxylic acid
  • Figure US20110082107A1-20110407-C00117
    • Method L
  • Phosphorus trichloride (0.54 mL, 6.20 mmol) was added drop-wise to the mixture of cyclopentanecarboxylic acid (14.2 g, 124 mmol) and bromine (7.35 mL, 143 mmol). The mixture was then gradually heated to 85° C. and stirred at this temperature in a sealed vessel for 12 h. After cooling to ambient temperature, the mixture was partitioned between EtOAc and water. The organic portion was separated, washed with water and brine, and conc. in vacuo to give the title compound as a white solid.
    • Example 82 Ethyl 1-bromocyclopentanecarboxylate
  • Figure US20110082107A1-20110407-C00118
  • DMF (a few drops) was added to a mixture of 1-bromocyclopentanecarboxylic acid (23.9 g, 124 mmol) and oxalyl chloride (11.6 mL, 130 mmol) in 250 mL of CH2Cl2. The mixture was stirred at ambient temperature for 2 h. After removing the low-boiling solvents in vacuo, ethanol (50 mL) was added to the residue followed by the addition of N,N-diisopropylethylamine (22.7 mL, 130 mmol). The mixture was stirred at ambient temperature for 20 min. After removing the low-boiling solvents in vacuo, the residue was partitioned between diethyl ether and water. The organic portion was washed with water and brine, and conc. in vacuo. The crude product was filtered through a plug of silica gel using 0 to 10% EtOAc in hexanes as the eluant. The title compound was obtained as a pale oil.
    • Example 83 Methyl 2-bromo-2-cyclohexylacetate
  • Figure US20110082107A1-20110407-C00119
    • Method L
  • A 100 mL round-bottomed flask was charged with cyclohexylacetic acid (5.0 g, 0.035 mol) and thionyl chloride (4.92 g, 3.0 mL, 0.041 mol). This solution was heated to reflux during which time gas evolution occurred. After 1 h at 80° C., bromine (7.03 g, 2.25 mL, 0.044 mol) and phosphorus tribromide (0.350 mL) were added. The reaction temperature was maintained at 80° C. until the color faded from dark red to a light pink (˜2 h) after which time MeOH (5.0 mL) was added, and the reaction mixture was refluxed for 30 min more. After cooling to room temperature, sodium thiosulfate was added, the suspension was filtered, and then concentrated in vacuo to provide the title compound. This bromo-ester was used without any further purification.
    • Example 84 Methyl 2-bromo-2-(tetrahydro-2H-pyran-4-yl)acetate
  • Figure US20110082107A1-20110407-C00120
    • Method L
  • A 250 mL round-bottomed flask was charged with 2-(tetrahydro-2H-pyran-4-yl) acetic acid (5.0 g, 0.035 mol) and 100 mL of MeOH. To this solution was added 5 drops of conc. H2SO4. This mixture was heated at reflux for 12 h, after which time the MeOH was removed in vacuo. The remaining residue was dissolved in EtOAc, washed with saturated aqueous NaHCO3, dried, and concentrated in vacuo to give the desired methyl ester. This compound was used directly in the next step without further purification.
  • To a dry 250 mL round-bottomed flask was added 2.20 g of methyl 2-(tetrahydro-2H-pyran-4-yl)acetate (0.014 mol) and 100 mL of dry THF. This solution was cooled to −78° C. and LDA (2.0 M in THF/heptane/ethyl benzene, 10.4 mL, 0.021 mol) was added. The resulting brown solution was stirred at −78° C. for 45 min. TMSCl (3.22 g, 3.5 mL, 0.028 mol) was then added at −78° C., and the reaction mixture was then warmed to room temperature. After being re-cooled to −78° C., N-bromosuccinimide (4.94 g, 0.028 mol) was added to the reaction mixture, and the resulting suspension was allowed to slowly warm to room temperature where it continued to stir for an additional 1.5 h. The suspension was then filtered thru a pad of SiO2 using diethyl ether as the eluant. Purification of the filtrate by column chromatography (SiO2 gel, 10:1 to 4:1 hexanes/ethyl acetate) delivered the desired α-bromo ester, which was used in subsequent steps without further purification.
    • Example 85 Ethyl 2-(pyridin-4-yl)propanoate
  • Figure US20110082107A1-20110407-C00121
    • Method M
  • To a solution of LiN(TMS)2 (Aldrich, 1.0 M solution in THF, 30 mL, 30 mmol) in THF (30 mL) was added ethyl 4-pyridylacetate (Aldrich, 4.7 mL, 30 mmol)) at 0° C. Methyl iodide (Aldrich, 2.4 mL, 38 mmol) was added 30 min later. After 1 h, the reaction mixture was concentrated in vacuo. The crude product was purified by silica gel chromatography. Mass Spec. m/z+ion 180 (M+1).
    • Example 86 Ethyl 2-bromo-2-(pyridin-4-yl)propanoate
  • Figure US20110082107A1-20110407-C00122
  • The above compounds were prepared according to the procedure reported in the literature: see D. Yang, J. Org. Chem. 2002, 67, 7429. MS: 258, 260 (M+1). To a solution of ethyl 2-(pyridin-4-yl)propanoate (5.3 g, 30 mmol), Mg(ClO4)2 (Aldrich, 2.0 g, 9.0 mmol) in CH3CN (60 mL) was added N-bromosuccinimide (Aldrich, 5.9 g, 33 mmol) at room temperature. After 2 h, the reaction mixture was diluted with ether (200 mL), and 10% Na2CO3. The organic phase was separated, dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by silica gel chromatography. Mass Spec. m/z+ion 258, 260 (M+1).
    • Example 87 Ethyl 2-bromo-2-(pyridin-3-yl)propanoate
  • Figure US20110082107A1-20110407-C00123
  • To a stirred mixture of ethyl 2-(pyridin-3-yl)propanoate (4.2 g, 23 mmol), CCl4 (100 mL), and N-bromosuccinimide (Aldrich, 4.6 g, 26 mmol) was added 2,2′-azobisisobutyronitrile (Aldrich, 0.8 g, 5 mmol) under N2 at room temperature. The mixture was gradually heated to reflux. After 7 h, the reaction mixture was concentrated in vacuo. The crude was purified by silica gel chromatography. Mass Spec. m/z+ion 258, 260 (M+1).
    • Example 88 4-(1,3-Dithian-2-ylidene)-6-fluoro-3,4-dihydro-2H-chromene
  • Figure US20110082107A1-20110407-C00124
    • Method N
  • To a solution of 2-trimethylsilyl-1,3-dithiane (5.10 g, 26.5 mmol) in 50 mL of anhydrous THF at −60° C. under N2 was added drop-wise n-BuLi (1.6 M solution in hexanes, 16.6 mL, 26.5 mmol). The mixture was left to warm slowly to 0° C. over 3 h and subsequently cooled to −60° C. A solution of 6-fluoro-2,3-dihydrochromen-4-one (4.40 g, 26.5 mmol) in 25 mL of THF was added drop-wise. The mixture was slowly warmed to ambient temperature overnight, then poured into water, and extracted with EtOAc. The combined organic portions were washed with brine, and conc. in vacuo. The crude product was purified by flash column chromatography (0 to 10% of EtOAc in hexanes). The title compound was obtained as a pale oil.
    • Example 89 Ethyl 4-chloro-6-fluoro-3,4-dihydro-2H-chromene-4-carboxylate
  • Figure US20110082107A1-20110407-C00125
  • A solution of 4-(1,3-dithian-2-ylidene)-6-fluoro-3,4-dihydro-2H-chromene (4.60 g, 17.1 mmol) in 45 mL of anhydrous THF in an addition funnel was added drop-wise to a stirring solution of N-chlorosuccinimide (11.7 g, 85.7 mmol) in 100 mL of CH3CN and 50 mL of EtOH at r.t. After 3 h, 50 mL of water was added. The mixture was partitioned between EtOAc and water. The combined organic portions were washed with brine, and conc. in vacuo. The residue was purified by flash column chromatography (0 to 10% of EtOAc in hexanes). The title compound was obtained as a colorless oil.
    • Example 90 (R)-2-Bromo-3-methylbutanoyl chloride
  • Figure US20110082107A1-20110407-C00126
    • Method K
  • To a 500 mL round-bottom flask was added 5.0 g (27.6 mmol) of (R)-2-bromo-3-methylbutanoic acid and 200 mL CH2Cl2. The resulting solution was cooled to 0° C. in an ice bath and then 3 mL of oxalyl chloride (34.4 mmol) was added in one portion. After 5 min, 0.2 mL of DMF (2.59 mmol) was added drop-wise. Once the addition was completed, the mixture was warmed to room temperature and stirred for 4 h. The mixture was then concentrated, triturated with hexanes (50 mL), and filtered. The residual solid was washed with hexane (2×10 mL) and the combined supernatant liquids were concentrated to afford the title compound as a pale yellow oil.
    • Example 91 (R)-2-Bromo-3-methylbutanoyl isothiocyanate
  • Figure US20110082107A1-20110407-C00127
  • A 100 mL round-bottom flask was charged with KNCS (0.786 g, 8.08 mmol). Acetone (24 mL) was added and the mixture stirred at room temperature until the solid was completely dissolved. A solution of (R)-2-bromo-3-methylbutanoyl chloride (1.51 g, 7.55 mmol, 1.0 equiv) in acetone (2 mL) was added drop-wise resulting in the formation of a white precipitate with concomitant color change of the solution from clear to pink to reddish orange. Once addition was complete, the mixture was stirred for 30 min at room temperature. The reaction mixture was then filtered through Celite in a sintered glass (medium porosity) funnel, and washed twice with acetone (10 mL each wash). The deep red solution was concentrated, taken up in hexanes (40 mL), and re-filtered. Concentration afforded the title compound as an orange oil.
    • Synthesis of Starting Materials: Thioureas and Amines (Procedures: Method-O, Method-P, Method-Q, Method-R, Method-S, Method-T, Method-U, Method-V, Method-W). Example 92 (±)-endo-1-(Bicyclo[2.2.1]heptan-2-yl)thiourea
  • Figure US20110082107A1-20110407-C00128
    • Method O
  • To a stirred solution of 1,1-thiocarbonyldiimidazole (1.94 g, 10.9 mmol) and triethylamine (3.0 mL, 21.8 mmol) in dichloromethane (22.0 mL) under nitrogen was added (±)-endo-2-aminonorborane HCl (1.21 g, 10.9 mmol) over 10 min at ambient temperature for 3 h. The solvent was then evaporated in vacuo, and the residue was dissolved in a 0.5M solution of ammonia in dioxane. After stirring at room temperature under nitrogen for 16 h, the resulting solid was filtered off, and the filtrate was evaporated in vacuo. Upon scratching the glass, the residue crystallized. The solid was placed on the high vacuum pump overnight to afford the title compound (1.16 g) as a brown crystalline solid. MS (ESI, pos. ion) m/z: 171.2 (M+H).
    • Example 93 1-Benzoyl-3-cyclooctylthiourea
  • Figure US20110082107A1-20110407-C00129
    • Method O
  • Benzoyl isothiocyanate (7.40 mL, 54.0 mmol) was added to a solution of cyclooctanamine (6.25 g, 49.1 mmol) in 200 mL of chloroform. The mixture was stirred at ambient temperature overnight. The solvents were removed in vacuo to give the title compound as a viscous light yellowish oil. MS m/z: 291.0 (M+H)+.
    • Example 94 1-Cyclooctylthiourea
  • Figure US20110082107A1-20110407-C00130
  • A mixture of 1-benzoyl-3-cyclooctylthiourea (14.3 g, 49.1 mmol) and potassium carbonate (34.6 g, 250 mmol) in methanol (200 mL), water (100 mL), and THF (100 mL) was stirred at ambient temperature overnight. The low boiling solvents were removed in vacuo, and the residue was partitioned between EtOAc and water. The organic portion was washed with brine, and concentrated in vacuo. The title compound was obtained as a white solid after flash column chromatography (0 to 100% of ethyl acetate in hexanes). MS m/z: 187.1 (M+H)+.
    • Example 95 (±)-exo-1-(Bicyclo[2.2.1]heptan-2-yl)thiourea
  • Figure US20110082107A1-20110407-C00131
    • Method P
  • A solution of exo-2-norbornylisothiocyanate (32.2 mL, 326 mmol) in 0.5M solution of ammonia in dioxane (1.3 L, 652 mmol) in a 2 L round-bottomed flask was stirred at room temperature for 16 h. The solvent was then evaporated in vacuo, and the solid was further dried under high vacuum to afford the title compound (39.0 g) as a white amorphous solid. MS (ESI, pos. ion) m/z: 171.2 (M+H).
    • Example 96 1-Adamantylthiourea
  • Figure US20110082107A1-20110407-C00132
    • Method-P
  • A mixture of 1-adamantyl isothiocyanate (4.83 g, 25.0 mmol, Aldrich) and ammonia (0.5 M solution in 1,4-dioxane, 100 mL, 50 mmol) was stirred at ambient temperature for 48 h. The solvents were removed in vacuo to give the title compound as a white solid. MS m/z: 211.1 (M+H)+.
    • Example 97
  • Figure US20110082107A1-20110407-C00133
  • (i) HSiCl3, allyl palladium(II) chloride, (R)-MOP, −3° C., 3 days; (ii) MeOH, Et3N, Et2O, 0° C. to r.t., overnight; (iii) KHF2, urea-H2O2, MnO2, MeOH, 60° C., overnight; (iv) PhCH2Br, NaOH, 15-Crown-5, THF, 10° C., 3 h; (v) PCC, CH2Cl2, 0° C.-r.t., overnight; (vi) Deoxo-Fluor, BF3—Et2O (0.1 eq), 55° C., 33 h; (vii) H2, Pd/C, MeOH, r.t., 3 h; (viii) L-Selectride, THF, −78° C., 3 h; H2O2, NaOH, 65° C., 10 h; (ix) Phthalimide, Ph3P, DEAD, THF, r.t., 70 h; (x) H2NNH2, EtOH, reflux, 5 h; HCl (aq), 60° C., 1.5 h; (xi) PhC(O)NCS, Et3N, CHCl3, r.t.; (xii) K2CO3, MeOH/THF/H2O, r.t.
    • (1R,2S,4R,5S)-2,5-Bis(trichlorosilyl)-bicyclo[2.2.1]heptane
  • Figure US20110082107A1-20110407-C00134
    • Method Q
  • A solution of allylpalladium(II) chloride (0.0180 g, 0.0492 mmol) and (R)-(+)-2-(diphenylphosphino)-2′-methoxy-1,1′-binaphthyl (0.105 g, 0.223 mmol) in benzene (2.5 mL) was placed into a double jacketed 250-mL three-neck flask equipped with a mechanical stirrer under nitrogen atmosphere. Trichlorosilane (20.0 mL, 198 mmol) was added, and the mixture was cooled to −3° C. Bicyclo[2.2.1]hepta-2,5-diene (8.3 mL, 76.9 mmol) was added slowly with mechanical stirring. After stirring at −3° C. for 69 h, the color of the mixture turned into a pale yellowish solid. The reaction mixture was dissolved in toluene (anhydrous, 60 mL), and then concentrated in vacuo to give a pale solid, which was used in the following reaction without further purification.
    • Example 98 (1R,2S,4R,5S)-2,5-Bis(trimethoxysilyl)bicyclo[2.2.1]heptane
  • Figure US20110082107A1-20110407-C00135
  • A mixture of methanol (anhydrous, 60 mL), triethylamine (anhydrous, 80 mL), and diethyl ether (anhydrous, 50 mL) was added slowly to (1R,2S,4R,5S)-2,5-bis(trichlorosilyl)-bicyclo[2.2.1]heptane (crude from the previous reaction, 76.9 mmol) in diethyl ether (anhydrous, 50 mL) at 0° C. under a nitrogen atmosphere. After the mixture was stirred at ambient temperature overnight, the precipitated salts were removed by filtration. The solids were washed with diethyl ether (50 mL×3). The combined filtrates were concentrated in vacuo to yield a light yellow slurry which was used in the next reaction without further purification.
    • Example 99 (1R,2S,4R,5S)-Bicyclo[2.2.1]heptane-2,5-diol
  • Figure US20110082107A1-20110407-C00136
  • To (1R,2S,4R,5S)-2,5-bis(trimethoxysilyl)bicyclo[2.2.1]heptane (76.9 mmol) was added potassium hydrogen fluoride (33.0 g, 423 mmol), tetrahydrofuran (80.0 mL), methanol (80.0 mL), and urea hydrogen peroxide addition compound (65.0 g, 691 mmol, Aldrich). The resulting white slurry was stirred overnight at 60° C. After cooling to ambient temperature, MnO2 (0.56 g, 6.4 mmol) was added, and the mixture was stirred at this temperature for 4 h. The solids were removed by filtration, and the filter cake was washed with methanol. The combined filtrates were concentrated in vacuo. The residue was dissolved in water (100 mL) and extracted with a CHCl3/i-PrOH mixture (3/1, v/v, 5×100 mL). The combined organic portions were dried over MgSO4 and conc. in vacuo. After triturating the residue with CH2Cl2 and EtOAc, the white solid was collected by filtration. This material was the title compound. A second crop of desired product was obtained by flash column chromatography (0-5% MeOH in EtOAc) from the concentrated filtrate.
    • Example 100 (1R,2S,4R,5S)-5-(Benzyloxy)bicyclo[2.2.1]heptan-2-ol
  • Figure US20110082107A1-20110407-C00137
  • To a stirred solution of (1R,2S,4R,5S)-bicyclo[2.2.1]-heptane-2,5-diol (1.15 g, 8.97 mmol) and 15-crown-5 (0.054 mL, 0.269 mmol) in tetrahydrofuran (30.0 mL, 8.97 mmol) were added at 10° C. (ice/water bath) finely ground sodium hydroxide (2.15 g, 53.8 mmol) and 1-(bromomethyl)benzene (1.07 mL, 8.97 mmol). After stirring at 10° C. for 3 h, the mixture was stirred at ambient temperature overnight. The mixture was partitioned between EtOAc and water, and the organic portions were washed with brine, and conc. in vacuo. The crude product was purified by flash column chromatography (0 to 80% of ethyl acetate in hexanes). The title compound was obtained as a colorless oil.
    • Example 101 (1R,4R,5S)-5-(Benzyloxy)bicyclo[2.2.1]heptan-2-one
  • Figure US20110082107A1-20110407-C00138
  • Silica gel 60 (particle size, 0.040-0.063 mm, CAS #63231-67-4, from EMD Chemical Inc. 9.0 g) was added to a solution of (1R,2S,4R,5S)-5-(benzyloxy)bicyclo[2.2.1]heptan-2-ol (2.79 g, 12.8 mmol) in anhydrous dichloromethane (60.0 ml). The mixture was cooled to 0° C., and pyridinium chlorochromate (4.40 g, 20.4 mmol) was added. The reaction mixture was warmed to ambient temperature and stirred at this temperature for 5 h. After this time, the mixture was diluted with dichloromethane (60 mL) and then filtered through a pad of Celite. The solvent was removed in vacuo, and the residue was purified by flash column chromatography (0 to 25% of ethyl acetate in hexanes) to give the title compound as a colorless oil.
    • Example 102 (1R,4R,5S)-5-(Benzyloxy)-2,2 difluorobicyclo-[2.2.1]heptane
  • Figure US20110082107A1-20110407-C00139
  • Deoxo-Fluor (50% in THF, 17.7 g, 40.0 mmol) was added to (1R,4R,5S)-5-(benzyloxy)bicyclo[2.2.1]heptan-2-one (2.45 g, 11.3 mmol) in a 250 mL round-bottom flask. The mixture was heated to 85° C. (oil bath temperature) and stirred at this temperature under nitrogen for 16.5 h. After cooling to ambient temperature, the mixture was diluted with ethyl acetate, then poured into sat'd NaHCO3 in ice. The organic portion was separated, washed with brine, dried over MgSO4, filtered, and conc. in vacuo. The crude product was purified by flash column chromatography (0 to 5% of ethyl acetate in hexanes) to give the title compound as a colorless oil.
    • Example 103 (1R,2S,4R)-5,5-Difluorobicyclo[2.2.1]heptan-2-ol
  • Figure US20110082107A1-20110407-C00140
  • Palladium (10 wt. % on activated carbon, 0.28 g) was added to a solution of (1R,4R,5S)-5-(benzyloxy)-2,2-difluorobicyclo[2.2.1]-heptane (1.43 g, 6.0 mmol) in methanol (15 mL), and the mixture was placed under a balloon full of hydrogen. After stirring at ambient temperature for 4 h, the mixture was filtered through a pad of Celite, and the filtrate was concentrated in vacuo. The residue was adsorbed onto a small pad of silica gel, and eluted with 20% of ethyl acetate in hexanes. The solvents were removed in vacuo to give the title compound as a white solid.
    • Example 104 (1R,4R)-5,5-Difluorobicyclo[2.2.1]heptan-2-one
  • Figure US20110082107A1-20110407-C00141
  • Silica gel 60 (particle size, 0.040-0.063 mm, CAS #63231-67-4, from EMD Chemical Inc. 4.0 g) was added to a solution of (1R,2S,4R)-5,5-difluorobicyclo[2.2.1]heptan-2-ol (0.800 g, 5.40 mmol) in anhydrous dichloromethane (20.0 ml). The mixture was cooled to 0° C., and pyridinium chlorochromate (1.86 g, 8.64 mmol) was added. The reaction mixture was warmed to ambient temperature and stirred at this temperature overnight. After this time, the mixture was diluted with dichloromethane (30 mL) and then filtered through a pad of silica gel. Removal of the solvents gave the title compound as a white solid.
    • Example 105 (1R,2R,4R)-5,5-Difluorobicyclo[2.2.1]heptan-2-ol
  • Figure US20110082107A1-20110407-C00142
  • To a solution of (1R,4R)-5,5-difluorobicyclo[2.2.1]heptan-2-one (0.540 g, 3.7 mmol) in anhydrous tetrahydrofuran (8.00 mL) at −78° C. under nitrogen was added drop-wise L-Selectride (1.0 M solution in tetrahydrofuran, 7.40 mL). After stirring at −78° C. for 3 h, 30% H2O2 (6.0 mL) and 10% NaOH (aq., 10.0 mL) were added. The mixture was warmed to r.t. and then stirred at 65° C. for 10 h. After cooling to ambient temperature, the mixture was extracted with EtOAc (50 mL×2). The combined organic portions were washed with brine, and conc. in vacuo. Flash column chromatography (0 to 30% of ethyl acetate in hexanes) gave the title compound as a white solid.
    • Example 106 2-((1R,2S,4R)-5,5-Difluorobicyclo[2.2.1]heptan-2-yl)isoindoline-1,3-dione
  • Figure US20110082107A1-20110407-C00143
  • A solution of diethyl azodicarboxylate (0.56 mL, 3.6 mmol) in anhydrous THF (3.0 mL) was added drop-wise to a mixture of (1R,2R,4R)-5,5-difluorobicyclo[2.2.1]heptan-2-ol (0.44 g, 3.0 mmol), phthalimide (0.50 g, 3.4 mmol), and triphenyl phosphine (0.78 mL, 3.4 mmol) in anhydrous tetrahydrofuran (15.0 mL) at r.t. under nitrogen. After stirring at ambient temperature for 66 h, the solvents were removed in vacuo. The residue was partitioned between ethyl acetate and water, and the organic portion was separated, washed with brine, and conc. in vacuo. Flash column chromatography (0 to 35% of ethyl acetate in hexanes) gave the title compound as an off-white solid.
    • Example 107 (1R,2S,4R)-5,5-Difluorobicyclo[2.2.1]heptan-2-amine hydrochloride
  • Figure US20110082107A1-20110407-C00144
  • To a suspension of 2-((1R,2S,4R)-5,5-difluorobicyclo[2.2.1]-heptan-2-yl)isoindoline-1,3-dione (0.58 g, 2.09 mmol) in ethanol (anhydrous, 30 mL) was added hydrazine (0.10 mL, 3.14 mmol). After refluxing this mixture under nitrogen for 5 h, it was cooled in an ice bath, and hydrochloric acid (37%, 0.50 mL) was added. After stirring at 60° C. for 1.5 h, the mixture was cooled to ambient temperature. After the white solid was removed by filtration, the filter cake was washed with methanol, and the filtrate was conc. in vacuo. The resulting residue was diluted in ˜50 mL of water, filtered, and the filtrate was washed with diethyl ether (30 mL×3). The filtrate was then treated with sodium carbonate monohydrate to saturation, and the aqueous layer was extracted with diethyl ether (50 mL×3). These organic layers were combined, dried over potassium carbonate (solid), and filtered. The solution was treated with hydrochloric acid (1M aqueous, 4 mL), stirred for 5 min, and then concentrated in vacuo to give the title compound as a white solid.
    • Example 108 1-Benzoyl-3-((1R,2S,4R)-5,5-difluorobicyclo-[2.2.1]heptan-2-yl)thiourea
  • Figure US20110082107A1-20110407-C00145
  • Benzoyl isothiocyanate (0.32 mL, 2.34 mmol) was added to the mixture of (1R,2S,4R)-5,5-difluorobicycle[2.2.1]heptan-2-amine hydrochloride (0.33 g, 1.80 mmol) and triethylamine (0.38 mL, 2.70 mmol) in anhydrous chloroform (25.0 mL) at ambient temperature under nitrogen. After stirring overnight, the reaction mixture was concentrated in vacuo. Water (50 mL) was added to the residue, and it was extracted with diethyl ether (2×50 mL). The organic portions were combined, washed with brine, and conc. in vacuo to give a light yellowish oil as the title compound that was used in the following reaction without purification. Mass Spec m/z: 311.1 (M+H)+.
    • Example 109 1-((1R,2S,4R)-5,5-difluorobicyclo[2.2.1]heptan-2-yl)thiourea
  • Figure US20110082107A1-20110407-C00146
  • A mixture of 1-benzoyl-3-((1R,2S,4R)-5,5-difluorobicyclo-[2.2.1]heptan-2-yl)thiourea (˜1.80 mmol) and potassium carbonate (1.49 g, 10.8 mmol) in methanol (5.0 mL), water (2.5 mL), and tetrahydrofuran (2.5 mL) was stirred at ambient temperature for 2 h. The reaction mixture was concentrated in vacuo, and the residue was partitioned between EtOAc and water. The organic portion was washed with brine, conc. in vacuo, and purified by flash column chromatography (0 to 65% of ethyl acetate in hexanes) to give the title compound as a white solid. MS m/z: 207.0 (M+H)+.
    • Example 110 2-(2-Chlorophenyl)-2-methylpropanenitrile
  • Figure US20110082107A1-20110407-C00147
    • Method R
  • A 500 mL round-bottomed flask was charged with 2-(2-chlorophenyl)acetonitrile (6.82 g, 0.045 mol) and 30 mL of THF. This solution was cooled to −40° C., and KHMDS (0.5 M in toluene, 200 mL, 0.100 mol) was added at such a rate that the internal temperature did not rise above −40° C. This solution was allowed to stir between −40 to −50° C. for an additional 1 h. After that time, MeI (14.2 g, 6.25 mL, 0.100 mol) was added and the solution was warmed to room temperature (a thick solid formed). The reaction was stirred for 1 h at room temperature then quenched by the addition of saturated aqueous NaHCO3. The layers were separated, and the aqueous phase was extracted with CH2Cl2. The combined organic extracts were dried and concentrated in vacuo to give an oil that was purified by column chromatography (SiO2, 100% hexanes to 90% hexanes/ethyl acetate) to provide 2-(2-chlorophenyl)-2-methylpropanenitrile as a colorless oil.
    • Example 111 2-(2-Chlorophenyl)propan-2-amine
  • Figure US20110082107A1-20110407-C00148
  • 2-(2-Chlorophenyl)-2-methylpropanenitrile (5.0 g, 0.028 mol) along with 50 mL of EtOH was added into a 250 mL round-bottomed flask. To this was added 50 mL of saturated aqueous K2CO3. This mixture was cooled to 0° C. then 85 mL of 30% aqueous H2O2 was slowly added. The reaction mixture was allowed to warm to room temperature, and then it was stirred at that temperature for 12 h. The mixture was extracted with CH2Cl2 (3×150 mL), and the combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo to give a viscous oil. To this oil was added 40 mL of CH3CN, 40 mL H2O, and 13.2 g (0.031 mol) of PhI(O2CCF3)2. This mixture was stirred at r.t. for 12 h, diluted with 300 mL of H2O, and then stirred for an additional 4 h at room temperature. The aqueous phase was extracted using MTBE (1×200 mL) follow by diethyl ether (2×100 mL). The aqueous layer was basified with 1N NaOH (pH=13) and then extracted with CH2Cl2 (3×100 mL). The organic extracts were dried and concentrated in vacuo to give the desired product as a colorless oil that was used in subsequent steps without further purification.
    • Example 112 2-Bromobicyclo[2.2.1]heptane-1-carboxylic acid
  • Figure US20110082107A1-20110407-C00149
    • Method S
  • To a 50 mL round-bottomed flask was added (1S,4R)-bicyclo[2.2.1]heptane-2-carboxylic acid (9.84 g, 70 mmol) and bromine (4.10 ml, 80 mmol). The suspension was stirred at room temperature until dissolution. Trichlorophosphine (0.30 ml, 3.4 mmol) was then added slowly and drop wise (significant exotherm observed). A reflux condenser was fitted to the flask with a nitrogen gas inlet and gas outlet (Tygon tubing) running into a scrubber solution of sodium sulfite (1 M, 200 mL). After the addition was complete, the reaction mixture was heated in a silicone oil bath at 80° C. for 4 h. After this time, the reaction was cooled to 10° C. and phosphorus-trichloride (4.23 ml, 48.3 mmol) was added drop-wise. The reaction was then heated to 80° C. During this time the color intensity of the reaction decreased, and after 8 h, the reaction mixture appeared dark orange. The reaction was then cooled to room temperature and diluted with ether (1 L). The ethereal solution was transferred to a separation funnel and washed with 1M sodium sulfite (2×500 mL), water (1×500 mL), and brine (1×500 mL). The organic layer was dried over MgSO4, filtered, and concentrated in vacuo to afford an oil. Ice cold pentane (50 mL) was then added to the crude product, and the mixture was stirred vigorously. After 20 min, a fine white precipitate formed, which was filtered and washed with pentane (20 mL) and then air dried under a gentle vacuum to afford (4S)-2-bromobicyclo[2.2.1]heptane-1-carboxylic acid (100.2 g, 457 mmol) as a white solid material.
    • Example 113 Bicyclo[2.2.1]heptane-1-carboxylic acid
  • Figure US20110082107A1-20110407-C00150
  • A 2-L reactor equipped with an overhead mechanical stirrer, condenser, nitrogen gas inlet port, temperature probe and reagent charging port, was placed under an atmosphere of nitrogen. The reactor was charged with zinc powder (<10 micron) (298 g, 4560 mmol) and acetic acid (500 mL). While vigorously stirring the heterogeneous mixture, (4S)-2-bromobicyclo[2.2.1]heptane-1-carboxylic acid (100 g, 456 mmol) was then added. A second portion of acetic acid (500 mL) was then used to rinse the walls of the reactor. The reaction mixture was brought to a gentle reflux (ca. 30 min) and then held at this temperature for 5 h. The cooled (room temperature) reaction mixture was passed through a pad of Celite, which was washed with acetic acid (1×300 mL) and ethyl acetate (1 (500 mL). The filtrate was concentrated, water (300 mL) was added, and then the mixture was stirred vigorously to induce precipitation. The precipitate was collected by filtration, washed with water, and dried under vacuum at 35° C. overnight. Pentane (50 mL) was then added, and the mixture was stirred vigorously for 20 min during which time a fine white precipitate formed. The resulting precipitate was filtered, washed with pentane (20 mL), and air dried to afford bicyclo[2.2.1]heptane-1-carboxylic acid (52 g) as a white solid.
    • Example 114 tert-Butyl bicyclo[2.2.1]heptan-1-ylcarbamate
  • Figure US20110082107A1-20110407-C00151
  • A 100 mL round-bottomed flask equipped with a condenser and nitrogen inlet was charged with bicyclo[2.2.1]heptane-1-carboxylic acid (2.00 g, 14.3 mmol), toluene (35 mL), triethylamine (2.18 ml, 15.7 mmol) and diphenylphosphoryl azide (3.38 ml, 15.7 mmol) at room temperature under an atmosphere of nitrogen. The reaction mixture was stirred at room temperature for 1 h before being heated to 50° C. for 3 h. Gas evolved from the reaction mixture for approximately 2-3 h. After 3 h at 50° C., the temperature of the reaction mixture was increased to 70° C. and stirring continued for another 2 h until no further gas evolution occurred. The reaction mixture was then cooled and then concentrated in vacuo. The resulting oil was dissolved in anhydrous t-BuOH (10 mL, 99.9% anhydrous packed under argon; Alfa Aesar), placed under and atmosphere of nitrogen, and refluxed in a 90° C. bath for 14 h. After this time, the reaction mixture was cooled and concentrated under reduced pressure to afford an off-white solid which was then dissolved in ether (50 mL), washed with water (20 mL), 1M NaOH (20 mL), water (20 mL) and brine (20 mL). After being dried over MgSO4, the mixture was filtered and concentrated in vacuo to afford 2.2 g of an off-white solid. Pentane (20 mL) was added, and solution was stirred vigorously until the majority of the material dissolved. The light orange colored precipitate that did not dissolve was removed through a fine grade sintered glass filter funnel. The mother liquor was concentrated to afford the title compound (2.2 g) as an off white solid.
    • Example 115 1-(Bicyclo[2.2.1]heptan-1-yl)thiourea
  • Figure US20110082107A1-20110407-C00152
  • A 100 mL RBF was purged with nitrogen gas before being charged with tert-butyl bicyclo[2.2.1]heptan-1-ylcarbamate (6.60 g, 31.0 mmol) and dichloromethane (66 mL). The solution was cooled in a 0° C. a bath, and then trifluoroacetic acid (12 mL, 18 g, 156 mL) was added. The cooling bath was removed, and the reaction mixture was allowed to warm to room temperature during which time a gas evolved from the reaction mixture. After 3 h at room temperature the reaction mixture was concentrated in vacuo to afford a viscous oil. This material was dissolved in dichloromethane (82 mL), and triethylamine (13.0 mL, 94 mmol) and benzoyl isothiocyanate (4.6 mL, 34 mmol) were added. After stirring at room temperature under an atmosphere of nitrogen for 14 h, the reaction mixture was concentrated in vacuo, and the resulting residue was dissolved in MeOH/THF/H2O (2:1:1, ca. 0.3 M). Potassium carbonate (22 g, 156 mmol) was added, and the biphasic solution was vigorously stirred for 3 h. The organic solvents were removed under reduced pressure during which time a yellow precipitate formed. The precipitate was filtered, washed with water (30 ml) and cold (−20° C.) diethyl ether to provide a white precipitate. This material was allowed to air dry for 10 min and then dried under high vacuum at room temperature for ca. 18 h to afford the title compound (3.8 g) as a fine white powder.
    • Example 116 4-(2-(4-Methyl-3-nitrophenoxy)ethyl)morpholine
  • Figure US20110082107A1-20110407-C00153
    • Method T
  • A mixture of 4-methyl-3-nitrophenol (1.53 g, 10 mmol.), 4-(2-chloroethyl)morpholine (2.79 g, 15 mmol), Cs2CO3 (9.78 g, 30 mmol) and NaI (145 mg, 1 mmol) in DMF (15 mL) was stirred for 3 h at 80° C. The reaction mixture was then cooled to room temperature, diluted with water, and extracted with EtOAc. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude residue was purified by flash chromatography (4:1:0.05 CH2Cl2/EtOAc/MeOH) to give the title compound as an oil.
    • Example 117 2-Methyl-5-(2-morpholinoethoxy)benzenamine
  • Figure US20110082107A1-20110407-C00154
  • To the mixture of 4-(2-(4-methyl-3-nitrophenoxy)ethyl)morpholine (532 mg, 2 mmol) in MeOH (50 mL) was added 10% Pd/C (250 mg). The mixture was stirred under an atmosphere of H2 (balloon) overnight. The contents of the reaction mixture were then filtered and concentrated in vacuo to give the title product, which was used without further purification.
    • Example 118 1-(2-Chlorophenyl)cyclopropanamine
  • Figure US20110082107A1-20110407-C00155
    • Method U
  • This compound was prepared using the method described by Bertus and Szymoniak; J. Org. Chem. 2003, 68, 7133.
    • Example 119 tert-Butyl 4-(4-(methylsulfonyl)phenyl)bicyclo[2.2.2]octan-1-ylcarbamate
  • Figure US20110082107A1-20110407-C00156
    • Method V
  • To a flame-dried 100 mL round-bottomed flask equipped with magnetic stirring and argon inlet/outlet was added 4-(4-(methylsulfonyl)phenyl)bicyclo[2.2.2]octane-1-carboxylic acid (200 mg, 649 μmol, prepared by the method described in US Patent Application: 2004/0133011 and 5 mL of toluene. Triethylamine (0.10 mL, 713 μmol) was added followed by diphenylphosphoryl azide (0.2 mL, 713 μmol), and the reaction mixture warmed in a 50° C. oil bath for 30 min, then to 70° C. for 5 h. tert-Butanol (5 mL, 53 mmol) was then added, and the reaction mixture continued to stir in the 70° C. bath. After 20 h, copper (I) chloride (10 mg, 101 μmol) was added, and the reaction continued to stir for ca 1.5 d at 70° C. The reaction was removed from the oil bath and then poured thru a 1 cm pad of Celite. The Celite pad was washed with CH2Cl2, and the filtrate was concentrated in vacuo. CH2Cl2 (50 mL) was added to the filtrate, and the organic layer was washed with 1M NaOH (2×), sat'd NH4Cl, sat'd NaHCO3, and brine. The organic layer was then dried over MgSO4, filtered and concentrated in vacuo to give tert-butyl 4-(4-(methylsulfonyl)phenyl)bicyclo[2.2.2]octan-1-ylcarbamate (mass=170 mg). The crude reaction product was taken onto the next step without further purification.
    • Example 120 4-(4-(Methylsulfonyl)phenyl)bicyclo[2.2.2]octan-1-amine
  • Figure US20110082107A1-20110407-C00157
  • To a 100 mL round-bottomed flask equipped with magnetic stirring was added tert-butyl 4-(4-(methylsulfonyl)phenyl)bicyclo[2.2.2]octan-1-ylcarbamate (170 mg, 448 μmol), 2 mL of CH2Cl2, ca. 5 drops of water, and trifluoroacetic acid (2 mL, 27 mmol). The reaction mixture was stirred at ambient temperature for 3.5 h, after which time the mixture was concentrated in vacuo. NaOH (ca. 50 mL of a 1M aq. solution) was added to the mixture, and the aqueous layer was extracted with CH2Cl2 (3×15 mL). The organic layers were combined, dried over K2CO3, filtered, and concentrated in vacuo to give 4-(4-(methylsulfonyl)phenyl)bicyclo[2.2.2]octan-1-amine (mass=120 mg, Mass Spec. m/z+ion=280.2) The crude reaction product was taken onto the next step without further purification.
    • Example 121 1-Benzoyl-3-(4-(4-(methylsulfonyl)phenyl)bicyclo[2.2.2]octan-1-yl)thiourea
  • Figure US20110082107A1-20110407-C00158
  • To a 100 mL round-bottomed flask equipped with magnetic stirring was added 4-(4-(methylsulfonyl)phenyl)bicyclo[2.2.2]octan-1-amine (120 mg, 429 μmol) in 2 mL of CH2Cl2, and benzoyl isothiocyanate (63.6 μl, 472 μmol). The reaction was stirred at ambient temperature for ca. 26 h, and then it was concentrated in vacuo to give 1-benzoyl-3-(4-(4-(methylsulfonyl)phenyl)bicyclo[2.2.2]octan-1-yl)thiourea (mass=185 mg, Mass spec. m/z+ion=443.2). The crude reaction product was taken onto the next step without further purification.
    • Example 122 1-(4-(4-(Methylsulfonyl)phenyl)bicyclo[2.2.2]octan-1-yl)thiourea
  • Figure US20110082107A1-20110407-C00159
  • To a 100 mL round-bottomed flask equipped with magnetic stirring was added a solution of 1-benzoyl-3-(4-(4-(methylsulfonyl)phenyl)bicyclo[2.2.2]octan-1-yl)thiourea (185 mg, 418 μmol) suspended in THF (1.5 mL) and methanol (3 mL). A solution of potassium carbonate (289 mg, 2090 μmol) in 1.5 mL of water was added, and the reaction mixture was stirred at ambient temperature. After 3.5 h, 3 mL more of THF was added. Then after 22.5 h, the lower boiling solvents of the reaction mixture were removed in vacuo. Water was added, and the aqueous layer was extracted with EtOAc (1×10 mL), CH2Cl2 (3×10 mL), and EtOAc (1×20 mL). The aqueous layer was the saturated with solid NaCl, and it was extracted with THF (3×10 mL). All organic layers were combined along with 30 mL more THF and dried over K2CO3, filtered, and concentrated in vacuo. The residue was absorbed onto silica gel and purified on a 40 g silica gel column using 1:2 hexanes-EtOAc+2% MeOH as the eluant followed by 1:2 hexanes-EtOAc+4.5% MeOH. Purified 1-(4-(4-(methylsulfonyl)phenyl)bicyclo[2.2.2]octan-1-yl)thiourea was isolated from the chromatography (43 mg, white solid, Mass spec. m/z+ion=339.2).
    • Example 123 Bicyclo[2.2.1]heptane-2-carboxamide
  • Figure US20110082107A1-20110407-C00160
    • Method W
  • A round-bottomed flask was charged with 450 g exo-2-norbornyl carboxylic acid (3200 mmol) in 100 mL of CH2Cl2. To the solution was added 0.23 mL of DMF (3.21 mmol) followed by the drop-wise addition of 325 mL of oxalyl chloride (3700 mmol). The reaction was stirred for 1 h at ambient temperature then warmed to 45° C. for an additional 30 min. The reaction was allowed to cool to ambient temperature and 2.5 L of 28% NH4OH was slowly added. The reaction was stirred for 1 h at ambient temperature. The desired product was isolated by filtration.
    • Example 124 1-Benzoyl-3-(bicyclo[2.2.1]heptan-2-ylmethyl)thiourea
  • Figure US20110082107A1-20110407-C00161
  • A dry 500 mL round-bottomed flask equipped with a magnetic stir bar under an atmosphere of N2 was charged with 3.96 g (28.5 mmol) of bicyclo[2.2.1]heptane-2-carboxamide in 30 mL of anhydrous THF. The mixture was cooled to 0° C. and 57 mL (57 mmol) of lithium aluminum hydride (1.0 M in THF) were added via syringe. The reaction was stirred for 10 min. at 0° C. then allowed to warm to ambient temperature and stirred an additional 15 h. The reaction solution was then cooled to 0° C., and 2.2 mL of H2O were added drop-wise followed by the addition of 2.2 mL of 15% aq. NaOH. Water (6.6 mL) was then added and the reaction was allowed to stir for 0.5 h at ambient temperature. The solids were removed by filtration through a Celite pad. Trifluoroacetic acid (2.6 mL) was then added to the filtrate, and the mixture stirred for 1 h at ambient temperature. The solvent was removed in vacuo providing amine salt as a white solid.
  • A dry 150 mL round-bottomed flask equipped with a magnetic stir bar under an atmosphere of N2 was charged with 5.46 g (22.8 mmol) of amine salt in 50 mL of CH2Cl2. To the solution was added 6.5 mL (46.6 mmol) of triethylamine followed by the drop-wise addition of 3.05 mL (22.7 mmol) of benzoyl isothiocyanate. After stirring the reaction mixture for 1.3 h at ambient temperature, the organic layer was washed with H2O (2×25 mL), 1M KOH (2×25 mL), 1M HCl (2×25 mL), and brine. The organic phase was dried over MgSO4, filtered, and concentrated in vacuo to provide the desired N-acylthiourea. MS (ESI, pos. ion) m/z: 289.2 (M+H).
    • Example 125 1-(Bicyclo[2.2.1]heptan-2-ylmethyl)thiourea
  • Figure US20110082107A1-20110407-C00162
  • A 250 mL round-bottomed flask equipped with a magnetic stir bar was charged with 6.17 g (22.4 mmol) of 1-benzoyl-3-(bicyclo[2.2.1]heptan-2-ylmethyl)thiourea in 30 mL of MeOH. KOH was added (2.55 g, 45.4 mmol) and the reaction was stirred at ambient temperature for 4 h. Water (150 mL) was then added to the reaction mixture, and the solid was removed by filtration. The flask and filter cake were rinsed with 40 mL of H2O. The collected solid was then suspended in 15 mL of MTBE, and the solid was collected by filtration providing the desired thiourea. MS (ESI, pos. ion) m/z: 185.2 (M+H).
    • Synthesis of Final Products. (Procedures: Method-X, Method-Y, Method-Z, Method-AA, Method-BB, Method-CC, Method-DD, Method-EE, Method-FF, Method-GG, Method-II, Method-JJ, Method-KK, Method-LL Method-MM, Method-NN, Method-OO, Method-PP). Example 126 6-(Cycloheptylamino)-5-thia-7-azaspiro[3.4]oct-6-en-8-one
  • Figure US20110082107A1-20110407-C00163
    • Method X
  • A mixture of 1-cycloheptylthiourea (0.255 g, 1.48 mmol) and ethyl 1-bromocyclobutanecarboxylate (0.25 mL, 1.48 mmol, Aldrich) in N,N-diisopropylethylamine (0.5 mL)and ethanol (1.0 mL) was heated in a sealed tube in a microwave oven (Emrys Optimizer from Personal Chemistry) at 155° C. for 2 h, then at 170° C. for 1.5 h. After removing the low-boiling solvents in vacuo, the residue was partitioned between EtOAc and water. The organic portion was separated, washed with brine, and conc. in vacuo. The residue was purified by flash column chromatography (0 to 35% of EtOAc in hexanes) to give the title compound as a tan solid. MS m/z: 253.2 (M+H)+
    • Example 127 Ethyl 4-oxo-2-(2-(trifluoromethyl)phenylamino)-4,5-dihydrothiazole-5-carboxylate
  • Figure US20110082107A1-20110407-C00164
    • Method X
  • To a stirred solution of 2-(trifluoromethyl)phenylthiourea (Menai Organics, 2.36 g, 10.7 mmol), Hunig's base (Aldrich, 1.9 mL, 10.7 mmol) in EtOH (10 mL) was added diethyl bromomalonate (2.0 mL, 10.7 mmol). After 1.5 h at room temperature, the reaction mixture was diluted with EtOAc, washed with saturated NaHCO3 and brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by silica gel chromatography. MS: 333 (M+1).
    • Example 128 (5R)-(±)-endo-2-(Bicyclo[2.2.1]heptan-2-ylamino)-5-isopropylthiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00165
    • Method Y
  • To a stirred solution of (±)-endo-1-(bicyclo[2.2.1]heptan-2-yl)thiourea (314 mg, 1.84 mmol) and (S)-2-bromo-3-methylbutanoic acid (334 mg, 1.84 mmol) in anhydrous ethanol (10 mL) under nitrogen, was added sodium acetate (182 mg, 2.21 mmol, 1.2 equ.) at room temperature. After refluxing the reaction mixture for 3 h, the solvent was evaporated in vacuo, and the residue was taken up in ethyl acetate (20 mL). The organic layer was washed with water (20 mL) followed by brine (20 mL), then dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash chromatography (SiO2 4:1 hexane/acetone) to afford the title compound (90 mg). MS (ESI, pos. ion) m/z: 253.1 (M+H).
    • Example 129 (S)-2-((rel-1R,2R,4S)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropylthiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00166
    • Method Z
  • To a solution of (R)-2-bromo-3-methylbutanoyl isothiocyanate (734 mg, 3.30 mmol) in CH2Cl2 at 0° C. was added drop-wise exo-2-aminonorbornane (0.4 mL, 3.37 mmol). The mixture was allowed to stir for 30 min at 0° C. Triethylamine (0.47 mL, 3.38 mmol, 1.02 equiv) was then added, and the mixture allowed to warm to room temperature and stirred overnight. The mixture was concentrated and the resulting oil triturated with THF (26 mL), filtered, and concentrated in vacuo. Flash chromatography (gradient of hexanes:acetone gradient—automated, hexanes:acetone 4:1—manual) furnished the title compound as a sticky white solid. Material was foamed by dissolution in CH2Cl2 followed by re-concentration.
    • Example 130 5-Isopropyl-5-methyl-2-(pyridin-2-ylmethylamino)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00167
    • Method Z
  • Pyridin-2-ylmethanamine (0.22 mL, 2.1 mmol) was added to 2-bromo-2,3-dimethylbutanoyl isothiocyanate (240 mg, 1.1 mmol) at room temperature. The reaction was exothermic, and was stirred at room temperature for 15 min. CH2Cl2 (2 ml) was added, and the resulting precipitate was removed by filtration. The CH2Cl2 solution was concentrated, and the mixture was purified by silica gel column (gradient 1% (10% NH3 in MeOH) to 30% (10% NH3 in MeOH) in CH2Cl2) to give the title compound as an off-white solid (123 mg). Mass Spec.=m/z+ion 264.1 (M+H)
    • Example 131 5-Cyclopentyl-5-fluoro-2-(2-fluorophenylamino)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00168
    • Method BB
  • A dry 100 mL round-bottomed flask was charged with 5-cyclopentyl-2-(2-fluorophenylamino)thiazol-4(5H)-one (0.200 g, 0.717 mmol) and 6.0 mL of THF. This solution was cooled to −78° C., and LDA (2.0 M in THF/heptane/ethyl benzene, 1.43 mL, 2.86 mmol) was added. The resulting brown solution was allowed to stir at that temperature for 1 h, then TMSCl (0.623 g, 0.725 mL, 5.74 mmol) was added. The solution was warmed to room temperature and allowed to stir for an additional 1 h. The solution was concentrated in vacuo to remove the volatiles and then redissolved in 10 mL of CH3CN. Selectfluor® (0.508 g, 1.43 mmol) was added at room temperature, and the resulting solution was stirred for 2 h. The reaction was quenched with saturated aqueous NaHCO3, and the resulting mixture was thoroughly extracted with CH2Cl2. This combined organic extracts were dried and concentrated in vacuo to give an oil which was purified by column chromatography (100% to 70% hexanes/30% ethyl acetate) to give the title compound as a colorless oil. Mass Spec (M+H)−; 297.1.
    • Example 132 2-(Bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5-(trifluoromethyl)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00169
    • Method CC
  • A dry 100 mL round-bottomed flask equipped with a magnetic stir bar under an atmosphere of N2 was charged with 528 mg (2.35 mmol) of 2-(bicyclo[2.2.1]heptan-2-ylamino)-5-methylthiazol-4(5H)-one in 5 mL of anhydrous THF. The reaction was cooled to −20° C. and 5.0 mL (5.0 mmol) of NaHMDS (1.0M in THF) were added drop-wise via syringe. The resulting reaction mixture was stirred at −20° C. for 30 min then 0.86 mL (6.78 mmol) of TMSCl was added drop-wise via syringe. The reaction mixture was held at −20° C. for 15 min, and then the mixture was allowed to warm to ambient temperature. After stirring the reaction mixture for an additional 1 h, the mixture was concentrated in vacuo. The reaction flask was again equipped with a magnetic stir bar and placed under an N2 atmosphere. Anhydrous CH3CN was added, and 978 mg (2.58 mmol) of S-(trifluoromethyl)dibenzothiophenium-3-sulfonate C2H5OH was added to the reaction mixture in one portion, and the resulting suspension was stirred at ambient temperature for 19 h. The solids were then removed by filtration through a Celite pad, and the reaction flask and pad were rinsed with CH2Cl2. The organic layer was washed with 20 mL of 1:1 H2O/sat'd NH4Cl, and the aqueous layer was extracted with an additional portion of CH2Cl2. The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. Flash chromatography (SiO2, CH2Cl2 to 5% MeOH/CH2Cl2) provided the desired compound. MS (ESI, pos. ion) m/z: 293.1 (M+H).
    • Example 133 Ethyl 5-(3-tert-butoxy-3-oxopropyl)-4-oxo-2-(2-(trifluoromethyl)phenylamino)-4,5-dihydrothiazole-5-carboxylate
  • Figure US20110082107A1-20110407-C00170
    • Method DD
  • The above compounds were prepared according to the procedure reported in the literature: see S. Muthusamy Synth. Commun. 2002, 32, 3247. To a stirred solution of ethyl 4-oxo-2-(2-(trifluoromethyl)phenylamino)-4,5-dihydrothiazole-5-carboxylate (1.1 g, 3.3 mol), tert-butyl acrylate (Aldrich, 2.5 mL, 16.5 mmol) in EtOH (10 mL) was added DBU (Aldrich, 0.25 mL, 1.6 mmol). The mixture was stirred at r.t. overnight and concentrated in vacuo. The crude product was purified by silica gel chromatography. MS: 461 (M+1).
    • Example 134 tert-Butyl 3-(4-oxo-2-(2-(trifluoromethyl)phenylamino)-4,5-dihydrothiazol-5-yl)propanoate
  • Figure US20110082107A1-20110407-C00171
  • To a mixture of ethyl 5-(3-tert-butoxy-3-oxopropyl)-4-oxo-2-(2-(trifluoromethyl)phenylamino)-4,5-dihydrothiazole-5-carboxylate (88.7 mg, 0.19 mmol), THF (1 mL), MeOH (0.3 mL), and water (0.3 mL) was added LiOH.H2O (Aldrich, 20 mg, 0.47 mmol) at room temperature. After 3 h, 1N HCl (0.7 mL) was added to the reaction mixture at 0° C. The mixture was extracted with EtOAc, and the organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by silica gel chromatography. MS: 389 (M+1).
    • Example 135 2-((1S,2S,4R)-Bicyclo[2.2.1]hept-2-ylamino)-8-oxa-1-thia-3-azaspiro[4.5]dec-2-en-4-one
  • Figure US20110082107A1-20110407-C00172
    • Method EE
  • To the mixture of 2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)thiazol-4(5H)-one (840 mg, 4.0 mmol) in THF (5.0 mL) was added LDA (2.0 M, 20 mL) at −78° C. The resulting mixture was stirred for 10 min at −78° C., and then 1-bromo-2-(2-bromoethoxy)ethane (3.71 g, 16 mmol) was added. The mixture was allowed to warm to room temperature and then stirred overnight. A sat'd solution of NaH2PO4 was added, and it was extracted with EtOAc. The organic layer was washed with sat'd NH4Cl, dried over MgSO4, filtered, and concentrated in vacuo. The crude residue was purified through flash chromatography (4:1:0.05; CH2Cl2/EtOAc/MeOH) to give the title compound as off-white solid. MS (ES+): 281 (M+H)+.
    • Example 136 2-((1S,2S,4R)-Bicyclo[2.2.1]heptan-2-ylamino)-5-(2-hydroxypropan-2-yl)-5-methylthiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00173
    • Method FF
  • To a solution of 2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-methylthiazol-4(5H)-one (1.10 g, 5.0 mmol) in THF (5 ml) at −78° C. was added LDA (2.0 M, 10 ml). After 5 min, acetone was added, and the reaction mixture was stirred for 1 h at −78° C. The resulting reaction mixture was poured into a sat'd NaH2PO4, and extracted with EtOAc. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude residue was purified by flash chromatography (4:1; Hexane:EtOAc) to give the title compound as a white solid. MS (ES+): 283 (M+H)+. The diastereomers were separated using standard HPLC methods described within this text.
    • Example 137 2-((1S,2S,4R)-Bicyclo[2.2.1]heptan-2-ylamino)-5-(2-fluoropropan-2-yl)-5-methylthiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00174
    • Method GG
  • To the solution of DAST (527 mg, 3.3 mmol) in CH2Cl2 (2 ml) at −78° C. was added a solution of 2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-(2-hydroxypropan-2-yl)-5-methylthiazol-4(5H)-one in CH2Cl2 (8 ml) over 10 min. After the addition, the cold bath was removed and the temperature was allowed to warm up to 0° C., and then quenched with sat'd NaHCO3. The mixture was extracted with CH2Cl2, dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by flash chromatography (4:1; Hexane:EtOAc) to give the title compound as white solid. MS (ES+): 285 (M+H)+. The diastereomers were separated using standard HPLC methods described within this text.
    • Example 138 5-Isopropyl-5-methoxy-2-(tricyclo[3.3.1.13,7]decan-1-ylamino)-thiazol-4-one
  • Figure US20110082107A1-20110407-C00175
    • Method II
  • A mixture of 5-(1-methylethyl)-2-(tricyclo[3.3.1.13,7]dec-1-ylamino)-1,3-thiazol-4(5H)-one (146 mg, 0.5 mmol) and NBS (107 mg, 0.6 mmol) in CCl4 (60 mL)was stirred at reflux for 30 min. The resulting mixture was cooled to 0° C., and filtered to remove the solid. The residue was then concentrated in vacuo and diluted with CH2Cl2 (20 mL). To this mixture was added MeOH (200 uL) and DIEA (200 uL). The mixture was stirred for 30 min, then was concentrated in vacuo and purified by flash chromatography (4:1; Hexane:EtOAc) to give the title compound as white solid. MS (ES+): 323 (M+H)+.
    • Example 139 2-(2-(1-Adamantylamino)-4-oxo-4,5-dihydrothiazol-5-yl)acetaldehyde
  • Figure US20110082107A1-20110407-C00176
    • Method JJ
  • A suspension of 2-(1-adamantylamino)-5-(2-hydroxyethyl)thiazol-4(5H)-one (0.25 g, 0.85 mmol) in CH2Cl2 (10 mL) was added to Dess-Martin periodinane (0.56 g, 1.28 mmol, Aldrich) in CH2Cl2 (10 mL). After stirring at ambient temperature for 1 h, the solvent was removed in vacuo. The residue was partitioned between ethyl acetate and saturated aqueous sodium thiosulfate and aqueous sodium bicarbonate. The organic portion was separated, washed with brine, and conc. in vacuo to give the title compound as a light yellowish solid. MS m/z: 293.6 (M+H)+.
    • Example 140 2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-(2-hydroxyethyl)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00177
    • Method KK
  • 1-((1S,2S,4R)-Bicyclo[2.2.1]heptan-2-yl)thiourea (887 mg, 5.25 mmol), 3-bromo-dihydrofuran-2(3H)-one (1.65 g, 5 mmol), EtOH (10 mL) and DIEA (5.0 mL) were placed in a microwave reaction vessel. The mixture was placed in a microwave synthesizer and was irradiated at 150° C. for 30 min. The resulting mixture was poured into water and extracted with EtOAc and dried over MgSO4. After being filtered and concentrated in vacuo, the title compound was obtained a brown solid. MS (ES+): 255 (M+H)+.
    • Example 141 2-((1S,2S,4R)-Bicyclo[2.2.1]heptan-2-ylamino)-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00178
  • The mixture of 2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-(2-hydroxyethyl)thiazol-4(5H)-one (3.2 g, 12.6 mmol) and p-toulenesulfonic acid (500 mg) in 3,4-dihydro-2H-pyran (10 mL) was stirred for 2 h at room temperature. The resulting mixture was diluted with CH2Cl2 (100 mL), then washed with sat'd NaH2PO4, and dried over MgSO4. After being filtered and concentrated in vacuo, the crude residue was purified by flash chromatography (3:2; Hexane:EtOAc) to give the title compound as an oil. MS (ES+): 339 (M+H)+.
    • Example 142 2-((1S,2S,4R)-Bicyclo[2.2.1]heptan-2-ylamino)-5-(2-methylallyl)-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00179
  • To the mixture of 2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)thiazol-4(5H)-one (1160 mg, 3.43 mmol) in THF (8.0 mL) cooled in a −78° C. bath was added LDA (2.0 M, 17.15 mL). The resulting mixture was stirred for 10 min at −78° C., and then 3-bromo-2-methylprop-1-ene (1.6 ml, 17.15 mmol) was added. After the reaction mixture was allowed to warm to room temperature and stirred ca. 18 h. Saturated NaH2PO4 was added, and the aqueous phase was extracted with EtOAc. The organic layer was washed with sat'd NH4Cl, dried over MgSO4, filtered, and concentrated in vacuo. The crude residue was purified by flash chromatography (4:1; Hexane:EtOAc) to give the title compound as yellow oil. MS (ES+): 393 (M+H)+.
    • Example 143 2-((1S,2S,4R)-Bicyclo[2.2.1]heptan-2-ylamino)-5-(2-hydroxyethyl)-5-(2-methylallyl)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00180
  • The mixture of 2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-(2-methylallyl)-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)thiazol-4(5H)-one (420 mg, 1.07 mmol) and p-toluenesulfonic acid (100 mg) in MeOH (5.0 mL) was stirred for 16 h at room temperature. The reaction mixture was then concentrated in vacuo, and sat'd NaH2PO4 was added. The mixture was then extracted with EtOAc, and the organic layer was washed with sat'd NH4Cl, dried over MgSO4, filtered and concentrated in vacuo. The crude residue was purified by flash chromatography (4:1; Hexane:EtOAc) to give the title compound as solid. MS (ES+): 309 (M+H)+.
    • Example 144 2-((1S,2S,4R)-Bicyclo[2.2.1]hept-2-ylamino)-7,7-dimethyl-8-oxa-1-thia-3-azaspiro[4.5]dec-2-en-4-one
  • Figure US20110082107A1-20110407-C00181
  • To a solution of 2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-(2-hydroxyethyl)-5-(2-methylallyl)thiazol-4(5H)-one (120 mg) in CH2Cl2 (3 mL) was added concentrated H2SO4 (200 uL). The resulting mixture was stirred for 16 h, then concentrated in vacuo. The residue was treated with sat'd NaH2PO4 and extracted with CH2Cl2. The organic layer was washed with sat'd NH4Cl, dried over MgSO4, filtered and concentrated in vacuo. The crude residue was purified by flash chromatography (4:1; Hexane:EtOAc) to give the title compound as solid. MS (ES+): 309 (M+H)+. The diastereomers were separated using standard HPLC methods described within this text.
    • Example 145 2-(Bicyclo[2.2.1]heptan-2-ylamino)-5-(2-(tert-butyldimethylsilyloxy)ethyl)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00182
    • Method LL
  • The title compound was prepared according to the procedure described in the preparation of tert-butyl 4-((2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-4-oxo-4,5-dihydrothiazol-5-yl)methyl)piperidine-1-carboxylate by using 2-(bicyclo[2.2.1]heptan-2-ylamino)thiazol-4(5H)-one (1.00 g, 4.76 mmol), lithium diisopropylamide (Aldrich, 2.0 M in heptane/THF/ethylbenzene, 8.5 mL, 19.0 mmol), and (2-bromoethoxy)(tert-butyl)dimethylsilane (Aldrich, 6.83 g, 28.5 mmol). The title compound was obtained as an off-white solid (950 mg). MS (ESI, pos. ion) m/z: 369 (M+H).
    • Example 146 2-(Bicyclo[2.2.1]heptan-2-ylamino)-5,5-bis(2-(tert-butyldimethylsilyloxy)ethyl)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00183
  • The title compound was prepared according to the procedure described in the preparation of tert-butyl 4-((2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-4-oxo-4,5-dihydrothiazol-5-yl)methyl)piperidine-1-carboxylate by using 2-(bicyclo[2.2.1]heptan-2-ylamino)-5-(2-(tert-butyldimethylsilyloxy)ethyl)thiazol-4(5H)-one (630 mg, 1.71 mmol), lithium diisopropylamide (Aldrich, 2.0 M in heptane/THF/ethylbenzene, 4.27 mL, 8.55 mmol), and (2-bromoethoxy)(tert-butyl)dimethylsilane (Aldrich, 2.46 g, 10.25 mmol). The title compound was obtained as a sticky orange solid (771 mg). MS (ESI, pos. ion) m/z: 413 (M-TBDMS+2H).
    • Example 147 2-(Bicyclo[2.2.1]heptan-2-ylamino)-5,5-bis(2-hydroxyethyl)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00184
  • A mixture of 2-(bicyclo[2.2.1]heptan-2-ylamino)-5,5-bis(2-(tert-butyldimethylsilyloxy)ethyl)thiazol-4(5H)-one (771 mg, 1.46 mmol) in 15 mL of a 1% HCl solution in ethanol was stirred at room temperature for 3 h. The reaction mixture was then concentrated in vacuo. Flash column chromatography (silica gel, 0-8% MeOH—CH2Cl2) afforded the title compound as a colorless thin film (390 mg). MS (ESI, pos. ion) m/z: 299 (M+H).
    • Example 148 Methanesulfonic acid 2-[2-(bicyclo[2.2.1]hept-2-ylamino)-5-(2-methanesulfonyloxy-ethyl)-4-oxo-4,5-dihydro-thiazol-5-yl]-ethyl ester
  • Figure US20110082107A1-20110407-C00185
  • To a mixture of 2-(bicyclo[2.2.1]heptan-2-ylamino)-5,5-bis(2-hydroxyethyl)thiazol-4(5H)-one (280 mg, 0.94 mmol) and diisopropylethylamine (Aldrich, 412 mg, 3.19 mmol) in CH2Cl2 (5 mL) was added methanesulfonyl chloride (344 mg, 3.00 mmol, 3.2 eq), and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was then concentrated in vacuo to provide the title compound which was used without further purification. MS (ESI, pos. ion) m/z: 455 (M+H).
    • Example 149 2-(Bicyclo[2.2.1]hept-2-ylamino)-8-cyclopentyl-1-thia-3,8-diaza-spiro[4.5]dec-2-en-4-one
  • Figure US20110082107A1-20110407-C00186
  • A mixture of methanesulfonic acid 2-[2-(bicyclo[2.2.1]hept-2-ylamino)-5-(2-methanesulfonyloxy-ethyl)-4-oxo-4,5-dihydro-thiazol-5-yl]-ethyl ester (half of the crude product from above) and cyclopentylamine (799 mg, 9.38 mmol) in CH2Cl2 (1.5 mL) was stirred at room temperature for 4 d. Flash column chromatography (silica gel, 0-10% MeOH in CH2Cl2) afforded the title compound as an off-white solid (52 mg). MS (ESI, pos. ion) m/z: 348 (M+H).
    • Example 150 tert-Butyl 4-((2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-4-oxo-4,5-dihydrothiazol-5-yl)methyl)piperidine-1-carboxylate
  • Figure US20110082107A1-20110407-C00187
    • Method AA
  • To a solution of 2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methylthiazol-4(5H)-one in anhydrous THF (30 mL) at −78° C. under N2 was added lithium diisopropylamide (Aldrich, 2.0 M in heptane/THF/ethylbenzene, 9.2 mL, 18.4 mmol). After stirring the reaction mixture at −78° C. for 1 h, a solution of 4-bromomethyl-piperidine-1-carboxylic acid tert-butyl ester (Pharma Core, 5.12 g, 18.4 mmol, 4.0 eq) in anhydrous THF (10 mL) was added under N2. The resulting reaction mixture was stirred at −78° C. for 4 h. The cooling bath was removed, and the reaction mixture was stirred at ambient temperature for ca. 18 h. Saturated NH4Cl was then added, and the THF was removed in vacuo. The residue was extracted with EtOAc (3×180 mL), and the combined organic layers were washed with saturated NaCl, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography (silica gel, 0-60% EtOAc in hexane) afforded the title compound as an off-white solid (1.42 g). MS (ESI, neg. ion) m/z: 420 (M−H).
    • Example 151 2-((2S)-Bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5-(piperidin-4-ylmethyl)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00188
    • Method MM
  • A mixture of tert-butyl 4-((2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-4-oxo-4,5-dihydrothiazol-5-yl)methyl)piperidine-1-carboxylate (1.42 g, 3.37 mmol, 1.0 eq) in 50 mL of a 4.7 M HCl solution in EtOAc was stirred at room temperature. After 4 h, the reaction mixture was concentrated in vacuo. Aqueous Na2CO3 (2.0 M, 20 mL) was then added, and water was removed in vacuo. The residue was then triturated with 10% MeOH—CH2Cl2 (6×100 mL), and the combined triturating solution were concentrated in vacuo. The crude product was dissolved in CH2Cl2, filtered, and concentrated in vacuo to afford the title compound as a light orange solid (1.08 g). MS (ESI, pos. ion) m/z: 322 (M+H).
    • Example 152 tert-Butyl 2-(3-(4-((2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-4-oxo-4,5-dihydrothiazol-5-yl)methyl)piperidine-1-carbonyl)phenoxy)ethylcarbamate
  • Figure US20110082107A1-20110407-C00189
  • A mixture of 2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5-(piperidin-4-ylmethyl)thiazol-4(5H)-one (534 mg, 1.66 mmol), 4-[2-(Boc-amino)ethyloxy]-benzoic acid (NeoMPS, 701 mg, 2.49 mmol), EDCI (Aldrich, 637 mg, 3.32 mmol, 2.0 eq), HOBt (Aldrich, 45 mg, 0.332 mmol, 0.2 eq) and triethylamine (Aldrich, 336 mg, 3.32 mmol, 2.0 eq) in CH2Cl2 (10 mL) was stirred at room temperature for ca. 18 h. The reaction was quenched with saturated NaHCO3 (100 mL), and the crude product was extracted with CH2Cl2 (3×100 mL). The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and concentrated. Flash column chromatography (silica gel, 0-5% MeOH in CH2Cl2) afforded the title compound as a white solid (800 mg). MS (ESI, pos. ion) m/z: 585 (M+H).
    • Example 153 5-((1-Acetylpiperidin-4-yl)methyl)-2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methylthiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00190
  • A mixture of 2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5-(piperidin-4-ylmethyl)thiazol-4(5H)-one (130 mg, 0.41 mmol), acetic anhydride (Aldrich, 83 mg, 0.81 mmol) and diisopropylethylamine (157 mg, 1.22 mmol) in CH2Cl2 (3 mL) was stirred at room temperature for ca. 18 h. Brine was then added, and the mixture was extracted with CH2Cl2 (4×60 mL). The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography (silica gel, 0-3.5% MeOH in CH2Cl2) afforded the title compound as a colorless thin film (116 mg). MS (ESI, pos. ion) m/z: 364 (M+H).
    • Example 154 2-((2S)-Bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5-((1-(methylsulfonyl)piperidin-4-yl)methyl)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00191
  • To a solution of 2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5-(piperidin-4-ylmethyl)thiazol-4(5H)-one (64 mg, 0.20 mmol) in CH2Cl2 (1.5 mL) was added methanesulfonyl chloride (Aldrich, 34 mg, 0.30 mmol) and triethylamine (60 mg, 0.60 mmol), and the reaction mixture was stirred at room temperature for ca. 18 h. Water (30 mL) was then added, and the crude product was extracted with CH2Cl2 (3×60 mL). The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography (silica gel, 0-3% MeOH in CH2Cl2) afforded the title compound as a white solid (34 mg). MS (ESI, pos. ion) m/z: 400 (M+H).
    • Example 155 2-((1S,2S,4R)-Bicyclo[2.2.1]heptan-2-ylamino)-5-(2-bromoethyl)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00192
    • Method NN
  • To a solution of 2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)thiazol-4(5H)-one (2.98 g, 14.2 mmol) in THF (15 ml) at −78° C. was added LDA (2.0 N, 28.4 ml). After 5 min, 1,2-dibromoethane (4.87 mL, 56.8 mmol) was added, and the reaction mixture was stirred for 3 h at −78° C. The resulting reaction mixture was poured into sat'd NaH2PO4 and extracted with EtOAc. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude residue was purified by flash chromatography (4:1; Hexane:EtOAc) to give the title compound as a white solid. MS (ES+): 317 (M+H)+.
    • Example 156 2-((1S,2S,4R)-Bicyclo[2.2.1]hept-2-ylamino)-6,6-dimethyl-7-oxa-1-thia-3-azaspiro[4.4]non-2-en-4-one and 5-((1S,2S,4R)-bicyclo[2.2.1]hept-2-ylamino)-4-thia-6-azaspiro[2.4]hept-5-en-7-one
  • Figure US20110082107A1-20110407-C00193
  • To a solution of 2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-(2-bromoethyl)thiazol-4(5H)-one (134 mg, 0.5 mmol) in THF (1 mL) at −78° C. was added LDA (2.0 N, 1.25 ml). After 5 min, acetone (500 uL) was added, and the reaction mixture was stirred for 3 h at −78° C. The resulting reaction mixture was poured into a sat'd NaH2PO4 and extracted with EtOAc. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude residue was purified through flash chromatography (4:1; Hexane:EtOAc) to give 2-((1S,2S,4R)-bicyclo[2.2.1]hept-2-ylamino)-6,6-dimethyl-7-oxa-1-thia-3-azaspiro[4.4]non-2-en-4-one as a white solid. (MS (ES+): 295 (M+H)+), and 5-((1S,2S,4R)-bicyclo[2.2.1]hept-2-ylamino)-4-thia-6-azaspiro[2.4]hept-5-en-7-one as a white solid. MS (ES+): 237 (M+H)+.
    • Example 157 2-(2-(Bicyclo[2.2.1]heptan-2-ylamino)-4-oxo-4,5-dihydrothiazol-5-yl)acetic acid
  • Figure US20110082107A1-20110407-C00194
    • Method OO
  • A stirred mixture of (±)-exo-1-(bicyclo[2.2.1]heptan-2-yl)thiourea (1.00 g, 5.87 mmol) and maleic anhydride (576 mg, 5.87 mmol) in glacial acetic acid (20 mL) was heated to reflux. After 1 h, the solvent was evaporated in vacuo, and the residue was azeotroped from toluene (3×15 mL). The resulting solid was suspended in water, filtered, washed with water (3×15 mL) and then hexane (2×10 mL). Air drying the solid afforded the title compound (1.57 g) as a cream-colored amorphous solid.
    • Example 158 5-(2-(Azepan-1-yl)-2-oxoethyl)-(±)-exo-2-(bicyclo[2.2.1]heptan-2-ylamino)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00195
  • To a stirred solution of 2-(2-(bicyclo[2.2.1]heptan-2-ylamino)-4-oxo-4,5-dihydrothiazol-5-yl)acetic acid (518 mg, 1.93 mmol) in N,N-dimethylformamide (20 mL) were added N,N-diisopropylethylamine (0.404 mL, 2.32 mmol) and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (807 mg, 2.12 mmol) at room temperature. After 20 min, hexamethyleneimine (0.218 mL, 1.93 mmol) was added. After an additional 3 h, the reaction was diluted with ethyl acetate (40 mL), washed with water (25 mL), and then brine (30 mL). The organic layer was then dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (SiO2, dichloromethane/methanol, 98:2 to 97:3) to afford the title compound (472 mg) as a cream-colored amorphous solid. MS (ESI, pos. ion) m/z: 350.2 (M+H).
    • Example 159 2-(2-(Bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-4-oxo-4,5-dihydrothiazol-5-yl)ethyl isonicotinate
  • Figure US20110082107A1-20110407-C00196
    • Method PP
  • A mixture of 2-(bicyclo[2.2.1]heptan-2-ylamino)-5-(2-hydroxyethyl)-5-methylthiazol-4(5H)-one (0.080 g, 0.30 mmol), isonicotinoyl chloride hydrochloride (0.056, 0.30 mmol), and N,N-diisopropylethylamine (0.13 mL, 0.75 mmol) in CH2Cl2(1.0 mL) was heated in a sealed tube in a microwave oven (SmithSynthesizer from Personal Chemistry) at 120° C. for 10 min. The reaction mixture was conc. in vacuo, and the residue was partitioned between EtOAc and water. The organic portion was separated, washed with brine, conc. in vacuo, and purified by RP-HPLC to give the title compound as a white solid. MS m/z: 374.1 (M+H)+.
    • Example 160 2-((2S)-Bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5-((1-(3-(2-morpholinoethoxy)benzoyl)piperidin-4-yl)methyl)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00197
  • (a) 4.0-4.7 M HCl/EtOAc, room temperature; (b) RCOOH, EDCI, HOBt or (RCO)2O, (Et)3N; (c) (ClCH2CH2)2O, KI, K2CO3
    • 5-((1-(3-(2-Aminoethoxy)benzoyl)piperidin-4-yl)methyl)-2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methylthiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00198
  • The title compound was prepared according to the procedure described in the preparation of 2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5-(piperidin-4-ylmethyl)thiazol-4(5H)-one by using tert-butyl 2-(3-(4-((2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-4-oxo-4,5-dihydrothiazol-5-yl)methyl)piperidine-1-carbonyl)phenoxy)ethylcarbamate (689 mg, 1.18 mmol) as the starting material. The title compound was obtained as an off-white solid (531 mg). MS (ESI, pos. ion) m/z: 485 (M+H)
    • N-(2-(3-(4-((2-((2S)-Bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-4-oxo-4,5-dihydrothiazol-5-yl)methyl)piperidine-1-carbonyl)phenoxy)ethyl)furan-3-carboxamide
  • Figure US20110082107A1-20110407-C00199
  • The title compound was prepared according to the procedure described in the preparation of tert-butyl 2-(3-(4-((2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-4-oxo-4,5-dihydrothiazol-5-yl)methyl)piperidine-1-carbonyl)phenoxy)ethylcarbamate by using 5-((1-(3-(2-aminoethoxy)benzoyl)piperidin-4-yl)methyl)-2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methylthiazol-4(5H)-one (93 mg, 0.19 mmol), 3-furoic acid (Aldrich, 39 mg, 0.35 mmol), EDCI (Aldrich, 74 mg, 0.38 mmol), HOBt (Aldrich, 5.2 mg, 0.038 mmol) and triethylamine (Aldrich, 39 mg, 0.38 mmol, 2.0 eq). The title compound was obtained as an off-white solid (89 mg). MS (ESI, pos. ion) m/z. 579 (M+H).
    • 2-((2S)-Bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5-((1-(3-(2-morpholinoethoxy)benzoyl)piperidin-4-yl)methyl)thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00200
  • A mixture of 5-((1-(3-(2-aminoethoxy)benzoyl)piperidin-4-yl)methyl)-2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methylthiazol-4(5H)-one (100 mg, 0.207 mmol), K2CO3 (114 mg, 0.83 mmol), KI (Aldrich, 6.9 mg, 0.041 mmol), 1-chloro-2-(2-chloroethoxy)ethane (Aldrich, 38 mg, 0.27 mmol) in CH2Cl2 (3 mL) was heated at reflux for 10 d. Saturated NaHCO3 (50 mL) was added, and the crude product was extracted with CH2Cl2 (4×60 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. Flash column chromatography (silica gel, CH2Cl2 with 0-4% MeOH) afforded the title compound as a colorless thin film (10 mg). MS (ESI, pos. ion) m/z: 555 (M+H).
  • The following table of compounds were prepared using the methodologies outlined above.
  • TABLE 1
    Mol Methods
    Structure Wt. Mass Spec Name of Prep.
    Figure US20110082107A1-20110407-C00201
         		280.3 281 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 7-oxa-1-thia-3- azaspiro[4.4]non-2-ene-4,6- dione X
    Figure US20110082107A1-20110407-C00202
         		266.4 267 2-((1R,2R,4S)- bicyclo[2.2.1]heptan-2- ylamino)-5-isopropyl-5- methylthiazol-4(5H)-one Y AA
    Figure US20110082107A1-20110407-C00203
         		252.4 253 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-isopropylthiazol- 4(5H)-one Y
    Figure US20110082107A1-20110407-C00204
         		278.4 279 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-cyclopentylthiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00205
         		292.4 293 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-cyclohexylthiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00206
         		292.4 293 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-cyclopentyl-5- methylthiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00207
         		306.5 307 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-cyclohexyl-5- methylthiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00208
         		266.4 267 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-tert-butylthiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00209
         		266.4 267 2-(cyclohexylamino)-5- cyclopentylthiazol-4(5H)-one P X
    Figure US20110082107A1-20110407-C00210
         		278.3 279 5-cyclopentyl-2-(2- fluorophenylamino)thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00211
         		294.5 295 2-(cyclooctylamino)-5- cyclopentylthiazol-4(5H)-one P X
    Figure US20110082107A1-20110407-C00212
         		318.5 319 2-(adamantylamino)-5- cyclopentylthiazol-4(5H)-one P X
    Figure US20110082107A1-20110407-C00213
         		280.4 281 2-(cyclohexylmethylamino)-5- cyclopentylthiazol-4(5H)-one P X
    Figure US20110082107A1-20110407-C00214
         		296.3 297 5-cyclopentyl-2-(2,4- difluorophenylamino)thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00215
         		308.5 309 5-cyclohexyl-2- (cyclooctylamino)thiazol- 4(5H)-one P X
    Figure US20110082107A1-20110407-C00216
         		332.5 333 2-(adamantylamino)-5- cyclohexylthiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00217
         		280.4 281 5-cyclohexyl-2- (cyclohexylamino)thiazol- 4(5H)-one P X
    Figure US20110082107A1-20110407-C00218
         		292.4 293 5-cyclohexyl-2-(2- fluorophenylamino)thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00219
         		270.4 271 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-fluoro-5- isopropylthiazol-4(5H)-one Y BB
    Figure US20110082107A1-20110407-C00220
         		274.4 275 2-(o-toluidino)-5- cyclopentylthiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00221
         		296.3 297 5-cyclopentyl-5-fluoro-2-(2- fluorophenylamino)thiazol- 4(5H)-one X BB
    Figure US20110082107A1-20110407-C00222
         		292.4 293 2-(o-toluidino)-5-cyclopentyl-5- fluorothiazol-4(5H)-one X BB
    Figure US20110082107A1-20110407-C00223
         		274.4 275 2-(o-toluidino)-5- cyclopentylthiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00224
         		288.4 289 2-(o-toluidino)-5- cyclohexylthiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00225
         		268.3 269 methyl 2-(2- fluorophenylamino)-4-oxo-4,5- dihydrothiazole-5-carboxylate X
    Figure US20110082107A1-20110407-C00226
         		292.4 293 5-cyclopentyl-2-(2- fluorophenylamino)-5- methylthiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00227
         		294.3 295 2-(2-fluorophenylamino)-5- (tetrahydro-2H-pyran-4- yl)thiazol-4(5H)-one L X
    Figure US20110082107A1-20110407-C00228
         		310.8 311 2-(2-chlorophenylamino)-5- (tetrahydro-2H-pyran-4- yl)thiazol-4(5H)-one L X
    Figure US20110082107A1-20110407-C00229
         		290.4 291 2-(o-toluidino)-5-(tetrahydro- 2H-pyran-4-yl)thiazol-4(5H)- one L X
    Figure US20110082107A1-20110407-C00230
         		294.8 295 2-(2-chlorophenylamino)-5- cyclopentylthiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00231
         		308.8 309 2-(2-chlorophenylamino)-5- cyclohexylthiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00232
         		296.4 297 2-(cyclohexylmethylamino)-5- (tetrahydro-2H-pyran-4- yl)thiazol-4(5H)-one P L X
    Figure US20110082107A1-20110407-C00233
         		308.4 309 2-(2-fluorophenylamino)-5- methyl-5-(tetrahydro-2H-pyran- 4-yl)thiazol-4(5H)-one L X AA
    Figure US20110082107A1-20110407-C00234
         		324.8 325 2-(2-chlorophenylamino)-5- methyl-5-(tetrahydro-2H-pyran- 4-yl)thiazol-4(5H)-one L X AA
    Figure US20110082107A1-20110407-C00235
         		304.4 305 2-(o-toluidino)-5-methyl-5- (tetrahydro-2H-pyran-4- yl)thiazol-4(5H)-one L X AA
    Figure US20110082107A1-20110407-C00236
         		280.3 281 2-(2-fluorophenylamino)-5- ((S)-tetrahydrofuran-3- yl)thiazol-4(5H)-one L X
    Figure US20110082107A1-20110407-C00237
         		296.8 297 2-(2-chlorophenylamino)-5- ((S)-tetrahydrofuran-3- yl)thiazol-4(5H)-one L X
    Figure US20110082107A1-20110407-C00238
         		294.3 295 2-(2-fluorophenylamino)-5- methyl-5-((S)-tetrahydrofuran- 3-yl)thiazol-4(5H)-one L X AA
    Figure US20110082107A1-20110407-C00239
         		310.8 311 2-(2-chlorophenylamino)-5- methyl-5-((S)-tetrahydrofuran- 3-yl)thiazol-4(5H)-one L X AA
    Figure US20110082107A1-20110407-C00240
         		280.4 281 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((S)- tetrahydrofuran-3-yl)thiazol- 4(5H)-one L X
    Figure US20110082107A1-20110407-C00241
         		282.4 283 2-(cyclohexylmethylamino)-5- ((S)-tetrahydrofuran-3- yl)thiazol-4(5H)-one P L X
    Figure US20110082107A1-20110407-C00242
         		294.4 295 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-((S)- tetrahydrofuran-3-yl)thiazol- 4(5H)-one L X AA
    Figure US20110082107A1-20110407-C00243
         		296.4 297 2-(cyclohexylmethylamino)-5- methyl-5-((S)-tetrahydrofuran- 3-yl)thiazol-4(5H)-one P L X AA
    Figure US20110082107A1-20110407-C00244
         		294.4 295 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(tetrahydro-2H- pyran-4-yl)thiazol-4(5H)-one L X
    Figure US20110082107A1-20110407-C00245
         		308.4 309 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5- (tetrahydro-2H-pyran-4- yl)thiazol-4(5H)-one L X AA
    Figure US20110082107A1-20110407-C00246
         		310.5 311 2-(cyclohexylmethylamino)-5- methyl-5-(tetrahydro-2H-pyran- 4-yl)thiazol-4(5H)-one P L X AA
    Figure US20110082107A1-20110407-C00247
         		280.3 281 2-(2-fluorophenylamino)-5- ((R)-tetrahydrofuran-3- yl)thiazol-4(5H)-one L X
    Figure US20110082107A1-20110407-C00248
         		296.8 297 2-(2-chlorophenylamino)-5- ((R)-tetrahydrofuran-3- yl)thiazol-4(5H)-one L X
    Figure US20110082107A1-20110407-C00249
         		280.4 281 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((R)- tetrahydrofuran-3-yl)thiazol- 4(5H)-one L X
    Figure US20110082107A1-20110407-C00250
         		282.4 283 2-(cyclohexylmethylamino)-5- ((R)-tetrahydrofuran-3- yl)thiazol-4(5H)-one P L X
    Figure US20110082107A1-20110407-C00251
         		294.4 295 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-((R)- tetrahydrofuran-3-yl)thiazol- 4(5H)-one L X AA
    Figure US20110082107A1-20110407-C00252
         		296.4 297 2-(cyclohexylmethylamino)-5- methyl-5-((R)-tetrahydrofuran- 3-yl)thiazol-4(5H)-one P L X AA
    Figure US20110082107A1-20110407-C00253
         		310.8 311 2-(2-chlorophenylamino)-5- methyl-5-((R)-tetrahydrofuran- 3-yl)thiazol-4(5H)-one L X AA
    Figure US20110082107A1-20110407-C00254
         		294.3 295 2-(2-fluorophenylamino)-5- methyl-5-((R)-tetrahydrofuran- 3-yl)thiazol-4(5H)-one L X AA
    Figure US20110082107A1-20110407-C00255
         		393.5 338; (M-t-Bu)+ tert-butyl 3-(2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-4-oxo-4,5- dihydrothiazol-5-yl)pyrrolidine- 1-carboxylate L X AA
    Figure US20110082107A1-20110407-C00256
         		293.4 294 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5- (pyrrolidin-3-yl)thiazol-4(5H)- one L X AA MM
    Figure US20110082107A1-20110407-C00257
         		335.5 336 5-(1-acetylpyrrolidin-3-yl)-2- ((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00258
         		409.9 354; (M-t-Bu)+ tert-butyl 3-(2-(2- chlorophenylamino)-5-methyl- 4-oxo-4,5-dihydrothiazol-5- yl)pyrrolidine-1-carboxylate L X AA
    Figure US20110082107A1-20110407-C00259
         		308.4 309 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5- ((tetrahydrofuran-3- yl)methyl)thiazol-4(5H)-one X AA
    Figure US20110082107A1-20110407-C00260
         		276.4 277 5-isopropyl-2-(2-phenylpropan- 2-ylamino)thiazol-4(5H)-one O X
    Figure US20110082107A1-20110407-C00261
         		290.4 291 5-isopropyl-5-methyl-2-(2- phenylpropan-2- ylamino)thiazol-4(5H)-one O X AA
    Figure US20110082107A1-20110407-C00262
         		282.8 283 2-(2-chlorobenzylamino)-5- isopropylthiazol-4(5H)-one O X
    Figure US20110082107A1-20110407-C00263
         		296.8 297 2-(2-chlorobenzylamino)-5- isopropyl-5-methylthiazol- 4(5H)-one O X AA
    Figure US20110082107A1-20110407-C00264
         		310.8 311 2-(2-(2-chlorophenyl)propan-2- ylamino)-5-isopropylthiazol- 4(5H)-one R O X
    Figure US20110082107A1-20110407-C00265
         		324.9 325 2-(2-(2-chlorophenyl)propan-2- ylamino)-5-isopropyl-5- methylthiazol-4(5H)-one R O X AA
    Figure US20110082107A1-20110407-C00266
         		359.9 360 2-(2-(2-chlorophenyl)propan-2- ylamino)-5-methyl-5-(pyridin- 4-yl)thiazol-4(5H)-one R L O X
    Figure US20110082107A1-20110407-C00267
         		248.3 249 2-(benzylamino)-5- isopropylthiazol-4(5H)-one O X
    Figure US20110082107A1-20110407-C00268
         		268.8 269 2-(2-(2-chlorophenyl)propan-2- ylamino)thiazol-4(5H)-one O X
    Figure US20110082107A1-20110407-C00269
         		262.4 263 2-(benzylamino)-5-isopropyl-5- methylthiazol-4(5H)-one O X AA
    Figure US20110082107A1-20110407-C00270
         		296.8 297 2-(2-chlorophenethylamino)-5- isopropylthiazol-4(5H)-one O X
    Figure US20110082107A1-20110407-C00271
         		310.8 311 2-(2-chlorophenethylamino)-5- isopropyl-5-methylthiazol- 4(5H)-one O X AA
    Figure US20110082107A1-20110407-C00272
         		262.4 263 5-isopropyl-2-((R)-1- phenylethylamino)thiazol- 4(5H)-one O X
    Figure US20110082107A1-20110407-C00273
         		262.4 263 5-isopropyl-2-((S)-1- phenylethylamino)thiazol- 4(5H)-one O X
    Figure US20110082107A1-20110407-C00274
         		276.4 277 5-isopropyl-5-methyl-2-((R)-1- phenylethylamino)thiazol- 4(5H)-one O X AA
    Figure US20110082107A1-20110407-C00275
         		496.1 496 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((1-(2- chlorophenylsulfonyl)piperidin- 4-yl)methyl)-5-methylthiazol- 4(5H)-one O X AA MM
    Figure US20110082107A1-20110407-C00276
         		497.6 498 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((1-(2,6- difluorophenylsulfonyl)piperidin- 4-yl)methyl)-5-methylthiazol- 4(5H)-one O X AA MM
    Figure US20110082107A1-20110407-C00277
         		482.1 482 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(1-(2- chlorophenylsulfonyl)piperidin- 4-yl)-5-methylthiazol-4(5H)- one O X L MM
    Figure US20110082107A1-20110407-C00278
         		280.4 281 2-((S)-1-(2- fluorophenyl)ethylamino)-5- isopropylthiazol-4(5H)-one Z
    Figure US20110082107A1-20110407-C00279
         		398.4 399 2-((S)-1-(3,5- bis(trifluoromethyl)phenyl) ethylamino)-5-isopropylthiazol- 4(5H)-one Z
    Figure US20110082107A1-20110407-C00280
         		330.4 331 5-isopropyl-2-((S)-1-(4- (trifluoromethyl)phenyl) ethylamino)thiazol-4(5H)-one Z
    Figure US20110082107A1-20110407-C00281
         		330.1 331 5-isopropyl-2-((S)-1-(2- (trifluoromethyl)phenyl) ethylamino)thiazol-4(5H)-one Z
    Figure US20110082107A1-20110407-C00282
         		412.4 413 2-((S)-1-(3,5- bis(trifluoromethyl)phenyl) ethylamino)-5-isopropyl-5- methylthiazol-4(5H)-one Z
    Figure US20110082107A1-20110407-C00283
         		344.4 345 5-isopropyl-5-methyl-2-((S)-1-(4- (trifluoromethyl)phenyl) ethylamino)thiazol-4(5H)-one Z
    Figure US20110082107A1-20110407-C00284
         		280.4 281 2-((S)-1-(4- fluorophenyl)ethylamino)-5- isopropylthiazol-4(5H)-one Z
    Figure US20110082107A1-20110407-C00285
         		276.4 277 (R)-5-isopropyl-5-methyl-2- ((S)-1- phenylethylamino)thiazol- 4(5H)-one Z AA
    Figure US20110082107A1-20110407-C00286
         		276.4 277 (S)-5-isopropyl-5-methyl-2- ((S)-1- phenylethylamino)thiazol- 4(5H)-one Z AA
    Figure US20110082107A1-20110407-C00287
         		252.4 253 2-(bicyclo[2.2.1]heptan-1- ylamino)-5-isopropylthiazol- 4(5H)-one S X
    Figure US20110082107A1-20110407-C00288
         		330.4 331 5-isopropyl-2-((R)-1-(2- (trifluoromethyl)phenyl) ethylamino)thiazol-4(5H)-one Z
    Figure US20110082107A1-20110407-C00289
         		280.4 281 2-((R)-1-(2- fluorophenyl)ethylamino)-5- isopropylthiazol-4(5H)-one Z
    Figure US20110082107A1-20110407-C00290
         		280.4 281 2-((R)-1-(4- fluorophenyl)ethylamino)-5- isopropylthiazol-4(5H)-one Z
    Figure US20110082107A1-20110407-C00291
         		292.3 293 2-(bicyclo[2.2.1]heptan-1- ylamino)-5-methyl-5- (trifluoromethyl)thiazol-4(5H)- one S X CC
    Figure US20110082107A1-20110407-C00292
         		358.4 359 2-((S)-1-(2- (trifluoromethyl)phenyl) ethylamino))-8-oxa-1-thia-3- azaspiro[4.5]non-2-ene-4-one O X EE
    Figure US20110082107A1-20110407-C00293
         		344.4 345 (S)-5-isopropyl-5-methyl-2- ((S)-1-(2- (trifluoromethyl)phenyl) ethylamino)thiazol-4(5H)-one Z AA
    Figure US20110082107A1-20110407-C00294
         		344.4 345 (R)-5-isopropyl-5-methyl-2- ((S)-1-(2- (trifluoromethyl)phenyl) ethylamino)thiazol-4(5H)-one Z AA
    Figure US20110082107A1-20110407-C00295
         		266.4 267 (S)-2-(bicyclo[2.2.1]heptan-1- ylamino)-5-isopropyl-5- methylthiazol-4(5H)-one S X AA
    Figure US20110082107A1-20110407-C00296
         		266.4 267 (R)-2-(bicyclo[2.2.1]heptan-1- ylamino)-5-isopropyl-5- methylthiazol-4(5H)-one S X AA
    Figure US20110082107A1-20110407-C00297
         		294.4 295 (S)-2-((S)-1-(2- fluorophenyl)ethylamino)-5- isopropyl-5-methylthiazol- 4(5H)-one Z AA
    Figure US20110082107A1-20110407-C00298
         		294.4 295 (R)-2-((S)-1-(2- fluorophenyl)ethylamino)-5- isopropyl-5-methylthiazol- 4(5H)-one Z AA
    Figure US20110082107A1-20110407-C00299
         		308.4 309 2-((S)-1-(2- fluorophenyl)ethylamino))-8- oxa-1-thia-3-azaspiro[4.5]non- 2-ene-4-one O X EE
    Figure US20110082107A1-20110407-C00300
         		252.3 253 2-((S)-1-(4- fluorophenyl)ethylamino)-5- methylthiazol-4(5H)-one O X
    Figure US20110082107A1-20110407-C00301
         		292.3 293 (R)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5- (trifluoromethyl)thiazol-4(5H)- one O Y CC
    Figure US20110082107A1-20110407-C00302
         		292.3 293 (S)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5- (trifluoromethyl)thiazol-4(5H)- one O Y CC
    Figure US20110082107A1-20110407-C00303
         		344.4 345 5-isopropyl-5-methyl-2-((R)-1-(2- (trifluoromethyl)phenyl) ethylamino)thiazol-4(5H)-one Z AA
    Figure US20110082107A1-20110407-C00304
         		294.4 295 2-((R)-1-(2- fluorophenyl)ethylamino)-5- isopropyl-5-methylthiazol- 4(5H)-one Z AA
    Figure US20110082107A1-20110407-C00305
         		294.4 295 2-((R)-1-(4- fluorophenyl)ethylamino)-5- isopropyl-5-methylthiazol- 4(5H)-one Z AA
    Figure US20110082107A1-20110407-C00306
         		252.3 253 2-((S)-1-(2- fluorophenyl)ethylamino)-5- methylthiazol-4(5H)-one Z
    Figure US20110082107A1-20110407-C00307
         		292.4 293 2-((S)-1-(2- fluorophenyl)ethylamino))-1- thia-3-azaspiro[4.4]non-2-ene 4-one O X
    Figure US20110082107A1-20110407-C00308
         		320.3 321 2-((S)-1-(4- fluorophenyl)ethylamino)-5- methyl-5- (trifluoromethyl)thiazol-4(5H)- one O X CC
    Figure US20110082107A1-20110407-C00309
         		294.4 295 (S)-2-((S)-1-(4- fluorophenyl)ethylamino)-5- isopropyl-5-methylthiazol- 4(5H)-one X AA
    Figure US20110082107A1-20110407-C00310
         		294.4 295 (R)-2-((S)-1-(4- fluorophenyl)ethylamino)-5- isopropyl-5-methylthiazol- 4(5H)-one X AA
    Figure US20110082107A1-20110407-C00311
         		234.3 235 5-methyl-2-((S)-1- phenylethylamino)thiazol- 4(5H)-one O X
    Figure US20110082107A1-20110407-C00312
         		302.3 303 5-methyl-2-((S)-1- phenylethylamino)-5- (trifluoromethyl)thiazol-4(5H)- one O X CC
    Figure US20110082107A1-20110407-C00313
         		320.4 321 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-isopropyl-5- (trifluoromethyl)thiazol-4(5H)- one O X CC
    Figure US20110082107A1-20110407-C00314
         		280.4 281 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-ethyl-5- isopropylthiazol-4(5H)-one O X AA
    Figure US20110082107A1-20110407-C00315
         		320.3 321 (R)-2-((S)-1-(2- fluorophenyl)ethylamino)-5- methyl-5- (trifluoromethyl)thiazol-4(5H)- one O Y CC
    Figure US20110082107A1-20110407-C00316
         		320.3 321 (S)-2-((S)-1-(2- fluorophenyl)ethylamino)-5- methyl-5- (trifluoromethyl)thiazol-4(5H)- one O Y CC
    Figure US20110082107A1-20110407-C00317
         		266.4 267 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylmethylamino)-5- isopropylthiazol-4(5H)-one W O X
    Figure US20110082107A1-20110407-C00318
         		238.3 239 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylmethylamino)-5- methylthiazol-4(5H)-one W O Y
    Figure US20110082107A1-20110407-C00319
         		316.3 317 5-isopropyl-2-((S)-2,2,2- trifluoro-1- phenylethylamino)thiazol- 4(5H)-one Z
    Figure US20110082107A1-20110407-C00320
         		278.4 279 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2- ylmethylamino)-1-thia-3- azaspiro[4.4]non-2-ene-4-one W O X
    Figure US20110082107A1-20110407-C00321
         		306.3 307 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylmethylamino)-5-methyl-5- (trifluoromethyl)thiazol-4(5H)- one W O Y CC
    Figure US20110082107A1-20110407-C00322
         		260.3 261 2-(5,5- difluorobicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one Q O Y
    Figure US20110082107A1-20110407-C00323
         		328.3 329 2-(5,5- difluorobicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5- (trifluoromethyl)thiazol-4(5H)- one Q O Y CC
    Figure US20110082107A1-20110407-C00324
         		282.4 283 ethyl 2-((1S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-4-oxo-4,5- dihydrothiazole-5-carboxylate X
    Figure US20110082107A1-20110407-C00325
         		298.4 299 2-((1S,4R)-Bicyclo[2.2.1]hept- 2-ylamino)-1,4-dioxo-4,5- dihydro-1H-1λ4-thiazole-5- carboxylic acid ethyl ester X
    Figure US20110082107A1-20110407-C00326
         		332.3 333 ethyl 4-oxo-2-(2- (trifluoromethyl)phenylamino)- 4,5-dihydrothiazole-5- carboxylate X
    Figure US20110082107A1-20110407-C00327
         		432.4 433 ethyl 5-(3-ethoxy-3-oxopropyl)- 4-oxo-2-(2- (trifluoromethyl)phenylamino)- 4,5-dihydrothiazole-5- carboxylate X DD
    Figure US20110082107A1-20110407-C00328
         		266.4 267 2-((1R,2R,4S)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5- propylthiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00329
         		306.4 307 2-((1R,2R,4S)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(2,2,2- trifluoroethyl)thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00330
         		343.3 344 2-(2-Trifluoromethyl- phenylamino)-1-thia-3,7-diaza- spiro[4.5]dec-2-ene-4,6-dione M X
    Figure US20110082107A1-20110407-C00331
         		293.4 294 2-((1R,2R,4S)- Bicyclo[2.2.1]hept-2-ylamino)- 1-thia-3,7-diaza-spiro[4.5]dec- 2-ene-4,6-dione M X
    Figure US20110082107A1-20110407-C00332
         		388.4 389 tert-butyl 3-(4-oxo-2-(2- (trifluoromethyl)phenylamino)- 4,5-dihydrothiazol-5- yl)propanoate X DD
    Figure US20110082107A1-20110407-C00333
         		293.4 294 2-((1S,2S,4R)- Bicyclo[2.2.1]hept-2-ylamino)- 1-thia-3,7-diaza-spiro[4.5]dec- 2-ene-4,6-dione M X
    Figure US20110082107A1-20110407-C00334
         		332.3 333 3-(4-oxo-2-(2- (trifluoromethyl)phenylamino)- 4,5-dihydrothiazol-5- yl)propanoic acid X DD
    Figure US20110082107A1-20110407-C00335
         		240.7 241 2-(2-chlorophenylamino)-5- methylthiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00336
         		387.4 388 N-isobutyl-3-(4-oxo-2-(2- (trifluoromethyl)phenylamino)- 4,5-dihydrothiazol-5- yl)propanamide X DD MM
    Figure US20110082107A1-20110407-C00337
         		407.4 408 3-(4-oxo-2-(2- (trifluoromethyl)phenylamino)- 4,5-dihydrothiazol-5-yl)-N- phenylpropanamide X DD MM
    Figure US20110082107A1-20110407-C00338
         		399.4 400 5-(3-oxo-3-(piperidin-1- yl)propyl)-2-(2- (trifluoromethyl)phenylamino) thiazol-4(5H)-one X DD MM
    Figure US20110082107A1-20110407-C00339
         		433.4 434 5-(3-(isoindolin-2-yl)-3- oxopropyl)-2-(2- (trifluoromethyl)phenylamino) thiazol-4(5H)-one X DD MM
    Figure US20110082107A1-20110407-C00340
         		301.4 302 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(pyridin- 4-yl)thiazol-4(5H)-one M X
    Figure US20110082107A1-20110407-C00341
         		351.4 352 5-methyl-5-(pyridin-4-yl)-2-(2- (trifluoromethyl)phenylamino) thiazol-4(5H)-one M X
    Figure US20110082107A1-20110407-C00342
         		317.8 318 2-(2-chlorophenylamino)-5- methyl-5-(pyridin-4-yl)thiazol- 4(5H)-one M X
    Figure US20110082107A1-20110407-C00343
         		301.3 302 2-(2-fluorophenylamino)-5- methyl-5-(pyridin-4-yl)thiazol- 4(5H)-one M X
    Figure US20110082107A1-20110407-C00344
         		415.6 416 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((1-(furan-4- carbonyl)piperidin-4- yl)methyl)-5-methylthiazol- 4(5H)-one X AA MM
    Figure US20110082107A1-20110407-C00345
         		506.7 507 tert-butyl 1-(4-((2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-4-oxo-4,5- dihydrothiazol-5- yl)methyl)piperidin-1-yl)-2- methyl-1-oxopropan-2- ylcarbamate X AA MM
    Figure US20110082107A1-20110407-C00346
         		406 407 5-((1-(2-amino-2- methylpropanoyl)piperidin-4- yl)methyl)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one X AA MM
    Figure US20110082107A1-20110407-C00347
         		289.4 290 2-(cyclohexylamino)-5-methyl- 5-(pyridin-4-yl)thiazol-4(5H)- one M X
    Figure US20110082107A1-20110407-C00348
         		341.5 342 2-(Adamantan-1-ylamino)-5- methyl-5-pyridin-4-yl-thiazol- 4-one M X
    Figure US20110082107A1-20110407-C00349
         		303.4 304 2-(cyclohexylmethylamino)-5- methyl-5-(pyridin-4-yl)thiazol- 4(5H)-one M X
    Figure US20110082107A1-20110407-C00350
         		301.4 302 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(pyridin- 3-yl)thiazol-4(5H)-one M X
    Figure US20110082107A1-20110407-C00351
         		317.8 318 2-(2-chlorophenylamino)-5- methyl-5-(pyridin-3-yl)thiazol- 4(5H)-one M X
    Figure US20110082107A1-20110407-C00352
         		317.8 318 2-(2-chlorophenylamino)-5- methyl-5-(pyridin-2-yl)thiazol- 4(5H)-one M X
    Figure US20110082107A1-20110407-C00353
         		301.4 302 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(pyridin- 2-yl)thiazol-4(5H)-one M X
    Figure US20110082107A1-20110407-C00354
         		433.6 434 5-((1-(1,2,3-thiadiazole-4- carbonyl)piperidin-4- yl)methyl)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one X AA MM
    Figure US20110082107A1-20110407-C00355
         		430.6 431 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-((1-(5- methylisoxazole-3- carbonyl)piperidin-4- yl)methyl)thiazol-4(5H)-one X AA MM
    Figure US20110082107A1-20110407-C00356
         		444.6 445 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((1-(3,5- dimethylisoxazole-4- carbonyl)piperidin-4- yl)methyl)-5-methylthiazol- 4(5H)-one X AA MM
    Figure US20110082107A1-20110407-C00357
         		416.5 417 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((1-(isoxazole-5- carbonyl)piperidin-4- yl)methyl)-5-methylthiazol- 4(5H)-one X AA MM
    Figure US20110082107A1-20110407-C00358
         		429.6 430 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-((1-(1- methyl-1H-imidazole-4- carbonyl)piperidin-4- yl)methyl)thiazol-4(5H)-one X AA MM
    Figure US20110082107A1-20110407-C00359
         		464.6 465 5-((1-(1H-indole-3- carbonyl)piperidin-4- yl)methyl)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one X AA MM
    Figure US20110082107A1-20110407-C00360
         		464.6 465 5-((1-(1H-indole-2- carbonyl)piperidin-4- yl)methyl)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one X AA MM
    Figure US20110082107A1-20110407-C00361
         		407.6 408 tert-butyl 4-(2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-4-oxo-4,5- dihydrothiazol-5-yl)piperidine- 1-carboxylate L X AA
    Figure US20110082107A1-20110407-C00362
         		307.2 308 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5- (piperidin-4-yl)thiazol-4(5H)- one L X AA MM(a)
    Figure US20110082107A1-20110407-C00363
         		349.5 350 5-(1-acetylpiperidin-4-yl)-2- ((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00364
         		401.5 402 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(1-(furan-4- carbonyl)piperidin-4-yl)-5- methylthiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00365
         		412.6 413 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(1- isonicotinoylpiperidin-4-yl)-5- methylthiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00366
         		412.6 413 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1- nicotinoylpiperidin-4- yl)thiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00367
         		412.6 413 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1- picolinoylpiperidin-4- yl)thiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00368
         		426.6 427 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1-(2- (pyridin-4-yl)acetyl)piperidin- 4-yl)thiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00369
         		426.6 427 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1-(2- (pyridin-3-yl)acetyl)piperidin- 4-yl)thiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00370
         		440.6 441 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1-(3- (pyridin-3- yl)propanoyl)piperidin-4- yl)thiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00371
         		403.6 404 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(1- (cyclopentanecarbonyl)piperidin- 4-yl)-5-methylthiazol-4(5H)- one L X AA MM
    Figure US20110082107A1-20110407-C00372
         		439.6 440 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1-(3- phenylpropanoyl)piperidin-4- yl)thiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00373
         		375.6 376 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(1- cyclopentylpiperidin-4-yl)-5- methylthiazol-4(5H)-one L X AA JJ
    Figure US20110082107A1-20110407-C00374
         		409.9 408 tert-butyl 4-(2-(2- chlorophenylamino)-4-oxo-4,5- dihydrothiazol-5-yl)piperidine- 1-carboxylate L X
    Figure US20110082107A1-20110407-C00375
         		357.5 358 2-(3-Hydroxy-adamantan-1- ylamino)-5-methyl-5-pyridin-4- yl-thiazol-4-one O M X
    Figure US20110082107A1-20110407-C00376
         		411.6 412 5-(1-benzoylpiperidin-4-yl)-2- ((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00377
         		418.6 419 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1- (thiazole-4-carbonyl)piperidin- 4-yl)thiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00378
         		416.5 417 2-((1S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1-(5- methylisoxazole-3- carbonyl)piperidin-4-yl)thiazol- 4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00379
         		457.6 458 2-((1S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(1-(3-(4- fluorophenyl)propanoyl)piperidin- 4-yl)-5-methylthiazol-4(5H)- one L X AA MM
    Figure US20110082107A1-20110407-C00380
         		468.6 469 N-(3-(4-(2-((1S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-4-oxo-4,5- dihydrothiazol-5-yl)piperidine- 1-carbonyl)phenyl)acetamide L X AA MM
    Figure US20110082107A1-20110407-C00381
         		317.4 318 2-((1S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(2-methoxypyridin- 4-yl)thiazol-4(5H)-one L X AA
    Figure US20110082107A1-20110407-C00382
         		468.6 469 N-(4-(4-(2-((1S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-4-oxo-4,5- dihydrothiazol-5-yl)piperidine- 1-carbonyl)phenyl)acetamide L X AA MM
    Figure US20110082107A1-20110407-C00383
         		425.6 426 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1-(2- phenylacetyl)piperidin-4- yl)thiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00384
         		429.6 430 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(1-(4- fluorobenzoyl)piperidin-4-yl)- 5-methylthiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00385
         		507.6 508 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1-(3-(4- (trifluoromethyl)phenyl) propanoyl)piperidin-4-yl)thiazol- 4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00386
         		417.6 418 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1- (thiophene-4- carbonyl)piperidin-4-yl)thiazol- 4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00387
         		453.6 454 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1-(4- phenylbutanoyl)piperidin-4- yl)thiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00388
         		517.7 518 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1-(3-(4- (methylsulfonyl)phenyl) propanoyl)piperidin-4-yl)thiazol- 4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00389
         		437.6 438 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(1- cinnamoylpiperidin-4-yl)-5- methylthiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00390
         		301.4 302 2-(bicyclo[2.2.1]heptan-1- ylamino)-5-methyl-5-(pyridin- 4-yl)thiazol-4(5H)-one M X
    Figure US20110082107A1-20110407-C00391
         		329.4 330 2-((S)-1-(4- fluorophenyl)ethylamino)-5- methyl-5-(pyridin-4-yl)thiazol- 4(5H)-one O M X
    Figure US20110082107A1-20110407-C00392
         		329.4 330 2-((S)-1-(2- fluorophenyl)ethylamino)-5- methyl-5-(pyridin-4-yl)thiazol- 4(5H)-one O M X
    Figure US20110082107A1-20110407-C00393
         		379.4 380 5-methyl-5-(pyridin-4-yl)-2- ((S)-1-(2- (trifluoromethyl)phenyl) ethylamino)thiazol-4(5H)-one O M X
    Figure US20110082107A1-20110407-C00394
         		308.4 309 5-Ethyl-2-(3-hydroxy- adamantan-1-ylamino)-5- methyl-thiazol-4-one O X
    Figure US20110082107A1-20110407-C00395
         		377.6 378 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(1- isobutyrylpiperidin-4-yl)-5- methylthiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00396
         		417.5 418 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1-(3,3,3- trifluoropropanoyl)piperidin-4- yl)thiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00397
         		375.5 376 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(1- (cyclopropanecarbonyl)piperidin- 4-yl)-5-methylthiazol-4(5H)- one L X AA MM
    Figure US20110082107A1-20110407-C00398
         		389.6 390 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(1- (cyclobutanecarbonyl)piperidin- 4-yl)-5-methylthiazol-4(5H)- one L X AA MM
    Figure US20110082107A1-20110407-C00399
         		395.5 396 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(1-(2-fluoro-2- methylpropanoyl)piperidin-4- yl)-5-methylthiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00400
         		363.5 364 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(1- propionylpiperidin-4-yl)thiazol- 4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00401
         		399.5 400 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(1-(2,2- difluoropropanoyl)piperidin-4- yl)-5-methylthiazol-4(5H)-one L X AA MM
    Figure US20110082107A1-20110407-C00402
         		331.4 332 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(2-methoxypyridin- 4-yl)-5-methylthiazol-4(5H)- one L X AA
    Figure US20110082107A1-20110407-C00403
         		329.4 330 2-((S)-1-(4- fluorophenyl)ethylamino)-5- methyl-5-(pyridin-2-yl)thiazol- 4(5H)-one O M X
    Figure US20110082107A1-20110407-C00404
         		329.4 330 2-((S)-1-(4- fluorophenyl)ethylamino)-5- methyl-5-(pyridin-3-yl)thiazol- 4(5H)-one O M X
    Figure US20110082107A1-20110407-C00405
         		337.4 338 2-((1R,2S,4R)-5,5- difluorobicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(pyridin- 4-yl)thiazol-4(5H)-one Q O M X
    Figure US20110082107A1-20110407-C00406
         		280.4 281 2-((cyclohexylmethyl)amino)- 1-thia-3-azaspiro[4.5]dec-2-en- 4-one P X
    Figure US20110082107A1-20110407-C00407
         		270.1 271 2-(cyclohexylmethylamino)-5- (2-hydroxyethyl)-5- methylthiazol-4(5H)-one P X
    Figure US20110082107A1-20110407-C00408
         		238.4 239 2-(bicyclo[2.2.1]heptan-2- ylamino)-5,5-dimethylthiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00409
         		294.4 295 5-(2-hydroxyethyl)-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one P X
    Figure US20110082107A1-20110407-C00410
         		304.5 305 2-(tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1-thia-3- azaspiro[4.4]non-2-en-4-one P L X
    Figure US20110082107A1-20110407-C00411
         		266.4 267 2-((cyclohexylmethyl)amino)- 1-thia-3-azaspiro[4.4]non-2-en- 4-one P L X
    Figure US20110082107A1-20110407-C00412
         		254.4 255 2-(bicyclo[2.2.1]heptan-2- ylamino)-5-(2- hydroxyethyl)thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00413
         		268.4 279 2-(Bicyclo[2.2.1]heptan-2- ylamino)-5-(2-hydroxyethyl)-5- methylthiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00414
         		321.4 322 8-acetyl-2-bicyclo[2.2.1]hept-2- ylamino)-1-thia-3,8- diazaspiro[4.5]dec-2-en-4-one L X
    Figure US20110082107A1-20110407-C00415
         		240.4 241 2-(cycloheptylamino)-5,5- dimethylthiazol-4(5H)-one P X
    Figure US20110082107A1-20110407-C00416
         		256.4 257 2-(cycloheptylamino)-5-(2- hydroxyethyl)thiazol-4(5H)-one P X
    Figure US20110082107A1-20110407-C00417
         		270.4 271 2-(cycloheptylamino)-5-(2- hydroxyethyl)-5-methylthiazol- 4(5H)-one P X
    Figure US20110082107A1-20110407-C00418
         		308.4 309 5-(2-Hydroxyethyl)-5-methyl- 2-(tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one P X
    Figure US20110082107A1-20110407-C00419
         		290.4 291 1-methyl-5- (tricyclo[3.3.1.1-3,7~]dec-1- ylamino)-4-thia-6- azaspiro[2.4]hept-5-en-7-one P L X
    Figure US20110082107A1-20110407-C00420
         		369.5 370 2-(1-adamantylamino)-5-(2- (phenylamino)ethyl)thiazol- 4(5H)-one P X JJ
    Figure US20110082107A1-20110407-C00421
         		290.4 291 6-(tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-5-thia-7- azaspiro[3.4]oct-6-en-8-one P X
    Figure US20110082107A1-20110407-C00422
         		252.4 253 6-(cycloheptylamino)-5-thia-7- azaspiro[3.4]oct-6-en-8-one P X
    Figure US20110082107A1-20110407-C00423
         		280.4 281 2-(cycloheptylamino)-1-thia-3- azaspiro[4.5]dec-2-en-4-one P X
    Figure US20110082107A1-20110407-C00424
         		318.5 319 2-(tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1-thia-3- azaspiro[4.5]dec-2-en-4-one P X
    Figure US20110082107A1-20110407-C00425
         		252.4 253 5-((cyclohexylmethyl)amino)- 1-methyl-4-thia-6- azaspiro[2.4]hept-5-en-7-one P L X
    Figure US20110082107A1-20110407-C00426
         		308.4 309 2-(cyclohexylmethylamino)-5- methyl-5-(2,2,2-trifluoroethyl)- thiazol-4(5H)-one P L X
    Figure US20110082107A1-20110407-C00427
         		254.4 255 2-(cyclohexylmethylamino)-5- propylthiazol-4(5H)-one P X
    Figure US20110082107A1-20110407-C00428
         		292.4 293 5-propyl-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one P X
    Figure US20110082107A1-20110407-C00429
         		308.4 309 2-(cycloheptylamino)-5-methyl- 5-(2,2,2-trifluoroethyl)thiazol- 4(5H)-one P L X
    Figure US20110082107A1-20110407-C00430
         		346.4 347 5-methyl-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-5-(2,2,2- trifluoroethyl)-1,3-thiazol- 4(5H)-one P L X
    Figure US20110082107A1-20110407-C00431
         		252.4 253 2-bicyclo[2.2.1]heptan-2- ylamino)-5-propylthiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00432
         		254.4 255 2-(cycloheptylamino)-5- propylthiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00433
         		268.4 269 2-(cyclohexylmethylamino)- 5,5-diethylthiazol-4(5H)-one P L X
    Figure US20110082107A1-20110407-C00434
         		268.4 269 2-(cycloheptylamino)-5,5- diethylthiazol-4(5H)-one P L X
    Figure US20110082107A1-20110407-C00435
         		268.4 269 2-(cyclohexylmethylamino)-5- methyl-5-propylthiazol-4(5H)- one P L X
    Figure US20110082107A1-20110407-C00436
         		306.5 307 5-methyl-5-propyl-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one P L X
    Figure US20110082107A1-20110407-C00437
         		254.4 255 2-(cyclohexylamino)-5-methyl- 5-propylthiazol-4(5H)-one P L X
    Figure US20110082107A1-20110407-C00438
         		254.4 255 2-(cyclohexylamino)-5,5- diethylthiazol-4(5H)-one P L X
    Figure US20110082107A1-20110407-C00439
         		294.3 295 2-(cyclohexylamino)-5-methyl- 5-(2,2,2-trifluoroethyl)thiazol- 4(5H)-one P L X
    Figure US20110082107A1-20110407-C00440
         		306.5 307 5,5-diethyl-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one P L X
    Figure US20110082107A1-20110407-C00441
         		240.4 241 2-(cyclohexylamino)-5-ethyl-5- methylthiazol-4(5H)-one P L X
    Figure US20110082107A1-20110407-C00442
         		252.4 253 2-bicyclo[2.2.1]heptan-2- ylamino)-5-ethyl-5- methylthiazol-4(5H)-one L X
    Figure US20110082107A1-20110407-C00443
         		292.4 293 5-ethyl-5-methyl-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one P L X
    Figure US20110082107A1-20110407-C00444
         		254.4 255 2-(cyclohexylmethylamino)-5- ethyl-5-methylthiazol-4(5H)- one P L X
    Figure US20110082107A1-20110407-C00445
         		264.4 265 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 1-thia-3-azaspiro[4.4]non-2-en- 4-one L X
    Figure US20110082107A1-20110407-C00446
         		268.4 269 2-(cycloheptylamino)-5- isopropyl-5-methylthiazol- 4(5H)-one P X AA
    Figure US20110082107A1-20110407-C00447
         		280.4 281 2-(cyclooctylamino)-1-thia-3- azaspiro[4.4]non-2-en-4-one O L X
    Figure US20110082107A1-20110407-C00448
         		264.4 265 2-((1R,2R,4S)- bicyclo[2.2.1]hept-2-ylamino)- 1-thia-3-azaspiro[4.4]non-2-en- 4-one L X
    Figure US20110082107A1-20110407-C00449
         		322.4 323 2-(cyclooctylamino)-5-methyl- 5-(2,2,2-trifluoroethyl)thiazol- 4(5H)-one O L X
    Figure US20110082107A1-20110407-C00450
         		278.4 279 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 1-thia-3-azaspiro[4.5]dec-2-en- 4-one X
    Figure US20110082107A1-20110407-C00451
         		278.4 279 2-((1R,2R,4S)- cicyclo[2.2.1]hept-2-ylamino)- 1-thia-3-azaspiro[4.5]dec-2-en- 4-one X
    Figure US20110082107A1-20110407-C00452
         		266.4 267 6-(cyclooctylamino)-5-thia-7- azaspiro[3.4]oct-6-en-8-one O X
    Figure US20110082107A1-20110407-C00453
         		335.5 336 2-(bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(2- (piperidin-1-yl)ethyl)thiazol- 4(5H)-one X JJ
    Figure US20110082107A1-20110407-C00454
         		411.5 412 2-(bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(2-(3- (trifluoromethyl)phenylamino) ethyl)thiazol-4(5H)-one X JJ
    Figure US20110082107A1-20110407-C00455
         		377.9 378 2-(bicyclo[2.2.1]heptan-2- ylamino)-5-(2-(3- chlorophenylamino)ethyl)-5- methylthiazol-4(5H)-one X JJ
    Figure US20110082107A1-20110407-C00456
         		337.5 338 2-(bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(2- morpholinoethyl)thiazol-4(5H)- one X JJ
    Figure US20110082107A1-20110407-C00457
         		353.5 354 2-(bicyclo[2.2.1]heptan-2- ylamino)-5-(2-(4- fluoropiperidin-1-yl)ethyl)-5- methylthiazol-4(5H)-one X JJ
    Figure US20110082107A1-20110407-C00458
         		371.5 372 2-(bicyclo[2.2.1]heptan-2- ylamino)-5-(2-(4,4- difluoropiperidin-1-yl)ethyl)-5- methylthiazol-4(5H)-one X JJ
    Figure US20110082107A1-20110407-C00459
         		373.5 374 2-(2-(bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-4-oxo-4,5- dihydrothiazol-5-yl)ethyl isonicotinate X
    Figure US20110082107A1-20110407-C00460
         		353.5 354 2-(bicyclo[2.2.1]heptan-2- ylamino)-5-(2-(3- fluoropiperidin-1-yl)ethyl)-5- methylthiazol-4(5H)-one X JJ
    Figure US20110082107A1-20110407-C00461
         		306.4 307 (S)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(2,2,2- trifluoroethyl)thiazol-4(5H)-one L X
    Figure US20110082107A1-20110407-C00462
         		306.4 307 (R)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(2,2,2- trifluoroethyl)thiazol-4(5H)-one L X
    Figure US20110082107A1-20110407-C00463
         		266.4 267 (S)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5- propylthiazol-4(5H)-one L X
    Figure US20110082107A1-20110407-C00464
         		266.4 267 (R)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5- propylthiazol-4(5H)-one L X
    Figure US20110082107A1-20110407-C00465
         		371.5 372 2-(bicyclo[2.2.1]heptan-2- ylamino)-5-(2-(3,3- difluoropiperidin-1-yl)ethyl)-5- methylthiazol-4(5H)-one X JJ
    Figure US20110082107A1-20110407-C00466
         		357.5 358 2-(bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(2- (methyl(phenyl)amino)ethyl) thiazol-4(5H)-one X JJ
    Figure US20110082107A1-20110407-C00467
         		349.4 350 2-(bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-(2-(2,2,2- trifluoroethylamino)ethyl) thiazol-4(5H)-one X JJ
    Figure US20110082107A1-20110407-C00468
         		282.80 283/285 2-(2-chlorophenylamino)-5- methyl-5-propylthiazol-4(5H)- one L X
    Figure US20110082107A1-20110407-C00469
         		276.4 277 6-(tricyclo[3.3.1.0~3,7~]non-3- ylamino)-5-thia-7- azaspiro[3.4]oct-6-en-8-one O X
    Figure US20110082107A1-20110407-C00470
         		290.4 291 2-(tricyclo[3.3.1.0~3,7~]non-3- ylamino)-1-thia-3- azaspiro[4.4]non-2-en-4-one O L X
    Figure US20110082107A1-20110407-C00471
         		278.4 279 5-ethyl-5-methyl-2- (tricyclo[3.3.1.0~3,7~]non-3- ylamino)-1,3-thiazol-4(5H)-one O L X
    Figure US20110082107A1-20110407-C00472
         		292.4 293 5-methyl-5-propyl-2- (tricyclo[3.3.1.0~3,7~]non-3- ylamino)-1,3-thiazol-4(5H)-one O L X
    Figure US20110082107A1-20110407-C00473
         		292.4 293 5,5-diethyl-2- (tricyclo[3.3.1.0~3,7~]non-3- ylamino)-1,3-thiazol-4(5H)-one O L X
    Figure US20110082107A1-20110407-C00474
         		436.4 436/438 2-(bicyclo[2.2.1]heptan-2- ylamino)-5-(2-((3- bromophenyl)(methyl)amino) ethyl)-5-methylthiazol-4(5H)-one X JJ
    Figure US20110082107A1-20110407-C00475
         		435.5 436 (3R)-ethyl 3-(2-(2- (bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-4-oxo-4,5- dihydrothiazol-5- yl)ethylamino)-4,4,4- trifluorobutanoate X JJ
    Figure US20110082107A1-20110407-C00476
         		278.4 279 5-(1-methylethyl)-2- (tricyclo[3.3.1.0~3,7~]non-3- ylamino)-1,3-thiazol-4(5H)-one O X
    Figure US20110082107A1-20110407-C00477
         		292.4 293 5-methyl-5-(1-methylethyl)-2- (tricyclo[3.3.1.0~3,7~]non-3- ylamino)-1,3-thiazol-4(5H)-one O X AA
    Figure US20110082107A1-20110407-C00478
         		308.4 309 (7R)-2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 7-(methyloxy)-1-thia-3- azaspiro[4.5]dec-2-en-4-one L X
    Figure US20110082107A1-20110407-C00479
         		308.4 309 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 8-(methyloxy)-1-thia-3- azaspiro[4.5]dec-2-en-4-one L X
    Figure US20110082107A1-20110407-C00480
         		282.4 283 2-((cyclohexylmethyl)amino)- 8-oxa-1-thia-3- azaspiro[4.5]dec-2-en-4-one P X EE
    Figure US20110082107A1-20110407-C00481
         		348.5 349 8-(methyloxy)-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1-thia-3- azaspiro[4.5]dec-2-en-4-one P L X
    Figure US20110082107A1-20110407-C00482
         		334.5 335 8-(methyloxy)-2- (tricyclo[3.3.1.0~3,7~]non-3- ylamino)-1-thia-3- azaspiro[4.5]dec-2-en-4-one O L X
    Figure US20110082107A1-20110407-C00483
         		310.5 311 2-((cyclohexylmethyl)amino)- 8-(methyloxy)-1-thia-3- azaspiro[4.5]dec-2-en-4-one P L X
    Figure US20110082107A1-20110407-C00484
         		296.4 297 2-(cyclohexylamino)-8- (methyloxy)-1-thia-3- azaspiro[4.5]dec-2-en-4-one P L X
    Figure US20110082107A1-20110407-C00485
         		310.5 311 2-(cycloheptylamino)-8- (methyloxy)-1-thia-3- azaspiro[4.5]dec-2-en-4-one P L X
    Figure US20110082107A1-20110407-C00486
         		304.4 305 7-(methyloxy)-2-((2- methylphenyl)amino)-1-thia-3- azaspiro[4.5]dec-2-en-4-one L X
    Figure US20110082107A1-20110407-C00487
         		296.4 297 2-(cyclohexylamino)-7- (methyloxy)-1-thia-3- azaspiro[4.5]dec-2-en-4-one P L X
    Figure US20110082107A1-20110407-C00488
         		310.5 311 2-((cyclohexylmethyl)amino)- 7-(methyloxy)-1-thia-3- azaspiro[4.5]dec-2-en-4-one P L X
    Figure US20110082107A1-20110407-C00489
         		310.5 311 2-(cycloheptylamino)-7- (methyloxy)-1-thia-3- azaspiro[4.5]dec-2-en-4-one P L X
    Figure US20110082107A1-20110407-C00490
         		324.5 325 2-(cyclooctylamino)-7- (methyloxy)-1-thia-3- azaspiro[4.5]dec-2-en-4-one O L X
    Figure US20110082107A1-20110407-C00491
         		374.5 375 2-(bicyclo[2.2.1]hept-2- ylamino)-5-methyl-5-(2-((6- (methyloxy)-3- pyridinyl)amino)ethyl)-1,3- thiazol-4(5H)-one X JJ
    Figure US20110082107A1-20110407-C00492
         		394.5 395 2-(bicyclo[2.2.1]hept-2- ylamino)-5-(2-(4- isoquinolinylamino)ethyl)-5- methyl-1,3-thiazol-4(5H)-one X JJ
    Figure US20110082107A1-20110407-C00493
         		308.4 309 2-bicyclo[2.2.1]hept-2- ylamino)-7-(methyloxy)-1-thia- 3-azaspiro[4.5]dec-2-en-4-one L X
    Figure US20110082107A1-20110407-C00494
         		346.4 347 2′-((1S,2S,4R)- bicyclo[2.21]heptan-2-ylamino- 6-fluoro-2,3-dihydro-spiro[4H- 1-benzopyran-4,5′(4′H)- thiazo]-4′-one N X
    Figure US20110082107A1-20110407-C00495
         		362.9 363/365 2′-((1S,2S,4R)- bicyclo[2.21]heptan-2-ylamino- 6-chloro-2,3-dihydro-spiro[4H- 1-benzopyran-4,5′(4′H)- thiazo]-4′-one N X
    Figure US20110082107A1-20110407-C00496
    Figure US20110082107A1-20110407-C00497
         		288.4 289 2-(5,5- difluorobicyclo[2.2.1]heptan-2- ylamino)-5-isopropylthiazol- 4(5H)-one/ 2-(6,6- difluorobicyclo[2.2.1]heptan-2- ylamino)-5-isopropylthiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00498
    Figure US20110082107A1-20110407-C00499
         		302.4 303 2-(5,5- difluorobicyclo[2.2.1]heptan-2- ylamino)-5-isopropyl-5- methylthiazol-4(5H)-one/ 2-(6,6- difluorobicyclo[2.2.1]heptan-2- ylamino)-5-isopropyl-5- methylthiazol-4(5H)-one X AA
    Figure US20110082107A1-20110407-C00500
    Figure US20110082107A1-20110407-C00501
         		300.4 301 2-((5,5- difluorobicyclo[2.2.1]hept-2- yl)amino)-1-thia-3- azaspiro[4.4]non-2-en-4-one/ 2-((6,6- difluorobicyclo[2.2.1]hept-2- yl)amino)-1-thia-3- azaspiro[4.4]non-2-en-4-one L X
    Figure US20110082107A1-20110407-C00502
         		288.4 289 2-((1R,2S,4R)-5,5- difluorobicyclo[2.2.1]heptan-2- ylamino)-5-isopropylthiazol- 4(5H)-one Q X
    Figure US20110082107A1-20110407-C00503
         		254.4 255 2-(cycloheptylamino)-5- isopropylthiazol-4(5H)-one P X
    Figure US20110082107A1-20110407-C00504
         		302.4 303 (R)-2-((1R,2S,4R)-5,5- difluorobicyclo[2.2.1]heptan-2- ylamino)-5-isopropyl-5- methylthiazol-4(5H)-one Q X AA
    Figure US20110082107A1-20110407-C00505
         		302.4 303 (S)-2-((1R,2S,4R)-5,5- difluorobicyclo[2.2.1]heptan-2- ylamino)-5-isopropyl-5- methylthiazol-4(5H)-one Q X AA
    Figure US20110082107A1-20110407-C00506
         		278.3 279 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5- (trifluoromethyl)thiazol-4(5H)- one X
    Figure US20110082107A1-20110407-C00507
         		306.4 307 2-(bicyclo[2.2.1]heptan-1- ylamino)-5-methyl-5-(2,2,2- trifluoroethyl)thiazol-4(5H)-one S L X
    Figure US20110082107A1-20110407-C00508
         		292.4 293 2-(S)-2-(1-(4- fluorophenyl)ethylamino)-1- thia-3-azaspiro[4.4]non-2-en-4- one O L X
    Figure US20110082107A1-20110407-C00509
         		334.3 335 2-((S)-1-(4- fluorophenyl)ethylamino)-5- methyl-5-(2,2,2- trifluoroethyl)thiazol-4(5H)-one O L X
    Figure US20110082107A1-20110407-C00510
         		280.4 281 5-ethyl-2-((S)-1-(4- fluorophenyl)ethylamino)-5- methylthiazol-4(5H)-one O L X
    Figure US20110082107A1-20110407-C00511
         		268.4 269 5-isopropyl-5-methyl-2- (thiophen-2- ylmethylamino)thiazol-4(5H)- one Z
    Figure US20110082107A1-20110407-C00512
         		263.4 264 5-isopropyl-5-methyl-2- (pyridin-2- ylmethylamino)thiazol-4(5H)- one Z
    Figure US20110082107A1-20110407-C00513
         		263.4 264 5-isopropyl-5-methyl-2- (pyridin-3- ylmethylamino)thiazol-4(5H)- one Z
    Figure US20110082107A1-20110407-C00514
         		263.4 264 5-isopropyl-5-methyl-2- (pyridin-4- ylmethylamino)thiazol-4(5H)- one Z
    Figure US20110082107A1-20110407-C00515
         		249.3 — 5-isopropyl-2-(pyridin-4- ylmethylamino)thiazol-4(5H)- one Z
    Figure US20110082107A1-20110407-C00516
         		249.3 250 5-isopropyl-2-(pyridin-2- ylmethylamino)thiazol-4(5H)- one Z
    Figure US20110082107A1-20110407-C00517
         		285.4 286 5-isopropyl-2-(isoquinolin-5- ylamino)thiazol-4(5H)-one Z
    Figure US20110082107A1-20110407-C00518
         		277.4 278 5-isopropyl-5-methyl-2-(1- (pyridin-2- yl)ethylamino)thiazol-4(5H)- one Z
    Figure US20110082107A1-20110407-C00519
         		277.4 278 5-isopropyl-5-methyl-2-(1- (pyridin-4- yl)ethylamino)thiazol-4(5H)- one Z
    Figure US20110082107A1-20110407-C00520
         		279.4 280 2-(1-azabicyclo[2.2.2]oct-3- ylamino)-1-thia-3- azaspiro[4.4]non-2-en-4-one O X
    Figure US20110082107A1-20110407-C00521
         		294.4 295 5-isopropyl-2-((1R,2R,4R)- 1,7,7- trimethylbicyclo[2.2.1]heptan- 2-ylamino)thiazol-4(5H)-one O X
    Figure US20110082107A1-20110407-C00522
         		308.5 309 5-isopropyl-5-methyl-2- ((1R,2R,4R)-1,7,7- trimethylbicyclo[2.2.1]heptan- 2-ylamino)thiazol-4(5H)-one O X AA
    Figure US20110082107A1-20110407-C00523
         		350.5 351 5-isopropyl-5-methyl-2-(4- pentylbicyclo[2.2.2]octan-1- ylamino)thiazol-4(5H)-one O X AA
    Figure US20110082107A1-20110407-C00524
         		420.6 421 5-isopropyl-2-(4-(4- (methylsulfonyl)phenyl) bicyclo[2.2.2]octan-1- ylamino)thiazol-4(5H)-one V O X
    Figure US20110082107A1-20110407-C00525
         		377.6 378 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((1- isobutylpiperidin-4-yl)methyl)- 5-methylthiazol-4(5H)-one Y LL JJ(b) MM(a)
    Figure US20110082107A1-20110407-C00526
         		363.5 364 5-((1-acetylpiperidin-4- yl)methyl)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00527
         		322.5 323 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5- ((tetrahydro-2H-pyran-4- yl)methyl)thiazol-4(5H)-one Y LL
    Figure US20110082107A1-20110407-C00528
         		383.5 384 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(2-(isoindolin-2-yl)- 2-oxoethyl)-5-methylthiazol- 4(5H)-one Y LL DD(b) OO(b)
    Figure US20110082107A1-20110407-C00529
         		417.6 418 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((1- (cyclopentanecarbonyl)piperidin- 4-yl)methyl)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00530
         		406.6 408 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((1-(2- (dimethylamino)acetyl)piperidin- 4-yl)methyl)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00531
         		414.6 415 5-((1-(1H-pyrrole-2- carbonyl)piperidin-4- yl)methyl)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00532
         		426.6 427 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((1- isonicotinoylpiperidin-4- yl)methyl)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00533
         		425.6 426 5-((1-benzoylpiperidin-4- yl)methyl)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00534
         		426.6 427 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-((1- nicotinoylpiperidin-4- yl)methyl)thiazol-4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00535
         		440.6 441 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-((1-(2- (pyridin-4-yl)acetyl)piperidin- 4-yl)methyl)thiazol-4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00536
         		434.6 435 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((1-(4- (dimethylamino)butanoyl) piperidin-4-yl)methyl)-5- methylthiazol-4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00537
         		448.6 449 N-(4-(4-((2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-4-oxo-4,5- dihydrothiazol-5- yl)methyl)piperidin-1-yl)-4- oxobutyl)acetamide Y LL MM
    Figure US20110082107A1-20110407-C00538
         		393.5 394 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((1-(2- methoxyacetyl)piperidin-4- yl)methyl)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00539
         		441.6 442 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((1-(4- hydroxybenzoyl)piperidin-4- yl)methyl)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00540
         		419.6 420 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-((1-((R)- tetrahydrofuran-2- carbonyl)piperidin-4- yl)methyl)thiazol-4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00541
         		419.6 420 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-((1-((S)- tetrahydrofuran-2- carbonyl)piperidin-4- yl)methyl)thiazol-4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00542
         		419.6 420 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-((1- (tetrahydrofuran-2- carbonyl)piperidin-4- yl)methyl)thiazol-4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00543
         		415.6 416 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-((1-(furan-2- carbonyl)piperidin-4- yl)methyl)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00544
         		526.7 527 N-(2-(3-(4-((2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-4-oxo-4,5- dihydrothiazol-5- yl)methyl)piperidine-1- carbonyl)phenoxy)ethyl) acetamide Y LL MM
    Figure US20110082107A1-20110407-C00545
         		306.5 307 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5- (cyclohexylmethyl)thiazol- 4(5H)-one Y LL
    Figure US20110082107A1-20110407-C00546
         		406.6 407 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5,5-bis((tetrahydro- 2H-pyran-4-yl)methyl)thiazol- 4(5H)-one Y LL
    Figure US20110082107A1-20110407-C00547
         		377.6 378 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-((1- propionylpiperidin-4- yl)methyl)thiazol-4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00548
         		415.6 416 5-((1-(1H-pyrazole-4- carbonyl)piperidin-4- yl)methyl)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00549
         		432.6 432 5-((1-(2-(1H-tetrazol-1- yl)acetyl)piperidin-4- yl)methyl)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00550
         		415.6 416 5-((1-(1H-imidazole-2- carbonyl)piperidin-4- yl)methyl)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00551
         		497.6 498 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-((1-(2- methyl-5- (trifluoromethyl)furan-4- carbonyl)piperidin-4- yl)methyl)thiazol-4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00552
         		431.5 432 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-methyl-5-((1-(3,3,3- trifluoropropanoyl)piperidin-4- yl)methyl)thiazol-4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00553
         		224.3 225 2-(bicyclo[2.2.1]heptan-1- ylamino)-5-methylthiazol- 4(5H)-one Y
    Figure US20110082107A1-20110407-C00554
         		421.6 422 tert-butyl 4-((2- (bicyclo[2.2.1]heptan-1- ylamino)-5-methyl-4-oxo-4,5- dihydrothiazol-5- yl)methyl)piperidine-1- carboxylate Y LL
    Figure US20110082107A1-20110407-C00555
         		321.5 322 2-(bicyclo[2.2.1]heptan-1- ylamino)-5-methyl-5- (piperidin-4-ylmethyl)thiazol- 4(5H)-one Y LL MM(a)
    Figure US20110082107A1-20110407-C00556
         		415.6 416 2-(bicyclo[2.2.1]heptan-1- ylamino)-5-((1-(furan-3- carbonyl)piperidin-4- yl)methyl)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00557
         		363.5 364 5-((1-acetylpiperidin-4- yl)methyl)-2- (bicyclo[2.2.1]heptan-1- ylamino)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00558
         		431.5 432 2-(bicyclo[2.2.1]heptan-1- ylamino)-5-methyl-5-((1-(3,3,3- trifluoropropanoyl)piperidin-4- yl)methyl)thiazol-4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00559
         		414.6 415 5-((1-(1H-pyrrole-2- carbonyl)piperidin-4- yl)methyl)-2- (bicyclo[2.2.1]heptan-1- ylamino)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00560
         		210.2 211 2-(2- fluorophenylamino)thiazol- 4(5H)-one Y
    Figure US20110082107A1-20110407-C00561
         		449.6 450 tert-butyl 4-((2-((S)-1-(4- fluorophenyl)ethylamino)-5- methyl-4-oxo-4,5- dihydrothiazol-5- yl)methyl)piperidine-1- carboxylate Y LL
    Figure US20110082107A1-20110407-C00562
         		349.5 350 2-((S)-1-(4- fluorophenyl)ethylamino)-5- methyl-5-(piperidin-4- ylmethyl)thiazol-4(5H)-one Y LL MM(a)
    Figure US20110082107A1-20110407-C00563
         		443.5 444 2-((S)-1-(4- fluorophenyl)ethylamino)-5- ((1-(furan-3-carbonyl)piperidin- 4-yl)methyl)-5-methylthiazol- 4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00564
         		391.5 392 5-((1-acetylpiperidin-4- yl)methyl)-2-((S)-1-(4- fluorophenyl)ethylamino)-5- methylthiazol-4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00565
         		459.5 460 2-((S)-1-(4- fluorophenyl)ethylamino)-5- methyl-5-((1-(3,3,3- trifluoropropanoyl)piperidin-4- yl)methyl)thiazol-4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00566
         		442.6 443 5-((1-(1H-pyrrole-2- carbonyl)piperidin-4- yl)methyl)-2-((S)-1-(4- fluorophenyl)ethylamino)-5- methylthiazol-4(5H)-one Y LL MM
    Figure US20110082107A1-20110407-C00567
         		335.5 336 2-(Bicyclo[2.2.1]hept-2- ylamino)-8-isobutyl-1-thia-3,8- diaza-spiro[4.5]dec-2-en-4-one Y LL
    Figure US20110082107A1-20110407-C00568
         		413.6 414 8-Adamantan-2-yl-2- (bicyclo[2.2.1]hept-2-ylamino)- 1-thia-3,8-diaza-spiro[4.5]dec- 2-en-4-one Y LL
    Figure US20110082107A1-20110407-C00569
         		268.4 269 2-((2S)-bicyclo[2.2.1]heptan-2- ylamino)-5-(1-hydroxyethyl)-5- methylthiazol-4(5H)-one Y FF
    Figure US20110082107A1-20110407-C00570
         		296.4 297 2-((S)-1-(4- fluorophenyl)ethylamino)-5-(1- hydroxyethyl)-5-methylthiazol- 4(5H)-one Y FF
    Figure US20110082107A1-20110407-C00571
         		266.4 267 5-acetyl-2-((2S)- bicyclo[2.2.1]heptan-2- ylamino)-5-methylthiazol- 4(5H)-one Y FF JJ(a)
    Figure US20110082107A1-20110407-C00572
         		294.4 295 5-acetyl-2-((S)-1-(4- fluorophenyl)ethylamino)-5- methylthiazol-4(5H)-one Y FF JJ(a)
    Figure US20110082107A1-20110407-C00573
         		288.4 289 2-((2S)-bicyclo[2.2.1]heptan-2- ylamino)-5-(1,1-difluoroethyl)- 5-methylthiazol-4(5H)-one Y FF JJ(a) GG
    Figure US20110082107A1-20110407-C00574
         		316.4 317 5-(1,1-difluoroethyl)-2-((S)-1- (4-fluorophenyl)ethylamino)-5- methylthiazol-4(5H)-one Y FF JJ(a) GG
    Figure US20110082107A1-20110407-C00575
         		278.4 279 5,5-dimethyl-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00576
         		254.4 255 2-(cyclooctylamino)-5,5- dimethyl-1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00577
         		336.5 337 ethyl 5-methyl-4-oxo-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-4,5-dihydro-1,3- thiazole-5-carboxylate X
    Figure US20110082107A1-20110407-C00578
         		292.4 293 5-(1-methylethyl)-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00579
         		326.5 327 5-phenyl-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00580
         		322.5 323 5-(1-methylethyl)-5- (methyloxy)-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one II
    Figure US20110082107A1-20110407-C00581
         		264.4 265 5-methyl-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00582
         		235.3 236 5-(1-methylethyl)-2-(3- pyridinylamino)-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00583
         		316.5 317 2-((4-cyclohexylphenyl)amino)- 5-(1-methylethyl)-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00584
         		340.5 341 5-methyl-5-phenyl-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00585
         		264.3 265 5-(1-methylethyl)-2-((2- (methyloxy)phenyl)amino)-1,3- thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00586
         		333.5 334 5-methyl-5-(1-pyrrolidinyl)-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one II
    Figure US20110082107A1-20110407-C00587
         		321.5 322 5-(methylamino)-5-(1- methylethyl)-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one II
    Figure US20110082107A1-20110407-C00588
         		235.3 236 5-(1-methylethyl)-2-(2- pyridinylamino)-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00589
         		252.3 253 2-((4-fluorophenyl)amino)-5- (1-methylethyl)-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00590
         		235.3 236 5-(1-methylethyl)-2-(4- pyridinylamino)-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00591
         		270.3 271 2-((2,4-difluorophenyl)amino)- 5-(1-methylethyl)-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00592
         		248.4 249 5-(1-methylethyl)-2-((2- methylphenyl)amino)-1,3- thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00593
         		294.4 295 5-methyl-5-(methyloxy)-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one X II
    Figure US20110082107A1-20110407-C00594
         		302.3 303 5-(1-methylethyl)-2-((2- (trifluoromethyl)phenyl)amino)- 1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00595
         		282.8 283 2-((5-chloro-2- methylphenyl)amino)-5-(1- methylethyl)-1,3-thiazol-4(5H)- one X
    Figure US20110082107A1-20110407-C00596
         		264.3 265 2-((2-fluorophenyl)amino)-1- thia-3-azaspiro[4.4]non-2-en-4- one X
    Figure US20110082107A1-20110407-C00597
         		274.4 275 2-(1H-indazol-5-ylamino)-5-(1- methylethyl)-1,3-thiazol-4(5H)- one X
    Figure US20110082107A1-20110407-C00598
         		273.4 274 2-(1H-indol-4-ylamino)-5-(1- methylethyl)-1,3-thiazol-4(5H)- one X
    Figure US20110082107A1-20110407-C00599
         		268.4 269 2-(((1S)-1- cyclohexylethyl)amino)-5-(1- methylethyl)-1,3-thiazol-4(5H)- one X
    Figure US20110082107A1-20110407-C00600
         		268.4 269 2-(((1R)-1- cyclohexylethyl)amino)-5-(1- methylethyl)-1,3-thiazol-4(5H)- one X
    Figure US20110082107A1-20110407-C00601
         		268.4 269 2-(cyclooctylamino)-5-(1- methylethyl)-1,3-thiazol-4(5H)- one X
    Figure US20110082107A1-20110407-C00602
         		266.3 267 2-((5-fluoro-2- methylphenyl)amino)-5-(1- methylethyl)-1,3-thiazol-4(5H)- one X
    Figure US20110082107A1-20110407-C00603
         		249.3 250 5-(1-methylethyl)-2-((3-methyl- 2-pyridinyl)amino)-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00604
         		308.4 309 5-methyl-5- ((methyloxy)methyl)-2- (tricyclo[3.3.1.1~3,7~]dec-1- ylamino)-1,3-thiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00605
         		266.3 267 2-((2-fluorophenyl)amino)-5- methyl-5-(1-methylethyl)-1,3- thiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00606
         		242.4 243 5-(1-methylethyl)-2-(((1S)- 1,2,2-trimethylpropyl)amino)- 1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00607
         		242.4 243 5-(1-methylethyl)-2-(((1R)- 1,2,2-trimethylpropyl)amino)- 1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00608
         		262.4 263 5-methyl-5-(1-methylethyl)-2- ((2-methylphenyl)amino)-1,3- thiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00609
         		252.3 253 5-ethyl-2-((2- fluorophenyl)amino)-5-methyl- 1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00610
         		302.3 303 5-ethyl-5-methyl-2-((2- (trifluoromethyl)phenyl)amino)- 1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00611
         		266.3 267 (5S)-2-((2- fluorophenyl)amino)-5-methyl- 5-(1-methylethyl)-1,3-thiazol- 4(5H)-one AA
    Figure US20110082107A1-20110407-C00612
         		266.3 267 (5R)-2-((2- fluorophenyl)amino)-5-methyl- 5-(1-methylethyl)-1,3-thiazol- 4(5H)-one AA
    Figure US20110082107A1-20110407-C00613
         		316.4 317 5-methyl-5-(1-methylethyl)-2-((2- (trifluoromethyl)phenyl)amino)- 1,3-thiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00614
         		300.4 301 2-((2-fluorophenyl)amino)-5- methyl-5-phenyl-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00615
         		270.3 271 2-((2,5-difluorophenyl)amino)- 5-(1-methylethyl)-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00616
         		224.3 225 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 5-methyl-1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00617
         		300.4 301 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 5-methyl-5-phenyl-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00618
         		282.8 283 2-((3-chloro-2- methylphenyl)amino)-5-(1- methylethyl)-1,3-thiazol-4(5H)- one X
    Figure US20110082107A1-20110407-C00619
         		268.4 269 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 5-methyl-5- ((methyloxy)methyl)-1,3- thiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00620
         		268.3 269 2-((2-fluorophenyl)amino)-5- (2-hydroxyethyl)-5-methyl-1,3- thiazol-4(5H)-one KK
    Figure US20110082107A1-20110407-C00621
         		242.3 243 5-(1-methylethyl)-2-(((2R)- tetrahydro-2- furanylmethyl)amino)-1,3- thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00622
         		264.4 265 5-(1-methylethyl)-2-((3- (methyloxy)phenyl)amino)-1,3- thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00623
         		268.8 269 2-((2-chlorophenyl)amino)-5- (1-methylethyl)-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00624
         		278.4 279 5-(1-methylethyl)-2-((2-methyl- 5-(methyloxy)phenyl)amino)- 1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00625
         		262.4 263 2-((2,5-dimethylphenyl)amino)- 5-(1-methylethyl)-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00626
         		282.8 283 2-((2-chlorophenyl)amino)-5- methyl-5-(1-methylethyl)-1,3- thiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00627
         		377.5 378 5-(1-methylethyl)-2-((2-methyl- 5-((2-(4- morpholinyl)ethyl)oxy)phenyl) amino)-1,3-thiazol-4(5H)-one T Z
    Figure US20110082107A1-20110407-C00628
         		316.8 317 2-((2-chlorophenyl)amino)-5- methyl-5-phenyl-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00629
         		280.8 281 2-((2-chlorophenyl)amino)-1- thia-3-azaspiro[4.4]non-2-en-4- one X
    Figure US20110082107A1-20110407-C00630
         		278.4 279 5-(1-methylethyl)-2-((2-methyl- 3-(methyloxy)phenyl)amino)- 1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00631
         		303.2 304 2-((2,6-dichlorophenyl)amino)- 5-(1-methylethyl)-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00632
         		298.8 299 2-((2-chlorophenyl)amino)-5- methyl-5-(2-(methyloxy)ethyl)- 1,3-thiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00633
         		284.8 285 2-((2-chlorophenyl)amino)-5- methyl-5-((methyloxy)methyl)- 1,3-thiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00634
         		296.8 297 2-((3-chloro-2- methylphenyl)amino)-5-methyl- 5-(1-methylethyl)-1,3-thiazol- 4(5H)-one AA
    Figure US20110082107A1-20110407-C00635
         		280.4 — 2-((4-fluoro-2- methylphenyl)amino)-5-methyl- 5-(1-methylethyl)-1,3-thiazol- 4(5H)-one AA
    Figure US20110082107A1-20110407-C00636
         		326.5 — 2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2- ylamino)-5-(2-(2- methoxyethoxy)ethyl)-5- methylthiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00637
         		316.8 317 (5S)-2-((2- chlorophenyl)amino)-5-methyl- 5-phenyl-1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00638
         		316.8 317 (5R)-2-((2- chlorophenyl)amino)-5-methyl- 5-phenyl-1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00639
         		282.8 283 (5R)-2-((2- chlorophenyl)amino)-5-methyl- 5-(1-methylethyl)-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00640
         		282.8 283 2-((2-chlorophenyl)amino)-5- methyl-5-(1-methylethyl)-1,3- thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00641
         		296.4 297 2-((2-fluorophenyl)amino)-5- (1-methylethyl)-5- ((methyloxy)methyl)-1,3- thiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00642
         		303.2 304 2-((2,4-dichlorophenyl)amino)- 5-(1-methylethyl)-1,3-thiazol- 4(5H)-one X
    Figure US20110082107A1-20110407-C00643
         		280.4 281 2-((1R,2R,4S)- bicyclo[2.2.1]hept-2-ylamino)- 8-oxa-1-thia-3- azaspiro[4.5]dec-2-en-4-one EE
    Figure US20110082107A1-20110407-C00644
         		280.4 281 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 8-oxa-1-thia-3- azaspiro[4.5]dec-2-en-4-one EE
    Figure US20110082107A1-20110407-C00645
         		294.4 295 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 7-(methyloxy)-1-thia-3- azaspiro[4.4]non-2-en-4-one EE
    Figure US20110082107A1-20110407-C00646
         		310.8 311 2-((2-chlorophenyl)amino)-7- (methyloxy)-1-thia-3- azaspiro[4.4]non-2-en-4-one EE
    Figure US20110082107A1-20110407-C00647
         		305.4 306 2-((2-methyl-1,3-benzothiazol- 5-yl)amino)-5-(1-methylethyl)- 1,3-thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00648
         		326.4 327 5-(1-methylethyl)-2-((4- (phenyloxy)phenyl)amino)-1,3- thiazol-4(5H)-one X
    Figure US20110082107A1-20110407-C00649
         		294.8 295 2-((2-chloro-4- methylphenyl)amino)-1-thia-3- azaspiro[4.4]non-2-en-4-one X
    Figure US20110082107A1-20110407-C00650
         		308.4 309 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 7,7-dimethyl-8-oxa-1-thia-3- azaspiro[4.5]dec-2-en-4-one KK
    Figure US20110082107A1-20110407-C00651
         		362.3 363 2-((2-bromophenyl)amino)-5- methyl-5-(4-pyridinyl)-1,3- thiazol-4(5H)-one M X
    Figure US20110082107A1-20110407-C00652
         		308.4 309 (5R)-2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 7,7-dimethyl-8-oxa-1-thia-3- azaspiro[4.5]dec-2-en-4-one KK
    Figure US20110082107A1-20110407-C00653
         		308.4 309 (5S)-2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 7,7-dimethyl-8-oxa-1-thia-3- azaspiro[4.5]dec-2-en-4-one KK
    Figure US20110082107A1-20110407-C00654
         		352.2 353 2-((2,4-dichlorophenyl)amino)- 5-methyl-5-(4-pyridinyl)-1,3- thiazol-4(5H)-one M X
    Figure US20110082107A1-20110407-C00655
         		331.8 332 2-((2-chloro-4- methylphenyl)amino)-5-methyl- 5-(4-pyridinyl)-1,3-thiazol- 4(5H)-one M X
    Figure US20110082107A1-20110407-C00656
         		236.3 237 5-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 4-thia-6-azaspiro[2.4]hept-5-en- 7-one AA
    Figure US20110082107A1-20110407-C00657
         		278.4 279 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 6-methyl-1-thia-3- azaspiro[4.4]non-2-en-4-one EE
    Figure US20110082107A1-20110407-C00658
         		294.4 295 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 6,6-dimethyl-7-oxa-1-thia-3- azaspiro[4.4]non-2-en-4-one NN
    Figure US20110082107A1-20110407-C00659
         		282.5 283 2-((S)-1- cyclohexylethylamino)-5- isopropyl-5-methylthiazol- 4(5H)-one AA
    Figure US20110082107A1-20110407-C00660
         		294.8 295 2-(((4- chlorophenyl)methyl)amino)-1- thia-3-azaspiro[4.4]non-2-en-4 one X
    Figure US20110082107A1-20110407-C00661
         		274.4 275 2-(((1S)-1-phenylethyl)amino)- 1-thia-3-azaspiro[4.4]non-2-en- 4-one X
    Figure US20110082107A1-20110407-C00662
         		324.8 325 2-((2-chlorophenyl)amino)-7,7- dimethyl-8-oxa-1-thia-3- azaspiro[4.5]dec-2-en-4-one KK
    Figure US20110082107A1-20110407-C00663
         		308.8 309 2-((1-(2- chlorophenyl)cyclopropyl)amino)- 5-(1-methylethyl)-1,3- thiazol-4(5H)-one U O X
    Figure US20110082107A1-20110407-C00664
         		322.9 323 2-((1-(2- chlorophenyl)cyclopropyl)amino)- 5-methyl-5-(1-methylethyl)- 1,3-thiazol-4(5H)-one AA
    Figure US20110082107A1-20110407-C00665
         		284.4 285 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 5-(1-fluoro-1-methylethyl)-5- methyl-1,3-thiazol-4(5H)-one FF GG
    Figure US20110082107A1-20110407-C00666
         		282.4 283 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 5-(1-hydroxy-1-methylethyl)-5- methyl-1,3-thiazol-4(5H)-one FF
    Figure US20110082107A1-20110407-C00667
         		355.5 356 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 7-phenyl-1-thia-3,7- diazaspiro[4.4]non-2-ene-4,6- dione X
    Figure US20110082107A1-20110407-C00668
         		310.4 311 2-((3- fluorotricyclo[3.3.1.1~3,7~]dec- 1-yl)amino)-5-(1-methylethyl)- 1,3-thiazol-4(5H)-one GG
    Figure US20110082107A1-20110407-C00669
         		324.4 325 2-((3- fluorotricyclo[3.3.1.1~3,7~]dec- 1-yl)amino)-5-methyl-5-(1- methylethyl)-1,3-thiazol-4(5H)- one GG
    Figure US20110082107A1-20110407-C00670
         		308.4 309 2-(bicyclo[2.2.1]hept-1- ylamino)-7,7-dimethyl-8-oxa-1- thia-3-azaspiro[4.5]dec-2-en-4- one KK
    Figure US20110082107A1-20110407-C00671
         		284.4 285 (5S)-2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 5-(1-fluoro-1-methylethyl)-5- methyl-1,3-thiazol-4(5H)-one FF GG
    Figure US20110082107A1-20110407-C00672
         		284.4 285 (5R)-2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 5-(1-fluoro-1-methylethyl)-5- methyl-1,3-thiazol-4(5H)-one FF GG
    Figure US20110082107A1-20110407-C00673
         		324.4 325 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 5-(4-hydroxytetrahydro-2H- pyran-4-yl)-5-methyl-1,3- thiazol-4(5H)-one FF
    Figure US20110082107A1-20110407-C00674
         		326.4 327 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 5-(4-fluorotetrahydro-2H- pyran-4-yl)-5-methyl-1,3- thiazol-4(5H)-one GG
    Figure US20110082107A1-20110407-C00675
         		336.4 337 2-(((1S)-1-(4- fluorophenyl)ethyl)amino)-7,7- dimethyl-8-oxa-1-thia-3- azaspiro[4.5]dec-2-en-4-one KK
    Figure US20110082107A1-20110407-C00676
         		310.4 311 2-(((1S)-1-(2- fluorophenyl)ethyl)amino)-5- (1-hydroxy-1-methylethyl)-5- methyl-1,3-thiazol-4(5H)-one FF
    Figure US20110082107A1-20110407-C00677
         		306.4 307 2-((1S,2S,4R)- bicyclo[2.2.1]hept-2-ylamino)- 5-(3,6-dihydro-2H-pyran-4-yl)- 5-methyl-1,3-thiazol-4(5H)-one GG
    Figure US20110082107A1-20110407-C00678
         		324.5 325 (5S, 7R)-2-(cyclooctylamino)- 7-(methyloxy)-1-thia-3- azaspiro[4.5]dec-2-en-4-one O L X
  • The following compounds are encompassed by the present invention and are prepared by one of the methodologies described herein:
  •
    Figure US20110082107A1-20110407-C00679
    Figure US20110082107A1-20110407-C00680
    Figure US20110082107A1-20110407-C00681
    Figure US20110082107A1-20110407-C00682
    MOLSTRUCTURE
    Figure US20110082107A1-20110407-C00683
    Figure US20110082107A1-20110407-C00684
    Figure US20110082107A1-20110407-C00685
    Figure US20110082107A1-20110407-C00686
    Figure US20110082107A1-20110407-C00687
    Figure US20110082107A1-20110407-C00688
    Figure US20110082107A1-20110407-C00689
    Figure US20110082107A1-20110407-C00690
    Figure US20110082107A1-20110407-C00691
    Figure US20110082107A1-20110407-C00692
    Figure US20110082107A1-20110407-C00693
    Figure US20110082107A1-20110407-C00694
    Figure US20110082107A1-20110407-C00695
    Figure US20110082107A1-20110407-C00696
    Figure US20110082107A1-20110407-C00697
    Figure US20110082107A1-20110407-C00698
    Figure US20110082107A1-20110407-C00699
    Figure US20110082107A1-20110407-C00700
    Figure US20110082107A1-20110407-C00701
    Figure US20110082107A1-20110407-C00702
    Figure US20110082107A1-20110407-C00703
    Figure US20110082107A1-20110407-C00704
    Figure US20110082107A1-20110407-C00705
    Figure US20110082107A1-20110407-C00706
    Figure US20110082107A1-20110407-C00707
    Figure US20110082107A1-20110407-C00708
    Figure US20110082107A1-20110407-C00709
    Figure US20110082107A1-20110407-C00710
    Figure US20110082107A1-20110407-C00711
    Figure US20110082107A1-20110407-C00712
    Figure US20110082107A1-20110407-C00713
    Figure US20110082107A1-20110407-C00714
    Figure US20110082107A1-20110407-C00715
    Figure US20110082107A1-20110407-C00716
    Figure US20110082107A1-20110407-C00717
    Figure US20110082107A1-20110407-C00718
    Figure US20110082107A1-20110407-C00719
    Figure US20110082107A1-20110407-C00720
    Figure US20110082107A1-20110407-C00721
    Figure US20110082107A1-20110407-C00722
    Figure US20110082107A1-20110407-C00723
    Figure US20110082107A1-20110407-C00724
    Figure US20110082107A1-20110407-C00725
    Figure US20110082107A1-20110407-C00726
    Figure US20110082107A1-20110407-C00727
    Figure US20110082107A1-20110407-C00728
    Figure US20110082107A1-20110407-C00729
    Figure US20110082107A1-20110407-C00730
    Figure US20110082107A1-20110407-C00731
    Figure US20110082107A1-20110407-C00732
    Figure US20110082107A1-20110407-C00733
    Figure US20110082107A1-20110407-C00734
    Figure US20110082107A1-20110407-C00735
    Figure US20110082107A1-20110407-C00736
    Figure US20110082107A1-20110407-C00737
    Figure US20110082107A1-20110407-C00738
    Figure US20110082107A1-20110407-C00739
    Figure US20110082107A1-20110407-C00740
    Figure US20110082107A1-20110407-C00741
    Figure US20110082107A1-20110407-C00742
    Figure US20110082107A1-20110407-C00743
    Figure US20110082107A1-20110407-C00744
    Figure US20110082107A1-20110407-C00745
    Figure US20110082107A1-20110407-C00746
    Figure US20110082107A1-20110407-C00747
    Figure US20110082107A1-20110407-C00748
    Figure US20110082107A1-20110407-C00749
    Figure US20110082107A1-20110407-C00750
    Figure US20110082107A1-20110407-C00751
    Figure US20110082107A1-20110407-C00752
    Figure US20110082107A1-20110407-C00753
    Figure US20110082107A1-20110407-C00754
    Figure US20110082107A1-20110407-C00755
    Figure US20110082107A1-20110407-C00756
    Figure US20110082107A1-20110407-C00757
    Figure US20110082107A1-20110407-C00758
    Figure US20110082107A1-20110407-C00759
    Figure US20110082107A1-20110407-C00760
    Figure US20110082107A1-20110407-C00761
    Figure US20110082107A1-20110407-C00762
    Figure US20110082107A1-20110407-C00763
    Figure US20110082107A1-20110407-C00764
    Figure US20110082107A1-20110407-C00765
    Figure US20110082107A1-20110407-C00766
    Figure US20110082107A1-20110407-C00767
    Figure US20110082107A1-20110407-C00768
    Figure US20110082107A1-20110407-C00769
    Figure US20110082107A1-20110407-C00770
    Figure US20110082107A1-20110407-C00771
    Figure US20110082107A1-20110407-C00772
    Figure US20110082107A1-20110407-C00773
    Figure US20110082107A1-20110407-C00774
    Figure US20110082107A1-20110407-C00775
    Figure US20110082107A1-20110407-C00776
    Figure US20110082107A1-20110407-C00777
    Figure US20110082107A1-20110407-C00778
    Figure US20110082107A1-20110407-C00779
    Figure US20110082107A1-20110407-C00780
    Figure US20110082107A1-20110407-C00781
    Figure US20110082107A1-20110407-C00782
    Figure US20110082107A1-20110407-C00783
    Figure US20110082107A1-20110407-C00784
    Figure US20110082107A1-20110407-C00785
    • GENERAL METHODOLOGIES QQ-YY Method QQ
  • Figure US20110082107A1-20110407-C00786
  • 1 eq. of 3-bromopyrrolidin-2-one (J. Med. Chem. 1987, 30, 1995-1998. H. Ikuta, H. Shirota, S. Kobayashi, Y. Yamagashi, K. Yamada, I. Yamatsu, K. Katayama) and 1.0 eq. of the appropriate thiourea were dissolved in acetone and heated to reflux for 8 h. The reaction mixture was cooled to RT, NaHCO3 (sat. solution) was added and the aqueous phase extracted with DCM. The organic phase was separated and concentrated in vacuo to give the crude product. The obtained crude product was dissolved in pyridine and a few drops of DMF were added followed by the appropriate benzoyl chloride (3.0 eq.) and the reaction mixture was shaken at RT. 10% HCl was added and the mixture extracted with DCM. The organic phase was concentrated in vaccum. Purification was performed using preparative HPLC.
    • Example 161 N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-1,3-thiazol-5-yl]ethyl}-6-chloronicotinamide
  • Figure US20110082107A1-20110407-C00787
  • 5-(2-aminoethyl)-2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-1,3-thiazol-4(5H)-one (0.050 g, 0.199 mmol) was suspended in MeCN (1 ml). 6-chloronicotinoyl chloride (0.140 g, 0.796 mmol) dissolved in MeCN (1 ml) was added and the reaction mixture was shaken at room temperature for 18 h. Solvents were removed in vacuo. Purification was performed using preparative HPLC (System A, 20-40% MeCN over 5 min).
  • 1H NMR (500 MHz, Solvent) 1.44-1.79 (m, 5 H) 2.12-2.28 (m, 1 H) 2.40-2.49 (m, 1 H) 2.84-3.02 (m, 2 H) 3.56-3.65 (m, 2 H) 3.76 (d, J=7.54 Hz, 1 H) 4.37-4.47 (m, 1 H) 6.02-6.11 (m, 1 H) 6.19-6.24 (m, 1 H) 7.52-7.56 (m, 1 H) 8.15-8.20 (m, 1 H).
  • HPLC-MS: 93%, RT=1.74 min (System A, 10-97% MeCN over 3 min), 92%, RT=1.60 min (System B, 10-97% MeCN over 3 min)
  • MS (ESI+) for C18H19N4O2S m/z 391 (M+H)+
    • Method RR
  • Figure US20110082107A1-20110407-C00788
  • 1.0 eq. of the appropriate thiourea and maleic anhydride (1.0 eq.) were heated to reflux in acetone for 5 h, yielding a white emulsion. Evaporation in vacuo afforded a white solid. The product was triturated with DCM, collected on a filter and air-dried giving the carboxylic acid product as a white powder.
  • The carboxylic acid (1.0 eq). and 2-chloro-1-methylpyridinium iodide (1.2 eq.), or similar coupling agent, were mixed in DCM for 10 minutes before the amine (1.0 eq.) was added followed by Et3N (1.5 eq.). The reaction mixture was stirred at RT for 16 h. The reaction mixture was poured onto a Hydromatrix column (pretreated with 1 M HCl) and the crude product was eluted with DCM. The obtained crude product was purified by reverse phase.
    • Example 162 2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-1,3-thiazol-5-yl}-N-(cyclopropylmethyl)-N-propylacetamide
  • Figure US20110082107A1-20110407-C00789
  • Cyclohexylmethyl thiourea (0.85 g, 4.94 mmol) and maleic anhydride (4.8 g, 4.94 mmol) were refluxed over night at 110° C. in acetic acid. The reaction was concentrated and triturated with EtOAc to give the product as a pure off-white solid. MS m/z 271 (M+H)+To a suspension of {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-1,3-thiazol-5-yl}acetic acid in DCM 5 ml was added thionyl chloride 1.5 eq and the reaction stirred for 30 minutes. The secondary amine (3 eq) was added and the reaction stirred overnight. Concentration and purification by reverse phase chromatography yielded the desired product.
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.26 (m, J=3.8, 1.10 Hz, 2 H) 0.54 (m, J=8.1, 1.22 Hz, 1 H) 0.65 (m, J=7.3 Hz, 1 H) 0.93 (m, 6 H) 1.25 (m, 3 H) 1.71 (m, 8 H) 2.82 (m, J=12.2 Hz, 1 H) 3.11 (m, 1 H) 3.23 (m, J=6.5 Hz, 2 H) 3.29 (m, 2 H) 3.42 (m, 1 H) 3.54 (m, 1 H) 4.44 (m, J=10.4, 1.7 Hz, 1 H) MS m/z 366 (M+H)+
  • HPLC 100% RT=3.15 min (System A. 10-97% MeCN over 3 min), 100% RT=1.60 min (System B. 2-95% MeCN over 2 min).
    • Method SS
  • The synthesis of oxazolone analogues was carried out using the procedure detailed in the scheme below.
  • Figure US20110082107A1-20110407-C00790
  • The oxazolones (F) were prepared according to the reaction scheme above from commercially available ketones (A), α-hydroxy acids (C), or α-hydroxy esters (D).
  • i) To a mixture of ketone (A) (1 eq) and KCN (1.1 eq) in H2O at 0° C. was added 40% H2SO4 over 40 min. After stirring the reaction for an additional 1 h at ambient temperature, diethyl ether and H2O were added. The phases were separated, and the aqueous layer was extracted with diethyl ether. The combined organic phases were washed with brine, dried over MgSO4, and concentrated in vacuo to yield cyanohydrine (B).
  • ii) The cyanohydrine (B) was dissolved in concentrated HCl and the mixture was stirred under heating for 8-48 h. The solvent was evaporated, and the residue was dried in vacuo to give the crude acid (C).
  • iii) To a solution of the α-hydroxy acid (C) in ethanol was added acid catalyst, and the mixture was stirred under reflux for 1-3 days. The solvent was removed to give α-hydroxy ester (D).
  • iv) A mixture of α-hydroxy ester (D) (1 eq) and guanidine (1-3 eq) in ethanol was stirred under reflux overnight. The solvent was removed, and the residue was purified by recrystalization from water/ethyl acetate (alternatively silica gel flash chromatography) to give 2-aminooxazolone (E).
  • v) A mixture of 2-aminooxazolone (E) (1 eq) and amine (2.5-3 eq) in 99.5% ethanol was heated in microwave oven for 20-120 min at 160-180 ° C. The solvent was removed, and the residue was purified by reverse-phase preparative HPLC to give oxazolone (F).
  • Figure US20110082107A1-20110407-C00791
  • Spiropiperidines (H) were obtained from F′ (synthesized from the corresponding ketone A) according to the scheme above.
  • vi) To a solution of the benzyl protected intermediate (F′) in 2-methoxyethanol was added catalytic amounts of 5% Pd/C and the mixture was exposed to H2 (50-60 psi) for 5-24 h. Celite was added to the reaction mixture, and after filtration and removal of the solvent crude spiropiperidine G was obtained.
  • vii) To a solution of spiropiperidine G (1 eq) and aldehyde (1 eq) in dichloroethane was added sodium triacetoxyborohydride (1.4 eq) and the reaction mixture was stirred at 25-50° C. overnight. The material was purified by reverse-phase preparative HPLC to give the product H.
    • Examples 163 2-Hydroxy-2,3-dimethylbutanenitrile
  • Figure US20110082107A1-20110407-C00792
  • To mixture of 3-methylbutan-2-one (4.71 g, 54.7 mmol) and KCN (3.92 g, 60.2 mmol) in H2O (10 mL) was dropwise added 40% H2SO4 (10 mL) over 40 min. The temperature was raised to ambient, and after stirring the reaction for 1 h, diethyl ether (25 mL) and H2O (15 mL) were added. The aqueous layer was extracted with diethyl ether (25 mL), and the combined organic phases were washed with brine (10 mL) and dried over MgSO4. Evaporation of the solvent yielded the product as a colorless liquid.
    • Example 164 2-Hydroxy-2,3-dimethylbutanoic acid
  • Figure US20110082107A1-20110407-C00793
  • A solution of 2-hydroxy-2,3-dimethylbutanenitrile (4.71 g, 54.7 mmol) in concentrated HCl was stirred at 75° C. for 5 h and then under reflux for 8 h. The solvent was removed to give the crude title compound as an off-white solid.
    • Example 165 Ethyl 2-hydroxy-2,3-dimethylbutanoate
  • Figure US20110082107A1-20110407-C00794
  • To a solution of 2-hydroxy-2,3-dimethylbutanoic acid (5.53 g, 41.8 mmol) in 99.5% ethanol (200 mL) was added 2 M HCl in diethyl ether (8 mL) and the mixture was stirred under reflux for 3 days. The solvent was carefully removed to give the crude α-hydroxy ester as a pale yellow liquid.
    • Example 166 2-Amino-5-isopropyl-5-methyl-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00795
  • A mixture of ethyl 2-hydroxy-2,3-dimethylbutanoate (2.92 g, 18.2 mmol), guanidine hydrochloride (1.74 g, 18.2 mmol), and K2CO3 (2.52 g, 18.2 mmol) in 99.5% ethanol (40 mL) was stirred under reflux for 20 h. The solvent was removed, and the residue was purified by silica gel flash chromatography (ethyl acetate/methanol 9:1) to give the product as a white solid.
    • Example 167 2-(Cyclooctylamino)-5-isopropyl-5-methyl-1,3-oxazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00796
  • A solution of 2-amino-5-isopropyl-5-methyl-1,3-oxazol-4(5H)-one (55.7 mg, 0.357 mmol) and cyclooctylamine (147 μL, 1.07 mmol) in 99.5% ethanol (1 mL) was heated in microwave oven in a sealed tube for 40 min at 180° C. The solvent was removed, and the residue was purified by preparative reverse-phase HPLC chromatography to yield the product as a white solid.
  • HPLC 100%, RT=2.56 (System A, 10-97% MeCN over 3 min), 100%, RT=1.47 min (System B, 2-95% MeCN over 2 min).
  • 1H NMR (400 MHz, DMSO-d6) δ 0.77-0.79 (m, 3 H), 0.90-0.93 (m, 3 H), 1.29 (s, 2.1 H, major rotamer), 1.31 (s, 0.9 H, minor rotamer), 1.40-1.80 (m, 14 H), 1.84-1.94 (m, 1 H), 3.67-3.77 (m, 1 H), 8.67 (d, J=7.9 Hz, 0.7 H, major isomer), 8.95 (d, J=7.9 Hz, 0.3 H, minor isomer).
  • MS (ESI+) for C15H26N2O2 m/z 267 (M+H)+.
    • Method TT
  • Figure US20110082107A1-20110407-C00797
  • R and R′ are bivalent alkylene and form a 3-8 membered ring with the nitrogen to which they are attached.
  • The thiazalones K were prepared according to the reaction scheme above from commercially available hydrazines. To a mixture of hydrazine I (1 eq) in DCM (5 mL/mmol amine) was added ethoxycarbonylisocyanate (1.1 eq) and the mixture stirred for 1 h at ambient temperature, followed by addition of 5M aq NaOH (5 mL/mmol amine) and heating for 1-2 h at 65° C. The cooled solution was extracted twice with DCM, then the combined organic layers washed consecutively with saturated aq NaHCO3, water and brine, and finally concentrated to give the thiourea J. Thiourea J (1 eq) was reacted with the appropriate α-bromoester (1 eq) in the presence of diisopropylethylamine (1.1 eq) in EtOH (5 mL/mmol) in the microwave oven for 1-2 h 150-155° C., or by thermal heating at 95-140° C. for several days in dioxane (1 mL/mmol) in the absence of base. Concentration followed by chromatographic purification gave the thiazalone K.
    • Example 168 2-(Azepan-1-ylamino)-5-isopropyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00798
  • N-(Homopiperidine)thiourea was prepared by stirring a mixture of aminopiperidine (1.0 g, 8.8 mmol) and ethoxycarbonylisocyanate (1.1 mL, 9.7 mmol) in DCM (50 mL) for 1 h, followed by addition of 5M aq NaOH (50 mL) and heating for 2 h at 65° C., during which time DCM evaporates. The cooled solution was extracted twice with DCM, then the combined organic layers washed consecutively with saturated aq NaHCO3, water and brine, and finally concentrated.
  • This thiourea (150 mg, 0.87 mmol) was then reacted with ethyl 2-bromoisovalerate (150 μL, 0.87 mmol) in the presence of Hunigs base (diisopropylethylamine, 160 μL, 0.96 mmol) in EtOH (4 mL) in the microwave for 1 h 15 min at 150° C. Concentration followed by purification by reversed-phase HPLC, then made basic with aq NaHCO3, gave the product as a white solid. 1H NMR (400 MHz, DMSO-D6) δ ppm 0.74 (d, J=6.59 Hz, 3 H) 0.91 (d, J=6.84 Hz, 3 H) 1.52 (d, J=2.20 Hz, 4 H) 1.60 (s, 4 H) 2.26 (td, J=6.53, 4.03 Hz, 1 H) 2.80-2.86 (m, 4 H) 3.95-4.00 (m, 1 H). MS(ESI) for C12H21N3OS m/z 256 (M+H).
    • Method UU
  • Figure US20110082107A1-20110407-C00799
  • The thiazalones were prepared according to the reaction scheme above from L (L was prepared according to Method A). (iii) To a solution of L (1 eq) in CCl4 (12 mL/mmol L) was added N-bromosuccinimide (1.5 eq) and warmed to 60-70° C. for 1 h. The warm mixture was filtered and the filtrate concentrated to give the bromo intermediate M. (iv) Reaction of M with an alcohol (10-40 eq in THF or neat) at ambient temp −70° C. for 2-24 h gave, after concentration and purification, the ethers N (X═O Y═C,O). Reaction of M with a chloroalcohol (20 eq in THF) at 60° C. for 3-24 h gave, after concentration and purification, the chloroether intermediates. Amination was performed by warming a solution of the chloroether (1 eq) in THF (0.3 mL/mmol chloroether) with an amine (0.3 mL/mmol chloroether) and a crystal of NaI either thermally at 80° C. for 4-24 h or in the microwave oven 180° C. 1 h. Concentration and purification gave the aminoethers N (X═O Y═N). Reaction of M with an amine (10-40 eq in THF or neat) at ambient temp for 10-30 min gave, after concentration and purification, the amines N (X═N Y═C,N).
    • Example 169 2-(Bicyclo[2.2.1]hept-2-ylamino)-5-methyl-5-(3-morpholin-4-ylpropoxy)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00800
  • To a solution of the thiazolone (150 mg, 0.67 mmol) in CCl4 (5 mL), was added N-bromosuccinimide (143 mg, 0.80 mmol) and warmed to 60° C. After 1 h, the mixture was filtered warm and concentrated to yield 244 mg of the product as a yellow solid. THF (3 mL) and 3-chloropropanol (2.2 mL, 26.8 mmol) were added and the solution warmed to 60° C. overnight. The resulting solution was concentrated and the product was purified by reversed-phase HPLC, then made basic with aq NaHCO3, to yield the chloroether as a colourless oil.
  • Morpholine (3 mL) and THF (3 mL) were added and the solution was allowed to stir at 80° C. for 4 h. The resulting solution was concentrated and the product was purified by reversed-phase HPLC, then made basic with aq NaHCO3, to yield the product as a white solid. 1H NMR (400 MHz, DMSO-D6) δ ppm 1.06-1.18 (m, 3 H) 1.36-1.48 (m, 4 H) 1.58-1.64 (m, 2 H) 1.66-1.71 (m, 3 H) 2.19-2.30 (m, 8 H) 3.09-3.17 (,. 2 H) 3.37-3.45 (m, 1 H) 3.48-3.57 (m, 4 H), 3.80 (m, 0.5H) 4.05 (m, 0.5H). MS(ESI) for C18H29N3O3S m/z 368 (M+H).
    • Example 170 2-(Bicyclo[2.2.1]hept-2-ylamino)-6-oxa-1-thia-3-azaspiro[4.4]non-2-en-4-one
  • Figure US20110082107A1-20110407-C00801
  • To a continuously N2-flushed solution of the thiazolone (200 mg, 0.95 mmol) in dry THF (10 mL) was added lithium diisopropylamide (1.9 mL of a 2M solution in THF/heptane/ethyl benzene, 3.8 mmol) at −78° C. The resulting brown solution was allowed to stir 1 h at this temperature after which time (3-bromopropoxy)tert-butyldimethylsilane (0.6 mL, 2.6 mmol) was added and the solution allowed to warm to 5° C. (2.5 h). The reaction was quenched with 6 mL 2/1 MeOH/HOAc followed by addition of a saturated solution of aq NaHCO3. The silyl-protected product (50% conversion according to HPLC) was extracted with EtOAc and the resulting solution was concentrated and the product was purified by reversed-phase HPLC. During purification, the alcohol function was deprotected to give the free alcohol.
  • To the free alcohol (0.17 mmol) in DCM (5 mL) was added Br2 (10 μL, 0.17 mmol) and a drop HBr (48% aqueous) and warmed to 60° C. 1 h. The resulting solution was quenched with aq NaS2O4 and extracted with DCM. The product was purified by reversed-phase HPLC, then made basic with aq NaHCO3, to yield the product as a white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.09-1.19 (m, 2 H) 1.21-1.30 (m, 2 H) 1.49-1.59 (m, 2 H) 1.70-1.77 (m, 1 H) 1.93 (d, J=2.93 Hz, 1 H) 1.99-2.10 (m, 1 H) 2.22-2.32 (m, 1 H) 2.36-2.48 (m, 3 H) 2.66 (dt, J=9.22, 4.55 Hz, 1 H) 3.30-3.36 (m, 1 H) 4.04-4.14 (m, 1 H) 4.15-4.23 (m, 1 H). MS(ESI) for C13H18N2O2S m/z 267 (M+H).
    • Method VV
  • The following examples serve to illustrate the preparative procedure employed for the synthesis of thiazolone analogues containing a heterocyclic side-chain at the 5-position.
    • Example 171 N-(2-Aminophenyl)-2-(2-anilino-4-oxo-4,5-dihydro-1,3-thiazol-5-yl)acetamide
  • Figure US20110082107A1-20110407-C00802
  • N-(2-Aminophenyl)-2-(2-anilino-4-oxo-4,5-dihydro-1,3-thiazol-5-yl)acetic acid, prepared using method 2 above, (30 mg, 1 eq) was dissolved in a mixture of DCM/DMF (2 mL/2 mL) and O-phenylendiamine (15 mg, 1.1 eq), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC, 30 mg, 1.3 eq) were then added sequentially. The reaction mixture was stirred 40° C. for 2 h. Separated between DCM and H2O, the organic layer concentrated to give a crude orange brown oil used directly in the next step: HPLC 43%, RT=0.93 min (System B, 2-95% MeCN over 2 min); MS [M+H]+ m/z =341.
    • Example 172 2-Anilino-5-(1H-benzimidazol-2-ylmethyl)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00803
  • N-(2-Aminophenyl)-2-(2-anilino-4-oxo-4,5-dihydro-1,3-thiazol-5-yl)acetamide (40.8 mg, 1 eq) was taken up in HOAc (2 mL), transferred to a micro-tube and run at 100° C. for 600 s. The reaction mixture was evaporated to give 42 mg, as a crude brown oil. Purified by HP-LCMS, to the pooled fractions was added NaOH (1M) to pH=14, the MeCN was evaporated and the aqueous layer extracted with DCM/H2O (9:1), dried and evaporated to give the title compound as an off-white powder: HPLC 99%, RT=2.02 min (System A, 10-97% MeCN over 3 min), 99%, RT=0.96 min (System B, 2-95% MeCN over 2 min); 1H NMR (400 MHz, METHANOL-D4) δ ppm 3.23 (m, 1 H) 3.80 (m, 1 H) 4.70 (m, 1 H) 7.02 (m, 1 H) 7.17 (m, 3 H) 7.32 (m, 2 H) 7.50 (m, 2 H) 7.62 (m, 1 H); MS [M+H]+ m/z=323.
    • Method WW
  • Figure US20110082107A1-20110407-C00804
  • The thiourea (1.0 eq.) and the α-bromoester/α-bromoacid (1.0 eq.) were dissolved in acetone (alternatively water, 1,4-dioxane, THF, 2-propanol or MeCN) and heated at 60-140° C. in a sealed tube or by microwave irradiation for 15-72 hours. The solvent was removed. And the product purified by crystallization from MeOH or preparative reverse-phase HPLC.
    • Example 173 2-(Bicyclo[2.2.1]hept-2-ylamino)-1-thia-3-azaspiro[4.4]non-2-en-4-one
  • Figure US20110082107A1-20110407-C00805
  • A solution of N-bicyclo[2.2.1]hept-2-ylthiourea (73.9 mg, 0.434 mmol) and methyl 1-bromocyclopentanecarboxylate (89.9 mg, 0.434 mmol) in 1,4-dioxane (600 μL) was stirred at 95° C. in a sealed tube for 20 h. The solvent was removed, and the residue was purified by silica gel flash chromatography (pentane/EtOAc, 6:4). The product-containing fractions were pooled, and the solvent was removed. Subsequent purification of the residue by preparative reverse-phase HPLC yielded the product as a white solid.
  • HPLC 100%, RT=2.98 (System A, 10-97% MeCN over 3 min), 100%, RT=1.45 min (System B, 2-95% MeCN over 2 min).
  • 1H NMR (400 MHz, DMSO-d6) δ 1.04-1.19 (m, 3 H), 1.34-1.51 (m, 4 H), 1.59-1.73 (m, 3 H), 1.78-1.99 (m, 4 H), 2.08-2.25 (m, 4 H), 3.18 (m, 0.3 H, minor isomer), 3.77 (m, 0.7 H, major isomer), 9.01 (d, J=6.7 Hz, 0.7 H, major isomer), 9.68 (s br, 0.3 H, minor isomer).
  • MS (ESI+) for C14H20N2OS m/z 265 (M+H)+.
    • Method XX
  • Figure US20110082107A1-20110407-C00806
  • According to the above synthetic scheme, X of R″X is halogen.
  • 5-monosubstituted thiazolones may also be further alkylated at the 5-position via the liathiated anion. The following examples illustrate how this methodology can be employed to introduce more complex side-chains.
    • Example 174 5-(4-Bromobutyl)-2-(cycloheptylamino)-5-methyl-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00807
  • To a continuous N2-flushed solution of 2-(cycloheptylamino)-5-methyl-1,3-thiazol-4(5H)-one hydrobromide (500 mg, 2.2 mmol) in dry THF (50 mL) was added lithium diisopropylamide (4.4 mL of a 2M solution in THF/heptane/ethyl benzene, 8.8 mmol) at −78° C. The resulting brown solution was allowed to stir 1 h at this temperature after which time 1,4-dibromobutane (2.1 mL, 17.7 mmol) was added and the solution allowed to warm to −30° C. After 1 h at this temperature, the reaction was quenched with 6 mL 2/1 MeOH/HOAc and allowed to stir overnight at rt. A saturated solution of aq. NaHCO3 was added and the product was extracted with EtOAc and then purified on SiO2 (gradient 4/1-1/1 hex/EtOAc) to give the bromide as a white solid. Yield 227 mg. HPLC 100% RT=2.34 min (System B, 10-97% MeCN over 3 min), 100% RT=2.41 min (System A, 10-97% MeCN over 3 min). 1H NMR (400 MHz, DMSO-D6) δ ppm 1.15 (td, J=7.20, 3.66 Hz, 1 H) 1.35-1.65 (m, 14 H) 1.68-1.79 (m, 4 H) 1.82-1.91 (m, 2 H) 3.49 (t, J=6.59 Hz, 2 H) 3.95 (dd, J=8.30, 3.91 Hz, 1 H) 9.10 (d, J=7.57 Hz, 1 H). MS(ESI) for C15H25BrN2OS m/z 361 (M+H).
    • Example 175 2-(Cycloheptylamino)-5-methyl-5-(4-morpholin-4-ylbutyl)-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00808
  • The bromide intermediate 5-(4-Bromobutyl)-2-(cycloheptylamino)-5-methyl-1,3-thiazol-4(5H)-one (52 mg, 0.14 mmol), described above, was dissolved in THF (3 mL), morpholine (0.84 mmol) added and warmed to 80° C. over the weekend. Purification by preprative HPLC and made basic with aq NaHCO3, gave the product as a colourless oil. HPLC 100% RT=1.45 min (System B, 10-97% MeCN over 3 min), 100% RT=1.63 min (System A, 10-97% MeCN over 3 min). 1H NMR (400 MHz, DMSO-D6) δ ppm 0.96-1.08 (m, 1 H) 1.34-1.60 (m, 18 H) 1.82-1.90 (m, 2 H) 2.18 (t, J=6.96 Hz, 2 H) 2.24-2.32 (m, 4 H) 3.52 (m, 4 H) 3.95 (s, 1 H) 9.08 (br s, 1H). MS(ESI) for C19H33N3O2S m/z 368 (M+H).
    • Method YY Example 176 5-[(dimethylamino)methyl]-5-methyl-2-[(2-methylphenyl)amino]-1,3-thiazol-4(5H)-one
  • Figure US20110082107A1-20110407-C00809
  • To a solution of {2-[(3-chloro-2-methylphenyl)amino]-4-oxo-4,5-dihydro-1,3-thiazol-5-yl}acetic acid (1 eq) in 1,4-dioxane was added N,N-dimethylmethyleneiminium chloride (2 eq) and the resulting mixture heated in a sealed tube in a microwave reactor at 150° C. for 5 minutes. The desired product was then isolated after removal of solvent in vacuo and purification by preperative HPLC.
  • 1H NMR (400 MHz, DMSO-D6) δ ppm 1.42 (s, 3 H) 2.12 (s, 2H) 2.2.3 (s, 6H) 2.57 (d, J=14.0 Hz, 1H) 2.70 (d, J=14.0 Hz, 1H) 3.30 (s, 3H) 6.83 (d, J=7.5 Hz, 1H) 7.03 (t, J=7.5 Hz, 1H) 7.15 (t, J=7.5 Hz, 1H) 7.21 (d, J=7.5 Hz, 1H); MS(ESI) for C14H19N3OS m/z 278 (M+H).
  • The following table of compounds were prepared using the methodologiesoutlined above.
  • TABLE 2
    Calc
    mono Exp mono Method of
    Structure mass mass Name Prep.
    Figure US20110082107A1-20110407-C00810
         		— 391 N-{2-[2- (bicyclo[2.2.1]hept- 5-en-2-ylamino)-4-oxo- 4,5-dihydro-1,3-thiazol- 5-yl]ethyl}-6- chloronicotinamide QQ
    Figure US20110082107A1-20110407-C00811
         		311.1667 311.1654 N-{2-[2- (cyclooctylamino)-4-oxo- 4,5-dihydro-1,3-thiazol- 5-yl]ethyl}acetamide trifluoroacetate QQ
    Figure US20110082107A1-20110407-C00812
         		375.0808 375.0809 2-[2- (bicyclo[2.2.1]hept-5-en- 2-ylamino)-4- oxo-4,5-dihydro- 1,3-thiazol-5-yl]-N- (2-chlorophenyl) acetamide RR
    Figure US20110082107A1-20110407-C00813
         		366 N-(2-chlorophenyl)- 2-[2- (cyclohexylamino)- 4-oxo-4,5-dihydro- 1,3-thiazol-5- yl]acetamide trifluoroacetate RR
    Figure US20110082107A1-20110407-C00814
         		359.1667 359.1662 2-[2- (cyclohexylamino)- 4-oxo-4,5-dihydro- 1,3-thiazol-5-yl]-N- (2,6- dimethylphenyl) acetamide RR
    Figure US20110082107A1-20110407-C00815
         		359.1667 359.1664 2-[2- (cyclohexylamino)- 4-oxo-4,5-dihydro- 1,3-thiazol-5-yl]-N- (2,5- dimethylphenyl) acetamide RR
    Figure US20110082107A1-20110407-C00816
         		359.1667 359.1664 2-[2- (cyclohexylamino)- 4-oxo-4,5-dihydro- 1,3-thiazol-5-yl]-N- (2,4- dimethylphenyl) acetamide RR
    Figure US20110082107A1-20110407-C00817
         		399.0575 399.582 2-[2- (cyclohexylamino)- 4-oxo-4,5-dihydro- 1,3-thiazol-5-yl]-N- (2,5- dichlorophenyl) acetamide RR
    Figure US20110082107A1-20110407-C00818
         		345.1511 345.1552 2-[2- (cyclohexylamino)- 4-oxo-4,5-dihydro- 1,3-thiazol-5-yl]-N- (2-methylphenyl) acetamide RR
    Figure US20110082107A1-20110407-C00819
         		365.2137 365.2141 2-{2- [(cyclohexylmethyl) amino]-4-oxo-4,5- dihydro-1,3-thiazol- 5-yl}-N- (cyclopropylmethyl)- N-propylacetamide RR
    Figure US20110082107A1-20110407-C00820
         		386 2- [(cyclohexylmethyl) amino]-5-[2-(3,4- dihydroquinolin- 1(2H)-yl)-2- oxoethyl]-1,3- thiazol-4(5H)-one RR
    Figure US20110082107A1-20110407-C00821
         		353.1773 353.1768 2- (cycloheptylamino)- 5-[2-(3- hydroxypiperidin-1- yl)-2-oxoethyl]-1,3- thiazol-4(5H)-one RR
    Figure US20110082107A1-20110407-C00822
         		339.1617 339.1611 2- (cycloheptylamino)- 5-(2-morpholin-4- yl-2-oxoethyl)-1,3- thiazol-4(5H)-one RR
    Figure US20110082107A1-20110407-C00823
         		349.1824 349.1818 5-(2-azepan-1-yl-2- oxoethyl)-2- (bicyclo[2.2.1]hept- 2-ylamino)-1,3- thiazol-4(5H)-one RR
    Figure US20110082107A1-20110407-C00824
         		359.0262 359.0263 N-(2,3- dichlorophenyl)-2- [4-oxo-2- (propylamino)-4,5- dihydro-1,3-thiazol- 5-yl]acetamide RR
    Figure US20110082107A1-20110407-C00825
         		425.1176 425.1194 N-(4-chloro-2,5- dimethoxyphenyl)- 2-[2- (cyclohexylamino)- 4-oxo-4,5-dihydro- 1,3-thiazol-5- yl]acetamide RR
    Figure US20110082107A1-20110407-C00826
         		345.1511 345.1514 2-[2- (cyclohexylamino)- 4-oxo-4,5-dihydro- 1,3-thiazol-5-yl]-N- (4-methylphenyl) acetamide RR
    Figure US20110082107A1-20110407-C00827
         		409.0419 409.0413 2-[2- (bicyclo[2.2.1]hept- 5-en-2-ylamino)-4- oxo-4,5-dihydro- 1,3-thiazol-5-yl]-N- (4-chlorophenyl) acetamide RR
    Figure US20110082107A1-20110407-C00828
         		409.0419 409.0413 2-[2- (bicyclo[2.2.1]hept- 5-en-2-ylamino)-4- oxo-4,5-dihydro- 1,3-thiazol-5-yl]-N- (2,5-dichlorophenyl) acetamide RR
    Figure US20110082107A1-20110407-C00829
         		283.1718 283.1731 2- (cyclooctylamino)- 5-(dimethylamino)- 5-methyl-1,3- thiazol-4(5H)-one UU
    Figure US20110082107A1-20110407-C00830
         		309.1875 309.1877 2- (cycloheptylamino)- 5-methyl-5- piperidin-1-yl-1,3- thiazol-4(5H)-one UU
    Figure US20110082107A1-20110407-C00831
         		297.1875 297.1868 2- (cyclooctylamino)- 5-isopropyl-5- (methylamino)-1,3- thiazol-4(5H)-one UU
    Figure US20110082107A1-20110407-C00832
         		368.2246 368.2252 2- (cycloheptylamino)- 5-methyl-5-[(3- morpholin-4- ylpropyl)amino]- 1,3-thiazol-4(5H)- one UU
    Figure US20110082107A1-20110407-C00833
         		424.2508 424.2503 tert-butyl 4-{[2- (cycloheptylamino)- 5-methyl-4-oxo-4,5- dihydro-1,3-thiazol- 5-yl]amino} piperidine-1- carboxylate UU
    Figure US20110082107A1-20110407-C00834
         		277.124882 277.126 5- [(dimethylamino) methyl]-5-methyl-2- [(2-methylphenyl) amino]- 1,3-thiazol-4(5H)- one YY
    Figure US20110082107A1-20110407-C00835
         		345.151097 345.15 2-anilino-5-(2- azepan-1-yl-2- oxoethyl)-5-methyl- 1,3-thiazol-4(5H)- one RR
    Figure US20110082107A1-20110407-C00836
         		365.119797 365.119 2-anilino-5-[2-(1,3- dihydro-2H- isoindol-2-yl)-2- oxoethyl]-5-methyl- 1,3-thiazol-4(5H)- one RR
    Figure US20110082107A1-20110407-C00837
         		379.135447 379.136 2-anilino-5-[2-(3,4- dihydroisoquinolin- 2(1H)-yl)-2- oxoethyl]-5-methyl- 1,3-thiazol-4(5H)- one RR
    Figure US20110082107A1-20110407-C00838
         		365.2129 365.213697 5-(2-azepan-1-yl-2- oxoethyl)-2- (cycloheptylamino)- 5-methyl-1,3- thiazol-4(5H)-one RR
    Figure US20110082107A1-20110407-C00839
         		385.1835 385.182397 2- (cycloheptylamino)- 5-[2-(1,3-dihydro- 2H-isoindol-2-yl)-2- oxoethyl]-5-methyl- 1,3-thiazol-4(5H)- one RR
    Figure US20110082107A1-20110407-C00840
         		399.1995 399.198047 2- (cycloheptylamino)- 5-[2-(3,4- dihydroisoquinolin- 2(1H)-yl)-2- oxoethyl]-5-methyl- 1,3-thiazol-4(5H)- one RR
    Figure US20110082107A1-20110407-C00841
         		379.2275 379.229347 5-(2-azepan-1-yl-2- oxoethyl)-2- (cyclooctylamino)- 5-methyl-1,3- thiazol-4(5H)-one RR
    Figure US20110082107A1-20110407-C00842
         		336.1049 336.10445 2- (cyclooctylamino)- 5-[2-(1,3-dihydro- 2H-isoindol-2-yl)-2- oxoethyl]-5-methyl- 1,3-thiazol-4(5H)- one RR
    Figure US20110082107A1-20110407-C00843
         		413.2138 413.213697 2-(cyclooctylamino)- 5-[2-(3,4- dihydroquinolin- 1(2H)-yl)-2- oxoethyl]-5-methyl- 1,3-thiazol-4(5H)- one RR
    Figure US20110082107A1-20110407-C00844
         		379.1352 379.135447 2-anilino-5-[2-(3,4- dihydroquinolin- 1(2H)-yl)-2- oxoethyl]-5-methyl- 1,3-thiazol-4(5H)- one RR
    Figure US20110082107A1-20110407-C00845
         		264.1296 264.1307 2- (bicyclo[2.2.1]hept- 2-ylamino)-1-thia-3- azaspiro[4.4]non-2- en-4-one WW
    Figure US20110082107A1-20110407-C00846
         		266.1453 266.1442 2- (cycloheptylamino)- 1-thia-3- azaspiro[4.4]non-2- en-4-one WW
    Figure US20110082107A1-20110407-C00847
         		280.1609 280.1611 2- (cyclooctylamino)- 1-thia-3- azaspiro[4.4]non-2- en-4-one WW
    Figure US20110082107A1-20110407-C00848
         		266.1453 266.1445 2-[(2,2,3,3- tetramethyl- cyclopropyl) amino]-1-thia-3- azaspiro[4.4]non-2- en-4-one WW
    Figure US20110082107A1-20110407-C00849
         		266.1453 266.146 2- (bicyclo[2.2.1]hept- 2-ylamino)-5- methyl-5-propyl- 1,3-thiazol-4(5H)- one WW
    Figure US20110082107A1-20110407-C00850
         		268.1609 268.1618 2- (cycloheptylamino)- 5-methyl-5-propyl- l,3-thiazol-4(5H)- one WW
    Figure US20110082107A1-20110407-C00851
         		282.1766 282.1774 2- (cyclooctylamino)- 5-methyl-5-propyl- 1,3-thiazol-4(5H)- one WW
    Figure US20110082107A1-20110407-C00852
         		268.1609 268.1609 5-methyl-5-propyl- 2-[(2,2,3,3- tetramethyl- cyclopropyl) amino]-1,3- thiazol-4(5H)-one WW
    Figure US20110082107A1-20110407-C00853
         		262.1296 252.1288 2- (bicyclo[2.2.1]hept- 2-ylamino)-5-ethyl- 5-methyl-1,3- thiazol-4(5H)-one WW
    Figure US20110082107A1-20110407-C00854
         		254.1453 254.1448 2- (cycloheptylamino)- 5-ethyl-5-methyl- 1,3-thiazol-4(5H)- one WW
    Figure US20110082107A1-20110407-C00855
         		254.1453 254.1443 5-ethyl-5-methyl-2- [(2,2,3,3-tetramethyl- cyclopropyl) amino]-1,3- thiazol-4(5H)-one WW
    Figure US20110082107A1-20110407-C00856
         		278.1453 278.1459 5-ethyl-5-methyl-2- (tricyclo[3.3.1.0~3,7~] non-3-ylamino)- 1,3-thiazol-4(5H)- one WW
    Figure US20110082107A1-20110407-C00857
         		280.1245 278.0941 2-[(1S,2S,4R)- bicyclo[2.2.1]hept- 2-ylamino]-8-oxa-1- thia-3- azaspiro[4.5]dec-2- en-4-one WW
    Figure US20110082107A1-20110407-C00858
         		252.1296 252.1296 2- (bicyclo[2.2.1]hept- 1-ylamino)-5-ethyl- 5-methyl-1,3- thiazol-4(5H)-one WW
    Figure US20110082107A1-20110407-C00859
         		268.1609 268.1601 2- (cyclooctylamino)- 5-ethyl-5-methyl- 1,3-thiazol-4(5H)- one WW
    Figure US20110082107A1-20110407-C00860
         		292.1609 292.1614 5-methyl-5-propyl- 2-(tricyclo [3.3.1.0~3,7~] non-3-ylamino)- 1,3-thiazol-4(5H)- one WW
    Figure US20110082107A1-20110407-C00861
         		266.1453 266.1443 2- (bicyclo[2.2.1]hept- 2-ylamino)-5,5- diethyl-1,3-thiazol- 4(5H)-one WW
    Figure US20110082107A1-20110407-C00862
         		282.1766 282.1758 2- (cyclooctylamino)- 5,5-diethyl-1,3- thiazol-4(5H)-one WW
    Figure US20110082107A1-20110407-C00863
         		292.1609 292.1622 5,5-diethyl-2- (tricyclo[3.3.1.0~3,7~] non-3-ylamino)- 1,3-thiazol-4(5H)- one WW
    Figure US20110082107A1-20110407-C00864
         		254.1453 254.1454 5-ethyl-5-methyl-2- [(1- methylcyclohexyl) amino]-1,3-thiazol- 4(5H)-one trifluoroacetate WW
    Figure US20110082107A1-20110407-C00865
         		268.1609 268.1609 5-methyl-2-[(1- methylcyclohexyl) amino]-5-propyl-1,3- thiazol-4(5H)-one trifluoroacetate WW
    Figure US20110082107A1-20110407-C00866
         		254.1453 254.1442 5-ethyl-5-methyl-2- [(4- methylcyelohexyl) amino]-1,3-thiazol- 4(5H)-one WW
    Figure US20110082107A1-20110407-C00867
         		282.1766 282.1766 5-ethyl-5-methyl-2- [(3,3,5- trimethylcyclohexyl) amino]-1,3-thiazol- 4(5H)-one WW
    Figure US20110082107A1-20110407-C00868
         		264.1296 264.1291 5,5-dimethyl-2- (tricyclo[3.3.1.0~3,7~] non-3-ylamino)- l,3-thiazol-4(5H)- one WW
    Figure US20110082107A1-20110407-C00869
         		252.1296 252.1289 2- (bicyclo[2.2.1]hept- 7-ylamino)-5-ethyl- 5-methyl-1,3- thiazol-4(5H)-one WW
    Figure US20110082107A1-20110407-C00870
         		266.1453 266.1459 2- (bicyclo[2.2.1]hept- 7-ylamino)-5- methyl-5-propyl- 1,3-thiazol-4(5H)- one WW
    Figure US20110082107A1-20110407-C00871
         		254.1453 254.1444 (5S)-2- (cycloheptylamino)- 5-ethyl-5-methyl- 1,3-thiazol-4(5H)- one WW
    Figure US20110082107A1-20110407-C00872
         		254.1453 254.1445 (5R)-2- (cycloheptylamino)- 5-ethyl-5-methyl- 1,3-thiazol-4(5H)- one WW
    Figure US20110082107A1-20110407-C00873
         		266.1453 266.144 2- (bicyclo[2.2.1]hept- 7-ylamino)-5,5- diethyl-1,3-thiazol- 4(5H)-one WW
    Figure US20110082107A1-20110407-C00874
         		266.1453 266.1445 2- (bicyclo[2.2.1]hept- 1-ylamino)-5,5- diethyl-1,3-thiazol- 4(5H)-one WW
    Figure US20110082107A1-20110407-C00875
         		266.1453 266.1445 2- (bicyclo[2.2.1]hept- 1-ylamino)-5- methyl-5-propyl- 1,3-thiazol-4(5H)- one WW
    Figure US20110082107A1-20110407-C00876
         		360.0871 360.0867 5-(4-bromobutyl)-2- (cycloheptylamino)- 5-methyl-1,3- thiazol-4(5H)-one XX
    Figure US20110082107A1-20110407-C00877
         		381.2814 381.281 2- (cycloheptylamino)- 5-[4- (diethylamino)butyl]- 5-propyl-1,3- thiazol-4(5H)-one XX
    Figure US20110082107A1-20110407-C00878
         		367.2293 367.2294 2- (cycloheptylamino)- 5-methyl-5-(4- morpholin-4- ylbutyl)-1,3-thiazol- 4(5H)-one XX
    Figure US20110082107A1-20110407-C00879
         		380.261 380.2612 2- (cycloheptylamino)- 5-methyl-5-[4-(4- methylpiperazin-1- yl)butyl]-1,3- thiazol-4(5H)-one XX
    Figure US20110082107A1-20110407-C00880
         		466.2978 466.2992 tert-butyl 4-{4-[2- (cycloheptylamino)- 5-methyl-4-oxo-4,5- dihydro-1,3-thiazol- 5-yl]butyl} piperazine- 1-carboxylate XX
    Figure US20110082107A1-20110407-C00881
         		351.198 351.1977 2- (bicyclo[2.2.1]hept- 2-ylamino)-5- methyl-5-(3- morpholin-4- ylpropyl)-1,3- thiazol-4(5H)-one XX
    Figure US20110082107A1-20110407-C00882
         		266.1453 266.1458 2-[(1S,2S,4R)- bicyclo[2.2.1]hept- 2-ylamino]-5,5- diethyl-1,3-thiazol- 4(5H)-one WW
    Figure US20110082107A1-20110407-C00883
         		270.1402 270.1401 2- (cyclooctylamino)- 5-methoxy-5- methyl-1,3-thiazol- 4(5H)-one UU
    Figure US20110082107A1-20110407-C00884
         		270.1402 270.139 2- (cycloheptylamino)- 5-ethoxy-5-methyl- 1,3-thiazol-4(5H)- one UU
    Figure US20110082107A1-20110407-C00885
         		284.1558 284.156 2- (cycloheptylamino)- 5-isopropoxy-5- methyl-1,3-thiazol- 4(5H)-one UU
    Figure US20110082107A1-20110407-C00886
         		298.1715 298.172 5-butoxy-2- (cycloheptylamino)- 5-methyl-1,3- thiazol-4(5H)-one UU
    Figure US20110082107A1-20110407-C00887
         		298.1715 298.1712 2- (cyclooctylamino)- 5-isopropyl-5- methoxy-1,3- thiazol-4(5H)-one UU
    Figure US20110082107A1-20110407-C00888
         		374.2028 374.2034 5-butoxy-2- (cyclooctylamino)- 5-phenyl-1,3- thiazol-4(5H)-one UU
    Figure US20110082107A1-20110407-C00889
         		300.1508 300.1517 2- (cycloheptylamino)- 5-(3- hydroxypropoxy)-5- methyl-1,3-thiazol- 4(5H)-one UU
    Figure US20110082107A1-20110407-C00890
         		296.1558 296.1558 2- (bicyclo[2.2.1]hept- 2-ylamino)-5- butoxy-5-methyl- 1,3-thiazol-4(5H)- one UU
    Figure US20110082107A1-20110407-C00891
         		326.2028 326.2036 5-butoxy-2- (cycloheptylamino)- 5-propyl-1,3- thiazol-4(5H)-one UU
    Figure US20110082107A1-20110407-C00892
         		284.1558 284.1547 2- (cycloheptylamino)- 5-methoxy-5- propyl-1,3-thiazol- 4(5H)-one UU
    Figure US20110082107A1-20110407-C00893
         		367.193 367.1934 2- (bicyclo[2.2.1]hept- 2-ylamino)-5- methyl-5-(3- morpholin-4- ylpropoxy)-1,3- thiazol-4(5H)-one UU
    Figure US20110082107A1-20110407-C00894
         		365.2137 365.2134 2- (bicyclo[2.2.1]hept- 2-ylamino)-5- methyl-5-(3- piperidin-1- ylpropoxy)-1,3- thiazol-4(5H)-one UU
    Figure US20110082107A1-20110407-C00895
         		266.2614 466.2619 tert-butyl 4-(3-{[2- (bicyclo[2.2.1]hept- 2-ylamino)-5- methyl-4-oxo-4,5- dihydro-1,3-thiazol- 5- yl]oxy}propyl) piperazine-1- carboxylate UU
    Figure US20110082107A1-20110407-C00896
         		326.1664 326.1666 2- (cycloheptylamino)- 5-methyl-5- (tetrahydrofuran-2- ylmethoxy)-1,3- thiazol-4(5H)-one UU
    Figure US20110082107A1-20110407-C00897
         		358.1926 358.1917 2- (cycloheptylamino)- 5-[2-(2- ethoxyethoxy) ethoxy]-5-methyl-1,3- thiazol-4(5H)-one UU
    Figure US20110082107A1-20110407-C00898
         		312.1508 312.1503 2- (cycloheptylamino)- 5-methyl-5- (tetrahydrofuran-3- yloxy)-1,3-thiazol- 4(5H)-one UU
    Figure US20110082107A1-20110407-C00899
         		362.1664 362.1675 2- (cycloheptylamino)- 5-methyl-5-(2- phenoxyethoxy)- 1,3-thiazol-4(5H)- one UU
    Figure US20110082107A1-20110407-C00900
         		324.1871 324.1869 2- (cycloheptylamino)- 5-(cyclohexyloxy)- 5-methyl-1,3- thiazol-4(5H)-one UU
    Figure US20110082107A1-20110407-C00901
         		266.1089 266.1076 2- (bicyclo[2.2.1]hept- 2-ylamino)-6-oxa-1- thia-3- azaspiro[4.4]non-2- en-4-one UU
    Figure US20110082107A1-20110407-C00902
         		323 2-anilino-5-(1H- benzimidazol-2- ylmethyl)-1,3- thiazol-4(5H)-one VV
    Figure US20110082107A1-20110407-C00903
         		343. 5-(1H- benzimidazol-2- ylmethyl)-2- [(cyclohexylmethyl) amino]-1,3-thiazol- 4(5H)-one VV
    Figure US20110082107A1-20110407-C00904
         		336.1049 336.1045 2-anilino-5-[(1- methyl-1H- benzimidazol-2- yl)methyl]-1,3- thiazol-4(5H)-one VV
    Figure US20110082107A1-20110407-C00905
         		255.1405 255.1397 2-(azepan-1- ylamino)-5- isopropyl-1,3- thiazol-4(5H)-one TT
    Figure US20110082107A1-20110407-C00906
         		255.1405 255.1401 2-(azepan-1- ylamino)-5-ethyl-5- methyl-1,3-thiazol- 4(5H)-one TT
    Figure US20110082107A1-20110407-C00907
         		267.1405 267.1399 5-ethyl-2- (hexahydrocyclopenta [c]pyrrol-2(1H)- ylamino)-5-methyl- 1,3-thiazol-4(5H)- one TT
    Figure US20110082107A1-20110407-C00908
         		269.1562 269.157 2-(azepan-1- ylamino)-5,5- diethyl-1,3-thiazol- 4(5H)-one TT
    Figure US20110082107A1-20110407-C00909
         		281.1562 281.1569 5,5-diethyl-2- (hexahydrocyclopenta [c]pyrrol-2(1H)- ylamino)-1,3- thiazol-4(5H)-one TT
    Figure US20110082107A1-20110407-C00910
         		271.1354 271.1344 5-isopropyl-2- {[(2R)-2- (methoxymethyl) pyrrolidin-1-yl]amino}- 1,3-thiazol-4(5H)- one TT
    Figure US20110082107A1-20110407-C00911
         		271.1354 271.1342 5-isopropyl-2-{[2- (methoxymethyl) pyrrolidin-1-yl]amino}- 1,3-thiazol-4(5H)- one TT
    Figure US20110082107A1-20110407-C00912
         		243.1041 243.1049 5-isopropyl-2- (morpholin-4- ylamino)-1,3- thiazol-4(5H)-one TT
    Figure US20110082107A1-20110407-C00913
         		269.1562 269.1553 2-[(2.6- dimethylpiperidin-1- yl)amino]-5- isopropyl-1,3- thiazol-4(5H)-one TT
    Figure US20110082107A1-20110407-C00914
         		253.1249 253.1249 5-ethyl-2- (hexahydrocyclopenta [c]pyrrol-2(1H)- ylamino)-1,3- thiazol-4(5H)-one TT
    Figure US20110082107A1-20110407-C00915
         		258.1368 258.136 2-(2,2- dimethylpyrrolidin- 1-yl)-5-phenyl-1,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00916
         		222.1368 222.1373 2- (bicyclo[2.2.1]hept- 2-ylamino)-5,5- dimethyl-1,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00917
         		270.1368 270.1356 2- (bicyclo[2.2.1]hept- 2-ylamino)-5- phenyl-1,3-oxazol- 4(5H)-one SS
    Figure US20110082107A1-20110407-C00918
         		281.1164 281.1163 5-phenyl-2-[(2- pyridin-2- ylethyl)amino]-1,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00919
         		284.1525 284.1513 5-benzyl-2- (bicyclo[2.2.1]hept- 2-ylamino)-1,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00920
         		300.1838 300.1843 5-benzyl-2- (cyclooctylamino)- 1,3-oxazol-4(5H)- one SS
    Figure US20110082107A1-20110407-C00921
         		252.1838 252.183 2- (cyclooctylamino)- 5-isopropyl-l,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00922
         		290.1944 290.1986 2-(1- adamantylamino)-5- isobutyl-1,3-oxazol- 4(5H)-one SS
    Figure US20110082107A1-20110407-C00923
         		266.1994 266 2- (cyclooctylamino)- 5-isobutyl-1,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00924
         		286.1681 286.1672 2- (cyclooctylamino)- 5-phenyl-1,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00925
         		310.1681 310.169 2-(1- adamantylamino)-5- phenyl-1,3-oxazol- 4(5H)-one SS
    Figure US20110082107A1-20110407-C00926
         		324.1838 324.1827 2-(1- adamantylamino)-5- benzyl-1,3-oxazol- 4(5H)-one SS
    Figure US20110082107A1-20110407-C00927
         		276.1838 276.1844 5-isobutyl-2- (tricyclo[3.3.1.0~3,7~] non-3-ylamino)- 1,3-oxazol-4(5H)- one SS
    Figure US20110082107A1-20110407-C00928
         		252.1838 252.1828 2- (cycloheptylamino)- 5,5-diethyl-1,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00929
         		266.1994 266.1991 2- (cyclooctylamino)- 5,5-diethyl-1,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00930
         		250.1681 250.1677 2- (bicyclo[2.2.1]hept- 2-ylamino)-5,5- diethyl-1,3-oxazol- 4(5H)-one SS
    Figure US20110082107A1-20110407-C00931
         		276.1838 276.183 5,5-diethyl-2- (tricyclo[3.3.1.0~3,7~] non-3-ylamino)- 1,3-oxazol-4(5H)- one SS
    Figure US20110082107A1-20110407-C00932
         		290.1994 290.1987 2-(1- adamantylamino)- 5,5-diethyl-1,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00933
         		262.1681 262.1675 5-isopropyl-2- (tricyclo[3.3.1.0~3,7~] non-3-ylamino)- 1,3-oxazol-4(5H)- one SS
    Figure US20110082107A1-20110407-C00934
         		278.1994 278.1984 2- (cyclooctylamino)- 1-oxa-3- azaspiro[4.5]dec-2- en-4-one trifluoroacetate SS
    Figure US20110082107A1-20110407-C00935
         		276.1838 276.1839 2-(1- adamantylamino)-5- isopropyl-1,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00936
         		276.1838 276.1832 2-(2- adamantylamino)-5- isopropyl-1,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00937
         		292.1787 292.1774 2-[(3-hydroxy-1- adamantyl)amino]- 5-isopropyl-1,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00938
         		290.1994 290.1995 2-(2- adamantylamino)- 5,5-diethyl-1,3- oxazol-4(5H)-one SS
    Figure US20110082107A1-20110407-C00939
         		306.1943 306.1953 5,5-diethyl-2-[(3- hydroxy-1- adamantyl)amino]- 1,3-oxazol-4(5H)- one SS
    Figure US20110082107A1-20110407-C00940
         		302.1994 302.1994 2-(2- adamantylamino)-1- oxa-3- azaspiro[4.5]dec-2- en-4-one SS
    Figure US20110082107A1-20110407-C00941
         		288.1838 288.1833 2-(2- adamantylamino)-1- oxa-3- azaspiro[4.4]non-2- en-4-one SS
    Figure US20110082107A1-20110407-C00942
         		341.2103 341.2113 8-benzyl-2- (cyclohexylamino)- 1-oxa-3,8- diazaspiro[4.5]dec- 2-en-4-one SS
    Figure US20110082107A1-20110407-C00943
         		248.1525 248.1519 2- (bicyclo[2.2.1]hept- 2-ylamino)-1-oxa-3- azaspiro[4.4]non-2- en-4-one SS
    Figure US20110082107A1-20110407-C00944
         		264.1838 264.1826 2- (cyclooctylamino)- 1-oxa-3- azaspiro[4.4]non-2- en-4-one SS
    Figure US20110082107A1-20110407-C00945
         		274.1681 274.1679 2- (tricyclo[3.3.1.0~3,7~] non-3-ylamino)-1- oxa-3- azaspiro[4.4]non-2- en-4-one SS
    Figure US20110082107A1-20110407-C00946
         		288.1838 288.1825 2-(1- adamantylamino)-1- oxa-3- azaspiro[4.4]non-2- en-4-one SS
    Figure US20110082107A1-20110407-C00947
         		304.1787 304.1778 2-[(3-hydroxy-1- adamantyl)amino]- 1-oxa-3- azaspiro[4.4]non-2- en-4-one SS
    Figure US20110082107A1-20110407-C00948
         		393.2416 393.2406 2-(2- adamantylamino)-8- benzyl-1-oxa-3,8- diazaspiro[4.5]dec- 2-en-4-one SS
    Figure US20110082107A1-20110407-C00949
         		316.1399 316.139 2-(2- adamantylamino)-5- methyl-5- (trifluoromethyl)- 1,3-oxazol-4(5H)- one SS
    Figure US20110082107A1-20110407-C00950
         		327.1947 327.1941 8-benzyl-2- (cyclopentylamino)- 1-oxa-3,8- diazaspiro[4.5]dec- 2-en-4-one SS
    Figure US20110082107A1-20110407-C00951
         		315.1947 315.1945 8-benzyl-2-(tert- butylamino)-1-oxa- 3,8- diazaspiro[4.5]dec- 2-en-4-one SS
    Figure US20110082107A1-20110407-C00952
         		292.1399 292.1397 2- (cyclooctylamino)- 5-methyl-5- (trifluoromethyl)- 1,3-oxazol-4(5H)- one SS
    Figure US20110082107A1-20110407-C00953
         		302.1242 302.1246 5-methyl-2- (tricyclo[3.3.1.0~3,7~] non-3-ylamino)-5- (trifluoromethyl)- 1,3-oxazol-4(5H)- one SS
    Figure US20110082107A1-20110407-C00954
         		335.1634 335.1628 2-anilino-8-benzyl- 1-oxa-3,8- diazaspiro[4.5]dec- 2-en-4-one SS
    Figure US20110082107A1-20110407-C00955
         		399.2134 399.2144 2-(2- adamantylamino)-8- (3,3,3- trifluoropropyl)-1- oxa-3,8- diazaspiro[4.5]dec- 2-en-4-one SS
  • The following tables of compounds are encompassed by the present invention and may be prepared by one of the above methodologies.
  • Compound Name
    Figure US20110082107A1-20110407-C00956
         		(S)-2-((1R,2R,4R)-5- hydroxybicyclo[2.2.1]heptan-2-ylamino)-5- isopropyl-5-methylthiazol-4(5H)-one-M1
    Figure US20110082107A1-20110407-C00957
         		(S)-2-((1R,2S,4R)-5- hydroxybicyclo[2.2.1]heptan-2-ylamino)-5- isopropyl-5-methylthiazol-4(5H)-one-M2
    Figure US20110082107A1-20110407-C00958
         		(S)-2-((1S,2S,4R)-6- hydroxybicyclo[2.2.1]heptan-2-ylamino)-5- isopropyl-5-methylthiazol-4(5H)-one-M3
    Figure US20110082107A1-20110407-C00959
         		(S)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2-ylamino)-5-((R)-1- hydroxypropan-2-yl)-5-methylthiazol-4(5H)- one-M4
    Figure US20110082107A1-20110407-C00960
         		(S)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2-ylamino)-5-((S)-1- hydroxypropan-2-yl)-5-methylthiazol-4(5H)- one-M6
    Figure US20110082107A1-20110407-C00961
         		(S)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2-ylamino)-5-(2- hydroxypropan-2-yl)-5-methylthiazol-4(5H)- one-M7
    Figure US20110082107A1-20110407-C00962
         		(S)-2-((1S,2S,4R)- bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5- (prop-1-en-2-yl)thiazol-4(5H)-one-M8
    Figure US20110082107A1-20110407-C00963
         		(S)-2-((1R,2S,4R)-5- hydroxybicyclo[2.2.1]heptan-2-ylamino)-5- isopropyl-5-methylthiazol-4(5H)-one-M10
  • In the table which follows, the variable n is defined as 0-8, the variables R and R1 and R2 are independently defined as hydrogen, C1-C8 alkyl, C1-C8 alkoxy, —NR10R10, —S—(C1-C8)alkyl, aryl and heterocyclyl; where R10 independently selected from hydrogen, C1-C8 alkyl, aryl-C1-C8 alkyl, C1-C8 alkoxy, —S—(C1-C8)alkyl, heterocyclyl and aryl; and any alkyl, alkoxy, heterocyclyl or aryl moiety may be substituted with one to three substituents selected from -halo, unsubstituted C1-C8 alkyl, unsubstituted C1-C8 alkoxy, unsubstituted C1-C8 thioalkoxy and unsubstituted aryl(C1-C4)alkyl.
  •
    Molecule Name
    Figure US20110082107A1-20110407-C00964
         		2-((S)-1-(2-chlorophenyl)ethylamino)-5- methyl-5-(trifluoromethyl)thiazol-4(5H)- one
    Figure US20110082107A1-20110407-C00965
         		2-((S)-1-(2-bromophenyl)ethylamino)-5- methyl-5-(trifluoromethyl)thiazol-4(5H)- one
    Figure US20110082107A1-20110407-C00966
         		2-((S)-1-(2-methoxyphenyl)ethylamino)-5- methyl-5-(trifluoromethyl)thiazol-4(5H)- one
    Figure US20110082107A1-20110407-C00967
         		2-((S)-1-(5-methyl-4-oxo-5- (trifluoromethyl)-4,5-dihydrothiazol-2- ylamino)ethyl)benzonitrile
    Figure US20110082107A1-20110407-C00968
         		2-((S)-1-(2,6-difluorophenyl)ethylamino)- 5-methyl-5-(trifluoromethyl)thiazol-4(5H)- one
    Figure US20110082107A1-20110407-C00969
         		2-(cyclooctylamino)-5-methyl-5- (trifluoromethyl)thiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00970
         		2-((S)-1-(2-tert-butylphenyl)ethylamino)-5- methyl-5-(trifluoromethyl)thiazol-4(5H)- one
    Figure US20110082107A1-20110407-C00971
         		2-(5-hydroxy-5- (trifluoromethyl)cyclooctylamino)-5- methyl-5-(trifluoromethyl)thiazol-4(5H)- one
    Figure US20110082107A1-20110407-C00972
         		2-(5,5-difluorocyclooctylamino)-5-methyl- 5-(trifluoromethyl)thiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00973
         		2-(cyclooctylamino)-5-isopropyl-5- methylthiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00974
         		2-(5-hydroxy-5- (trifluoromethyl)cyclooctylamino)-5- isopropyl-5-methylthiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00975
         		2-(5,5-difluorocyclooctylamino)-5- isopropyl-5-methylthiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00976
         		2-((S)-8-fluoro-1,2,3,4- tetrahydronaphthalen-1-ylamino)-5-methyl- 5-(trifluoromethyl)thiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00977
         		2-((S)-8-chloro-1,2,3,4- tetrahydronaphthalen-1-ylamino)-5-methyl- 5-(trifluoromethyl)thiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00978
         		2-((S)-7-chloro-2,3-dihydro-1H-inden-1- ylamino)-5-methyl-5- (trifluoromethyl)thiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00979
         		2-((S)-7-fluoro-2,3-dihydro-1H-inden-1- ylamino)-5-methyl-5- (trifluoromethyl)thiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00980
         		2-((S)-1-(2-fluoro-6- methylphenyl)ethylamino)-5-methyl-5- (trifluoromethyl)thiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00981
         		2-((S)-1-(2-chloro-6- methylphenyl)ethylamino)-5-methyl-5- (trifluoromethyl)thiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00982
         		2-((S)-1-(2-chlorophenyl)ethylamino)-5- isopropyl-5-methylthiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00983
         		2-((S)-1-(2-ethynylphenyl)ethylamino)-5- isopropyl-5-methylthiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00984
         		2-((S)-1-(2-ethynylphenyl)ethylamino)-5- methyl-5-(trifluoromethyl)thiazol-4(5H)- one
    Figure US20110082107A1-20110407-C00985
         		2-((S)-1-(2-chlorophenyl)ethylamino))-8- oxa-1-thia-3-azaspiro[4.5]non-2-ene-4-one
    Figure US20110082107A1-20110407-C00986
         		2-((S)-1-(2-bromophenyl)ethylamino))-8- oxa-1-thia-3-azaspiro[4.5]non-2-ene-4-one
    Figure US20110082107A1-20110407-C00987
         		2-((S)-1-(2-bromophenyl)ethylamino))-1- thia-3-azaspiro[4.4]non-2-ene-4-one
    Figure US20110082107A1-20110407-C00988
         		2-((S)-1-(2-chlorophenyl)ethylamino))-1- thia-3-azaspiro[4.4]non-2-ene-4-one
    Figure US20110082107A1-20110407-C00989
         		2-((1S,5R)-6,6- difluorobicyclo[3.1.0]hexan-3-ylamino)-5- isopropyl-5-methylthiazol-4(5H)-one
    Figure US20110082107A1-20110407-C00990
         		2-((1S,5R)-6,6- difluorobicyclo[3.1.0]hexan-3-ylamino)-5- isopropyl-5-(trifluoromethyl)thiazol-4(5H)- one
    Figure US20110082107A1-20110407-C00991
         		2-(6,6-difluorobicyclo[3.1.0]hexan-3- ylamino)-1-thia-3-azaspiro[4.4]non-2-ene- 4-one
    Figure US20110082107A1-20110407-C00992
    Figure US20110082107A1-20110407-C00993
    Figure US20110082107A1-20110407-C00994
    Figure US20110082107A1-20110407-C00995
    Figure US20110082107A1-20110407-C00996
    Figure US20110082107A1-20110407-C00997
    Figure US20110082107A1-20110407-C00998
    Figure US20110082107A1-20110407-C00999
    Figure US20110082107A1-20110407-C01000
    Figure US20110082107A1-20110407-C01001
    Figure US20110082107A1-20110407-C01002
    Figure US20110082107A1-20110407-C01003
    Figure US20110082107A1-20110407-C01004
    Figure US20110082107A1-20110407-C01005
    Figure US20110082107A1-20110407-C01006
    Figure US20110082107A1-20110407-C01007
    Figure US20110082107A1-20110407-C01008
    Figure US20110082107A1-20110407-C01009
    Figure US20110082107A1-20110407-C01010
    Figure US20110082107A1-20110407-C01011
    Figure US20110082107A1-20110407-C01012
    Figure US20110082107A1-20110407-C01013
    Figure US20110082107A1-20110407-C01014
    Figure US20110082107A1-20110407-C01015
    Figure US20110082107A1-20110407-C01016
    Figure US20110082107A1-20110407-C01017
    Figure US20110082107A1-20110407-C01018
    Figure US20110082107A1-20110407-C01019
    Figure US20110082107A1-20110407-C01020
    Figure US20110082107A1-20110407-C01021
    Figure US20110082107A1-20110407-C01022
    Figure US20110082107A1-20110407-C01023
    Figure US20110082107A1-20110407-C01024
    Figure US20110082107A1-20110407-C01025
    Figure US20110082107A1-20110407-C01026
    Figure US20110082107A1-20110407-C01027
    Figure US20110082107A1-20110407-C01028
    Figure US20110082107A1-20110407-C01029
    Figure US20110082107A1-20110407-C01030
    Figure US20110082107A1-20110407-C01031
    Figure US20110082107A1-20110407-C01032
    Figure US20110082107A1-20110407-C01033
    Figure US20110082107A1-20110407-C01034
    Figure US20110082107A1-20110407-C01035
    Figure US20110082107A1-20110407-C01036
    Figure US20110082107A1-20110407-C01037
    Figure US20110082107A1-20110407-C01038
    Figure US20110082107A1-20110407-C01039
    Figure US20110082107A1-20110407-C01040
    Figure US20110082107A1-20110407-C01041
    Figure US20110082107A1-20110407-C01042
    Figure US20110082107A1-20110407-C01043
    Figure US20110082107A1-20110407-C01044
    Figure US20110082107A1-20110407-C01045
    Figure US20110082107A1-20110407-C01046
    Figure US20110082107A1-20110407-C01047
    Figure US20110082107A1-20110407-C01048
    Figure US20110082107A1-20110407-C01049
    Figure US20110082107A1-20110407-C01050
    Figure US20110082107A1-20110407-C01051
    Figure US20110082107A1-20110407-C01052
    Figure US20110082107A1-20110407-C01053
    Figure US20110082107A1-20110407-C01054
    Figure US20110082107A1-20110407-C01055
    Figure US20110082107A1-20110407-C01056
    Figure US20110082107A1-20110407-C01057
    Figure US20110082107A1-20110407-C01058
    Figure US20110082107A1-20110407-C01059
    Figure US20110082107A1-20110407-C01060
    Figure US20110082107A1-20110407-C01061
    Figure US20110082107A1-20110407-C01062
    Figure US20110082107A1-20110407-C01063
    Figure US20110082107A1-20110407-C01064
    Figure US20110082107A1-20110407-C01065
    Figure US20110082107A1-20110407-C01066
    Figure US20110082107A1-20110407-C01067
    Figure US20110082107A1-20110407-C01068
    Figure US20110082107A1-20110407-C01069
    Figure US20110082107A1-20110407-C01070
    Figure US20110082107A1-20110407-C01071
    Figure US20110082107A1-20110407-C01072
    Figure US20110082107A1-20110407-C01073
    Figure US20110082107A1-20110407-C01074
    Figure US20110082107A1-20110407-C01075
    Figure US20110082107A1-20110407-C01076
    Figure US20110082107A1-20110407-C01077
    Figure US20110082107A1-20110407-C01078
    Figure US20110082107A1-20110407-C01079
    Figure US20110082107A1-20110407-C01080
    Figure US20110082107A1-20110407-C01081
    Figure US20110082107A1-20110407-C01082
    Figure US20110082107A1-20110407-C01083
    Figure US20110082107A1-20110407-C01084
    Figure US20110082107A1-20110407-C01085
    Figure US20110082107A1-20110407-C01086
    Figure US20110082107A1-20110407-C01087
    Figure US20110082107A1-20110407-C01088
    Figure US20110082107A1-20110407-C01089
    Figure US20110082107A1-20110407-C01090
    Figure US20110082107A1-20110407-C01091
    Figure US20110082107A1-20110407-C01092
    Figure US20110082107A1-20110407-C01093
    Figure US20110082107A1-20110407-C01094
    Figure US20110082107A1-20110407-C01095
    Figure US20110082107A1-20110407-C01096
    Figure US20110082107A1-20110407-C01097
    Figure US20110082107A1-20110407-C01098
    Figure US20110082107A1-20110407-C01099
    Figure US20110082107A1-20110407-C01100
    Figure US20110082107A1-20110407-C01101
    Figure US20110082107A1-20110407-C01102
    Figure US20110082107A1-20110407-C01103
    Figure US20110082107A1-20110407-C01104
    Figure US20110082107A1-20110407-C01105
    Figure US20110082107A1-20110407-C01106
    Figure US20110082107A1-20110407-C01107
    Figure US20110082107A1-20110407-C01108
    Figure US20110082107A1-20110407-C01109
    Figure US20110082107A1-20110407-C01110
    Figure US20110082107A1-20110407-C01111
    Figure US20110082107A1-20110407-C01112
    Figure US20110082107A1-20110407-C01113
    Figure US20110082107A1-20110407-C01114
    Figure US20110082107A1-20110407-C01115
    Figure US20110082107A1-20110407-C01116
    Figure US20110082107A1-20110407-C01117
    Figure US20110082107A1-20110407-C01118
    Figure US20110082107A1-20110407-C01119
    Figure US20110082107A1-20110407-C01120
    Figure US20110082107A1-20110407-C01121
    Figure US20110082107A1-20110407-C01122
    Figure US20110082107A1-20110407-C01123
    Figure US20110082107A1-20110407-C01124
    Figure US20110082107A1-20110407-C01125
    Figure US20110082107A1-20110407-C01126
    Figure US20110082107A1-20110407-C01127
    Figure US20110082107A1-20110407-C01128
    Figure US20110082107A1-20110407-C01129
    Figure US20110082107A1-20110407-C01130
    Figure US20110082107A1-20110407-C01131
    Figure US20110082107A1-20110407-C01132
    Figure US20110082107A1-20110407-C01133
    Figure US20110082107A1-20110407-C01134
    Figure US20110082107A1-20110407-C01135
    Figure US20110082107A1-20110407-C01136
    Figure US20110082107A1-20110407-C01137
    Figure US20110082107A1-20110407-C01138
    Figure US20110082107A1-20110407-C01139
    Figure US20110082107A1-20110407-C01140
    Figure US20110082107A1-20110407-C01141
    Figure US20110082107A1-20110407-C01142
    Figure US20110082107A1-20110407-C01143
    Figure US20110082107A1-20110407-C01144
    Figure US20110082107A1-20110407-C01145
    Figure US20110082107A1-20110407-C01146
    Figure US20110082107A1-20110407-C01147
    Figure US20110082107A1-20110407-C01148
    Figure US20110082107A1-20110407-C01149
    Figure US20110082107A1-20110407-C01150
    Figure US20110082107A1-20110407-C01151
    Figure US20110082107A1-20110407-C01152
    Figure US20110082107A1-20110407-C01153
    Figure US20110082107A1-20110407-C01154
    Figure US20110082107A1-20110407-C01155
    Figure US20110082107A1-20110407-C01156
    • Preparation of a Pharmaceutical Composition Example 177 Preparation of Tablets
  • Ingredients mg/tablet
    1. Active compound of formula (I) 10.0
    2. Cellulose, microcrystalline 57.0
    3. Calcium hydrogen phosphate 15.0
    4. Sodium starch glycolate 5.0
    5. Silicon dioxide, colloidal 0.25
    6. Magnesium stearate 0.75
  • The active ingredient 1 is mixed with ingredients 2, 3, 4 and 5 for about 10 minutes. The magnesium stearate is then added, and the resultant mixture is mixed for about 5 minutes and compressed into tablet form with or without film-coating.
  • The present invention is not to be limited in scope by the exemplified aspects which are intended as illustrations of single aspects of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.
  • All references cited herein are hereby incorporated by reference in their entirety.

Claims (16)

1. A compound of the general formula (III):
Figure US20110082107A1-20110407-C01157
wherein:
R5 is selected from C3-10-cycloalkyl and aryl;
wherein any aryl or cycloalkyl is optionally independently substituted by one or more halogen, halo-C1-C8-alkyl, HO—C1-C8-alkyl, R8R9N—C1-C8-alkyl, C1-C8-alkyl-OR10, —OR10, (C3-C10)-cycloalkyl or C1-C8-alkyl-sulfonyl;
R6 is C1-8-alkyl;
R7 is C1-8-alkyl;
wherein alkyl is optionally substituted by one or more of, —C1-C8-alkyl, —OH, —OR10, C1-C8-alkyl-SO2—, —SO2-aryl, —C(O)—(CR8R9)n-carbamate, —C(O)—O—C1-C8-alkyl, —C(O)—C1-C8-alkyl, —C(O)—(CR8R9)n—C(O)—NR8R9, —C(O)—(CR8R9)n—NR8—C(O)—C1-C8-alkyl, —C(O)—(CR8R9)n—NR8R9, —C(O)—C3-C10-cycloalkyl, —C(O)-aryl, —C(O)—(CR8R9)n-heteroyclyl, —C1-C8 alkyl-OR8, —C(O)-halo-C1-C8-alkyl or —C(O)—(CR8R9)n-aryl,
wherein any aryl, alkyl, cycloalkyl, or heterocyclyl is optionally independently substituted by one or more C1-8-alkyl, aryl, halogen, —NR10R10, C1-C8-haloalkyl, HO—C1-C8-alkyl, R8R9N—C1-C8-alkyl, C1-C8-alkyl-OR10, —OR10, (C3-C10)-cycloalkyl or C1-C8-alkyl-sulfonyl, —O—(CR8R9)n-heterocyclyl, —O—(CR8R9)n—C(O)—NR8R9, —O—(CR8R9)n—NR8R9, —Y—(CR8R9)n—NR8—C(O)—C1-C8-alkyl, —Y—(CR8R9)n-heterocyclyl, —O—(CR8R9)n—NR8R9, C1-C8-alkyl-SO2, or —O—(CR8R9)n—N—C(O)-heterocyclyl, wherein n is 0-5, Y is NR10, O or S;
wherein R8 and R9 are each independently selected from hydrogen, C1-C8 alkyl, C1-C8 alkoxy, —NR10RR, —S—(C1-C8)alkyl, aryl and heterocyclyl;
any alkyl, alkoxy, heterocyclyl or aryl may be substituted with one to three substituents selected from -halo, unsubstituted C1-C8 alkyl, unsubstituted C1-C8 alkoxy, unsubstituted C1-C8 thioalkoxy and unsubstituted aryl(C1-C4)alkyl;
wherein R10 is independently selected from hydrogen, C1-C8 alkyl, aryl-C1-C8 alkyl, C1-C8 alkoxy, —S—(C1-C8)alkyl, heterocyclyl and aryl;
any alkyl, heterocyclyl or aryl may be substituted with one to three substituents selected from -halo, unsubstituted C1-C8 alkyl, unsubstituted C1-C8 alkoxy, unsubstituted C1-C8 thioalkoxy and unsubstituted aryl(C1-C4)alkyl;
or a pharmaceutically acceptable salt, tautomer, optical isomer, or N-oxide thereof, with the proviso that:
when
R6═R7=methyl, then R5 is not phenyl or 4-iodophenyl
2. The compound according to claim 3, wherein
R5 is selected from cyclohexyl, cycloheptyl, cyclooctyl, 2,2,3,3-tetramethylcyclopropyl, bicyclo[2.2.1]hept-2-yl, tricyclo[3.3.1.0˜3,7˜]non-3-yl, phenyl, 2-methylphenyl, 3-methylphenyl, 2-isopropylphenyl, 2-fluorophenyl, 2-chlorophenyl, and 2-phenylpropyl, and
R6 and R7 are each independently selected from methyl, ethyl, isopropyl, isobutyl, and tert-butyl;
3. The compound of claim 1, wherein R6 is methyl and R7 is isopropyl.
4. The compound of claim 1, wherein R5 is aryl.
5. The compound of claim 4, wherein R5 is optionally substituted phenyl.4. The compound of claim 3, wherein R6 is selected from methyl, ethyl, n-propyl or iso-propyl.
6. The compound of claim 1, wherein R6 is selected from methyl, ethyl, n-propyl or isopropyl.
7. A compound selected from:
2-(bicyclo[2.2.1]hept-2-ylamino)-5,5-dimethyl-1,3-thiazol-4(5H)-one;
2-(cycloheptylamino)-5,5-diethyl-1,3-thiazol-4(5H)-one;
and
pharmaceutically acceptable salts, tautomers, optical isomers, and N-oxides thereof.
8. A pharmaceutical formulation comprising a compound according to claim 3 as active ingredient, in combination with a pharmaceutically acceptable diluent or carrier.
9. The pharmaceutical formulation of claim 8, wherein the formulation is formulated for oral delivery.
10. The pharmaceutical formulation of claim 9, wherein the oral delivery is in the form of a tablet.
11. A process for the preparation of a compound of Formula (III) and pharmaceutically acceptable salts, tautomers, optical isomers, and N-oxides thereof:
Figure US20110082107A1-20110407-C01158
comprising the following reaction scheme:
Figure US20110082107A1-20110407-C01159
wherein:
X is S;
R5 is selected from C3-10-cycloalkyl and aryl;
wherein any aryl or cycloalkyl is optionally independently substituted by one or more C1-8-alkyl, aryl, halogen, halo-C1-C8-alkyl, HO—C1-C8-alkyl, R8R9N—C1-C8-alkyl, C1-C8-alkyl-OR10, —OR10, (C3-C10)-cycloalkyl or C1-C8-alkyl-sulfonyl;
R6 is C1-8-alkyl;
R7 is C1-8-alkyl;
wherein alkyl is optionally substituted by one or more of —C1-C8-alkyl, -halo, —OH, —OR10, C1-C8-alkyl-SO2—, —SO2-aryl, —C(O)—(CR8R9)n-carbamate, —C(O)—O—C1-C8-alkyl, —C(O)—C1-C8-alkyl, —C(O)—(CR8R9)n—C(O)—NR8R9, —C(O)—(CR8R9)n—NR8—C(O)—C1-C8-alkyl, —C(O)—(CR8R9)n—NR8R9, —C(O)—C3-C10-cycloalkyl, —C(O)-aryl, —C(O)—(CR8R9)n-heterocyclyl, —C1-C8 alkyl-OR8, —C(O)-halo-C1-C8-alkyl or —C(O)—(CR8R9)n-aryl,
wherein any aryl, alkyl, cycloalkyl, or heterocyclyl is optionally independently substituted by one or more C1-8-alkyl, aryl, halogen, —NR10R10, C1-C8-haloalkyl, HO—C1-C8-alkyl, R8R9N—C1-C8-alkyl, C1-C8-alkyl-OR10, —OR10, (C3-C10)-cycloalkyl or C1-C8-alkyl-sulfonyl, —O—(CR8R9)n-heterocyclyl, —O—(CR8R9)n—C(O)—NR8R9, —O—(CR8R9)n—NR8R9, —Y—(CR8R9)n—NR8—C(O)—C1-C8-alkyl, —Y—(CR8R9)n-heterocyclyl, —O—(CR8R9)n—NR8R9, C1-C8-alkyl-SO2, or —O—(CR8R9)n—N—C(O)-heterocyclyl; wherein n is 0-5, Y is NR10, O or S.
wherein R8 and R9 are each independently selected from hydrogen, C1-C8 alkyl, C1-C8 alkoxy, —NR10R10, —S—(C1-C8)alkyl, aryl and heterocyclyl;
any alkyl, alkoxy, heterocyclyl or aryl may be substituted with one to three substituents selected from -halo, unsubstituted C1-C8 alkyl, unsubstituted C1-C8 alkoxy, unsubstituted C1-C8 thioalkoxy and unsubstituted aryl(C1-C4)alkyl;
wherein R10 is independently selected from hydrogen, C1-C8 alkyl, aryl-C1-C8 alkyl, C1-C8 alkoxy, —S—(C1-C8)alkyl, heterocyclyl and aryl;
any alkyl, heterocyclyl or aryl may be substituted with one to three substituents selected from -halo, unsubstituted C1-C8 alkyl, unsubstituted C1-C8 alkoxy, unsubstituted C1-C8 thioalkoxy and unsubstituted aryl(C1-C4)alkyl; and
LG is a leaving group
12. The method of claim 11, wherein LG is selected from halide, tosylate, mesylate and triflate.
13. The method of claim 11, wherein the chiral base is a chiral lithium base.
14. A compound selected from
(S)-2-((1R,2R,4R)-5-hydroxybicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one
(S)-2-((1R,2S,4R)-5-hydroxybicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one,
(S)-2-((1S,2S,4R)-6-hydroxybicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one,
(S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-((R)-1-hydroxypropan-2-yl)-5-methylthiazol-4(5H)-one,
(S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-((S)-1-hydroxypropan-2-yl)-5-methylthiazol-4(5H)-one,
(S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-(2-hydroxypropan-2-yl)-5-methylthiazol-4(5H)-one,
(S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-5-(prop-1-en-2-yl)thiazol-4(5H)-one,
(S)-2-((1R,2S,4R)-5-hydroxybicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one, and
pharmaceutically acceptable salts, tautomers, optical isomers, and N-oxides thereof
15. The compound of claim 1, wherein R5 is selected from cyclohexyl, norbornyl and adamantyl.
16. The compound of claim 1, wherein R5 is norbornyl.
US12/898,279 2004-05-24 2010-10-05 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 Abandoned US20110082107A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/898,279 US20110082107A1 (en) 2004-05-24 2010-10-05 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US13/233,699 US8686011B2 (en) 2004-05-24 2011-09-15 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0401324A SE0401324D0 (en) 2004-05-24 2004-05-24 New compounds
SE0401324-9 2004-05-24
SE0402509-4 2004-10-15
SE0402509A SE0402509D0 (en) 2004-10-15 2004-10-15 New compounds
US65077705P 2005-01-31 2005-01-31
US11/135,662 US7253196B2 (en) 2004-05-24 2005-05-24 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US11/819,607 US7807700B2 (en) 2004-05-24 2007-06-28 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US12/898,279 US20110082107A1 (en) 2004-05-24 2010-10-05 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/819,607 Continuation US7807700B2 (en) 2004-05-24 2007-06-28 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/233,699 Continuation US8686011B2 (en) 2004-05-24 2011-09-15 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

Publications (1)

Publication Number Publication Date
US20110082107A1 true US20110082107A1 (en) 2011-04-07

Family

ID=35134299

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/135,662 Expired - Fee Related US7253196B2 (en) 2004-05-24 2005-05-24 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US11/596,982 Abandoned US20070281938A1 (en) 2004-05-24 2005-05-24 Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1
US11/819,607 Expired - Fee Related US7807700B2 (en) 2004-05-24 2007-06-28 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US12/898,279 Abandoned US20110082107A1 (en) 2004-05-24 2010-10-05 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US11/135,662 Expired - Fee Related US7253196B2 (en) 2004-05-24 2005-05-24 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US11/596,982 Abandoned US20070281938A1 (en) 2004-05-24 2005-05-24 Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1
US11/819,607 Expired - Fee Related US7807700B2 (en) 2004-05-24 2007-06-28 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

Country Status (16)

Country Link
US (4) US7253196B2 (en)
EP (1) EP1753736B1 (en)
JP (1) JP4789934B2 (en)
CN (1) CN1964956B (en)
AR (1) AR049344A1 (en)
AT (1) ATE417837T1 (en)
AU (1) AU2005247929B2 (en)
BR (1) BRPI0510394A (en)
CA (1) CA2568186C (en)
DE (1) DE602005011795D1 (en)
EA (1) EA014419B1 (en)
ES (1) ES2318503T3 (en)
GE (1) GEP20094666B (en)
MY (1) MY148480A (en)
TW (1) TWI352700B (en)
WO (1) WO2005116002A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183938B2 (en) 2014-12-16 2019-01-22 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors
US10370370B2 (en) 2015-06-10 2019-08-06 Axovant Sciences Gmbh Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754709B2 (en) * 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
EA014419B1 (en) 2004-05-24 2010-12-30 Эмджен Инк. 5,5-disubstituted-2-amino-4-thiazolidinone and process for preparation thereof, pharmaceutical composition and method for treatment
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
CN102816081A (en) 2005-01-05 2012-12-12 雅培制药有限公司 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7511175B2 (en) 2005-01-05 2009-03-31 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
EP1866298A2 (en) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
US7563813B2 (en) 2005-05-13 2009-07-21 Wyeth Iminothiazolidinone derivatives as SFRP-1 antagonists
AU2006255465A1 (en) * 2005-06-09 2006-12-14 Merck Frosst Canada Ltd Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
DE602006011360D1 (en) 2005-11-22 2010-02-04 Amgen Inc CATALYSIS METHOD FOR THE PREPARATION OF C-5 SUBSTITUTED HETEROCYCLIC INHIBITORS OF TYPE 1 11BETA HYDROXYSTEROIDDEHYDROGENASE
EP1979335A2 (en) 2006-01-18 2008-10-15 F.Hoffmann-La Roche Ag Thiazoles as 11 beta-hsd1 inhibitors
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US9090604B2 (en) 2006-07-27 2015-07-28 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
EP2064187A2 (en) * 2006-08-25 2009-06-03 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US20110150825A1 (en) * 2006-11-14 2011-06-23 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions
WO2008090356A1 (en) * 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
RU2479577C2 (en) * 2007-05-25 2013-04-20 Эбботт Гмбх Унд Ко.Кг Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
US8765788B2 (en) 2007-06-14 2014-07-01 Amgen Inc. Tricyclic inhibitors of hydroxysteroid dehydrogenases
CA2692128A1 (en) * 2007-06-21 2008-12-31 Amgen Inc. Process for making substituted 2-amino-thiazolones
ATE554078T1 (en) 2007-07-26 2012-05-15 Vitae Pharmaceuticals Inc SYNTHESIS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 INHIBITORS
JP5736098B2 (en) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド Pharmaceutical composition for treating central nervous system disorders
JPWO2009038064A1 (en) * 2007-09-19 2011-01-06 株式会社医薬分子設計研究所 Heterocyclic derivatives having type I 11β-hydroxysteroid dehydrogenase inhibitory activity
AR069207A1 (en) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc CYCLIC UREAS AS INHIBITORS OF THE 11 BETA - HIDROXI-ESTEROIDE DESHIDROGENASA 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
EP2252601B1 (en) 2008-01-24 2012-12-19 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2254872A2 (en) 2008-02-15 2010-12-01 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CA2722427A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009134387A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP2011524914A (en) * 2008-06-20 2011-09-08 アムジエン・インコーポレーテツド Method for making substituted 2-amino-thiazolones
CN102105454A (en) 2008-07-25 2011-06-22 贝林格尔.英格海姆国际有限公司 Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
KR20110050459A (en) 2008-07-25 2011-05-13 비타이 파마슈티컬즈, 인코포레이티드 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201016691A (en) 2008-07-25 2010-05-01 Boehringer Ingelheim Int Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
BRPI0916270A2 (en) * 2008-07-29 2018-10-16 Amgen Inc asymmetric process for the production of substituted 2-amino thiazolones
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
WO2010089303A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
MA33216B1 (en) 2009-04-30 2012-04-02 Boehringer Ingelheim Int CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1
ES2350077B1 (en) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. INHIBITING COMPOUNDS OF 11BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1.
JP5656986B2 (en) 2009-06-11 2015-01-21 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Cyclic inhibitor of 11β-hydroxysteroid dehydrogenase 1 based on 1,3-oxazinan-2-one structure
JP5750449B2 (en) 2009-11-05 2015-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New chiral phosphorus ligand
EP2576570A1 (en) 2010-05-26 2013-04-10 Boehringer Ingelheim International GmbH 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
JP5860042B2 (en) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Substituted 5, 6 and 7 membered heterocycles, medicaments containing such compounds and their use
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
SG2014013460A (en) 2010-09-23 2014-09-26 Abbvie Inc Monohydrate of an azaadamantane derivative
US20130310431A1 (en) * 2010-10-15 2013-11-21 Amgen Inc Uses for substituted 2-amino-thiazolones in treating alzheimer's disease
AU2011325286B2 (en) 2010-11-02 2015-04-16 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
CN102408392A (en) * 2011-11-10 2012-04-11 浙江大学 Green preparation method of 2-(N, N-disubstituted amino)-4-isothiazolinone in water phase
RU2483722C1 (en) * 2012-05-22 2013-06-10 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Aminothiazole derivatives of usnic acid as novel anti-tuberculosis agents
WO2021091823A1 (en) * 2019-11-06 2021-05-14 Albert Einstein College Of Medicine Small molecule prostagladin transport inhibitors
CN115322208B (en) * 2021-05-10 2023-04-11 中国药科大学 2-aminothiazole derivative and preparation method and medical application thereof
CN115010616B (en) * 2022-07-01 2024-03-26 常州锐博生物科技有限公司 Synthesis method of 1-aminocyclopropane hydrochloride

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2701248A (en) * 1950-12-30 1955-02-01 Monsanto Chemicals Esters of pseudothiohydantoin-5-acetic acid and method for their preparation
US2786838A (en) * 1957-03-26 Cshy b
US4428948A (en) * 1977-02-03 1984-01-31 Rohm And Haas Company Novel heterocyclic compounds
US4587256A (en) * 1983-06-23 1986-05-06 Hoffmann-La Roche Inc. Novel thiazolidine derivatives
US5736545A (en) * 1996-02-26 1998-04-07 Pharmacia & Upjohn Company Azolyl piperazinyl phenyl oxazolidinone antimicrobials
US6414003B1 (en) * 1996-06-25 2002-07-02 Takeda Chemical Industries, Ltd. Oxazolone derivatives and their use as anti-helicobacter pylori agents
US20040097566A1 (en) * 2001-12-06 2004-05-20 Magnus Pfahl 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US20050009821A1 (en) * 2003-05-21 2005-01-13 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US20050239853A1 (en) * 2004-02-04 2005-10-27 Tjeerd Barf New compounds
US7253196B2 (en) * 2004-05-24 2007-08-07 Amgen, Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE929549C (en) 1951-11-29 1955-08-01 Hoechst Ag Process for the preparation of substituted pseudothiohydantoins and their hydrohalides
FR6278M (en) * 1966-12-14 1968-09-02
JPS58183603A (en) * 1982-04-19 1983-10-26 Mitsubishi Chem Ind Ltd Fungicide for soil blight
ZA844557B (en) * 1983-06-23 1985-02-27 Hoffmann La Roche Novel thiazolidine derivatives
JPH08277266A (en) * 1983-09-14 1996-10-22 Alcon Lab Spirocyclic aromatic succinimide derivative,and remedy for human and animal diabetes complication
JPS6360987A (en) * 1986-08-29 1988-03-17 Tanabe Seiyaku Co Ltd Production of quinazolinone derivative
SE0001899D0 (en) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2002353717B2 (en) 2001-11-22 2006-08-03 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2002353716A1 (en) 2001-11-22 2003-06-10 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2002353718B2 (en) * 2001-11-22 2007-05-10 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2004240885A1 (en) 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I
SE0301886D0 (en) 2003-06-25 2003-06-25 Biovitrum Ab New use V
SE0301885D0 (en) 2003-06-25 2003-06-25 Biovitrum Ab New use IV
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
SE0301882D0 (en) 2003-06-25 2003-06-25 Biovitrum Ab New use I
SE0301888D0 (en) 2003-06-25 2003-06-25 Biovitrum Ab New use VII
SE0301884D0 (en) 2003-06-25 2003-06-25 Biovitrum Ab New use III
SE0301883D0 (en) 2003-06-25 2003-06-25 Biovitrum Ab New use II

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2786838A (en) * 1957-03-26 Cshy b
US2701248A (en) * 1950-12-30 1955-02-01 Monsanto Chemicals Esters of pseudothiohydantoin-5-acetic acid and method for their preparation
US4428948A (en) * 1977-02-03 1984-01-31 Rohm And Haas Company Novel heterocyclic compounds
US4587256A (en) * 1983-06-23 1986-05-06 Hoffmann-La Roche Inc. Novel thiazolidine derivatives
US5736545A (en) * 1996-02-26 1998-04-07 Pharmacia & Upjohn Company Azolyl piperazinyl phenyl oxazolidinone antimicrobials
US6414003B1 (en) * 1996-06-25 2002-07-02 Takeda Chemical Industries, Ltd. Oxazolone derivatives and their use as anti-helicobacter pylori agents
US20040097566A1 (en) * 2001-12-06 2004-05-20 Magnus Pfahl 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US20050009821A1 (en) * 2003-05-21 2005-01-13 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US20050239853A1 (en) * 2004-02-04 2005-10-27 Tjeerd Barf New compounds
US7253196B2 (en) * 2004-05-24 2007-08-07 Amgen, Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US7807700B2 (en) * 2004-05-24 2010-10-05 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183938B2 (en) 2014-12-16 2019-01-22 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors
US10370370B2 (en) 2015-06-10 2019-08-06 Axovant Sciences Gmbh Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors

Also Published As

Publication number Publication date
JP4789934B2 (en) 2011-10-12
EP1753736A2 (en) 2007-02-21
AU2005247929A1 (en) 2005-12-08
AU2005247929B2 (en) 2010-03-11
WO2005116002B1 (en) 2006-08-24
JP2008500353A (en) 2008-01-10
US20080045503A1 (en) 2008-02-21
ES2318503T3 (en) 2009-05-01
US7807700B2 (en) 2010-10-05
EP1753736B1 (en) 2008-12-17
DE602005011795D1 (en) 2009-01-29
CN1964956A (en) 2007-05-16
TWI352700B (en) 2011-11-21
ATE417837T1 (en) 2009-01-15
CA2568186A1 (en) 2005-12-08
WO2005116002A2 (en) 2005-12-08
BRPI0510394A (en) 2007-11-13
EA014419B1 (en) 2010-12-30
US20070281938A1 (en) 2007-12-06
EA200602191A1 (en) 2007-06-29
TW200609227A (en) 2006-03-16
US20060142357A1 (en) 2006-06-29
GEP20094666B (en) 2009-04-10
WO2005116002A3 (en) 2006-07-06
CN1964956B (en) 2013-03-27
MY148480A (en) 2013-04-30
US7253196B2 (en) 2007-08-07
CA2568186C (en) 2011-11-15
AR049344A1 (en) 2006-07-19

Similar Documents

Publication Publication Date Title
US7253196B2 (en) Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US8541592B2 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
US7030135B2 (en) Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
JP5242857B2 (en) Aminopyrimidines as Syk inhibitors
US20050239853A1 (en) New compounds
KR20050044577A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US8686011B2 (en) Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US7094792B2 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
KR101296408B1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2012204095A1 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION